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Human immunodeficiency virus (HIV) infects about 40 million people worldwide. HIV is
the causative agent of acquired immunodeficiency syndrome (AIDS). AIDS is characterised
by a progressive decline in protective immunity that leads to opportunistic infection and
eventually death. Although HIV-1 causes a decline in CD4' T-cell number and this
undoubtedly contributes to the general immune deficit of AIDS, CD4+ T-cell loss does not
completely explain the pathogenesis of AIDS. Death and anergy of uninfected T-cells is
observed in AIDS, as are deficits in innate and specific immunity. Antigen presenting cells
(APCs, including macrophages and dendritic cells, DCs, which are infectable by M-tropic
strains ofHIV-1 via the CCR-5 chemokine receptor) play a key role in orchestrating innate
and adaptive immune responses and controlling T-cell activities including activation, anergy,
deletion, tolerisation and memory by the provision of appropriate signals. APC dysregulation
results in deficits of innate and adaptive immune responses. It is known that HIV-1 can cause
APC dysregulation; this thesis examines some mechanisms by which this might occur.
The HIV-1 envelope glycoprotein gpl20 mediates HIV-1 infection by binding to
target cells via CD4 and CCR-5 and is focussed on throughout this work. Because gpl20 is
found on the surface of HIV-1 and dissolved in the serum of HIV-1 infected patients, it has
the ability to disrupt the function of both infected and uninfected APCs.
Data in this thesis demonstrate that gp 120 causes a decline of cell-surface CD4 from
human macrophages in vitro. A mechanism for this loss is proposed based on observations
that it is significantly more substantial when CCR-5-binding gpl20, derived from M-tropic
HIV-1 is used as opposed to CXCR-4-binding gpl20. CD4 loss is absent from macrophages
that fail to express surface CCR-5 due to homozygosity for the naturally occurring ccr5A32
mutation. It appears that CD4 loss by this novel CCR-5-dependent mechanism requires
cross-linking of CCR-5, CD4 and gp 120 at the cell surface leading to receptor-mediated
endocytosis of this protein complex. Confocal microscopy was used to visualise these
endocytosed proteins inside macrophages and RT-PCR was used to investigate
transcriptional regulation ofCD4 and CCR-5 recovery. Endocytosis of the protein complex
may change antigen presentation efficiencies. Possible implications for protective- and auto¬
immunity are discussed.
This thesis also presents evidence that pre-treatment with gp!20 leads to reduction in
an APC's ability to stimulate antigen-specific proliferation of a T-cell line. Because this
effect is not dependent on the tropism of the HIV-1 strain from which the gpl20 is derived,
an alternative mechanism to CD4-loss was sought. The hypothesis that APC dysfunction is
due to HIV-1 subversion of physiological mechanisms involving prostaglandin and the
Notch signalling pathway, leading to inappropriate tolerance induction, was examined.
Treatment ofmacrophages and DCs with gpl20 caused the transcriptional up-regulation of
genes involved in the Notch pathway including Notch ligands, the presence of which on an
APC has previously been shown to abrogate T-cell activation by the induction of an anergic
phenotype.
Preventing HIV-1 infection of APCs and the subsequent dysregulation of immune responses
is a therapeutic goal. Branched, synthetic peptides based on discontinuous epitopes of gpl20
and previously demonstrated to disrupt binding to CD4 and CCR-5 are shown to protect
macrophages from infection with M-tropic HIV-1Bal- Possible refinements to peptide
structure and their utility as anti-HIV-1 therapeutics or vaccines are discussed.
2
DECLARATION
I hereby declare that the work presented in this thesis is my own, except where stated
in the text. The work has not been submitted in any previous application for a degree.
Timothy John Hewson
We have our philosophical persons, to make modern and
familiar, things supernatural and causeless.
All's Well That Ends Well, II, iii
© Timothy John Hewson, 2000
No part of this publication may be reproduced, copied or transmitted save with written permission, or
in accordance with the provisions of the Copyright, Designs and Patents Act 1988, or under the teims
of the license granted to The University of Edinburgh Library.
Timothy John Hewson has asserted his moral right to be identified as the author of this work in
accordance with the Copyright, Designs and Patents Act 1988.
The author's published papers have been included in this thesis (appendix 3) with the formal
permission of the publishers and all joint authors.
All Trademarks and Registered Trademarks are acknowledged as the property of their respective
owners.
3




Amino acid abreviations 20
Genes of the Notch pathway 21
Chapter 1: Introduction 23
Human immunodeficiency viruses 23
AIDS 23
HIV-1 transmission 24
Progression to AIDS 24
Type 1 human immunodeficiency virus (HIV-1) 26
HIV-1 clades 28
CD4 and HIV-1 29
Cellular tropism ofHIV-1 29
Antigen presenting cells (APCs) 33
Introduction 33
Antigen presenting cell types 33
Antigen presenting cell - CD4+ T-cell interactions 34
APC - HIV-1 interactions 35
HIV-1 as antigen 36
Gpl20 induces changes in APC cytokine production 37
Does HIV-1 induce a Thl to Th2 switch? 38
Gpl20 induces a cell-signalling defect 41
Other HIV-1 proteins induce cell-signalling defects 41
The role of gpl20 in inducing leukocyte apoptosis 42
HIV-1 / cell binding and membrane fusion: potential for dysregulation.... 43
Factors effecting HIV-1 infection and disease progression 44
HLA polymorphisms and HIV-1 disease progression 45
Other possibly important host factors 45
Virus genetic factors effecting HIV-1 disease progression 46
Chemokine receptor polymorphisms and disease progression rate 47
5
HIV-1 replicative cycle 48
The long terminal repeat (LTR): HIV-l's promoter 51
HIV-1 induced syncytia: implications for HIV-1 transcription 52
Immune status and HIV-1 replication rate 55
Loss ofAPC numbers in HIV-1 disease 56
Damage done to the immune system by APCs in the presence ofHIV-1 .. 56
Role of APCs in HIV-1 dissemination 58
Conclusion 58
Specific questions 60
Chapter 2: Materials and methods 62
Cell separation and tissue culture 62
Source ofmaterial 62
Precautions for the safe handling of potentially infective material 63
Preparation of 'off the clot' human serum 63
Isolation of peripheral blood mononuclear cells (PBMCs) 63
Cryo-preservation of cells 64
Macrophage culture 64
Dendritic and Langerhans cell differentiation and culture 65
CD4+ T-cell purification 66
Gamma irradiation of PBMC 66
Maintenance ofHA1.7 T-cell clone 66
[3H]-thymidine incorporation proliferation assay 67
HIV-1 infection assay 68
Flow cytometry methods 69
Preparation of monoclonal antibodies and control IgG 69
Lowry protein assay 71
Phenotyping of cells 72
Quantification of cell-surface antigen levels 73
Annexin V staining 74
Microscopy methods 74
Standard light microscopy 74
FITC conjugation of protein 74
6
Staining of macrophages for fluorescence microscopy 75
Fluorescence microscopy 77




Nucleic acid purification methods 79
DNA isolation 79
RNA isolation 79
Nucleic acid quantification 80
Polymerase chain reaction (PCR) methods 80
Bioinformatics and primer design 80
Reverse transcription (RT) 80





Real-time (kinetic) RT-PCR 84
Reverse transcription for real-time PCR 85
Reaction set-up for real-time PCR 86
Real-time PCR program 87
Primer and probe sequences for real-time PCR 87
Statistics from real-time PCR 88
Chapter 3: Results: Distribution of the ccr5A32 genotype 90
Background 90
The discovery ofHIV-1 coreceptors 90
Ccr-5 coreceptor gene polymorphism 91
Ccr5A32 homozygous cells are protected from infection by M-tropic HIV-1
92
The ccr5A32 allele protects HIV-1 infected individuals from rapid disease
progression 93
7
Other phenotypes of the ccr5A32 allele 94
Aims of chapter 94
Methods 95
Literature search 95
Hardy-Weinberg equilibrium calculations 95
Regression analysis 96
Ccr5A32 genotyping 96
HIV-Ibal Infectivity assay 96
Results 97
Ccr5A32 allele frequency 97
Infection of homozygous ccr5A32 mutant macrophages 113
Discussion 114
CCR-5-tropic HIV-1 can not infect ccr5 null macrophages 114
The ccr5A32 mutation is generally in Hardy-Weinberg equilibrium in non-
HIV-1 infected populations 115
The incidence of the ccr5A32 mutation in SE Scotland is as predicted ... 115
Possible explanations for the distribution of ccr5A32 116
Chapter 4: Results: Gpl20 induced CD4 loss 118
Background 118
HIV-1 infection and gpl20 causes immune system dysregulation 118
Physiological roles of CD4, CCR-5 and CXCR-4 119
HIV-1 induced changes to cell surface phenotype 119
Endocytosis and phagocytosis 120
Implications of endocytosis by APCs 122
Summary 123
Specific questions 123
Materials and methods 124
Reagents and antibodies 124
Results 126
Antibody titration 126
Semi-quantitative RT-PCR optimisation 127
Gpl20 induces a loss of macrophage surface CD4 127
8
CD4 loss is dependent on gpl20 tropism and cell surface CCR-5 127
M- and T-tropic gpl20 can both bind to the macrophage surface 127
CD4 and CCR-5 ligands IL-16 and MlP-la fail to induce a CD4 loss.... 128
Levels ofCD 18, a control antigen, remain unchanged 128
Neutralisation ofTNF-a does not inhibit CD4 loss 129
Loss of surface CD4 is accompanied by increased levels of CD4 in an
internal MHC class II+ pool 129
CCR-5 tropic gpl20 is endocytosed by a pathway resembling receptor
mediated phagocytosis 130
R5-tropic gpl20 enters macrophages along with CD4, gpl20mB and BSA
do not 131
R5-tropic gpl20 induces an up-regulation ofmRNA for CCR-5 and CD4
131
Discussion 151




Mechanisms of T-cell tolerance 158
Oral and nasal tolerance 160
Linked suppression, bystander suppression and APCs 161
Tolerance induction 164
Tolerance and HIV-1 164
Measurements of tolerance 165
Notch and cell-to-cell interactions 165
The Notch signalling pathway 167
Notch activation 169
Activated Notch targets - HES-1 171
Activated Notch targets - Deltex 172
Integration with other pathways 173
Notch in immune system development 175
Notch and tolerance 179
9
Semen, prostaglandin and tolerance 182
HIV-1, gpl20 and prostaglandin 184
Summary of tolerance signals 185
Notch experimental difficulties 187





Cell harvesting and analysis 191
Results 191
Cell purities 191
PCR standard curves 191
The Notch pathway is involved in experimental T-cell line anergy induction
192
Inhibition ofHA1.7 antigen specific proliferation 192
Gpl20 treatment does not cause macrophage apoptosis 193
Gpl20 can induce serrate mRNA in CD4+ T-cells 193
The Notch pathway may be involved in reduced macrophage and LC
capacity to support proliferation 194
Peptide 3.7 may be able to mimic some of gp!20's actions 195
Prostaglandin may mediate gpl20 effects 195
In addition to the Notch pathway, cytokines may be involved in APC
tolerance induction 196
Discussion 229
HIV-1 induced immune deficits = tolerance? 229
Notch and HA1.7 T-cells 229
HA1.7 T-cell proliferation, gpl20 and Notch 230
Semen and Notch 232
DCs are special 232




Current anti-HIV-1 drugs 234
HIV-1 entry inhibitors 235
Current HIV-1 entry inhibitors 237
Manufacture of peptides 238
F-moc chemistry in automated peptide synthesis 239
Anti-HIV vaccines 240
Early work on synthetic gpl20 peptides 241
GC-1 analogues 243
Biological activities of synthetic peptides 243
HIV-1 infectivity assays 245
Aims of chapter 247
Methods 248






Stability of peptides 253
Blocking efficiency 254
Infection enhancement 254
3.7 as an vaccine 255
Future directions 256




Antigen presenting cells 262
HIV-1, gpl20 and APC dysregulation 263
Gp 120 and CD4 264
Gpl20 and inappropriate tolerance 265
11
HIV prostaglandin and Notch 266
Semen and tolerance 268





Appendix 1: Reagent recipes 332
Appendix 2: PCR primer / probe sequence data 334






























gpl20 based peptide (see chapter 6)
tritiated deoxythymidine triphosphate
adenine (base) / (deoxy)adenosine (nucleoside) /
(deoxy)adenylate (nucleotide), Ampere
antibody
a Der P II specific T-cell line
antibody dependent enhancement (of infection)
activation-induced cell death
acquired immune deficiency syndrome
allelomorph(ic form of a polymorphic gene)
(transcription) activator protein 1
antigen presenting cell
AIDS-related complex









bovine serum albumin (fraction V)
cytosine (base) / (deoxy)cytidine (nucleoside) /
(deoxy)cytidylate (nucleotide), complement component (CI to
C9), constant (domain of protein), carboxyl (terminal of
peptide)
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CAMP cyclic adenosine monophosphate
CBF-1 C-promoter binding factor 1 / core binding factor 1
CCR CC (a) chemokine receptor
CD cluster of differentiation (FILDA designation)
CDC (USA) Center for Disease Control and Prevention
cDNA complimentary DNA
CDR complimentarity determining region




Con A concanavalin A
COX cyclooxygenase
CPM counts per minute
CSF colony-stimulating factor
CTL cytotoxic T lymphocyte / killer T-cell
CTLA-4 cytotoxic T lymphocyte antigen (CD 152)
CXCR CXC (P) chemokine receptor
D Dalton
DC dendritic ceil
DC-SIGN DC-specific, ICAM-3 grabbing non-integrin
Dde 4,4-dimethyl-2,6-dioxocyclohex-1 -ylidine
Der p 1 Dermatophagoides pteronyssinus (house dust mite) allergen
DMSO dimethyl sulphoxide
DNA deoxyribo(se) nucleic acid
dNTP deoxynucleoside triphosphate
DSL Delta / Serrate / Lag-2 (motif)
dT deoxythymidine
EAE experimental autoimmune / allergic encephalitis (animal
model ofMS)
EBNA Epstein-Barr (virus) nuclear antigen
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EBV Epstein-Barr virus
EDTA ethylene di-amino tetra-acetic acid
EGF epidermal growth factor
ELISA enzyme-linked immuno-sorbant assay
env HIV envelope gene
ER endoplasmic reticulum
EU European Union, exposed-uninfected
F(ab') antigen-binding fragment of Ig
FAM carboxyfluorescein-N-hydroxysuccinimide
FasL Fas ligand
Fc crystalline fragment of Ig
FcR Fc receptor
FCS foetal calf serum
FITC fluorescein isothiocyanate
FMDV foot and mouth disease virus
F-moc 9-fluorenylmethoxycarbonyl
F.S. forward light scatter
ft foot
g gram
g acceleration due to gravity (~10 m s"2)
G guanine (base) / (deoxy)guanosine (nucleoside) /
(deoxy)guanylate (nucleotide), gap phase of cell cycle (e.g.,
Go, G2), GTP binding (e.g., G-protein)
gag HIV group-specific antigen gene
GAP-DH glyceraldehyde 3-phosphate dehydrogenase
GC-1 / -2 gpl20 based peptide (originally made by Garry Cotton)
G-CSF granulocyte CSF
GLP good laboratory practice
GM-CSF granulocyte-monocyte/macrophage CSF
gp glycoprotein





HA1.7 an influenza haemagglutinin specific T-cell line
HAART highly active anti-retrovirus therapy
HeLa a cervical carcinoma cell line
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HES hairy and enhancer of split
HI-NABHS heat inactivated normal blood-group AB human serum
HIV-1 / -2 human immunodeficiency virus -type 1 / -type 2
HLA human leukocyte antigen
HLDA 1-7 human leukocyte differentiation antigen (workshops 1-7)
hr hour
HTLV-III human T-cell leukaemia virus type III (now HIV-1)
HWE Hardy-Weinberg equilibrium
IBD inflammatory bowel disease
ICAM intercellular adhesion molecule
IFN interferon
IgG, IgM etc immunoglobulin class G, M etc
IH-1 / -2 gpl20 based peptide (originally made by Ian Heslop)
IL interleukin
IMDM Iscove's modified Dulbecco's medium
IRF IFN regulatory factor
ISRE IFN-stimulated response element
JNK c-Jun N-terminal kinase
1 litre
L ligand
LAK lymphokine-activated killer (cell)
LAV lymphadenopathy-associated virus (now HIV-1)
LC Langerhans cell
LNC lymph node cell
LNR Lin-12 / Notch repeat (motif)
LPS lipopolysaccharide
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MAP mitogen activated protein
MBP mannose binding protein, myelin basic protein
M-CSF monocyte/macrophage CSF
MHC major histocompatibility complex
min minute
MIP macrophage inflammatory protein (chemokine)
MM6 mono/mac 6 (cell line)
MnIX mean fluorescence intensity ofX
MOI multiplicity of infection
mol. mole
Mona monocytic adaptor
MRC (UK) Medical Research Council
mRNA messenger RNA
MS multiple sclerosis
N nucleotide / nucleoside / base (e.g. in dNTP), amino terminal
(of peptide)
NCR Notch cytokine response (protein region)
N.D. not determined
nef FIIV early regulatory gene
NFAT nuclear factor of activated T-cells
NF-kB nuclear (transcription) factor kB
NIBSC (UK) National Institute for Biological Standards and Controls
NK natural killer (cell)
NOD non-obese diabetic
NSI non-SI
OVA (hen egg) ovalbumin
P probability value
PBMC peripheral blood mononuclear cell
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PBS phosphate-buffered saline
PCR polymerase chain reaction
PE phycoerythrin, Perkin Elmer (trademark)




pGEM Promega molecular weight marker
PGL persistent generalised lymphadenopathy
pH -log10[H+]
PI propidium iodide
pol E1IV polymerase / integrase / endonuclease gene
r ribosomal
R receptor, rectus (clockwise)
R5-tropic CCR5-tropic
RANTES regulated upon activation, normal T-cell expressed and
secreted
RBPJk recombination recognition sequence binding protein at the Jk
site (synonym of CBF-1)
rev HIV early regulatory gene
RNA ribo(se)nucleic acid
ROX carboxyxrhodamine-N-hydroxysuccinimide
R-PE R enantiomer of PE
rpm revolutions per minute
RPMI 1640 Roswell Park Memorial Institute (culture medium number)
1640
rRNA ribosomal RNA
RT reverse transcript / transcription / transcriptase, room
temperature, respiratory tract
RT-PCR reverse transcript directed PCR
s second
S Svedberg (sedimentation coefficient), sense (PCR primer)
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SDF stromal-derived factor
SHIV SIV / HIV-1 artificially produced chimeric virus
SI syncytium inducing (virus strain)
SIV simian immunodeficiency virus
SNBTS Scottish National Blood Transfusion Service
SPE seminal plasma extract
S.S. side (90°) light scatter
STAT signal transducer and activator of transcription
T thymine (base) / deoxythymidine (nucleoside) /
deoxythymidylate (nucleotide)
TAMRA carboxytertramethylrhodamine-N-hydroxysuccinimide
TAN-1 truncated allele of notch-1 (oncogene)
TAP transporter associated with antigen processing
Taq Thermus aquaticus DNA polymerase
tat trans-acting transcriptional activator
TBE tris / boric acid / EDTA buffer
Tc T cytotoxic (killer cell)
TCID50 50% tissue culture infectious dose
TCLA T-cell line adapted (HIV strains)
TCR T-cell receptor
TGF transforming growth factor
Th T helper (cell)
Tm melting (denaturing) temperature of nucleic acid
TM TaqMan® (real time PCR probe)
TNF tumour necrosis factor
Tr T regulatory (cell)
tris tris (hydroxymethyl) aminomethane
TRITC tetramethyl rhodamine isothiocyanate
Ts T suppressor (cell)
U uracil (base) / uridine (nucleoside) / uridylate (nucleotide),
(WHO validated international activity) unit
UNAIDS Elnited Nations / WHO AIDS programme
19
UNG Uracil N-glycosylase
uv ultra violet (radiation)
V Volts, variable (domain of protein)
v// viral infectivity factor
vpr viral protein R
vpu viral protein U
VSV vesicular stomatitis virus
v/v volume per unit volume
WHO World Health Organization
wt wildtype
w/v weight (mass) per unit volume
X4-tropic CXCR4-tropic
AMINO ACID ABREVIATIONS
Single letter abbreviation Three letter abbreviation Full name
A Ala alanine
C Cys cysteine
D Asp aspartic acid


























GENES OF THE NOTCH PATHWAY
Many ofthe genes involved in Notch signalling (chapter 5) were
independently identified in different species. This means that a large number
ofnames, and acronyms have been used to describe each gene and its protein
product. The list below gives the principle genes discussed in this thesis,
synonyms and names oforthologues that will be encountered in the literature.
Vertebrate names have mainly been used except were this would result in the
use ofunwieldy and rarely used acronyms. Note that the situation, especially
in mammals, is further complicated by homologues which may or may not be
functionally equivalent (e.g., notch-1, -2, -3 etc). The convention ofgiving
gene names in italics and corresponding protein names in upright characters
with uppercase initial letter has been followed.




suppressor ofhairless / Su(H) (Drosophila melanogaster)
delta
DeltaD (Zebra fish)
















abruptex (D. melanogaster gain of function allele)
glp-1 (C. elegans)
int-2 (mouse notch-4, mammary tumour oncogene)
I'm-12 (C. elegans)
motch (mouse notch-1)
split (D. melanogaster allele)













"Everybody knows that pestilences have a way ofrecurring in the world; yet
somehow we find it hard to believe in ones that crash down on our heads
from a blue sky "
Albert Camus, The Plague, 1948 (Camus, 1989)
In 1981 a new disease originally dubbed GRID (gay-related immunodeficiency
disease) was reported amongst gay men in San Francisco (Anon., 1981). The name
was changed to AIDS (acquired immune deficiency syndrome) in August 1982 in
recognition that it is not just a disease of gay men (Harris et al., 1983). AIDS is a
disease caused and characterised by the breakdown of the host immune system
leading to the appearance of opportunistic infections and malignancies normally kept
at bay by a healthy immune system (see Castro et al., 1993, and table 1.1 for a list of
AIDS defining conditions).
Remarkably quickly after the discovery of AIDS, the causative retrovirus
agent, now called type 1 human immunodeficiency virus (HIV-1), was isolated from
the lymph node of a patient (BarreSinoussi et al., 1983). A second related retrovirus,
HIV-2 was isolated a few years later from patients in West Africa with AIDS-like
symptoms (Clavel et al., 1986; Blanc, 1986; Clavel et al., 1987). HIV-2 is more
closely related than HIV-1 to subsequently identified simian immunodeficiency
viruses (SIV, Kanki et al., 1986; Franchini and Bosch, 1989). Since its discovery
HIV-2 has remained mainly localised to West Africa where it causes a less severe
disease than HIV-1. The majority ofHIV infections world-wide are by HIV-1 and
this virus is the main focus ofHIV research.
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HIV-1 transmission
HIV-1 is transmitted by exchange of bodily fluids (VanDerGraaf and Diepersloot,
1986; Tomaso et al., 1995). This may be by homosexual (Weller et al., 1987) or
heterosexual activity (Vilmer et al., 1984; Clotet et al., 1986; Alcami and
Koszinowski, 2000), from mother to foetus during pregnancy or birth (Vilmer et al.,
1984; Coulaud et al., 1986), by the use of non-sterile medical equipment especially
syringes in medical procedures or intravenous drug abuse (Desjarlais et al., 1988) or
by engraftment of infected tissue (Gluckman et al., 1985), blood or blood products
(Melief and Goudsmit, 1986; Alter, 1987). Although HIV-1 has been detected in
urine and saliva and can be transmitted by oral-genital contact (Kaplan et al., 1985;
Scully and Porter, 2000), there have been no substantiated reports of transmission
due to normal social contact (Operskalski and Mosley, 1986; Philipson and Lorincz,
1986; McDonald and Rogers, 1986; Friedland etal., 1986; Friedland et al., 1986),
nor have biting insects been implicated in transmission. The mode of transmission
may involve the transfer of free virions or HIV-1 infected cells (Fan and Peden,
1992; Zhu et al., 1995; Zacharopoulos et al., 1997).
Progression to AIDS
Initial (acute) infection with HIV-1 results in clinical symptoms within one to three
weeks in at least half of those newly infected. These symptoms are similar to
influenza infection or mononucleosis, along with a non-pruritic macular
erythematous rash (Fox et al., 1987). Shortly after acute infection, most patients
undergo seroconversion. This is followed by a period of clinical latency, which may
last from three to more than 15 years (Buchbinder et al., 1994), before AIDS
develops and the patient eventually dies of multiple infections and/or malignancies
(Castro et al., 1993). Progression to AIDS is accompanied by loss of CD4+ T-
lymphocytes with symptoms being noted at blood levels less than 500-cells/pl. AIDS
related complex (ARC) is a term used to indicate the presence of some immune
system abnormality and low-grade clinical disease (such as malaise) in HIV positive
patients who have yet to develop to 'full-blown AIDS' as indicated by the presence
24
of a defined set of infections or cancers (Castro et al., 1993) See table 1.1 for the
CDC clinical classification ofHIV-1 disease.
Although the vast majority of those who are infected with HIV-1 will develop
AIDS there is mounting evidence that some people are able to live with the virus for
extended periods of time without developing clinical disease. Such individuals are
termed 'long term non-progressors' or 'long term survivors', although only time will
tell if this group will also succumb to disease (Buchbinder et al., 1994). Factors
which affect the rate of progression to AIDS (for review see Levy, 1994), include
age (most HIV-1 infected infants progress relatively slowly, Blanche, 1996; Blanche
et al., 1997; Blanche, 1996), general health (the presence of other infections may
speed progression to AIDS, Wahl and Orenstein, 1997) and lifestyle (tobacco
smoking, Twigg et al., 1994, alcohol, Bagasra et al., 1993a, and drug use, Bagasra
and Pomerantz, 1993b, may all speed progression). Differences in the infecting
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(moderate to severe) /
cervical carcinoma in situ;
constitutional symptoms,
such as fever (28.5°C) or




least two distinct episodes








Candidiasis of bronchi, trachea or lungs;
candidiasis, oesophageal; cervical cancer,
invasive; coccidoidomycosis, disseminated or
extrapulmonary; crytoccosis, extrapulmonary;
cryptosporidiosis, chronic intestinal (> I
month's duration); cytomegalovirus disease
(other than liver, spleen or nodes); cytomegalo¬
virus retinitis (with loss of vision); encephalo¬
pathy, HIV-related; herpes simplex; chronic
ulcer(s) (>1 month's duration); or bronchitis,
pneumonitis, or oesophagitis; histoplasmosis,
disseminated or extrapulmonary; isosporiasis,
chronic intestinal (> 1 month's duration);
Kaposi's sarcoma; lymphoma, Burkitt's (or
equivalent term); lymphoma, immunoblastic (or
equivalent term); lymphoma, primary, or brain;
Mycobacterium avium complex or M. kansasii,
disseminated or extrapulmonary; Mycobacter¬
ium, other species or unidentified species,
disseminated or extrapulmonary; Pneumocystis
carinii pneumonia; pneumonia, persistent;
progressive multifocal leukoencephalopathy;
salmonella septicaemia, recurrent; toxoplas¬
mosis of brain; wasting syndrome due to HIV
(caption over)
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Table 1.1 (previous page). CDC revised classification system for HIV
infection. Persons with category C conditions or category 3 CD4+ T-cell
counts are reported as AIDS cases to the surveillance authorities in most
countries.
Table taken from Castro eta!., 1993
Type 1 human immunodeficiency virus (HIV-1)
HIV-1 is a lentivirus of the family Retroviridae. Lentiviruses have a long incubation
period and several are associated with the haematopoeitic and immune systems
(Levy, 1994). Related mammalian lentiviruses include feline immunodeficiency
virus (FIV, Yamamoto et al., 1987), and simian immunodeficiency virus (SIV, Kanki
et al., 1986; Guo et al., 1987; Fukasawa et al., 1988). Both FIV and SIV have been
used as models for HIV-1 infection with some success, although infection of animals
with these viruses, or the infection ofmonkeys with HIV-1 or HIV-2 does not
resemble human infection with HIV-1 in all aspects. Small animals are not infectable
by HIV-1 or FIIV-2 (Morrow et al., 1987). HIV-1 has the structure characteristic of a
lentivirus (figure 1.1); this consists of a truncated cone shaped core, which contains
two copies of a single-stranded RNA genome (figure 1.2) and the enzyme reverse
transcriptase. A protein matrix enclosed in a lipid envelope, which bears 72 knobs of
the envelope glycoprotein gpl60 surrounds the core. Gpl60 consists of an external
gpl20 peptide and a gp41 transmembrane component.
Because HIV-1 utilises a reverse transcriptase enzyme with a low fidelity
(Preston et al., 1988) it has a very high mutation rate and consequently much genetic
diversity. Viral diversity exists on several levels but is particularly important in the






Figure 1.1. Diagram of HIV-1 structure. HIV-1's genomic RNA and reverse
transcriptase (encoded by pol) is packaged inside a truncated-cone shaped
nucleocapsid made of p25 (also known as p24) protein subunits encoded by
the gag gene. HIV-1 is enveloped in a host cell derived lipid bilayer, which is
supported by a matrix of p17 subunits which are also gag encoded. Exposed
on the surface of the virion is gp41 and gp120, which are non-covalently
associated cleavage products of the gp160 protein encoded by the envgene.
Host membrane proteins such as MHC molecules and CD4 may also be
found on the virion envelope.




Figure 1.2. The genomic organisation of HIV-1. The approximately 10kb
genome is flanked 3' and 5' by LTRs (long terminal repeats) which act as
HIV-1 's promoter. Several of the genes are overlapping and tat and rev are
discontinuous. Full length, sub-genomic and spliced mRNA are therefore
required for complete translation of the viral genome. Gag encodes p25, p17,
p9 and p6 (figure 1.1). Pol codes for reverse transcriptase and RNase H. Env
encodes gp160. Other genes are involved in various stages of the HIV-1
replication cycle.
Figure redrawn from Levy, 1994. ©American Society for Microbiology, 1994.
HIV-1 eludes
The comparison of genomic sequences encoding the V3 region of gpl20 has allowed
twelve HIV-1 subtypes (clades) to be identified (A-J, plus the O grouping for outliers
and the N (New) grouping from Cameroon, Simon et ul., 1998). The clades show
broad but distinct geographic ranges. Clade A is prominent in central Africa, clade B
in north America and Europe, clade C in South Africa and India, clade D in central
Africa, clade E in Thailand and clade F in south America. Such a distribution pattern
could be due to patterns of spread, to differences in host immunology brought about
by the geographic distribution of selective pressure from other pathogens, and/or to
differences in the predominant transmission mode. The HIV-1 epidemic in Thailand
is largely due to heterosexual transmission. There is some suggestion (SotoRamirez
et al., 1996; Pope et al., 1997) that the clade E virus, common in Thailand, is
especially well suited to this transmission route as it is able to replicate better than
clade B viruses in Langerhans cells, which have been implicated in transmission
across the vaginal mucosa. Clade B viruses may be better adapted to the homosexual
and intravenous transmission routes most common in North America and Europe.
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CD4 and HIV-1
The main cell surface receptor for HIV-1 is the CD4 molecule (Dalgleish et al.,
1984); and CD4+ T-cells are a major cellular target for infection. The gpl20 envelope
glycoprotein on the virion surface binds to CD4 and then to a chemokine receptor
(usually CXCR-4 or CCR-5, D'Souza and Harden, 1996) on the target cell. After
CD4 and CCR-5 binding, a conformational change in gpl20 allows a fusogenic
region of gp41 to become exposed and mediate the fusion of the viral envelope with
the target cell membrane (Demaria and Bushkin, 1996; Pereira et al., 1997; Jones et
al., 1998; Ji et al., 1999; Mashikian et al., 1999). CD4 is an important molecule in
the immune system. In addition to acting as an MHC class II coreceptor on T-cells
(Janeway and Travers, 1996), it is also a receptor for interleukin-16 (IL-16, originally
called lymphocyte chemoattractant factor) on several immune cell types (Center et
al., 1995). CD4 is also found on activated cells of the monocyte, macrophage and
dendritic lineages; these cells have a role as antigen presenting cells (APCs) and are
infected by HIY-1 both in vitro and in vivo (BarreSinoussi, 1988; Spira et al., 1996).
Cellular tropism ofHIV-1
The crystal structure of the CD4 binding site has recently been published (Kwong et
al.. 1998) and involves several conserved residues in the gpl20 molecule. However,
it had long been suspected that HIV-1 required an additional, secondary, receptor in
order to infect cells. Research since 1995 (for reviews see D'Souza and Harden,
1996, and Berger, 1997) has identified the secondary receptor as a member of the
chemokine receptor family (see figure 1.4). At least 10 different chemokine receptors
have been identified. HIV-1 can utilise several of these molecules as a secondary
receptor but most commonly uses CCR-3, CCR-5 and/or CXCR-4 (Zhang and
Moore, 1999; for a review of chemokine and chemokine receptor function and
nomenclature see Baggiolini et al., 1997). The type of chemokine receptor which the
virion is able to use depends on the sequence of its gpl20. The V3 loop of gpl20 is
particularly important in determining coreceptor usage (Fouchier et al., 1992). The
viral DNA encoding this region is highly variable between viral strains and also
mutates during the course of infection allowing the virus to change its coreceptor
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usage, and therefore phenotype, with time (Schuitemaker et al., 1992). However, it
has recently been shown that conserved regions of gpl20 are also important in
binding to chemokine receptors (Verrier et al., 1997). The conformation of the V3
loop changes on CD4 binding (Demaria and Bushkin, 1996); this may allow
previously hidden conserved residues access to chemokine receptors (see figure 1.3
and Jones et al., 1998).
Because of a differential distribution of chemokine receptors between cell
types and a poorly understood apparent differential availability of these receptors for
gpl20 binding (Yi et al., 1999), the type of receptor that a particular gpl20 is able to
bind to influences the cellular tropism of the virion (Moore et al., 1997; Tscherning
et al., 1998). Most primary isolates of virus from patients, at least during the early
stages of infection, are macrophage- (M-) tropic, can infect both macrophages
(including alveolar macrophages, Park et al., 1999) and T-cells, and use the CCR-5
coreceptor, which is expressed on both cell types. Lab adapted strains grown for
many passages on T cell lines use CXCR-4 as a coreceptor. Although CXCR-4 is
present on both macrophages and T-cells, most T-cell line adapted viruses can only
use the CXCR-4 on T-cells or T-cell lines, the CXCR-4 coreceptor on macrophages
appears to be unavailable for binding in this case (Yi et al., 1999). Dual-tropic viral
strains (Doranz et al., 1996) which can use both CCR-5 and CXCR-4 are probably
more common in patients than solely CXCR-4 utilising T-tropic strains. Dual tropic
strains are able to infect both macrophages and T-cells; interestingly, macrophage
CXCR-4 appears to be available as an entry coreceptor for some dual-tropic HIV-1
strains (Yi et al., 1999). Dendritic cells (DCs) behave similarly to macrophages in
respect to HIV-1 tropism, presumably because of their similar chemokine receptor
expression. An alternative and complementary classification of HIV-1 tropism refers
to the chemokine receptor used as a coreceptor rather than the cellular range of
infectable targets. Under this scheme HIV-1 may be classified as R5 (CCR-5), X4
(CXCR-4) or R5X4 (CCR-5 and CXCR-4) tropic. It is important to realise that the
designation of viral strains to particular tropisms is only an approximation of reality
(Stent et al., 1997b) and that the two classification schemes outlined above do not
always equate with each other (Yi et al., 1999). Tropisms overlap and the
infectability of a cell depends on its activation state as well as its phenotype. Almost
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all HIV-1 strains enter and replicate in activated T-cells if added to cultures at
sufficiently high concentrations (Moore et al., 1997), and there are reports of certain
TCLA SI HIV-1 strains using CXCR-4 to infect macrophages, including CCR-5
deficient macrophages (Simmons et al., 1998; Verani et al., 1998). HIV-1 is able to
target a fairly wide range of cell types for infection (see Levy, 1994, for a
comprehensive list) and can use a variety of coreceptors to do this. Neuronal and
microglial HIV-1 infections are of importance in the aetiology of AIDS related
dementia; CCR-5 is the main coreceptor used to infect these cell types (Donaldson et
al., 1994; He et al., 1997; Albright et al., 1999). HIV-1 may also disrupt the function
of cells without infecting them or even binding to them.
HIV-1 membrane
Figure 1.3. Interactions leading to HIV-1 fusion with target cell. CD4
binds to gp120 and causes exposure of the V3 loop, allowing a chemokine
receptor to interact with the gp120 / gp41 / CD4 complex leading to the
exposure of a previously hidden gp41 fusion peptide. The hydrophobic fusion
peptide induces membrane attraction and destabilisation, resulting in the viral
envelope and plasmalemma fusing.
















Figure 1.4, HIV-1 interactions with APC cell surface receptors. HIV-1 and
its shed surface protein gp120 are able to interact with a number of receptor
molecules on APCs. Gp120 has binding sites for CD4 and chemokine
receptors (CKRs) such as CCR-5. It can also interact with Fc or complement
receptors via anti-HIV-1 antibodies. Outcomes of HIV-1 proteins binding to
APC receptors include infection of the cell by HIV-1 (a process which can be
enhanced by antibodies to HIV-1, antibody enhanced infection, Toth et al.,
1994), and phagocytosis of receptor complexes bound to soluble gp120,
leading to the loss of receptors such as CD4 and possible entry of the
receptor / gp120 complex into antigen processing pathways. It should be
noted that all of the HIV-1 receptors are linked to intra-cellular signalling
pathways, which may be activated on binding HIV-1 or gp120, and that this
could lead to disruption of the cell's function.
Figure adapted from Hewson eta/., 1999. Artwork by Nazir Lone. © Blackwell
Science Asia, 1999.
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Antigen presenting cells (APCs)
Introduction
Recognition of antigen by T-cells is a vital event in the immune system. It is
involved in the initiation of protective humoral and cell-mediated immunity and, via
antigen specific induction of anergy (Frauwirth et al., 2000; Oda et al., 2000;
Bouhdoud et at, 2000) and regulatory cells (Chen et at, 1994; Sakaguchi et at,
1996; Kumar and Sercarz, 1998), the induction of immune tolerance. Unlike B-cells,
T-cells are unable to respond to native antigen. T-cells require that antigen is first
processed into peptides of suitable length and presented to the T-cell receptor whilst
bound to an MHC molecule (Shimojo et at, 1990; Nygard et at, 1992; Marshall et
at, 1994). All nucleated cells have the ability to present peptides in MHC class I
molecules to CD8+ T-cells. However, CD4+ T-cells need peptide presented by MHC
class II, which is only expressed on a limited range of cell types. In order to be
activated, naive T-cells must receive additional, co-stimulatory signals, as well as
properly presented peptide (see below for details). Professional APCs have a vital
role in the immune system. As well as acting as effectors of the innate (phagocytic)
immune system (Janeway and Travers, 1996), APCs link the innate and adaptive
immune systems by efficiently presenting T-cells with processed antigen peptides
bound to MHC class I and II, and by giving T-cells additional, non-antigen-specific,
signals (co-stimulation, cytokines and others) to direct the T-cell in mounting an
appropriate response (Kuribayashi et at, 1997). Any disease that disrupts APCs
therefore has the potential to disrupt both innate and acquired immune responses.
Antigen presenting cell types
Although B-cells are able to act in many ways like professional antigen presenting
cells, the term APC is often used to mean macrophages and DCs. Haematopoiesis
begins with pluripotent stem cells (Till and McCulloch, 1961) in the bone marrow of
adults or in the foetal liver, which give rise to all blood cell types including
monocytes which circulate in the blood. Upon entering tissue, monocytes
differentiate into macrophages or DCs. Both these cell types are highly
heterogeneous in terms of their MHC and co-stimulatory molecule expression,
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cytokine profiles, phagocytic and migratory abilities. The local tissue
microenvironment is able to maintain specialised sub-types of macrophages and DCs
such as microglia in the brain (monocyte / macrophage-like) and Langerhans cells
(LCs) in the mucosa and skin (DC like). An APC's history of antigenic exposure also
influences its phenotype (e.g., Johnston et al., 1996).
Antigen presenting cell - CD4 T-cell interactions
The interaction between MHC class II-bound antigenic peptides on the surface of
antigen presenting cells (APCs), and the T-cell receptor (TCR) and CD4 on the
surface of T-helper cells is crucial to the initiation ofmost antigen specific immune
responses (Janeway and Travers, 1996). In addition to TCR interaction with antigen-
MHC II on the APC cell surface, the T-cell must receive co-stimulatory signals. If
the TCR is triggered in the absence of co-stimulation T-cells become anergic or
undergo apoptosis mediated through Fas / CD95-Fas-ligand interactions (Wesselborg
et al., 1993; Boehme et al., 1995; TucekSzabo et al., 1996; Arimilli et al., 1996;
Alberolalla et al., 1997; Chung et al., 1997; Wong et al., 1997; Maier and Greene,
1998; Walker et al., 1998). Thl cells are reported to be more sensitive to apoptosis
via this type of activation than Th2 cells due to their greater Fas-ligand expression
(Ramsdell et al., 1994; Zhang et al., 1997; Alberolalla et al., 1997; Oberg et al.,
1997; Ledru et al., 1998). Similarly if CD4 alone is cross-linked on the T-cell surface
either in vitro (Desbarats et al., 1996; Hashimoto et al., 1997) or in vivo (Howie et
al., 1994; Malcomson et al., 1997) death of the cell results. There are a variety of co-
stimulatory signals requiring cell-cell contact including ICAM-1 / LFA-1, CD40 /
CD40 ligand and CD28 / B7 all of which trigger intracellular activation pathways in
the T-cell (June et al., 1994; Durie et al., 1994; Croft and Dubey, 1997; Chambers
and Allison, 1997). Naive CD4+ T-cells have a greater co-stimulatory signal
requirement than memory CD4+ T-cells (Wingren et al., 1995; Dubey and Croft,
1996; Carter et al., 1998). In addition to these direct contact interactions, the APC
and other local tissue cells (e.g. other leukocytes, stromal cells, epithelial cells,
endothelial cells and fibroblasts) release cytokines and other soluble mediators,
which also stimulate intracellular activation pathways in the T-cell (Chatila et al.,
1987; Vink et al., 1990; McKay and Leigh, 1991; Murphy et al., 1994; Filler et al.,
34
1996; Rochester et al., 1996; Egan etal., 1996;Hilkens etal., 1996; Rasmussen et
al., 1997; Joseph et al., 1998). Macrophages, DCs and LCs all process and present
antigenic peptides in cell surface MHC II molecules (Hirschberg et al., 1982; Cohen
and Kaplan, 1983; Ashwell et al., 1984; Krieger et al., 1985; Kapsenberg et al.,
1986; Tiegs et al., 1990; Ellis et al., 1991). APCs with which T-cells interact can
differ in their cell-surface co-stimulatory molecule expression. The tissue
microenvironment, by determining the soluble mediator milieu, will also influence
signals received by T-cells. The overall balance of signals determines whether a
naive CD4+ T-cell differentiates into a Type 1 or a Type 2 helper cell or whether a
memory CD4+ T-cell becomes functional.
The functional ability of an APC (in common with many other cell types)
depends on the cell's lineage, history and its in vivo or in vitro microenvironment
(Winzler et al., 1997; Soares and Finn, 1998; Luft et al., 1998). Naive CD4+ T-cells
are preferentially activated by mature DCs compared to macrophages and B
lymphocytes, whilst memory T-cells can be activated by all three cell types (Croft,
1994; Dubey and Croft, 1996). Functional competence ofAPCs can change over
time. For example, LCs can phagocytose antigen but lack significant co-stimulatory
activity. When activated by uptake of antigen they migrate from the skin and travel
in the blood as veiled cells to the T-cell areas of lymph nodes where they once more
change their phenotype becoming functional DCs. Once in the lymph node they up-
regulate accessory molecules and cytokines and lose their phagocytic properties
(VanWilsem et al., 1994). Thus, during the maturation of a DC its functional role
changes from that of acquiring antigen, to transporting antigen, to stimulating T-cells
(Balfour et al., 1981; Streilein etal., 1990; Cumberbatch etal., 1991; VanWilsem et
al., 1994; Rattis et al., 1996; Udey, 1997; Davis et al., 1997).
APC - HIV-1 interactions
HIV-1 interacts with cells of the immune system in many different ways. Many of
the effects ofHIV-1 have been principally investigated using T-cells or T-cell lines,
but it has become obvious that the interaction of HIV-1 with cells extends much
further than simply infecting CD4+ T-cells. HIV-1 is able to target a wide range of
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cell types for productive infection (see Levy, 1994, for a comprehensive list) which
is a multistage process with possibilities for dysregulation of the immune system at
every step (Hewson et al., 1999). In addition HIV-1 may disrupt the function of, or
even kill, other immune cells without infecting them. Extracellular gpl20, present in
the serum ofHIV-1+ patients (Oh et al., 1992), can also alter the function of APCs.
HIV-1 as antigen
Infected individuals develop CD8+ cytotoxic T-cells which recognise epitopes on a
number ofHIV-1 proteins, including gpl20, and these may control initial infection
(Klein et al., 1998; Goh et al., 1999). The surface glycoprotein gpl20, probably
because of its exposed position on the virion surface, evokes an especially strong
antibody response (Spicer et al., 1999). However, the anti-gpl20 antibody response
is ultimately ineffective in controlling HIV-1 infection in most patients (Wyatt et al.,
1998a; Wyatt and Sodroski, 1998b) despite the ability ofmany anti-gpl20 antibodies
to block infection in vitro (McKnight et al., 1997; Fu et al., 1999). Gpl20 is not only
found on the virion surface, but can be shed into the extracellular compartment (Oh
et al., 1992) and is found in the plasmalemma of infected cells (Blumenthal et al.,
1994). In the extracellular compartment gpl20 can act as a T-cell (Laurence et al.,
1992) and B-cell (Karray and Zouali, 1997) superantigen, and cause the functional
loss of lymphocyte subsets. The anti-gpl20 antibody response ofmost patients is
highly skewed. Antibodies using the VH3 gene segment dominate normal human
antibody responses. However antibody responses to HIV-1 in infected individuals
rapidly lose any contribution from VH3 and there is over-representation of the VH4
locus. The deletion of VH3-using B-cells is attributed to a gpl20 superantigen
incorporating sites in the C2 and V4C4 domains of gpl20 (Karray and Zouali, 1997).
The exception to this is seen in long-term non-progressors who do have VH3
antibodies present in their serum but do not make antibodies to the superantigen
determinant (Jones et al., 1998).
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Gpl20 induces changes in APC cytokine production
Gpl20 in the absence of any other viral component is able to induce interferon (IFN,
mainly a with some y) production in PBMCs (Ankel et al., 1996). The inductive
effect of gpl20 is abrogated by the addition of soluble CD4 (sCD4) and is dependent
on the V3 loop. This suggests that binding and presumably the resultant clustering of
CD4 and a chemokine receptor is required and sufficient for IFN production to
result.
More recent work (Gessani et al., 1997) has shown that the ability of APCs to
produce cytokines in response to gpl20, and the ability of cells to respond to
cytokines can depend on the differentiation state of the cell. As monocytes
differentiate to macrophages they show an enhanced IFN-P production in response to
HIV-1 infection or LPS (bacterial lipopolysaccharide) or gpl20 treatment (Gessani et
al., 1997). Concomitant to this, the cells' sensitivity to IFN, as measured by the
induction of protection from VSV (vesicular stomatitis virus) granted by IFN-P,
increased with differentiation to macrophages because of up-regulation of IFN
receptors.
IL-10 secretion in response to gpl20 was also observed, but the level of this
did not depend on the cells' differentiation state. IL-10 secretion could cause the
switch from Thl to Th2 helper subtypes observed in FIIV-1 disease (Clerici and
Shearer, 1993). Cells only produced IL-12 in response to gpl20 if they had been
previously primed by IFN-p. Only macrophages could be primed by IFN-P,
presumably due to their greater sensitivity to this cytokine (Gessani et al., 1997).
The effects cytokines have on the rest of the immune system and on FIIV-1
replication are complex. IFN is able to down-regulate HIV-1 expression in
macrophages (Poli and Fauci, 1993). In contrast, TNF-a has been shown to up-
regulate HIV-1 expression in macrophages by most (Rabbi et al., 1997; Fortis et al.,
1999), but not all (Lane et al., 1999) researchers. The question of whether TNF-a
production is of benefit to either the patient or HIV-1 remains under debate and is
complicated by the fact that although TNF-a is generally regarded as increasing
HIV-1 production by cells, it can also cause an increased production of infection-
blocking cytokines (Lane et al., 1999) and an enhancement ofNK and LAK
mediated killing of infected cells (Fortis et al., 1999). The exact role ofmany
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cytokines, including the novel chemokines and other newly identified signalling
molecules, awaits further investigation.
Does HIV-1 induce a Thl to Th2 switch?
The Thl to Th2 switch hypothesis as proposed by Clerici and Shearer (Clerici and
Shearer, 1993) states that progression to AIDS is dependant on a switch from Thl to
Th2 as the dominant T-helper subset (figure 1.7). The evidence to support this
assertion includes the observation that in short-term PBMC culture, cells taken from
patients of increasing clinical progression show a concomitant increase in IL-4 and
IL-10 production and a loss of IL-2 and IFN-y production (Clerici and Shearer,
1993). In addition, data show that T-cell clones from HIV infected skin biopsies are
more likely to be classified as Th2 clones than clones derived from healthy control
skin (Romagnani et al., 1994a; Romagnani et al., 1994b). Clerici and Shearer show
that many HIV-1 exposed but uninfected individuals are able to generate strong Thl
type responses, and suggest that these individuals are protected from disease by the
failure to undergo the normal Thl to Th2 switch (Clerici and Shearer, 1993).
The mechanism by which the switch operates may involve T-cell or APC
produced cytokines to bias the Th response to Th2. For example, in PBMCs and lung
macrophages the HIV-1 protein Tat inhibits production of the Thl cytokine IL-12
(Ito et al., 1998).
There is, however, some evidence that argues against the Thl to Th2 switch
hypothesis (Graziosi et al., 1994; Maggi et al., 1994; Miedema et al., 1994). There
has been difficulty in reproducing the observations by Clerici and Shearer on IFN-y,
IL-1 and IL-4 production in short term PBMC culture system (Romagnani et al.,
1994a). There are arguments against using PBMCs for such experiments because as
well as containing Th-cells, PBMCs contain monocytes, B-cells, NK-cells and CD8+
T-cells all of which are capable of producing cytokines. The proportions and absolute
numbers of these different cell types change as disease progresses. Changes in the
cytokine profile attributed to a Th subtype switch could be due to selective deletion
of Th-cell subtypes. The T-cells present in skin biopsies may not reflect the types
found elsewhere in the body.
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The Thl to Th2 switch hypothesis has recently become more complicated
with evidence that Th2 and ThO cells are able to replicate HIV-1 more efficiently
than Thl cells (Maggi et al., 1994; Vyakarnam et al., 1995). Whether this translates
into a longer or shorter life span for the infected cells is unclear. IL-4 has been shown
to up-regulate, and IL-12 down-regulate CXCR-4 expression and therefore
infectability by the T-cell tropic HIV-1 strains associated with disease progression
(Meyaard et al., 1996; Klein et al., 1997; Suzuki et al., 1999). This observation
might argue for a Th2 (IL-4) shift increasing selective pressure on HIV-1 to use
CXCR-4 and explain why we see a shift in coreceptor usage from CCR-5 to CXCR-4
as disease progresses (Zhang et al., 1998). However, another Th2 cytokine, IL-10
increases CCR-5 (associated with macrophage tropism) expression (Graziosi et al.,
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Figure 1.5. HIV-1 control of antigen presentation and APC-T-cell
interactions. Anti-HIV-1 T-cell responses are observed in HIV-1 disease so
APCs must be able, on occasion, to present HIV-1 protein epitopes together
with costimulatory signals to T-cells. However, HIV-1 infection is able to
induce B7 (CD80) loss from the surface of APCs; this can result in antigen
(from HIV-1 and other pathogens) being presented to T-cells in a context
which, rather than activating the T-cell, can induce T-cell anergy or activation
induced cell death. As well as giving inappropriate signals to mature T-cells,
HIV-1 infected APCs can disrupt thymocyte development by inappropriate
intra-thymic signalling. HIV-1 infected APCs can also affect the nature of a
T-cell response by producing cytokines such as IFN and IL-10 which cause
immune deviation from a Th1 to a Th2 response, the Th2 response being
less effective at combating HIV-1 disease.
Figure adapted from Hewson etal., 1999. Artwork by Nazir Lone. © Blackwell
Science Asia, 1999.
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Gpl20 induces a cell-signalling defect
In T-cells gpl20 is able to cause dissociation of cell surface CD4 from cytoplasmic
p56lck (Hubert et al., 1995). This results in down-regulation ofCD4 expression (a
possible mechanism of avoiding HIV-1 superinfection) and an abrogation of
signalling through the TCR / CD3 complex (Hubert et al., 1995). In the context of
macrophages, CD4 plays a different role to that in T-cells (Center et al., 1995) but it
may still be associated with a protein kinase, which becomes phosphorylated
(activated) as a result of CD4 cross-linking by anti-CD4 antibody or gpl20. P56lck
has never been reported in primary monocytes or macrophages although other src
kinases such as Lyn are present (Bowers et al., 1997) and there is a single report of
p56kk being found in the monocytic cell line THP-1 and being phosphorylated in
response to CD4 cross linking by anti-CD4 or gpl20 (Hui et al., 1995). It is also
possible that gpl20 can inhibit signalling through CD4 in macrophages by causing
CD4 / src kinase dissociation and reduced CD4 expression.
Gpl20 may also interfere more directly with CD4 function by competing
with its other ligands (MHC class II on APCs and IL-16). It has also been suggested
(Levy, 1994), although not proven, that anti-idiotypic antibody mirroring gpl20 may
have a role in HIV-1 pathogenesis.
Other HIV-1 proteins induce cell-signalling defects
Nef and Vpu are two other HIV-1 proteins that have been shown to induce cell-
signalling defects in infected cells.
Many activities have been attributed to Nef; the function for which it evolved
is still not fully understood. It is needed to maintain high viral loads (Kestler et al.,
1991) and may achieve this by inhibiting the super-infection of cells (this could
result in the death of a cell before it had been used to produce many virions, De et
al., 1998) or by optimising protein sorting to the viral membrane during virus particle
assembly (Craig et al., 1998).
When the monocyte / macrophage-like cell line, U937, was transfected with
nefa down regulation of FcyRI and FcyRII, and a changed cytokine response to LPS
and PMA were observed (De et al., 1998). In myeloid cells neftransfection caused
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an up-regulation ofMHC class I surface expression, in contrast to T-cells where nef
transfection induced a down-regulation ofMHC class I (Peter, 1998) by causing
rapid endocytosis ofNef and MHC class I complexes (Schwartz et al., 1996). Nef
has also been demonstrated to induce a CD4 down-regulation, at least in T-cells
(Rhee and Marsh, 1994). The HIV-1 protein Vpu is unique among primate
Lentiviruses in being only found in HIV-1 and the closely related SIVcpz (Cullen,
1998), it complexes with nascent CD4 in the endoplasmic reticulum and leads to its
retention and degradation (Willey et al., 1992).
The role ofgpl20 in inducing leukocyte apoptosis
It has been reported (Bour et al., 1995) that gpl20 interacting with its receptors in the
absence of signalling through the TCR can lead to T-cell anergy and priming of the
T-cell for AICD (activation induced cell death, a form of apoptosis) upon receiving a
subsequent signal via the TCR. Whether gpl20 can prime APCs for apoptosis, and
what trigger would result in cell death is not known (figure 1.5).
It has also been reported (Cottrez et al., 1997) that HIV-1 infected APCs can
prime HIV-1-specific T-cells to undergo AICD. The priming of cells requires two
signals from the APC to the T cell to be delivered simultaneously. The first signal is
antigen specific and is delivered through the TCR. The second signal is delivered
(presumably via CD4 and/or chemokine receptors) by gpl20 expressed on the
surface of the APC. Experiments involving the transfection ofmonocytes to express
single HIV-1 proteins have shown that gpl60 alone is sufficient to constitute the
second signal and that no other viral component is required. The second signal can be
blocked, and cells rescued from AICD, by the addition of the CD4 ligand, IL-16
(Idziorek etal., 1998).
AICD can result in hidden damage to the immune system in the absence of a
significant decline in overall T-cell number. T-cell clones, that are required to
provide protection against HIV-1 and other pathogens present in the host, are
selectively destroyed because it is these T-cells which will receive antigen-specific
signals from APCs.
It has been reported that HIV-1 infection ofmacrophages leads to increased
expression of Fas ligand (FasL) by macrophages (Badley et al., 1996; Dockrell et al.,
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1998), and that this mediates apoptosis of uninfected T-cells (Badley et al., 1996).
Recent controversy over the reliability of anti-FasL reagents (Restifo, 2000),
however, casts doubt on the validity of these results.
HIV-1 infected APCs may be unable to deliver appropriate co-stimulatory
signals to CD4+ T-cells (Mosier and Sieburg, 1994); this could result in T-cell anergy
or apoptosis. Monocytes / macrophages in HIV-1 disease may produce subnormal
levels of IL-12 resulting in T-cell death (Gougeon and Montagnier, 1993b; Ameisen
et al., 1994; Ameisen et al., 1995). T-cell deletion in HIV-1 disease may be the result
of an HIV-1 encoded super-antigen; although this has yet to be identified, some
authors have suggested Nef as a candidate (Montagnier, 1995; DeSimone et al.,
1996). There is some evidence (Buttke and Sandstrom, 1994; Greenspan and
Aruoma, 1994) that the HIV-1 gene, Tat, can be secreted by infected cells and taken
up by surrounding non-infected cells (Frankel and Pabo, 1988; Zauli et al., 1992;
Westendorp et al., 1994). Once in cells, Tat can induce oxidative stress by activating
NF-kB and TNF-a expression (Dezube et al., 1992); such oxidative stress can prime
cells for apoptosis. Additionally, Tat may be able to directly down-regulate the
expression of bcl-2, an anti-apoptotic gene (Derossi et al., 1994).
Other HIV-1 proteins can be cytotoxic in isolation. Gp41 is toxic to cells
probably through increasing membrane permeability (Miller et al., 1993). Domains
ofNef, Tat and gp41 all show similarities to neurotoxins (Werner et al., 1991; Garry
and Koch, 1992). Nef can change the membrane potential of cells (Werner et al.,
1991) and Tat has been demonstrated to cause neurone death (Sabatier et al., 1991).
HIV-1 / cell binding and membrane fusion: potentialfor dysregulation
As discussed previously, HIV-1 binds to the surface of target cells by using gpl20,
which interacts with host CD4 and a chemokine receptor. Although both cellular
receptors are usually required for infection there have been reports (for example,
Livingstone et al., 1996) ofHIV-1 infected CD4" CD8+ T-cells. Possible mechanisms
for this include a CD4-independent infection mechanism (Clapham et al., 1996),
possibly involving the use of galactosylceramide (Hammache et al., 1996), or the
infection of double positive thymocytes. An alternative explanation would be that the
CD8+ T-cells became infected during activation, where a transient expression of CD4
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is seen (Flamand et al., 1998). This last mechanism would cause preferential loss of
the very CD8+ cells needed to protect against pathogens.
The efficiency of HIV-1 infection of APCs and other cell types bearing Fc
receptors or complement receptors can be enhanced by non-neutralising antibody, a
phenomenon known as antibody-dependent enhancement (ADE, Prohaszka et al.,
1997). In some studies (Toth et al., 1994) ADE abrogated the requirement for CD4
binding and allowed the infection of CD4" cells. In other studies (Perno et al., 1990)
CD4 / gp 120 binding was reported as essential for infection. Ligation of Fc receptors
and complement receptors must also have implications with respect to intracellular
signalling, regardless ofwhether infection results.
In some cases HIV-1 may bind to the surface of a cell in the absence of
envelope / plasmalemma fusion and without infection of the cell, possible by
DC-SIGN mediated interactions (Geijtenbeek et al., 2000a). This bound virion could
'piggy-back' on a migrating cell and lead to the dissemination of the virus. DCs have
been implicated in transporting bound virus from mucosal entry sites to lymph nodes
(Spira et al., 1996).
After virion binding, in order for infection to become established, the target
plasmalemma must fuse with the viral envelope. Fusion appears to be mediated by a
fusogenic portion of gp41 (Pereira et al., 1997). It is important to remember that both
the inner and outer lipid monolayers must fuse and that each fusion may be an
independent event. It is possible that partial-fusion could result in the core being
unable to enter the cytoplasm. Neutralising antibodies mostly act by preventing
virion binding (Chamat et al., 1992); some, especially those against gp41, may
interfere with the envelope protein's fusogenic function. Some anti-AIDS drugs also
work by disrupting plasmalemma / envelope fusion (see chapter 6).
Factors effecting HIV-1 infection and disease progression
Several host factors have been shown to effect HIV disease progression rate (for a
review see Roger, 1998). As well as providing clinically useful prognostic markers,
an understanding of the mechanisms involved in controlling infection and
progression rates may be helpful in the search for novel therapeutic approaches.
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Genetic factors so far identified as important include chemokine receptor
polymorphism (see below and chapter 3), HLA polymorphism and less clearly
defined host factors which contribute to differential levels of cytokine and
chemokine production and immune cell activity.
HLA polymorphisms and HIV-1 disease progression
HLA (MHC class I and II) genotype has been shown to influence the time taken for
HIV-1 disease to progress to AIDS. Certain alleles or allelic combinations (for
example, B27, B51 and (A25+TAP2.3) are protective, whilst other alleles such as
B37 and (B6+(TAP2.1 or TAP2.3) are associated with rapid progression (Saah et al.,
1998). HLA polymorphism may exert its effects through differences in HIV-1
antigen presentation causing different efficiencies of anti-HIV-1 immune response
(Tomiyama et al., 1997). An alternative explanation involves molecular mimicry.
The V3 loop of HIV-1 gpl20 mimics HLA DR5 and HLA DR6, and this is known to
influence the anti-HIV-1 TCR repertoire by the deletion of self reactive CD8+ T-cells
during central self-tolerance induction (Itescu et al., 1994).
HLA allele associations with disease progression rates may be due to genetic
linkage between HLA loci and other loci of the MHC such as those that code for the
TNF and complement components. TNF-a can induce HIV-1 infected cells to
produce virus through activation ofNF-KB. Polymorphisms of the tnf-a promoter
have been associated with differential rates of disease progression (Khoo et al., 1997;
Brinkman et al., 1997). The complement component, C4, has two null alleles, which
are associated with low plasma C4 concentrations, poor antibody responses and rapid
disease progression (Cameron et al., 1990; Hentges et al., 1992).
Other possibly important hostfactors
A Danish study (Garred et al., 1997) showed an association between homozygosity
for loci conferring low serum levels ofmannose binding protein (MBP) and
increased HIV-1 susceptibility and shorter survival time from AIDS diagnosis.
Many cytokines, especially those which are pro-inflammatory (TNF, IL-ip,
and IL-6) up-regulate viral replication in infected cells, whilst other cytokines (11-4,
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IL-10 and IFN-P) down-regulate HIV-1 production (Cohen et al., 1997a). It is
conceivable that genetic polymorphisms in the inducibility of such cytokines could
influence HIV-1 disease progression rate.
P-chemokines inhibit macrophage-tropic HIV-1 infection (Zagury et al.,
1998; Cota et al., 2000), and a-chemokines such as stromal cell-derived factor (SDF-
1) inhibit T-cell-tropic HIV-1 infection (Oberlin et al., 1996). A G to A substitution
in the promoter of sdf-1 has been shown to accelerate progression to AIDS (Winkler
et al., 1998; VanRij et al., 1998).
Virus genetic factors effecting HIV-1 disease progression
The lack ofHIV-1 disease progression in some long-term survivors (LTSs) can not
be attributed to any as yet identified host factors. An alternative explanation for the
lack of disease progression is that at least some of the LTSs are infected with HIV-1
of a low pathogenicity (Huang et al., 1998). Rapid clinical progression is associated
with rapid viral replication (Schuitemaker et al., 1992; Connor and Ho, 1994).
Defects in the viral genes nef vif vpr, vpu, tat, rev, gag and env have all been
associated with slowed replication or delayed clinical progression. (Kirchhoff et al.,
1995; Deacon et al., 1995; Michael et al., 1995a; Michael et al., 1995b; Premkumar
etal., 1996;Mariani et al., 1996; Wang et al., 1996; Zhang et al., 1997; Menzo et al.,
1998; Huang et al., 1998). A methionine to isoleucine substitution in the initial
amino-acyl residue of Gag and premature stop codons have been associated with
long-term survival (Huang et al., 1998). A G to A nucleotide substitution in the LTR
results in a low viral load and long-term survival (Zhang et al., 1997). A shift from a
CCR-5- to a CXCR-4-tropic virus population as controlled by the sequence of env is
associated with disease progression (Schuitemaker et al., 1992). LTSs have also been
identified infected with HIV-1 that carries a rare env mutation which renders the
virus nearly completely unable to infect CD4+ cell lines, activated PBMC or
macrophages (Menzo et al., 1998).
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Chemokine receptor polymorphisms and disease progression rate
The study of coreceptor usage has lead to some interesting clinical observations.
Ccr5 and ccr2 are both closely linked on chromosome 3p21 -22 (Martin et al.,
1998b). Ccr5 has three relatively common alleles; wildtype, and two mutations, the
A32 deletion (Mummidi et al., 1998) and the m303 premature truncation (Quillent et
al., 1998). The most frequent ccr5 null mutation is the A32 deletion which will be
discussed in detail in chapter 3. Both mutant alleles result in a failure of functional
receptor to appear on the cell surface. In populations of European descent,
homozygosity for a null mutation in the ccr5 gene is present at surprisingly high
frequencies; about 18% are heterozygous for a ccr5 mutation and about 1% are
homozygous (see chapter 3 and Landau, 1997).
The mutations do not confer a selective disadvantage on healthy individuals
but, at least when homozygous, protect the individual against infection by HIV-1 or
confer a long-term non-progressive disease course (Michael et al., 1997). The
reasons why such individuals do not become infected by virus utilising an alternative
coreceptor (X4 / T-tropic strains using CXCR-4 for example) are obscure. It could be
that M-tropic strains (using CCR-5) are responsible for the initial mucosal infection
of APCs required for sexual transmission ofHIV-1 (Landau, 1997). Mucosal
epithelia constitutively express the CXC chemokine SDF-1; this causes down-
modulation of CXCR-4 on mucosal and submucosal lymphocytes (Agace et al.,
2000). This may explain why transmission across mucosal surfaces is rarely
mediated by infection of T-cells with X4-tropic HIV-1 strains.
During asymptomatic HIV-1 infection, the virus replicates rapidly and with
low fidelity (Ho et al., 1995; Grossman et al., 1999). This produces a great deal of
diversity in viral proteins and can allow HIV-1 to evolve resistance to therapeutic
drugs. However, during the asymptomatic phase it is usually only possible to isolate
CCR-5 utilising virus. It is only during the symptomatic phase, when the immune
system collapses, that broadening of coreceptor usage is seen (Schuitemaker et al.,
1992). There is also a switch from the non-syncytium-inducing (NSI) to the more
cytopathic syncytium-inducing (SI) viral phenotype (Connor and Ho, 1994). It has
been suggested (Landau, 1997) that in the early-stages of infection the immune
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system suppresses viruses with expanded coreceptor specificity, although the
mechanism by which this would be achieved remains obscure.
The extent of protection from infection and disease progression gained by the
ccr5 wt/A32 genotype is controversial. Protection is probably only partial and may
only be from transmission by heterosexual sex and not from homosexual and inter-
venous infection routes (Hoffman et al., 1997; Edelstein et al., 1997; Rousseau et al.,
1997; Roger, 1998). A ccr2b mutation, 641 (valine to isoleucine substitution) has also
been epidemiologically linked to reduced disease progression rate in HIV-1 +
individuals (Kostrikis et al., 1998; Roger, 1998; EugenOlsen et al., 1998;
Magierowska et al., 1999). The amino-acyl residue substitution manifested in the 641
allele is conservative and found in a trans-membrane region of the protein. This
observation, together with the fact that HIV-1 rarely uses CCR-2b as an important
coreceptor (Zhang et al., 1998), suggests that the ccr2b64Iallele may not effect
disease progression directly. It is possible that the ccr2b64I allele is a linkage marker
for another locus that is able to confer protection. One candidate locus to show a
linkage to ccr2b is the ccr5 promoter (ccr5p). An A/G polymorphism at the ccr5p
locus has been linked to lower promoter activity and a progression to AIDS three or
four years more slowly than the wildtype ccr5p (McDermott et al., 1998; Garred,
1998). Alternatively, the ccr2b64I allele may influence chemokine secretion or
CCR-5 or CXCR-4 expression (Horuk, 1999). In the absence of any demonstrated
effect of the ccr2b64I allele on ccr5 mRNA levels (Mariani et al., 1999), it has
recently been suggested that the mutant form ofCCR-2b is able to form a
heterodimer with wildtype CCR-5 and sequester this in a form unusable to HIV-1
(Mellado et al., 1999).
HIV-1 replicative cycle
After fusion with a cell, the core of the HIV-1 particle enters the host cytoplasm, and
the genome and reverse transcriptase molecules are unpacked. The single-stranded
RNA genome is reverse transcribed and eventually forms double-stranded DNA.
This DNA is then transported to the cell nucleus where it is circularised and
integrated into a random site on the host DNA (Varmus, 1988). Non-integrated viral
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DNA may be able to produce infectious HIV-1, but integration is a requirement for
efficient, long-term virion production (Stevenson et al., 1990).
HIV-1 can enter resting CD4+ T-cells, and the initiation of reverse
transcription can take place in these cells (Sun et al., 1997). Formation of the full
length viral DNA requires the cell to be activated by TCR ligation (signal one), a
signal which normally regulates the Go to Gi transition. Transport of the viral DNA
to the nucleus of T-cells to allow for integration requires an additional signal (signal
two, co-stimulation via CD28 ligation). The second signal was shown to be IL-2
receptor dependent and sensitive to cyclosporin A (Sun et al., 1997). The signals
required to stimulate HIV-1 production in APCs may be different from those
required by T-cells; but the differentiation / activation state of the cell will still be
important (figure 1.6). For discussion of the dynamics of HIV-1 replication, see
(Zack et al., 1990; Zack et al., 1992; Finzi and Siliciano, 1998; Grossman et al.,
1999)
Although macrophages express less CD4 than their monocyte precursors,
macrophages are more susceptible than monocytes to HIV-1 infection (Valentin et
al., 1991). In contrast to resting T-cells, non-dividing, resting macrophages can
become productively infected (Weinberg et al., 1991). However, macrophages
produce HIV-1 at a slower rate than do T-cells. This may be a result of smaller
intracellular pools of nucleotides and other precursors in macrophages, which have
slower division rates than T-cells.
GM-CSF has been implicated in some of the signals controlling HIV-1
production by APCs of the monocyte / macrophage lineage. GM-CSF, a cytokine
produced by many cell types including activated T-cells, can effect the replication of
HIV-1 in cells ofmacrophage lineage at several levels (Crowe and Lopez, 1997;
Manfredi et al., 1997; Kedzierska et al., 1998).
GM-CSF promotes monocyte survival through inhibition of apoptosis and
stimulation of proliferation, which increases the number ofHIV-1 targets. GM-CSF
also promotes the differentiation ofmonocytes. GM-CSF on its own stimulates
differentiation to macrophages; whilst with IL-4 also present, monocytes are driven
to become dendritic-like cells (Kiertscher and Roth, 1996; Chapuis et al., 1997).
Differentiation ofmonocytes down either of these pathways appears to result in the
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down regulation of surface CD 14 (Kruger et al., 1996), although one study (Bagasra
et al., 1992) claims that in the monocyte / macrophage cell line Ul, GM-CSF up-
regulates CD 14 expression. GM-CSF-driven differentiation may be important in
HIV-1 disease because it turns monocytes, cells that are relatively resistant to
infection, into more likely target cells. GM-CSF sources include macrophages /
monocytes (Sasaki et al., 1999; Malur et al., 1999); epithelial cells of the nose
(Terada et al., 1999), bronchioles (Sanders et al., 1999), colonic mucosa (McCartney
et al., 1999), and retina (Crane et al., 1999); nasal endothelial cells (Terada et al.,
1999); synoviocytes (Breese et al., 1999); and airway smooth muscle (Hallsworth et
al., 1999) and fibroblasts (Spoelstra et al., 1999).








Figure 1.6. Regulation of virus production by APCs. The rate of HIV-1
production by APCs is highly influenced by the activation state of the cell.
Signalling through cell surface receptors such as CD4 (see figure 1.4) can
effect the cellular activation state. Cytokines produced by other cells in
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response to HIV-1 or other pathogens also have an influence on HIV-1
production. IFN and IL-10 have been shown to down regulate HIV-1
production, other cytokines such as TNF-a may stimulate an increase in
HIV-1 production. The cell's maturation / differentiation state, as influenced
by the tissue microenvironment and cytokines such as GM-CSF, can alter the
cell's susceptibility to infection, or the rate of HIV-1 production by an infected
cell.
Figure adapted from Hewson et al., 1999. Artwork by Nazir Lone. © Blackwell
Science Asia, 1999.
The long terminal repeat (LTR): HIV-l'spromoter
After HIV-1 DNA has been integrated into a host chromosome, the production of
new virions requires the transcription, by host transcriptases, of the provirus to
produce both viral mRNA and genomic viral RNA for packaging. Transcription of
viral genes is under the control of the LTR, a viral promoter found directly 3' and 5'
to the viral genes. The effects of cellular activation and cytokines on HIV-1
expression can be explained in terms of the transcriptional effects on the LTR
(Vicenzi et al., 1997; Rabbi et al., 1997; Roebuck and Saifuddin, 1999).
The initiation ofHIV-1 transcription is under the control of cellular factors
which bind to the LTR. Nuclear factor-kb (NF-kB), nuclear factor of activated
T-cells (NFAT), activation protein 1 (AP-1, consisting of a Jun / Fos heterodimer)
and Sp-1 have all been shown to activate HIV-1 transcription (for reviews see
Gaynor, 1992; Roebuck and Saifuddin, 1999). Once transcription has begun, the viral
protein Tat (transactivator) can interact with the tar regulatory element and the
requirement for cellular transcription factors may be reduced.
The transcription factor NF-kB in resting T-cells is sequestered in an inactive
form bound to an inhibitory subunit, I-kB. Activation signals received by the cell
through the TCR have the downstream effect of phosphorylating I-kB; this allows
NF-kB to be released, bind to, and activate both host and viral genes (Briant et al.,
1998). Alcami et al., 1995, showed that NF-kB transcriptional activation is an
absolute requirement for HIV-1 transcription and that Tat / tar mediated
amplification can only occur as a result of earlier NF-kB effects.
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CD 14 levels can also be important in the control of HIV-1 expression. CD 14
acts as a receptor for bacterial lipopolysaccharide (LPS) / LPS binding protein
complexes and thus mediates responses to LPS (Wright et al., 1990). CD 14,
therefore, has a role in mediating LPS induced up-regulation ofHIV-1 expression in
HIV-1 infected monocytes; anti-CD 14 antibodies abrogate this up-regulation
(Bagasra et al., 1992; Kedzierska et al., 1998).
As mentioned above GM-CSF has been shown to have an effect on CD 14
expression (Kruger et al., 1996) as well as an effect on HIV-1 expression by
enhancing in vitro virus production in primary monocytes and macrophages, but not
in T-cells or LCs (Crowe and Lopez, 1997). See Vicenzi et al., 1997, for a discussion
of the role of other cytokines and chemokines in HIV-1 replication.
Work on the U937 monocytic cell line (Thornton et al., 1996), produced
evidence that HIV-1 can subvert the normally anti-viral interferon response to reduce
its control over viral replication. HIV-1 has a sequence in its regulatory region
mimicking the IFN-stimulated response element (ISRE). The ISRE normally
activates transcription of anti-viral defence genes in response to the binding of a
member of the IFN regulatory factor (IRF) family. Use of IRF-dependent
transcription could be of advantage to HIV-1 because IRF proteins are activated on
viral infection.
HIV-1 induced syncytia: implicationsfor HIV-1 transcription
An important in vivo and in vitro feature ofHIV-1 is its ability to induce syncytia
(multinucleate cells) by the fusion of an infected cell with other, infected or
uninfected, cells (figure 1.7). Cell to cell fusion and syncytia formation involves
CD4, a chemokine receptor, gpl20 and gp41; it appears to be similar to cell / virion
fusion (Levy, 1994). Fusion into syncytia may result from gpl60 leaking onto the
plasmalemma of infected cells and interacting with CD4 and chemokine receptors on
other cells. Usually primary macrophage tropic strains, using CCR-5, do not form
syncytia in T-cell lines, whereas viruses able to utilise CXCR-4 often do. The
categorisation of strains into syncytium inducing (SI) and non-SI (NSI) phenotypes
based on coreceptor usage is, undoubtedly, an over simplification; although
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coreceptor usage must be important (Moore et al., 1997) the activity of nef is also
involved (Horuk, 1999).
It has been suggested (Burke, 1997) that cell-to-cell fusion is an important
HIV-1 evolutionary strategy, analogous to sex, which facilitates recombination
between viral strains by allowing them to come together in a syncytium, a structure
likened to a mating ground. From a molecular-biological point of view, syncytium
formation may be important in bringing together transcription factors from different
cells to allow efficient HIV-1 expression. It has been suggested (GranelliPiperno et
al., 1995) that syncytium formation could allow HIV-1 replication to take place in
non-activated memory T-cells. Experiments have shown that NF-kB and Sp-1 are
both vital transcription factors for HIV-1. Non-activated T cells fail to express HIV-1
because they contain Sp-1 but not NF-kB. Purified DCs fail to support HIV-1
replication because they lack Sp-1, despite containing high levels ofNF-kB. DC /
T-cell syncytia bring together the two factors and allow up-regulation of viral












Figure 1.7. Other HIV-1 / APC induced cellular damage. HIV-1 infected
macrophages have been shown to produce nitric oxide, which is a
neurotoxin. The damage done to neurons in this way may contribute to AIDS-
related dementia. Immune system damage may result from the HIV-1
proteins gp41 and gp120 leaking onto the plasmalemma of infected cells. In
the case of gp41, this can be directly cytotoxic due to the formation of pores
in the cell membrane. Leakage of viral proteins to the cell surface can also
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induce cell / cell fusion in a fashion similar to cell / virion fusion. The resulting
syncytium not only results in the loss of the daughter cells, but the cell / cell
fusion can be advantageous to the virus as it brings nuclear factors important
for HIV-1 transcription such as NF-kB and Sp1 together in the same cell; this
allows for accelerated virus production. Syncytia may also be sites at which
inter-strain recombination can take place, increasing virus genome variability.
Figure adapted from Hewson et al., 1999. Artwork by Nazir Lone. © Blackwell
Science Asia, 1999.
Immune status andHIV-1 replication rate
The activation state of the host immune system has an important control over HIV-1
replication rates. Vaccination and infection can both activate immune cells, and lead
to an increase in viremia (Wahl and Orenstein, 1997). See Rousseau et al., 1999, for
a recent review of the responses ofHIV-1 infected individuals to a range of
vaccinations. Its seems that the stage ofHIV-1 disease progression is an important
factor when assessing the risks and benefits of offering vaccinations to HIV-1
infected people. Vaccination early in the course ofHIV-1 infection and when
HAART is being successfully used can elicit beneficial protective immunity to
secondary infections. Later vaccination is more likely to promote HIV-1 replication.
There is an addition risk associated with the use of live-attenuated vaccines in that
the vaccination microbe may be pathogenic in a recipient with an immune system
weakened by HIV-1. Increased HIV-1 replication under the influence of other
microbes can be a result of changes in immune cell activation or of a more direct
interaction. For example, early gene-products of human herpes virus can exert an
effect on HIV-l's LTR and enhance HIV-1 expression (Gaynor, 1992).
Recently attention has been given to the therapeutic activation of T-cells with
IL-2 under the cover of highly active anti-retrovirus therapy (HAART) in order to
flush HIV-1 out of latently infected T-cells (Chun et al.. 1999).
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Loss of APC numbers in HIV-1 disease
HIV-1 disease leads to a reduction in the number of APCs in the periphery (losses in
skin, blood and gut have all been described, Knight and Patterson, 1997b). There are
several possible reasons for this loss in cell number (Ng et al., 1996).
The loss of cells may be due to the lysis of infected cells by the CTL
(cytotoxic T lymphocyte) response. DCs can be targeted in vitro by anti-HIV-1 CTLs
(Knight and Patterson, 1997b). It may be that the killing of an APC by the CTL that
it has just activated is part of a normal negative-feedback mechanism of controlling
excessive T-cell activation. Such a mechanism would only become a problem in
HIV-1 disease because of the persistence of infection (leading to sustained, long-
term loss ofAPCs) and the reduced capacity for APC replacement (see below).
Loss of LCs from the skin (Knight et al., 1997a) may simply reflect migration
of cells from the periphery to the lymph nodes in response to activation. APCs may
be lost by being fused with T-cells during syncytia formation or they may die in situ
by apoptosis as a direct result of infection. Alternatively a reduction in LC numbers
in skin could be due to a failure of haematopoiesis or a failure of tissue colonisation
by cells from bone marrow progenitors. CD34+ bone marrow derived stem cells
show little capacity to develop (morphologically or functionally) into DCs in patients
with advanced AIDS (Knight and Patterson, 1997b).
Levy (1994) suggests that host cells could be destroyed in an autoimmune
fashion by other immunocytes which recognise host proteins on these cells as foreign
because they have previously been seen linked to an HIV-1 protein (gpl20, for
example) acting as a hapten. Antibodies to cellular proteins including CD4 and a
wide range of autoimmune disorders have been detected in HIV-1 infection (Chams
et al., 1988; Schattner and Ragerzisman, 1990; Caporossi et al., 1998). It is possible
that loss of APCs is due to targeting by autoimmune mechanisms.
Damage done to the immune system by APCs in the presence ofHIV-1
As has been previously noted, HIV-1 infected APCs or APCs that have interacted
with HIV-1 proteins show a reduced capacity to stimulate T-cell effector function
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(Roberts et al., 1994), and may even prime T-cells for AICD (Banda et al., 1992).
The decline in stimulatory capacity may result from the loss of immunologically
important APC surface molecules in HIV-1 infection. Gabrilovich et al., 1994,
showed that infected DCs down-regulate MHC class II, CD44 and CD54.
APCs are not only important in initiating an immune response, but in
determining the direction which the response takes. It has been suggested (Kuchroo
et al., 1995) that the divergence of the T-cell response to the Thl (cytotoxic) or Th2
(humoral) subtype is controlled by differential expression of B7.1 (CD80) and B7.2
(CD86) by APCs. A switch from a Thl (IL-2 and IFN-y mediated) to a Th2 (IL-4
and IL-10 mediated) response has been suggested as a critical step in HIV-1-disease
establishment and progression. This switch is absent in many seronegative HIV-1-
exposed ('resistant') individuals who continue to generate Thl type responses to
HIV-1 (Clerici and Shearer, 1993).
APC type and the concentration and type of antigen may be important in
fixing the response type (Knight and Patterson, 1997b). It would be interesting to
know to what extent HIV-1 is able to instruct the APC to take a Thl to Th2 switch
(caused by changing expression of B7.1/B7.2 or other surface molecules or by
changes in APC cytokine production).
APCs not only exert an effect on T-cells during the induction of an immune
response. They are important regulators of T-cell development (figure 1.7). Infected
DCs in the thymus may result in inappropriate signalling to developing thymocytes;
this would result in the development of an abnormal T-cell repertoire (Knight and
Patterson, 1997b). Thymus volume declines during disease progression (Vigano et
al., 1999; Vigano et al., 2000)
In her controversial danger hypothesis, Matzinger (1994) suggests a
mechanism whereby LCs in the skin can induce tolerance (i.e., anergy or death) in
CD4+ T-cells. Her idea is that LCs in the skin express self-antigen / MHC class II
complexes but not co-stimulatory molecules. T-cells interacting with these LCs
would receive signal one but not signal two and would be tolerised. Matzinger
suggests that tissue LCs might phagocytose and present environmental antigen, but
viral antigen might also be presented by LCs (at the site of initial infection) to virus
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specific CD4+ T-cells in the absence of signal two, this would result in the deletion
or anergy of these T-cells.
Of course, it is not only cells of the immune system that are damaged by
HIV-1. HIV-1 infection induces macrophages to produce nitric oxide (Bukrinsky et
al., 1995), a molecule implicated in the neurological disease seen in some AIDS
patients (figure 1.7).
Role of APCs in HIV-1 dissemination
After sexual transmission, HIV-1 is initially localised to the point of entry, but AIDS
is a systemic disease with HIV-1 infecting cells throughout the body. APCs have
been implicated in allowing virus to spread throughout the body.
SIV infection in rhesus macaques has been used as a model for the early
events in heterosexual HIV-1 infection (Miller et al., 1989; Spira et al., 1996). When
macaques are inoculated intravaginally with SIV, the virus first appears in, or bound
to, DCs of the lamina propria of the vaginal mucosa. Within two days, infected cells
are detectable in the draining lymph nodes and by day five, the infection becomes
systemic with SIV detectable in the blood (Spira et al., 1996).
DCs can bind HIV-1 and once these cells have matured and are expressing
co-stimulatory molecules (this would be in the lymph node in vivo) they can
stimulate T-cells (Hubert et al., 1995). The stimulation of the T-cells activates them
and allows them to support productive infection by the virus passed from the infected
DCs. The recently described DC-SIGN integrin (Geijtenbeek et al., 1999; Steinman,
2000; Geijtenbeek et al., 2000a; Geijtenbeek et al., 2000b) provides a mechanism for
HIV-1 to piggy-back onto DCs and be transported by them without necessarily
infecting them.
Conclusion
It has been 19 years since AIDS was first identified. About 40 million people are
now infected with HIV-1 (1% of the world's sexually active population, WHO 1999
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figures). There have been some recent advances in treatment (for review see
Clumeck and Hermans, 1996) which have allowed the life span ofHIV-1+ patients
who can afford these new therapies to be increased. Most of the progress in drug
treatment has come from an increased understanding ofHIV-1 virology and
biochemistry. However, in order to find improved treatments and eventually a cure,
and to start to think about reconstructing a battered immune system after successful
treatment to reduce viral load, a greater understanding of immunology will be
required.
The APC plays a central role in the immune system regulating the actions of
other cell types. The goal ofHIV vaccine development may also be served by a
greater understanding of APC interactions with the viral components of a putative
vaccine. A successful outcome of vaccination (the only option for counties that can't
afford HAART treatment) depends on appropriate APC / HIV interactions as the first
stage of a protective immune response, rather than APC / HIV interactions acting to
cause immune system dysfunction and disruption.




The work described in this thesis was undertaken in order to investigate some of the
interactions ofHIV-1 with antigen presenting cells. The work aimed to uncover some
of the fundamental processes ofAPC immunology, such as the role of APCs in
T-cell activation verus tolerance induction, by learning how HIV-1 is able to subvert
them.
Work was particularly focused on the HIV-1 envelope glycoprotein, gpl20,
and examinations of how this protein is able to dysregulate APCs through
interactions with cell surface receptors (CD4 and chemokine receptors). It was also
an aim to evaluate potential therapeutic agents and vaccine candidates with a mode
of action based on blocking gp 120 / APC interactions.
Specific questions
• CHAPTER 3. What is the incidence of the ccr5A32 allele in the east of
Scotland? How does the allele frequency fit with world-wide distribution
patterns?
• CHAPTER 4. How does gpl20 alter the cell-surface phenotype of APCs? Does
gpl20 receptor tropism or APC chemokine receptor genotype make any
difference to any changes?
• CHAPTER 5. Do cellular changes induced by gpl20 have any functional
consequences for the APC?
• CHAPTER 5. Can gpl20-induced changes to APCs be explained as a
subversion of physiological processes of tolerance induction?
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• CHAPTER 6. Can potential pharmaceutical agents aimed at preventing HIV-1





Unless otherwise stated, all chemicals were bought from Sigma Ltd (Poole, Dorset,
UK) or Fishers Scientific Ltd (Loughborough, Leicestershire, UK). All cell culture
reagents and plasticware were bought from Life Technologies Ltd (Paisley,
Strathclyde, UK).
See appendix 1 for recipes of solutions described.
Cell separation and tissue culture
Sterile technique was used for all cell preparation and tissue culture steps.
Source ofmaterial
Anonymous single-donor Buffy coats were obtained from the Scottish National
Blood Transfusion Service (SNBTS). These were made from single unit (450ml)
blood donations from individuals giving blood on the previous day in the East of
Scotland region. Occasionally, whole blood was taken from healthy laboratory
colleagues. In both cases, blood was drawn into containers with anticoagulant present
(1 unit per ml of porcine heparin in the case of blood drawn within the Pathology and
Respiratory Medicine Departments). Blood collected without anticoagulant for the
production of human AB serum was also obtained from the SNBTS.
All blood donors to SNBTS were screened to exclude donors at high risk of
carrying blood-borne diseases. Male homosexuals, sex-workers, intravenous drug
users and those returning from high-risk countries are among those excluded. Blood
donations were screened by the SNBTS for antibodies against HIV-1, HIV-2,
hepatitis B, hepatitis C and syphilis. Only blood which was negative in these tests
was used. Other blood borne organisms such as cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) may have been present in the blood donations used for this
work.
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Precautions for the safe handling ofpotentially infective material
Blood from the SNBTS was assumed to be of low infection risk. However, good
laboratory practice and 'Universal Precautions' (Kibber, 1997) were adopted. All
laboratory personnel working with human material were vaccinated against hepatitis
B. Work with viable HIV-1 was carried out in the category-three pathogen-
containment facility at the University of Edinburgh Centre for HIV Research.
Training and supervision in accordance with the Centre's local rules and code of
practice was undertaken.
Preparation of offthe clot' human serum
Units ofwhole group AB blood were collected by the SNBTS without an
anticoagulant. This blood arrived as a large clot in a bag surrounded by serum. One
of the outlet tubes to the bag was surface-sterilised with 70% ethanol and cut. The
serum (about 300ml in total) was squeezed into 50ml collection tubes. The serum
was centrifuged at 300g for 10 minutes to pellet any remaining cells and small clots.
Additional centrifugation was carried out, if required, until the serum had attained
clarity. The resultant serum was then heated in a 56°C water-bath for 1 hour to
inactivate complement. After a final 300g7 10 minute centrifugation the serum
supernatant was 0.2pm filter sterilised, aliquoted, and stored at -20°C until required.
Isolation ofperipheral blood mononuclear cells (PBMCs)
Based on method of Valentin et al., 1991. Mononuclear cells (PBMCs) were isolated
from single-donor Buffy coats or whole blood by centrifugation over Lymphoprep™
(Nycomed Pharma AS, Oslo, Norway). Buffy coat or whole blood volume was made
up to 200ml with PBS. 25ml aliquots of this blood were then carefully layered onto
15ml of Lymphoprep™ in eight 50ml centrifuge tubes. The tubes were spun at 1000g
for 18 minutes with no centrifuge brake. After centrifugation the erythrocytes and
granulocytes had sedimented and the PBMCs were sucked out of their position at the
Lymphoprep™-serum interface using pastettes. The PBMCs were washed in PBS,
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centrifuged for 10 minutes at 300g and resuspended in 100ml of fresh PBS. The
PBMCs were then further purified by a second centrifugation over four tubes of
Lymphoprep™ and a second PBS wash. The two stage Lymphoprep™ procedure
resulted in PMBCs completely free of red cell contamination and with much reduced
levels of platelet contamination. A small sample (about 106 cells) of PBMC was
retained from each Buffy coat for genotyping purposes.
Cryo-preservation ofcells
Cell lines, PBMCs or fractions thereofwere frozen for future use by suspending
washed cells at about 5xl07mr' in 'freezing mix' (90% FCS, 10% DMSO). Cells
were then aliquoted into 1.5ml cryo-tubes. Cells were frozen slowly by wrapping
them in paper tissue and placing them in an expanded polystyrene box in a -70°C
freezer for at least 2 days. For long term storage, cells were transferred to liquid
nitrogen. Cells were thawed at room temperature and the outside of the cryo-tube
was sterilised with 70% ethanol. The defrosted cells were washed several times in
PBS or medium to remove residues ofDMSO. Viable cell recovery was usually
about 70%. If required, dead cells were removed by centrifuging the cells over
Lymphoprep™ in a method similar to that described above for the isolation of
PBMCs.
Macrophage culture
See Bennett and Breit, 1994, for a discussion of the variables involved in
macrophage isolation and culture of relevance to HIV research. PBMCs were plated
onto tissue culture plates or placed into tissue culture flasks placed on their sides at
5xl06 cells ml"1 in serum-free IMDM containing antibiotics (50 IU ml"1 penicillin
and 50pg ml"1 streptomycin). Monocytes were allowed to adhere to the tissue culture
plastic for one hour in a 5% CO2 humidified 37°C incubator. Non-adherent cells
were removed and retained for T-cell culture if required. Adherent monocytes were
washed several times with PBS and fresh medium (IMDM + antibiotics as above +
5% heat-inactivated AB normal human serum, SNBTS) was added. Cells were
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cultured overnight at 37°C with 5% CC^and humidity. The following day floating
cells were removed. Adherent cells were cultured for a further 4 to 7 days before use.
At this time they were typically >95% CD14+, MHCII+ and CD4+ macrophages by
flow cytometry.
Dendritic and Langerhans cell differentiation and culture
Based on methods of Kiertscher and Roth, 1996; Jonuleit et al., 1996; Chapuis et al.,
1997; Buelens et al., 1997; Palucka et al., 1998; Woodhead et al., 1998. The majority
of human B-cells from most donors are EBV+ (Ferres et al., 1995; Fathalla et al.,
1996). EBV can transform B-cells and occasionally, in culture, a B-lymphoblast
clone can proliferate out of control and take over the cell culture. Because IL-4 is a
B-cell growth factor (Floward et al., 1983; Farrar et al., 1983) and the dendritic cell
differentiation method described here uses IL-4 supplemented medium, dendritic cell
cultures are more prone than macrophage cultures to contamination by an EBV+ B-
lymphoblast. Thorough washing of lymphocytes when setting up dendritic cell
cultures reduces the chance of B-lymphoblast contamination. All dendritic cell
cultures were regularly checked for contamination and any showing blasting
lymphocytes were discarded.
Dendritic cells were differentiated from monocytes. Starting with PBMCs the
method for macrophage culture as detailed above was followed with the addition of
recombinant IL-4 (250 U ml" , R&D Systems Europe Ltd., Abingdon, Oxfordshire,
UK) and GM-CSF (500 U ml"1, R&D Systems Europe Ltd.) to the first serum-
containing medium. On day 3, cells were fed with an equal volume of fresh
additional cytokine-containing medium. Cells were used on day 7. A Langerhans-
like cell type differentiated on the addition of 50 U ml"1 of TNF-a (NIBSC
Centralised Facility for AIDS Reagents, South Mimms, Hertfordshire, UK) one day




Using commercially available columns (Human T-cell CD4 subset column kit, R&D
Systems Europe Ltd.) this method was used to purify CD4+ T-cells from PBMC. The
manufacturer's instructions were followed and all reagents were provided in the kit.
Briefly, a PBMC suspension was incubated with a mixture of monoclonal antibodies
and loaded onto the depletion column. The column contained anti-Ig coated glass
beads. B-cells and CD8+ T-cells were bound and retained in the column by F(ab)
interactions. Monocytes were retained by Fc interactions. The column eluate
contained a highly enriched population of CD4+ T-cells.
Gamma irradiation ofPBMC
When PBMCs were used as antigen presenting cells in the maintenance of the HA 1.7
T-cell clone, they were first gamma-irradiated to prevent proliferation. Up to 2xl08
PBMCs were suspended in PBS in a 25ml 'Universal' tube and carried on ice to an
Atomic Energy ofCanada Gammacell 1000 Caesium-137 source (MDS Nordion,
Kanata, Ontario, Canada) situated in the blood transfusion laboratories of the Royal
Infirmary of Edinburgh. The tube of cells was exposed to the gamma radiation
source for 12.8 minutes. This exposure time was calibrated to give the whole sample
a dose of >28.8 Gy and no one part a dose of >49.14 Gy. After irradiation, the
sample was returned, on ice, to the laboratory.
Maintenance ofHA1.7 T-cell clone
The HLA DR1*0101 restricted HA1.7 human T-cell clone (Eckels et al., 1982) was
raised against influenza haemagglutinin and shown to react against a synthetic
TIO
peptide of haemagglutinin (HA" " , Lamb et al., 1982a). It was donated as a
growing culture by Prof. Margaret Dallman (Department of Biology, Imperial
College of Science, Technology and Medicine, London, UK) along with a supply of
HA306"318 peptide. It was kept proliferating specifically on a weeklong selection and
antigen stimulation cycle. Cells were used for proliferation assays when in their most
quiescent state on day 7 before restimulation.
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Day 7/0. lxlO6 T-cells and lxlO6 irradiated HLA DR1*0101+ PBMCs were mixed
in 5ml of RPMI-1640 (+ 2mM L-glutamine + 50 IU mf1 penicillin + 50pg ml"1
streptomycin + 5% HI-NABHS) in a 25ml tissue culture flask. 0.5ml of
T-LF-Lymphocult® (Biotest (UK) Ltd., Solihull, West Midlands, UK) and lpg/ml
HA306"3'8 peptide was added. Cells were incubated in 5% CO2 in a humidified 37°C
incubator.
Day 3 or 4. Cells were checked. If the medium looked yellow, half the medium was
replaced with fresh and 0.5ml of Lymphocult® was added.
Day 7/0. Cells were washed in PBS by centrifugation and either used for a
proliferation assay or maintained for another week with fresh PBMCs, medium and
peptide (see above).
[3H]-thymidine incorporation proliferation assay
This assay was used to measure the extent of T-cell proliferation. 2xl05 HA1.7
antigen specific T-cells were placed in 96 well plates in 200pl of IMDM + 5% heat-
inactivated AB normal human serum (SNBTS), in the presence of 2x104 monocyte
derived macrophages or LCs (APCs) from a donor with a presentation competent
HLA type.
Cell stimulation. The cells were stimulated by the addition of antigen, or as a
positive control, 5pg ml"1 of the T-cell mitogen, concanavalin A. Cells were left to
proliferate (37°C, humidified, 5% CO2) for 5 days. 24 hours before the end of the
13stimulation lpCi per well of -35 Ci mmof [ H]-thymidine (ICN, Basingstoke,
Hampshire, UK) was added. At the end of the cell stimulation period the cells were
-5
either harvested immediately or frozen to -20°C to arrest [ H]-thymidine
incorporation.
Cell harvesting. A 96 well Tomtec plate harvester (Wallac, Crownhill,
Buckinghamshire, UK) was used to harvest the cellular nucleic acids onto a filter mat
(Wallac). The mat was dried at room temperature or in a 60°C oven.
Scintillation counting. The filter mat was sealed into a bag (Wallac) with 10ml of
'Betaplate™ Scinf liquid scintillation fluid (Fisons, Loughborough, Leicestershire),
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placed into a holding cassette and counted on a 1205 Betaplate™ scintillation counter
(Wallac) allowing 20 seconds of counting from each sample.
HIV-1 infection assay
This assay was used to test putative HIV-1-infection blocking agents and to assess
the infectability ofmacrophages of known genotype. Monocyte derived macrophages
were set up to culture in 24 well plates as described above. On day 5 the macrophage
culture had its medium removed and retained. lOOpl per well of the agent under test
in PBS (or just PBS as a control) was added to the cells and left for an hour whilst
the cells were taken into the category 3 pathogen-containment facility. 150pl of
HIV-Ibal supernatant (a gift from Dr Marilyn Moore, University of Edinburgh
Centre for HIV Research, Edinburgh, UK) was then added to the cells on top of the
existing lOOpl of solution. The macrophages were then incubated at 37°C in a
humidified 5% CO2 incubator for 30 minutes. A further 750pl of the original
medium was then added to each well. The cells were then returned to the incubator.
72hrs and 96hrs after the addition ofHIV-1Bal, RNA was harvested from the cells
using Qiagen kits as described below. All RNAs was treated with DNase (see
below). Tubes containing RNA were sprayed with 70% ethanol and removed from
the category 3 containment lab. The presence ofHIV-1 mRNA, and hence, viral
entry, reverse-transcription, probably integration, and transcription within the
macrophages, was assayed by RT-PCR. 0.1 pg of each DNase treated RNA was
reverse-transcribed as described below. A HIV-1 mRNA specific fragment of the
resultant cDNA was then amplified by semi-quantitative PCR (see below) and the
amount of amplified product taken as a measure of the extent ofHIV-1 Bal infection
of the macrophage culture.
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Flow cytometry methods
Flow cytometric analysis was carried out using a Coulter EPICS XL flow cytometer
(Beckman-Coulter Electronics, Luton, UK) with a 15mW, single argon ion laser
operating at A,488nm. Viable cells were gated for analysis using forward and side
(90°) scatter characteristics.
Preparation ofmonoclonal antibodies and control IgG
Cell culture. Elybridoma cell lines secreting antibodies against CD 14 (UCHM1) and
HLA DR (DA6 231) were obtained, respectively, from Prof. Sir Peter Beverley (The
Edward Jenner Institute for Vaccine Research, Compton, Berkshire, UK) and Dr.
Keith Guy (Department of Biological Sciences, Napier University, Edinburgh, UK)
(Hogg et al., 1984; Gruneberg et al., 1997). Cell lines were growth at 37°C with
humidity and 5% CO2 in about 50ml ofRPMI-1640 medium + 2mM L-glutamine +
50 IU ml"1 penicillin + 50pg ml"1 streptomycin + 10% FCS in a 200ml tissue culture
flask. Once a week, most of the supernatant was removed and retained; and about
three-quarters of the cells were removed and disposed of. The culture was then made
up to 50ml with fresh medium. Retained supernatant was stored at -20°C until
approximately 500ml had been collected from each cell line.
Concentrating the supernatant. Thawed supernatant was concentrated by dialysis.
About 5ft of 28mm diameter Visking dialysis tubing (Medicell International,
London, UK) was wetted with cold tap water and tied securely at one end. Using a
funnel, the supernatant was poured into the tubing and the tubing knotted at the open
end. The tied dialysis tubing was placed in a plastic box and sprinkled with about
40g of polyethylene glycol. The box was left at 4°C overnight. The following day,
the 500ml of supernatant should have reduced in volume to 25-40ml. If further
dialysis was required, more polyethylene glycol was added to the tubing, which was
then left for a few hours longer. If the supernatant had been over-concentrated, its
volume was increased by leaving the tubing in a beaker of distilled water for 20
minutes or so. The tubing was washed free of polyethylene glycol under the cold tap
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and the concentrated supernatant removed. The concentrated supernatant was either
stored at -20°C or used immediately.
IgG affinity Isolation. This protocol was used to isolate monoclonal IgG from
concentrated hybridoma supernatants. It was also used to isolate control, pre-immune
serum from mouse and sheep serum (SAPU, Carluke, Lanarkshire, UK). See
appendix 1 for details of the solutions mentioned below.
A clamped 7mm x 10cm glass liquid chromatography column (catalogue number
C3669, Sigma) was filled with a slurry of 2ml of fast-flow™ protein G conjugated
sepharose beads (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire,
UK) in phosphate buffer (appendix 1). 100ml of phosphate buffer was run through
the column to wash the beads free of their ethanol preservative, the flow was stopped
just before the buffer reached the top of the beads to prevent them from drying out.
About 25-40ml of concentrated hybridoma supernatant or about 3ml of serum was
then added to the column and followed by 50ml of phosphate buffer to wash off any
unbound proteins. The beads were not allowed to dry out at any stage.
Elution of column. 25ml of glycine / HC1 buffer (appendix 1) was run through the
column to remove bound IgG. As it came off the column, eluate was collected into
tubes in 12 consecutive fractions of about 2ml each. The column was then re-
equilibrated with 25ml of phosphate buffer and stored at 4°C with about 2ml of
buffer still in the column. 0.02% (w/v) of NaN3 was added to each column as a
preservative, this was washed out before the column was reused.
Selection of fraction(s). 5pl of each fraction was dotted onto a labelled position on
an approximately A7 sized piece of nitro-cellulose paper (Amersham Pharmacia
Biotech). This paper was dried completely in a 37°C oven and stained in Coomassie
blue mixture for 5 seconds. The paper was then destained in destain mixture for 1
minute or until most of the background staining had been removed. The paper was
baked at 37°C for 30 minutes between pieces of number 1 filter paper (Whatman,
Maidstone, Kent, UK) to intensify the blue staining of the protein dots. Figure 2.1
shows an example of a stained nitro-cellulose paper. The fractions showing the most
intense staining (fractions 2 and 3 in figure 2.1) were pooled. All other fractions were
discarded. Pooled fractions were adjusted to pH 6.5 - 7.5 by addition of 0.01 M
NaOH; pFI was tested using indicator sticks (Sigma). Protein content of purified IgG
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was measured using the Lowry assay (see below). The purified monoclonal antibody
was then aliquoted and stored at -70°C
Figure 2.1. Coomassie stained dot-blots of eluate fractions.
Lowryprotein assay
This assay is based on that ofLowry et al.,1951, and was carried out on a 96-well
ELISA plate (Life Technologies Ltd). The reagents listed in appendix 1 were made
up using distilled water.
The unknown protein sample(s) was/were diluted in triplicate in 5ml tubes with 0.1M
NaOH to give a final volume of200pl each (a 1:40 dilution worked well for protein
G column eluates). 1ml of alkaline carbonate solution was added to all samples and
BSA protein standards (appendix 1) and the tubes were vortexed to mix. Tubes were
left to stand for 10 minutes. lOOpl of 1M Folin and Ciocalteu's phenol reagent was
added to all tubes. The tubes were vortexed and left to stand for 30 minutes. 200pi of
each BSA protein standard and sample was added to an ELISA plate and read at
570nm on a MR 5000 microplate reader (Dynatech Laboratories, Billinghurst, West
Sussex, UK). Plate loading order was as detailed in the Lowry assay software file
"kimlowry.asy" (BioLinx 2.20, Dynatech Laboratories). The software assay file drew
a standard curve and calculated the protein concentration of the unknown samples.
71
Phenotyping ofcells
Flow cytometry was used to phenotype cultured cells and assess the purity of cell
cultures used in experiments. The presence or absence of the cell surface antigens
listed in table 2.1 was used to identify cells as monocytes, macrophages, dendritic
/Langerhans cells, T-cells or B-cells.
Cells for phenotyping were taken from culture (a 30 minute incubation with sterile
0.02% (w/v) EDTA and gentle cell scraping, if required, was used on adherent cell
populations). Cells were placed in a round bottomed 96 well plate in aliquots of
about 105 cells per well. The plate was centrifuged at lOOg for 3 minutes, and the
supernatant discarded. The cells were washed by re-suspension in 200pl of chilled
flow buffer and a second centrifugation. The supernatant was again removed and the
cells were re-suspended in lOpl of the primary antibody solution. The primary
antibodies and the concentrations used are listed in table 2.1. The cells were
incubated with the primary antibody for 30 minutes on ice. Cells were then washed
as above and resuspended in 10pl of the secondary antibody (R-PE-conjugated goat
F(ab')2 anti-mouse Ig (Dako, Cambridge, Cambridgeshire, UK) at 67pg mf1 in flow
buffer) if the primary antibody was not fluorochrome conjugated. Cells were
incubated with secondary antibody for 30 minute on ice in the dark, and then washed
in flow buffer. After staining cells were re-suspended in 200pl of fresh flow buffer
and transferred to labelled flow cytometry tubes containing 200pl of flow fix. Cells
were either put through the flow cytometer immediately or kept at 4°C in the dark for
up to 2 weeks.
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Antigen Clone Supplier Cone, used / pg ml"1 Isotype
CDla NA1/34 Dako 50 IgG2ax
CD3 UCHT-1 Immunotech 1:10 IgGlK
CD3-FITC UCHT-1 Dako Neat (100) IgGlK
CD4 MT310 Dako 10 IgGlK
CD4-FITC QS4120 Sigma Neat IgGl
CD8H-FITC 30324X Pharmingen Neat IgGlK
CD 14 UCHM1 P. Beverley 28 lgG2a
CD18 MHM23 Dako 10 IgGlK
CD40 11E9 Novocastra 1:40 IgGl
CD45 (ICAM-1) T29/33 Dako 13 IgM
CD54 15.2 Novocastra 1:40 IgGl
CD80 (B7.1) BB-1 B. D. 50 IgM
HLA DR,DP,DQ
(p chain)
CR3/43 Dako 8 IgGlK
Isotype control UPC 10 Sigma - IgG2aK
Isotype control MOPC Sigma - IgGlK
Table 2.1. Details of primary antibodies used for phenotype cells.
Monoclonal antibodies were supplied by Dako, Sigma, Becton Dickinson /
Pharmingen, Coulter-lmmunotech (Luton, Bedfordshire, UK), and Novocastra
Laboratories (Newcastle, Tyne and Wear, UK) or prepared from supernatants
of hybridoma cell lines from Prof. Sir Peter Beverley (The Edward Jenner
Institute for Vaccine Research, Compton, Berkshire, UK). Concentrations
used are stated as pg ml"1 or, were absolute concentration was not stated by
the manufacturer, as dilutions from supplied stock. Three of the antigens
listed above were FITC conjugated and not used with a secondary reagent.
Quantification ofcell-surface antigen levels
For the antigens CD4 and CD 18 flow cytometry was used to not only detect the
presence or absence of the antigen but to quantify the relative level of antigen on
different macrophage populations. So that increases as well as decreases in antigen
level could be seen reproducibly, an appropriate primary antibody concentration for
use in subsequent experiments was determined by carrying out a titration of antibody
concentration. Staining was as described above and results from the antibody
titration tests are presented in chapter 4.
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Annexin Vstaining
Apoptotic cells loose their membrane-bilayer asymmetry; negatively charged
phospholipids normally on the internal face of the membrane appear on the external
face. Annexin V can bind these lipids; if this annexin V is FITC conjugated apoptotic
cells can be selectively stained with this reagent. The intact membrane-impermeant
dye propidium iodide (PI) can be used in conjunction with annexin V staining to
indicate necrotic cells. This technique was carried out using the Pharmingen Annexin
V-FITC apoptosis detection kit (Becton Dickinson UK Ltd.).
A suspension of at least 1 x 105 cells was washed twice in cold PBS and then
resuspended in lOOpl of binding buffer. 5pl of annexin V-FITC and 2pl of PI (as
supplied) was added to the cells, which were mixed and incubated in the dark at
room temperature. 400pl of binding buffer was then added to the cells, which were
analysed by flow cytometry within 1 hr. Unstained and singly stained cells from each
specimen were also analysed.
Microscopy methods
Standard light microscopy
Cells in culture were regularly examined and counted on a haemocytometer (Sigma)
by a CK2 phase contrast microscopy (Olympus, London, UK).
FITC conjugation ofprotein
Gpl20 was conjugated to the fluorochrome FITC using the following protocol based
on that from Holmes et al., 1997. The gpl20 was supplied sterile and its sterility was
retained by using only sterile reagents (listed in appendix 1) for the conjugation.
Solutions were filter sterilised if required. Note that the success of conjugation is
highly dependent on the quality of the reagents used. The FITC and DMSO used
must be anhydrous. Because these substances are hydroscopic, small quantities were
purchased fresh before beginning the experiment.
A fresh vial ofR5-tropic gpl20 or X4-tropic gpl20mB (NIBSC Centralised Facility
for AIDS Reagents) containing 50pg of gpl20 was made up to 500pl with distilled
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water. The gpl20 was then loaded into a Slide-A-Lyser™ dialysis cassette (Pierce &
Warriner, Chester, Cheshire, UK) as per manufacturer's instructions. The gpl20 was
dialysed for 2 days at 4°C against 4 changes of 500ml of FITC labelling buffer. The
gpl20 was removed from the Slide-A-Lyser™ to a 5ml tube and 2pl of 5pg ml"1
FITC in DMSO was added to the gpl20. The gpl20 / FITC was left for 2 hours in
the dark at room temperature to allow conjugation to take place. The labelled gpl20
was loaded into a new Slide-A-Lyser™ and dialysed against 4 changes of 500ml of
final dialysis buffer at 4°C for 2 days. The product was removed and the FITC:gp 120
ratio determined. FITC conjugated gpl20 was stored at -20°C until required.
Determination of FITC:gpl20 ratio. The molar ratio of FITC to gpl20 should be
between 6 and 20. This is so it is comparable to the molar ratio of FITC to protein of
the control protein, FITC-BSA, which had a ratio of 11.2. If the ratio was too low
then the fluorescent signal would have been too weak for detection. If there was too
much FITC bound to the gpl20, the likelihood of the gpl20 losing its binding
properties because of steric hindrance would gave been increased. The FITC:gpl20
ratio was determined by taking spectrophotometer measurements of a sample of
FITC conjugated gpl20.
Using a PU 8620 spectrophotometer (Philips, Cambridge, UK) and a Quartz
(UV transparent) cuvette a sample of FITC-gpl20 was diluted in final dialysis buffer,
and absorption at 492nm was measured after blanking the instrument with final
dialysis buffer.
The following formulae (Holmes et al., 1997) were used to calculate the molar ratio
of FITC:gpl20 in FITC-gpl20.
moles qp120 = mq ml"1 protein Moles FITC = Abs4g?
1.2 x 105 6.9 x 105
molar ratio = moles FITC
moles gp120
Staining ofmacrophagesforfluorescence microscopy
Monocyte-derived human macrophages were grown from Buffy coats as detailed
above, except that 1ml of cells were plated onto 70% ethanol-sterilised glass
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coverslips (BDH, Poole, Dorset, UK) sitting in the bottom of 6 well plates; by this
method macrophages differentiated whilst adhering to the glass cover-slips. All
media formulations, cell-washing stages, cell densities and phenotypes were as
previously described. After 6 days of differentiation, cells were incubated with FITC-
conjugated gpl20 (see above) or FITC conjugated BSA (Sigma) for various lengths
of time. Cells were then fixed by removal of their medium and the addition of 1ml of
2% paraformaldehyde in PBS to each well for 20 minutes at room temperature. At
this stage fixed coverslips could be stored for several months at -20°C in coverslip
racks; if this was done, cells were defrosted by 5 minutes of immersion in 2%
paraformaldehyde in PBS at room temperature.
After fixation, cells were washed three times in PBS in 6 well plates. Cells
were then permeabilised by the addition of 0.1% Triton X-100 in PBS at 1ml per
well for 5 minutes at room temperature. Cells were washed thrice in PBS. Cells were
blocked to prevent non-specific binding of antibody with 1ml per well of 0.2% BSA
in PBS at room temperature for 10 minutes. Cells were stained with directly
fluorochrome-conjugated and/or primary and secondary antibodies as detailed in
table 2.2 (see below). Antibodies were diluted in flow buffer (see above) and all
fluorochrome conjugates were kept in the dark. lOOpl of each antibody was added
for 30 minutes at room temperature and followed by three PBS washes. Antibody
was added using the inverted coverslip method described in figure 2.2. Coverslips
were carefully floated off the Parafilm™ after staining and washed (cell side up) in
PBS in 6 well plates. After staining, a final 3 washes were carried out in 6 well plates
with distilled water. Coverslips were then dabbed dry at the edges and mounted on
glass slides (BDH) using Vector-shield anti-photo-bleaching glycerol-based
mounting medium (Vector Labs Ltd., Orton Southgate, Cambridgeshire, UK). The
edges of the coverslips were sealed with nail varnish (Boots the Chemist,
Nottingham, UK) and the slides stored in the dark at 4°C for up to 2 weeks before
examination.
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Antigen Clone Supplier Cone, used / pg ml"1 Conjugate
HLA DR DA6 231 K. Guy 3 Non-conjugated
CD4 MT310 Dako 1.8 FITC
Mouse IgG Goat polyclonal Sigma 1:100 from stock TRITC
Table 2.2. Details of antibodies used to stain macrophages for
fluorescence microscopy. See table 2.1 caption and method above for
details of suppliers. Anti-CD4 was directly conjugated to a fluorochrome and
celts were stained in a single stage at the concentration used. HLA-DR
staining was a two-stage process, utilising the goat anti-mouse reagent as a
secondary antibody. HLA-DR was always stained before CD4.




Figure 2.2. The inverted coverslip method of staining. A 10Ojal drop of the
diluted antibody was added to a piece of Parafilm™, which was placed on a
damp paper tissue in a plastic tray, the coverslip to be stained was then
carefully lowered, taking care to avoid trapping air bubbles, onto the drop
with the cell side facing down. The coverslip was then incubated at room
temperature for 30 minutes. In order to avoid creating a vacuum under the
coverslip, which would distort the cells, the coverslip was gently floated off
the Parafilm™ with PBS.
Fluorescence microscopy
Stained cells were visualised on an Axiophot fluorescent microscope (Carl Ziess Ltd,
Welwyn Garden City, Hertfordshire, UK) using FITC and TRITC filter sets. This
microscope was used to check specimens before examining them by confocal
microscopy.
Laser-scanning confocal microscopy
Stained macrophages were visualised on a DMRE laser scanning confocal
microscope with a TCS NT image capture computer system (Leica Microsystems,
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Heildelberg, Germany). Images were saved to CD-ROM as tagged image files (.tif)
and analysed by the TCS NT system and Scion Image (Scion Corp., Frederick, MD,
USA). Invaluable technical assistance in the capture of confocal images was




IL-10, IL-12 and TGF-pi levels were determined in cell culture supernatants using
Quantikine® enzyme-linked immuno-sorbant assay (ELISA) kits (R&D Systems
Europe Ltd) as described in the manufacturer's instructions. Plates were washed
using a HandyWash manual microplate washer (Dynatech Laboratories) and read at
450nm on a Revelation 3.04 microplate reader (Dynex Technologies, Billinghurst,
West Sussex, UK) with the correction wavelength set to 550nm.
All samples and standards were set up in duplicate as recommended by the
manufacturer. The plate reader software automatically drew standard concentration
curves and calculated cytokine concentrations of unknown samples.
For IL-10 and IL-12 determination supernatants were diluted 1:13 in
calibrator diluent before being assayed. For TGF-pi determination it was necessary
to first activate the samples to liberate immunoreactive TGF-pi from its latent
complexes. This was achieved by 10 minutes of room temperature incubation with
0.17M HC1, followed by neutralisation with 0.17M NaOH and 71mM HEPES.
Prostaglandin measurements
PGE2 in cell culture supernatants was immunoassayed by Vivien Grant (MRC Centre
for Reproductive Biology, Edinburgh).
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Nucleic acid purification methods
DNA isolation
Genomic DNA was isolated from PBS washed frozen pellets of 1-5x106 PBMCs
using the Wizard® Genomic DNA purification Kit (Promega, Southampton,
Hampshire, UK). Cell structure was disrupted by 4 freeze-thaw cycles using liquid
nitrogen and a 95°C water bath. Nuclear Lysis Solution from the Wizard® kit was
then added to the cell sample and the manufacturer's protocol followed from this
point onwards.
RNA isolation
Cellular RNA was isolated from samples using the RNeasy spin column kit as per
the manufacturer's instructions (Qiagen Ltd, Crawley, West Sussex, UK). The first
cell lysis buffer (RTL) was added to a pellet of cells or, in the case of adherent cells,
directly to the cells in the tissue culture vessel after removal of the medium.
DNase treatment of RNA. The majority ofRNA was not DNase treated because the
RNA isolation method used gave very low levels ofDNA contamination and for
PCR experiments, where DNA contamination could have given misleading results,
intron-spanning, message-specific primers or appropriate controls were used.
However, when RNA was isolated from HIV-1 infected cultures, the RNA was
DNase treated as a safety precaution to eliminate possibly infectious HIV-1 pro-
virus. Only after this had been completed, was the RNA allowed out of the category-
three pathogen-containment facility. To the 50pl volume ofRNA, 10pl of 5xRT
buffer from the Expand RT® kit (Roche Diagnostics Lewes, East Sussex, UK) was
added and the solution mixed. 10U of DNase I (FPLCpure®, Amersham Pharmacia
Biotech) was then mixed with each RNA sample. The sample was incubated at room
temperature with the DNase for 30 minutes. The DNase was then inactivated by the
addition of 5pl of 25mM EDTA (Life Technologies Ltd) and heating in a waterbath
to 65°C for 10 minutes.
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Nucleic acid quantification
Extracted RNA and DNA were quantified using a GeneQuant II photospectrometer
(Amersham Pharmacia Biotech) and UV-transparent quartz cuvettes. The sample
dilution was varied in order to give 260nm absorbency reading of at least 0.010 and
preferably of at least 0.020. RNase free water was used as diluent and to 'zero' the
instrument. Quantified RNA was stored at -70°C, DNA at -20°C.
Polymerase chain reaction (PCR) methods
Bioinformatics andprimer design
The sequences used for PCR primers came from publications or from Dr Marilyn
Moore and Donald Innes (PPL Therapeutics, Roslin, Midlothian, UK) as detailed in
Appendix 2. All sequences used were verified against the GenBank database held at
the National Center for Biotechnology Information web site
(http://www.ncbi.nlm.nih.gov/). Where possible, message specific, intron-spanning
primers were used. Primers were synthesised by Oswel DNA Service (Southampton,
Hampshire, UK) or Life Technologies Ltd.
Reverse transcription (RT)
cDNA was synthesised using the Expand RT® kit (Roche Diagnostics). All other
reagents were purchased from Promega UK. Ideally, lpg ofRNA was reverse
transcribed; however, in many cases the amount of RNA available was below this
and 0.2pg or O.lpg ofRNA was used instead. For semi-quantitative applications, an
equal mass of each RNA was used in the experiment. For each sample the following
reagents were added to a labelled thin-walled 0.5ml Eppendorf® tube (Advanced
Biotechnologies Ltd, Epsom, Surrey, UK):
RNA 1pg, 0.2pg or 0.1pg






Tubes were vortexed to mix, and micro-centrifuged (momentary pulse to 104 rpm) to
gather contents at the bottom of the tube. Contents were denatured by heating for 10
minutes to 65°C on an Omn-E™ or OmniGene™ thermal cycler (Hybaid,
Teddington, Middlesex, UK). Oligo dT was then annealed to the poly A tail of
mRNA by cooling the tubes on ice for at least 2 minutes. The following reaction mix
was made up and 11.5jul of it was added to each tube, which was then vortexed and
centrifuged as above:
(Note, quantities given below were multiplied by the number of reaction tubes.)
5x Expand RT® buffer 4pl
100mM dithiothreitol 2pl
3.3mM of each dNTP 4pl
RNasin® ribonuclease inhibitor 0.5pl (20 Units)
50 Unit pi"1 Expand RT® enzyme (added last) 1ul
Volume per sample 11.5pl
The tubes were then heated to 42°C for 1 hour on a thermal cycler to allow the RT
reaction to proceed. Synthesised cDNA was stored at -20°C for up to several years.
Basic PCR protocol
PCR was carried out using Taq Supreme DNA polymerase kits (Helena Biosciences,
Sunderland, Tyne and Wear, UK) and an Omn-E™ or OmniGene™ thermal cycler
with tube temperature control (Hybaid). All other reagents were purchased from
Promega UK. 2pl of each cDNA or 2pl (approximately 0.1 pg) of each genomic
DNA of interest (the 'template') was aliquoted into a separate, labelled, thin-walled
0.5ml Eppendorf® tube (Advanced Biotechnologies Ltd) for each primer pair used.
The following 'master mixes' were made up for each amplicon of interest:
(Note, quantities given below were multiplied by the number of reaction tubes which
was the number of templates under investigation plus an addition tube with no
template which was used as a negative control.)
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RNase free water
10x MgCI2-free Tag buffer
3.3mM of each dNTP
25pM sense primer
25pM anti-sense primer
100mM MgCI (final concentration of 1.5mM)










18pil aliquots of'master mix' were added to each template tube; the 18pl of each
master mix left over was retained as a negative control to be run alongside the other
samples. All tubes were vortexed and centrifuged to gather contents at the bottom of
the tube and a single drop of molecular grade mineral oil (Sigma) was added to each
tube. All tubes were placed on a thermal cycler and the appropriate cycling program
(see below) was run.
PCR programs
The following programs were run on an Omn-E™ or OmniGene™ thermal cycler
with tube temperature control (Hybaid)
hiv and (3-actin (94°C 45s
55°C 35s
68°C 2min 30s) x n cycles (variable)
ccr5A32 and (3-actin (94°C 1min
55°C 1min
72°C 1min 30s) x 5 cycles
(94°C 30s
60°C 30s
72°C 45s) x 35 or n cycles




72°C 3min) x n cycles (variable)
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cd4 and fi-actin (94°C
58°C
72°C






2min) x n cycles (variable)
45s
45s
45s) x n cycles (variable)
10min
DNA gels
PCR gels were made up and run in Tris / borate / EDTA (TBE) buffer, see appendix
1 for recipes.
Agarose (Sigma) gels from 1 to 3.5% (w/v) were made by mixing agarose with an
appropriate volume of lxTBE buffer and heating the mixture in a microwave oven
until the agarose had dissolved. The gel was then allowed to cool until it was still
molten but cool enough to hold with the bare hand. Ethidium bromide was then
mixed with the molten gel to give a final concentration of lOOmg l"1. The gel was
cast into a mould using an appropriate sample comb to form loading wells. When set,
the comb was removed and the gel transferred to an electrophoresis tank containing
the recommended volume of TBE as running buffer. 2pl of loading dye (0.25% (w/v)
orange G (molecular grade, Promega), 50% (v/v) glycerol, 50% (v/v) RNase / DNase
free water) was added to lOpl of each DNA sample, which was then loaded into a
well on the gel. pGEM® molecular weight markers (Promega) were run in one lane
to allow for PCR product size determination. Markers were added as recommended
by the manufacturer.
Electrophoresis was at no more than 70 mA, until the dye-front had migrated
a sufficient distance towards the anode for DNA fragment size to be resolved.
Gel documentation
Gels were visualised by UV trans-illumination and images were captured, saved to
floppy disk and printed using the Enhanced Analysis System (EASY, version 4.19,
Scotlab, Coatbridge, Lanarkshire, UK)
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Semi-quantitative PCR
'Semi-quantification' of relative mRNA level was carried out as devised by Wang et
al., 1989. This method attempts to equate relative band intensity on a PCR gel with
relative level of a specific mRNA in the starting material. An equal mass of each
RNA was reverse transcribed. A variable cycle number PCR reaction was carried out
to determine the optimum number of cycles required for a near-linear relationship
between the RNA level and resultant DNA band intensity. All cDNAs were then
amplified by PCR for this number of cycles and the band intensities as determined by
the EASY were recorded. To allow for errors in the initial equalisation ofRNA mass
between samples, samples were compared as ratios of the intensity of a band
amplified from the gene of interest to the intensity of the j.3-actin housekeeping gene
band from the same cDNA.
Real-time (kinetic) RT-PCR
This technique was carried out in collaboration with Professor Rodney Kelly and
Gail Baldie (MRC Centre for Reproductive Biology, Edinburgh) using a ABI Prism
7700 sequence detector (PE Biosystems, Warrington, Cheshire, UK). All reagents
and consumables for use with this technique were purchased from PE Biosystems.
There are several kinetic PCR systems in use (Higuchi et al., 1992; Higuchi et al.,
1993); these studies used the PE Biosystems TaqMan® system
(http://www.pebio.com/ab/about/pcr.html, Holland et al., 1991; Fouchier et al.,
1992; Livak et al., 1995), which is based around amplifying a specific sequence
between two unlabelled primers during a thermal cycling program, as in
conventional PCR. To allow a target-specific signal to be detected concomitantly
with amplification, an oligonucleotide 'TaqMan ' probe is designed to anneal to the
target sequence between the sense and anti-sense primers at a Tm higher than the Tm
of the primers. The TaqMan® probe is chemically modified to be non-extendable at
the 3' end and labelled with a fluorescent reporter dye (FAM or VIC) at the 5' end.
The fluorescence of the reporter dye is quenched with a quencher dye (TAMRA)
attached seven nucleotides from the 5' end so that the reporter dye is only able to
fluoresce when released into the reaction mixture having been separated from the
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quencher dye. During PCR amplification cycles Taq polymerase extends the primers
in a 5' to 3' fashion, and exhibits 5' to 3' exonuclease activity on the TaqMan® probe,
this un-quenches the reporter dye and allows the instrument to detect an increase in
reporter-dye fluoresce which is proportional to the rate of target amplification. The
PCR reactions were carried out in duplicate in 96-well PCR plates fitted with
optically transparent caps on a heated lid thermal cycling block. Two amplification
reactions were run in each sample-well simultaneously and distinguished by the use
of different reporter dyes, The fluorochrome FAM was used to report the
amplification of the gene under analysis and the fluorochrome VIC was used to
report the amplification of cDNA derived from the 'house-keeping' 18S ribosomal
(r) RNA. The intra-cellular level of 18S rRNA is assumed to be constant in a
population of non- or asynchronously-dividing cells and was measured as an internal
control to compare to the level ofmRNA for the gene under analysis. The two
reactions were designed so that the 18S amplification was complete by 16 thermal
cycles and the amplification of the analyte was beginning in ernest only after 18
thermal cycles, this minimised interference between the two amplification reactions
due to competition for dNTPs. Each well was irradiated and its fluorescence
monitored by the instrument at the end of each thermal cycle. A third fluorochrome,
ROX, was present in the reaction mixture are a passive control to allow automatic
compensation for instrument irregularity and reaction volume errors.
Reverse transcription for real-time PCR
RNA was extracted using RNeasy kits as described above. cDNA was synthesised
using the MultiScribe RT® kit (PE Biosystems). Ideally, 0.2pg ofRNA was reverse
transcribed; however, if the amount ofRNA available from some samples was below
this, 0.1 pg ofRNA was used instead throughout the whole experiment. The
following reaction mix was made up, vortexed then centrifuged:
(Note, quantities given below were multiplied by the number of reaction tubes.)
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10x TaqMan® buffer 1pl
25mM MgCI2 2.2pl
2.5mM of each dNTP 2pl
20 Unit fj.1"1 RNase inhibitor 0.2pl
50pM Random hexamer primers 0.5pl
50 Unit pi"1 MultiScribe RT® enzyme
(added last) 0.25ul
Total volume 6.15pl
Each RNA was added to a 0.5ml Eppendorf® tube and diluted in nuclease-free water
to give a volume of 3.85pl. 6.15pl of the reaction mix was added to each tube,
which was vortexed and centrifuged before placing on an Omn-E™ thermal cycler
with tube temperature control and a heated lid (Hybaid). Tubes were incubated at
25°C for 1 hour, 48°C for 45 minutes and then 95°C for 5 minutes to allow the RNA
to be reverse transcribed and then denature the reverse transcriptase. After reverse
transcription cDNAs were diluted 5:1 with nuclease free water before proceeding to
the PGR step.
Reaction set-up for real-time PCR
PCR was carried out using PE Biosystems TaqMan® Universal PCR Master Mix
which is optimised for TaqMan® reactions and contains AmpliTaq Gold® DNA
polymerase, AmpErase® UNG, dNTPs with dUTP, passive reference dye 1 (ROX)
and optimised buffer components. The 18S rRNA internal control reagents were
purchased as a ready optimised mixture and used as recommended by PE
Biosystems. All reactions were run in duplicate. 2.5pl of each cDNA diluted as
above was aliquoted into two separate wells of a MicroAmp® optical 96 well plate
for each primer pair used. A cDNA sample reverse transcribed from RNA extracted
from a large batch of the T-47D breast cancer cell line (Keydar et al., 1979) by Gail
Baldie and found to be positive for most of the genes of interest was run in duplicate
with each primer / probe set as a positive control as was a no-template negative
control. The following 'master mixes' were made up for each amplicon of interest,
vortexed and centrifuged:
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(Note, quantities given below were multiplied by the number of reaction wells,
which was twice the number of templates under investigation plus an addition two
wells with no template as a negative control and two wells set up with positive
control cDNA.)
TaqMan® Universal Master Mix 12.5pl
2.5pM sense primer 3pl
2.5pM anti-sense primer 3pl
5pM TaqMan probe 1pl
Nuclease free water 2.625pl
TaqMan® 18S rRNA control reagent 0.375ul
Volume per well 22.5pl
22.5pl aliquots of 'master mix' were added to each well used to bring the total well
volume to 25pi. MicroAmp® optical caps were carefully pressed onto each well and
the plate was placed in the ABI Prism 7700 sequence detector running SDS software
(PE Biosystems) and using a heated lid. The same cycling program (see below) was





60°C 1min) x 40 cycles
Primer andprobe sequences for real-time PCR
See appendix 2 for details of the primer and probe sequences used. All primers and
probe sequences were designed by Professor Rodney Kelly using PrimerExpress®
software (PE Biosystems) and verified by PE Biosystems' technical experts. Because
of the constraints on primer design imposed by the TaqMan® system and the limited
GenBank availability of genomic sequences, most of the primers used were not
intron-spanning and could, in theory, have amplified genomic DNA contaminating
the cDNA. In order to rule out this possibility, a portion of each RNA investigated
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was added to a highly efficient (3-actin PCR reaction and found to give no detectable
product in the absence of a reverse transcription step.
Statistics from real-time PCR
The real time PCR machine took readings of fluorescence at the end of each PCR
cycle at wavelengths corresponding to the analyte, 18S housekeeping-control and
passive reference fluorochrome-emissions. Figure 2.3 shows a typical set of data as it
was presented by the SDS software (PE Biosystems) at the end of a PCR run. Note
that the fluorescence statistic (termed Rn) has been normalised relative to the passive
reference fluorochrome. The threshold marker was set as high as possible on the
curve but before any of the signals began to plateaux. The software then analysed the
data and output a pair of 'ct' values for each sample tube. Ct is the number of cycles
that each sample needs to produce a signal crossing the threshold; each tube yielded
two ct values, ctgene sample n for the gene of interest and cftgs sample« for the 18S
housekeeping control. The ct values were exported to a Microsoft Excel97
spreadsheet and the following formulae were used to calculate 2"AAU samplewhich is
a value which represents the relative mRNA levels of samples linearly, so that the
value of 6 signifies twice as much mRNA as a value of 3.
ActSample n ~ Ctgene sample n ~ Ctl8S sample n
AACtsample n = ActSample n ~ ACtuntreated control
88







Number of thermal cycles (ct) -»
Figure 2.3. Typical real time PCR data. These data shows the 18S
housekeeping signal from a set of samples and negative controls. It can be
seen that as the samples undergo an increasing number of thermal cycles,
the fluorescence of the tubes increases in line with the built up of specific
PCR product. It can also be seen that the signals from the negative control
wells cross the line at about 39 cycles, this is expected and is due to
background signal caused by of non-specific probe cleavage.
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CHAPTER 3: RESULTS
DISTRIBUTION OF THE CCR5A32 GENOTYPE
Background
The discovery ofHIV-1 coreceptors
Very soon after the discovery ofHIV-1, the cell surface molecule CD4 was
identified as the virus' primary entry receptor (Dalgleish et al., 1984; Klatzmann et
al., 1984; Maddon et al., 1986). However, from these early days it was suspected that
CD4 alone was not sufficient to allow HIV-1 entry (Clapham et al., 1991) and the
hunt for coreceptors which would explain cellular tropism (see introduction) began.
After some false starts such as mistaking complement receptor 3 for HIV-l's
coreceptor (Stoiber et al., 1997), it was shown that a chemokine receptor is the
coreceptor on T-cells and APCs (Dragic et al., 1996; Deng et al., 1996; Choe et al.,
1996; Doranz et al., 1996; Rottman et al., 1997; Jones etal., 1998; Albright etal.,
1999, reviewed in D'Souza and Harden, 1996; Weiss, 1996; Ross et al., 1999).
M-tropic viruses, important in sexual transmission and initial infection, generally use
CCR-5 as a coreceptor. T-tropic viruses generally use CXCR-4 (Follis et al., 1998;
Tscherning et al., 1998). An alternative classification scheme groups viral strains as
being R5-tropic or X4-tropic. M(R5)-tropic viruses can infect both macrophages and
T-cells because both cell types express CCR-5. Although both cell types express
CXCR-4, T-tropic viruses that use this coreceptor are usually only able to infect
T-cells. It appears that macrophage CXCR-4 is unavailable for binding by many
T(X4)-tropic viruses possibly due to differences in its formation ofmultimers
(Lapham et al., 1999a; Lapham et al., 1999b), or tyrosine sulphation (Farzan et al.,
1999).
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Ccr-5 coreceptor gene polymorphism
Chemokine receptors are members of the seven-transmembrane-span, serpentine, G-
protein-binding family of receptors which includes the p-adrenergic receptor and
bacteriorhodopsin. As discussed in the introduction, genetic polymorphisms of
chemokine receptor genes have been described (Smith et al., 1997; Quillent et al.,
1998; EugenOlsen et al., 1998; Lee et al., 1998; Martin et al., 1998a; Magierowska
et al., 1999; Su et al., 1999; Mariani et al., 1999). Eight polymorphisms have been
identified in the ccr5 gene (AnsariLari et al., 1997). The most common
polymorphism in Caucasian populations is the ccr5A32 frame-shift deletion. This
mutation results in the synthesis of an incomplete molecule of CCR-5 and a failure of
cell-surface expression, making the carrier effectively null for surface CCR-5 (Rana
et al., 1997, figure 3.1). Homozygosity for the ccr5A32 allele was discovered in a
high proportion of people repeatedly exposed to HIV-1 but who had failed to become
infected (Samson et al., 1996; Liu et al., 1996; Hoffman et al., 1997). More recently
it has been shown that ccr5A32 homozygosity is not the only factor which can
account for HIV-1-exposed but uninfected (EU) individuals, as EU people are also
present in ethnic groups in which the ccr5A32 allele is absent (Li et al., 1997;




Figure 3.1. Diagram of the structure of CCR-5 showing likely
configuration in the plasmalemma. The position of the m303 premature
stop mutation (Quillent et al., 1998) and the A32 deletion mutation are
marked. Neither of these mutations allows a complete molecule of CCR-5 to
reach the plasmalemma.
Diagram adapted from Quillent et al., 1998. © The Lancet 1998.
Ccr5A32 homozygous cells are protectedfrom infection by M-tropic HIV-l
In vitro infection assays have been used to show that primary cultures of
homozygous ccr5A32 T-cells and monocyte derived macrophages are resistant to
infection by the M-tropic CCR-5-ultilising HIV-l strains BAL, SF162 and JR-FL.
T (X4)-tropic strains HXB and IIIB were able to infect T-cells but not macrophages.
The dual (R5X4) tropic HIV-l strain 89.6 was able to infect both ccr5 null
macrophages and T-cells by utilising CXCR-4 (Rana et al., 1997). The observation
that macrophage CXCR-4 is accessible to some dual tropic HIV-l strains and
inaccessible to T-tropic strains is in line with work identifying two distinct
mechanisms for dual-tropism (Yi et al., 1999). Additional data will be presented
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below which confirm the observation that HIV-Ibal is unable to infect monocyte-
derived macrophages homozygous for ccr5A32.
Heterozygous PBMC and T-cells express slightly reduced levels of CCR-5
and, on average require a higher viral dose to be infected in vitro with M-tropic
HIV-1 (Kim etal., 1998; Paxton etal., 1999).
The ccr5A32 allele protects HIV-1 infected individuals from rapid disease
progression
Homozygosity for the A32 allele at the ccr5 locus protects individuals from HIV-1
infection. Evidence for this comes from epidemiological studies of HIV-1
transmission in homosexual men (Huang et al., 1996; Paxton et al., 1998), injecting
drug abusers (Alvarez et al., 1998), haemophiliac recipients of infected clotting
factors (Wilkinson et al., 1998; Kupfer et al., 1999), and babies born to HIV-1
infected mothers (Philpott et al., 1999). While heterozygosity at the ccr5 locus does
not confer protection from infection (Edelstein et al., 1997; Rousseau et al., 1997;
Husman and Schuitemaker, 1998; Misrahi et al., 1998; Mangano et al., 1998), it
limits the patient's viral load (Katzenstein et al., 1997; Buseyne et al., 1998) and
slows progression of HIV-1 disease, at least in the early stages of infection when
M-tropic HIV-1 predominates (Huang et al., 1996; Dean et al., 1996; Husman et al.,
1997; Rappaport et al., 1997; Paxton et al., 1998; Misrahi et al., 1998; Bratt et al.,
1998). Reduced risks for the appearance of several opportunistic infections including
toxoplasmosis (Meyer et al., 1999), and non-Hodgkin's lymphoma (Dean et al.,
1999) and AIDS dementia complex (VanRij et al., 1999) have also been reported in
ccr5A32 heterozygotes.
Although the correlation between ccr5A32 and protection from rapid disease
progression has been demonstrated independently many times, it is not the sole
determinant of progression rate or transmission risk (Cohen et al., 1997b) and there
are a small number of studies (e.g., Schinkel et al., 1999) which fail to show
heterozygous protection from progression. Although such people are rare, several
HIV-1+ individuals have been identified who are homozygous for ccr5A32 (Balotta
etal., 1997; O'Brien etal., 1997; Theodorou etal., 1997; Biti etal., 1997; Husain et
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al., 1998; Michael et al., 1998; Kuipers et al., 1999; Heiken et al., 1999). Invariably,
when HIV-1 isolated from these individuals is phenotyped, it is found to be CXCR-4
tropic (whether or not it has the unusual ability to use CXCR-4 on macrophages has
not been reported). Why CXCR-4 tropic HIV-1 is not usually transmitted is poorly
understood. It could be that macrophage / dendritic cell infection that is usually
CCR-5 mediated is required for efficient transmission across an anal / genital
mucous membrane. This explanation does not account for why ccr5A32
homozygotes are protected from intra-venous transmission of HIV-1.
Other phenotypes ofthe ccr5A32 allele
In healthy individuals in the absence ofHIV-1 infection, the ccr5A32 allele, in either
its homozygous or heterozygous form does not confer any phenotype. The immune
system acts normally without CCR-5 even though it functions as a receptor for the
pro-inflammatory chemokines MlP-la, MIP-ip and RANTES (Combadiere et al.,
1996). This is presumable due to redundancy in the chemokine system.
Increased levels ofMlP-la have been detected in cerebrospinal fluid of
multiple sclerosis (MS) patients; however, CCR-5 deficiency fails to protect against
MS (Bennetts et al., 1997), or against insulin dependent diabetes mellitus, another
disease associated with pro-inflammatory chemokines (Philpott et al., 1999).
However, the ccr5A32 allele does influence some of the clinical variables (including
a reduction in the degree of joint stiffness and presence of IgM rheumatoid factor) of
rheumatoid arthritis (Garred et al., 1998; GomezReino et al., 1999).
Aims of chapter
• To undertake a meta-analysis of data on the global distribution of the ccr5A32
allele from published sources to demonstrate the reported high incidence of
ccr5A32 in north European populations.
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• To use statistical methods to analyse this data in such as way as to be able to
make a prediction of ccr5A32 incidence in south east Scotland.
• To ccr5 genotype blood donors attending sessions of the SNBTS in south east
Scotland to find the actual allele frequencies in comparison to the prediction.
• To validate the infection assay used in this thesis by confirming that the
CCR-5-tropic strain HIV-Ibal is unable to infect homozygous ccr5A32
macrophages.
Methods
See chapter 2 for details of procedures mentioned below.
Literature search
Reported ccr5A32 allele frequencies for various populations were obtained from 28
different published papers and tabulated in a standard form alongside the
approximate latitude of each population's position on the globe (Wilett, 1985).
Hardy-Weinberg equilibrium calculations
Allele frequencies were calculated from reported genotype frequencies. Expected
genotype frequencies were calculated on the assumption that the alleles were in
Hardy-Weinberg equilibrium (HWE) as described in Connor and FergusonSmith,
1993, and Mange and Mange, 1989. The Chi-squared test (Excel97, Microsoft) was
then used to compare actual genotype frequencies with the expected frequencies if
HWE applied. The results of this test calculated to the 95% confidence level, were
then reported as a Yes/No answer to the question, "are the ccr5A32 and wt alleles at
HWE in this population?"
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Regression analysis
Regression analysis was performed in order to correlate allele frequency and latitude
data. Because allele frequency is proportional data it cannot be used directly in
regression analysis. Data was first transformed using the logistic (logit)
transformation. The logit transform of each reported allele frequency (y) was then
correlated against the latitude (x) by Bill Adams (University of Edinburgh Medical
Statistics Unit) using weighted regression and Genstat 5.4.1 software.
Ccr5A32 genotyping
Blood donors were genotyped for ccr5A32 using a PCR-based method, which could
be applied equally successfully to cDNA or genomic DNA. cDNA was usually used
because it had been synthesised for use in other experiments. RNA was isolated from
PBMC from Buffy coats from South East Scotland blood donor sessions (SNBTS).
This RNA was then reverse-transcribed to cDNA. Alternatively, genomic DNA was
isolated from blood donor PBMC samples. Using either cDNA or genomic DNA and
primers detailed in chapter 2 and appendix 2, PGR was used to amplify a section of
the ccr5 gene spanning the A32 deletion site. When the PCR products were
electrophoresed on a 2.5% agarose DNA gel the ccr5A32 mutant allele could be
distinguished from the wildtype allele by a size difference. This allowed homozygous
wildtype, homozygous A32 and heterozygous individuals to be identified and
counted.
HIV-Ibal Infectivity assay
HIV-Ibal was incubated with wildtype or homozygous ccr5A32 monocyte-derived
macrophages for 96 hours, as described in chapter 2, before a PCR-based assay was
used to detect the presence ofHIV-1 mRNA (indicative of infection). 32 thermal
cycles were used for the PCR reaction, a number determined to be optimal for the




The ccr5A32 allele is not evenly distributed either geographically or across ethnic
groups. Tables 3.1 to 3.6 show the global distribution and HWE status of the
ccr5A32 allele compiled from various sources.
The mutant allele has been reported to be present in all European populations
at a frequency of 0.9% (Corsica) to 15.5% (Poland, table 3.1). Regression analysis
was used to examine the relationship between mutant allele frequency and latitude of
population (°N). Figure 3.2 shows the result of this analysis, which indicate
significant correlation between the variables. The regression line predicts an allele
frequency of 12.61% for South East Scotland (56°N), with a 95% confidence interval
of 8.42% to 16.80%.
In the vast Ural-Volga region and Northern Asia (table 3.2) incidence of the
ccr5A32 allele is very variable. The mutation is present in both Caucasian members
of this region and non-Caucasian groups such as the Tartars. The mutant allele
frequency in some of these non-Caucasian groups is so high that it is unlikely to be
the result of intermarriage with Caucasian settlers. This data, therefore, dispels the
myth that the ccr5A32 allele is exclusively present in Caucasian populations. The
mutant allele is however, completely absent in Oriental and East Asian populations.
The mutation is absent from African populations (Table 3.3) with the
exception of Mediterranean Africans. The highest reported incident in an African
population was in a group ofMoroccans, Algerians and Tunisians living in Paris. No
Africans were found homozygous for the defective allele.
In the Middle East the mutation was almost completely absent from all
groups except Israeli Jews. Caucasian Jews had the highest incidence of ccr5A32
(table 3.4).
The incidence data for the Asia Pacific is shown in table 3.5. In East Asia the
mutation is absent. There is a low mutation incidence in many populations from the
Indian sub-continent. Aboriginal Australians have an allele frequency of near zero,
but Caucasian Australians have a frequency similar to that ofNorthern or Central
Europeans. A similar situation exists in the Americas (table 3.6); native populations
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and African and Asian settlers have a ccr5A32 allele frequency of zero or very low
(this could be due to intermarriage with Caucasians). Caucasian Americans have an
allele frequency similar to Europeans.
Out of 127 populations tested for HWE, 8 (6.3%) showed deviation from this
at the 95% confidence level. However at this confidence level one would expect
about 6.4 (5% of 127) false negatives. The HWE test may not be an appropriate test
for small samples and those that consist of a mixture of groups.
In South East Scotland out of 94 blood donors genotyped (figure 3.3) 70 were
homozygous wildtype, 20 were heterozygous and 4 were homozygous mutant. This
gives a ccr5A32 allele frequency of 14.89% and a wildtype allele frequency of 85.11.
If the alleles were at HWE, one would expect 69.06 wt/wt, 23.87 A32/wt and 2.06
A32/A32 genotypes. The Chi-squared test shows that the deviation from this
expected result is not significant (P=0.114), thereby providing evidence that the
alleles are in HWE in South East Scotland's blood donors.
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Figure 3.2. Correlation between latitude and ccr5A32 allele frequency.
Using data of European incidence of ccr5A32 from table 3.1, and weighted
regression, the logistic transform of ccr5A32 frequency was correlated with
latitude.
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Figure 3.3. Genotyping of ccr5. RNA extracted from donors 1, 2 and 3 was
subjected to RT-PCR for (3-actin and ccr-5. The ccr-5 products show a length
polymorphism with wildtype message amplifying to a 190 base pair product
and the z!32 mutant message amplifying to a 158 base pair product. This
allows sample 1 to be detected as homozygous for the A32 mutation. Sample
2 is heterozygous and sample 3 is homozygous wildtype. pGEM = molecular
weight marker (Promega), MM = master-mix no-template negative control.
Infection ofhomozygous ccr5A32 mutant macrophages
The macrophage (R5)-tropic HIV-1 strain BAL was unable to infect macrophages
which were homozygous for ccr5A32 within the 96 hour time-frame allowed by the
assay used. Figure 3.4 shows the results of one of these infectivity assays.
Macrophages from three homozygous wildtype donors and one heterozygous donor
were demonstrated to be able to support infection by HIV-1 bal- Macrophages from
two donors homozygous for the ccr5A32 mutation were unable to support detectable
infection.
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Figure 3.4. HIV-1Bal infectivity assay. An RT-PCR based assay was used
to detect mRNA for HIV-1 and /3-actin from macrophages of the genotype
indicated. The figure shows positive signals for both HIV-1 and (5-actin from
RNA extracted from the wildtype macrophages. The mutant macrophages
yielded only a signal for p-actin. MM = master mix, no-template negative
control for the preceding two lanes. pGEM = molecular weight marker
(Promega).
Discussion
CCR-5-tropic HIV-1 can not infect ccr5 null macrophages
It has been previously reported that T-cells (Wu et al., 1997; Paxton et al., 1999) and
whole PBMC (Quillent et al., 1998) from individuals homozygous for the ccr5A32
mutation are resistant to infection with CCR-5 utilising, M-tropic isolates ofHIV-1.
This is supported by the observation (figure 3.4) that HIV-1Bal, an M-tropic isolate
of HIV-1 is unable to infect homozygous mutant monocyte-derived macrophages.
Taken together these data strengthen the evidence for CCR-5 as the major entry
coreceptor for HIV-Ibal, The fact that M-tropic HIV-1 isolates require CCR-5 to
infect cells and that usually this role of CCR-5 can not be replaced by another
coreceptor gives hope for therapeutics aimed at blocking CCR-5 such as those
discussed in chapter 6. Because ccr5 null cells have no known phenotype in healthy
individuals, it is hoped that CCR-5 could be functionally blocked with few side
effects.
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The ccr5A32 mutation is generally in Hardy-Weinberg equilibrium in non-HIV-1
infectedpopulations
If two alleles A and a have respective population frequencies of p and q and are in
Hardy-Weinberg equilibrium (HWE) the frequency of the genotype AA is predicted
to be (within random statistical variation) p . The frequency of the genotype Aa is
2pq, and the frequency of aa is q (Mange and Mange, 1989; Connor and
FergusonSmith, 1993). HWE is disrupted if there is selective pressure for or against
one of the genotypes. Small populations, migration of individuals, non-random
mating and populations which are really mixtures of two or more populations may
also deviate from HWE. Because the ccr5A32 homozygous genotype is protective
against HIV-1, cohorts ofHIV-1 infected individuals are not in HWE for this gene.
The number of ccr5A32 homozygotes is less than that predicted by the Hardy-
Weinberg formula (Michael et al., 1997). Populations that are HIV-1 exposed but
uninfected will contain more ccr5A32 homozygotes than predicted and will not be in
HWE either (Hoffman et al., 1997; Husman et al., 1997).
Out of the 127 populations meta-analysed (tables 3.1 to 3.6) which contain
the ccr5A32 allele, all but eight are in HWE. Because the HWE was calculated to a
95% confidence interval, one would expect about 5% (6.35 out of 127) of the
populations to be designated as not in HWE just due to random variation of gene
distribution. Also, some of the populations are rather small and some population may
be mixtures of several ethnic groupings. Overall, the data from the populations in
tables 3.1 to 3.6 would suggest that in populations which have not been significantly
exposed to HIV-1, the ccr5A32 allele is in equilibrium with its wildtype counterpart
and is not currently under any selection pressure. This statement raises a very
important question; if there is currently no pressure, apart from HIV-1, for the
selection of particular ccr5 alleles, what forces led to the non-random geographic
distribution of the ccr5A32 allele that we see today?
The incidence ofthe ccr5A32 mutation in SE Scotland is as predicted
The 14.89% frequency of the ccr5A32 mutation in SE Scotland blood donors is as
one would predict for a north European country. It fits within the figure 3.2
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regression curve, and is not significantly different from the 11.1% value previously
calculated for England (Martinson et al., 1997).
Possible explanations for the distribution ofccr5A32
In order to speculate about the origin of the ccr5A32 mutation and the evolutionary
forces that lead to its spread and maintenance, it would be useful to know when it
arose. The mutation's geographical distribution can give some clues to this. The fact
that the mutant allele is present in Caucasian New World populations at similar
frequencies to those in the founding European populations (Tables 3.5 and 3.6)
would suggest that the mutation arose before mass emigration to the New World
from Europe. Genetic studies (Stephens et al., 1998; Libert et al., 1998) using
microsatellite repeat sequence data and the coalescence of haplotype theory suggest
that the mutation arose, only once in North Eastern Europe about 700 years ago.
Nothing in the geographic distribution data presented here contradicts this theory.
For a mutation as recent as 700 years old to have spread around Europe with such
speed to give the present day distribution patterns, there must have been a strong
evolutionary advantage in carrying the mutation. ETIV-1 would be a candidate to
cause such selective pressure if it had been around hundreds of years ago. HWE data
(tables 3.1 to 3.6) show that at the present time, apart from HIV-1, there is no other
selective pressure for or against the ccr5A32 mutation. Therefore, it seems likely that
an earlier epidemic of a disease for which ccr5A32 provided protection and which is
no longer prevalent would have provided the selection force required to explain the
mutation's spread. One could argue that such a rapid spread of the mutant allele
required a very strong selection force and that an epidemic which was able to exert
this force (by extremely widespread and high mortality) would not have escaped
historical documentation. Several authors have suggested that the Black Death (The
Plague, Yersiniapestis) which spread through Europe from 1333 onwards (Ziegler,
1969), arrived in Britain in 1348 (Nikiforuk, 1992) and struck Edinburgh badly in
1568 (Skeyne, 1969) and London in 1665 (the 'Great Plague', Defoe, 1960) could
have provided the selection pressure needed for the spread ofccr5A32. The Black
Death certainly produced sufficient levels ofmortality with 15 to 50% of Europeans
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dying (Nikiforuk, 1992). However, no-one has been able to show that the ccr5A32
allele offers any protection against Yersinia pestis or suggest a convincing
mechanism of chemokine involvement in the pathogenesis of plague. The disease
still strikes today, mainly in the third world (although a small outbreak occurred in
Glasgow in 1900, Chalmers, 1901) so there ought to be an opportunity to study the
incidence of ccr5A32 genotypes in plague victims and survivors.
Although the plague theory provides for a sufficient die-off at an appropriate
date, it does not explain why the ccr5A32 allele did not spread to India, a region
ravaged by plague during a similar period to Europe (Ziegler, 1969); maybe there
was not time for the mutation to spread this far.
Rhesus macaques (Macaca mulatto), sooty mangabeys (Cercocbus torquatus
atys) and red-capped mangabeys (Cercocbus torquatus torquatus) naturally carry
SIV. Homozygosity for a 24 base deletion in the ccr-5 gene (ccr5A24) of these
healthy monkeys results in no functional CCR-5 being produced and offers
protection from CCR-5-tropic SIV strains (Chen et al., 1998; Palacios et al., 1998). It
seems more likely that the ccr5A24 monkey allele was maintained as a defence
against SIV than Yersiniapestis as there is no evidence that these monkeys ever
occurred in plague regions (Szalay and Delson, 1979). Although the monkey
ccr5A24 mutation arose independently of the human ccr5A32 mutation, it provides
evidence that primate retroviruses have long been using CCR-5 for entry and that the
hosts have responded to this ancient threat by removing the receptor from the path of
the virus. This theory is compatible with the view that the human ccr5A32 mutation
spread as a defence to an ancient human retrovirus.
In conclusion, much more work needs to be done in order to explain with any
degree of certainty the reason for the human ccr5A32 mutation. The Plague theory
may be the best that has been offered so far but it remains unconvincing in several
ways. It seems likely that an ancient epidemic led to the spread of the ccr5A32
mutation but the disease in question remains elusive. Maybe a now dormant
retrovirus was responsible or maybe HIV-1 itself was responsible and it is not such a
modern virus as we suppose
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CHAPTER 4: RESULTS
GP120 INDUCED CD4 LOSS
Background
HIV-1 infection andgpl20 causes immune system dysregulation
As reviewed in the introduction to this thesis, HIV-1 causes AIDS by disrupting the
anti-pathogen immune response (Rodriguez and Hard, 1995). HIV-1 is able to infect
CD4+ T-cells and CD4+ antigen presenting cells (APCs), including macrophages and
dendritic cells (BarreSinoussi, 1988; Hewson et al., 1999; Fidler and Rees, 1999).
There is also evidence that both T-cell and APC function can be compromised in
uninfected cells ofHIV-1+ patients (Wagner et al., 1992; Desbarats et al., 1996;
Chirmule and Pahwa, 1996; Karsten et al., 1996; Ng et al., 1996; Heinkelein et al.,
1997; Kaneko et al., 1997; Hewson and Howie, 1998). HIV-1 associated alteration of
APC function has downstream consequences for the generation of adaptive immune
responses. In addition, altered macrophage function has implications for the innate
immune response to pathogens. In particular, lack of IL-12 production by HIV-1
infected individuals is associated with increased opportunistic infection (Chehimi
and Trinchieri, 1994; Marshall et al., 1999). Although all the proteins ofHIV-1 have
been implicated in disrupting infected immune cell function (Willey et al., 1992;
Rhee and Marsh, 1994; De et al., 1998; Peter, 1998; Hewson et al., 1999) secreted
gpl20 is arguably the most damaging viral product because it has the potential to
dysregulate the function of uninfected CD4+ cells in HIV-1 infected individuals.
Gpl20 is found in the plasma ofHIV-1+ patients with AIDS or AIDS related
complex (ARC), mainly in the form of immune complexes (Oh et al., 1992).
The structure of gpl20 determines viral tropism such that gpl20 derived from
most primary / macrophage-tropic isolates binds to both CD4 and CCR-5 (R5-tropic
gpl20) while T lymphocyte-tropic variants bind to CD4 and CXCR-4 (X4-tropic
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gp 120, Wu et al., 1996; Rizzuto et al., 1998; Choe, 1998; Hoffman and Doms,
1999).
Physiological roles ofCD4, CCR-5 and CXCR-4
CD4 on the surface of T lymphocytes acts as a ligand for MHC class II on the
surface of APCs. Interactions between MHC class II and multiple CD4 molecules
stabilise the MHC class II / TCR interaction required for signal one transmission to
the T-cell (Sakihama et al., 1995; Janeway and Travers, 1996). CD4 binding ofMHC
class II causes signals to be transmitted through p56lck, a second messenger
associated with the cytoplasmic tail ofCD4 in T cells (Veillette et al., 1988). CD4
association with P56lck in T-cells prevents the constitutive CD4 internalisation and
recycling of CD4 seen in non-lymphoid cells (PelchenMatthews et al., 1991;
PelchenMatthews et al., 1992). CD4 on the surface of APCs is not associated with
p56lck (Bowers et al., 1997) but on both T-cells and APCs, CD4 acts as a receptor for
the chemotactic cytokine IL-16 (Center et al., 1996). IL-16 and gpl20 have both
been demonstrated to inhibit the mixed lymphocyte reaction by binding to CD4 and
disrupting CD4 / TCR / CD3 complexes (Theodore et al., 1996). It has been reported
that gpl20 can signal through CD4 and chemokine receptors to mimic the
chemotactic actions of IL-16 and chemokines. M-tropic gpl20 can mediate
chemotaxis of CD4+ T-cells by signalling through CD4 (Iyengar et al., 1999).
T-tropic gpl20 is able to signal through CXCR-4 in a CD4 independent fashion to
cause phosphorylation of Pyk2 (Misse et al., 1999) and chemoattraction of CD4+ and
CD8+ T-cells (Iyengar et al., 1999; Misse et al., 1999).
HJV-1 induced changes to cell surface phenotype
There have been several reports of gpl20 modulating cell surface CD4 levels.
Incubating X4-tropic gpl20 with CD4+ T-cells leads to loss of surface CD4 after 6
hours, CD4 loss reaches a nadir at 24 hours and starts to recover after 96 hrs
(Theodore et al., 1994). CD4 loss reduces the ability of T-cells to exhibit chemotaxis
in response to anti-CD3 or anti-CD4 antibodies. The ability to migrate in response to
either of these stimuli returns when CD4 levels recover, a process which can be
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blocked by cycloheximide, and is therefore likely to involve de novo synthesis of
CD4 (Theodore et al., 1994). Naturally expressed X4-tropic gpl20 from HIV-Ihib
has been shown to cause surface CD4 loss from monocytes over a period of a few
days (Wahl et al., 1989). This down-regulation of CD4 resulted in a reduced
chemotactic response to IL-16 and was suggested to be due to gpl20-induced
monocyte to macrophage differentiation (Wahl et al., 1989). Various other authors
have demonstrated gpl20 induced surface CD4 loss from macrophage or monocyte
cell surfaces. Experiments with recombinant gpl20 from HIV-Tub showed 30% loss
of CD4 from in vitro derived macrophages after 6-12 hrs of incubation with gpl20
(Karsten et al., 1996). This CD4 loss was dependent on TNF-a secretion in response
to CD4 cross-linking and the activation of the ras pathway (Karsten et al., 1996;
Tamma et al., 1997). Another study showed that X4-tropic gpl20 was able to induce
a CD4 loss and a deficit in T-cell stimulation in a tuberculin antigen presentation
assay (DurrbaumLandmann et al., 1994). Other agents, such as 1,25-dihydroxy
vitamin-D3 (Rigby et al., 1990) have been shown to cause CD4 loss from
macrophage cell surfaces. LPS induces a CD4 loss via the induction of TNF and
IL-1P (Herbein et al., 1995).
There have been no reports of the effect ofR5-tropic gpl20 on macrophage
or monocyte cell surface molecules, nor any reports ofX4-tropic gpl20 inducing
more than 30% loss of surface CD4 as measured by the intensity of flow cytometry
staining.
Endocytosis andphagocytosis
Endocytosis is the process of a cell internalising components of its environment,
whether they be liquid (pinocytosis - 'cell drinking') or solid. Endocytosis is a very
important function ofmacrophages both immunologically (Janeway and Travers,
1996), and in the clearance of effete, necrotic or apoptotic cells during tissue
development and remodelling (Loegering, 1985; Brewton and Maccabe, 1988; Stoll
et al., 1989; Stern et al., 1992; Savill et al., 1996; Mitchell et al., 1999; Bird et al.,
1999; Moffatt et al., 1999). Endocytosis by an APC allows previously external
potential antigens to enter MEIC loading machinery and be presented to T-cells in an
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immuno-stimulatory or tolerogenic context (Kurts et al., 1998; Allison et al., 1998;
Peterson et al., 1999). Endocytosed protein is cleaved into suitable length peptides,
which are mainly loaded into MHC class II molecules for presentation to CD4
T-cells. MHC class I molecules are mainly filled with peptides derived from
endogenous protein. There is however some leakage of the MHC loading pathways
so that a limited amount of exogenously derived peptide can be presented by MHC
class I molecules, and endogenously derived peptide can be presented by class II
molecules (Bachmann et al., 1995).
Phagocytosis is a from of endocytosis where an exogenous solid is engulfed
by a cell. Phagocytosis takes in a greater volume of material in a single 'gulp' than
pinocytosis (Cohn and Steinman, 1982; Pratten and Lloyd, 1986) and is mediated by
cell surface receptors for the solid being engulfed. Phagocytosis is triggered by
receptor recognition of a ligand, whereas pinocytosis is constitutive (Cohn and
Steinman, 1982). A wide range of receptors can be involved in receptor-mediated
phagocytosis including Fc receptors (Mellman, 1982; Kim and Schreiber, 1999; May
et al., 2000) and complement receptors (Kusner and Hall, 1996; Kim and Schreiber,
1999; Webster et al., 2000). The intracellular destinations of endocytosed material
can be various; the route of entry and nature of the material influences this (Dermine
and Desjardins, 1999; Clemens et al., 2000). If endocytosed material is to be
antigenic ifmust be correctly processed into suitable peptides and then loaded into
MHC molecules before being presented at the cell surface (Janeway and Travers,
1996).
Endocytosed material can be detected as vesicles inside the engulfing cell by
confocal microscopy (Ojcius et al., 1996). Pinocytic vesicles can be distinguished
from phagosomes in that they are usually much smaller and more numerous (Cohn
and Steinman, 1982; Pratten and Lloyd, 1986; Hewlett et al., 1994). If endocytosed
material is subsequently discovered in an MHC-containing compartment it is
possible that presentation of this material will result if it can be suitably processed
and loaded into MHC molecules.
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Implications ofendocytosis by APCs
Because endocytosed material contributes almost entirely to the peptides presented
by APCs in MHC class II and also to a far lesser degree to MHC class I held
peptides, the efficiency of endocytosis has the potential to influence the efficiency of
antigen presentation, particularly to CD4+ T-cells.
Autoreactive T-cells are not all deleted in the thymus nor completely silenced
by peripheral tolerance mechanisms (Genain et al., 1994; Fang et al., 1997; Williams
et al., 1998). In order for a T-cell to become activated, an above-threshold number of
its cell surface TCRs need to be simultaneously engaged (Valitutti et al., 1995).
Functional tolerance to many self antigens may result because antigenic epitopes are
not normally presented on APCs at densities high enough to stimulate autoimmune
T-cell activation. Any process that increases the presentation of autoimmune epitopes
has the potential to break this tolerance. Once tolerance of this nature has been
broken it may be difficult to re-establish since memory T-cells with lower
stimulation thresholds will have been generated (Hurst et al., 1999; Saparov et al.,
1999; Bachmann et al., 1999; London et al., 2000). Presentation of endocytosed
material might also break functional tolerance because the endocytic pathway may
process self-proteins differently to the endogenous antigen pathway, thereby
revealing cryptic epitopes.
There have been several reports of autoimmunity in HIV-1 infected patients.
T-cell autoimmunity to the CD4 molecule was found in one quarter of an HIV-1
infected Italian cohort, cases of autoimmunity being more common in cohort
members with markers for disease progression (Caporossi et al., 1998).
Autoantibodies to platelets (Magnac et al., 1990), CD4 (Chams et al., 1988), T-cell
receptors (Marchalonis et al., 1997) and Fas (Strieker et al., 1998) have been found
in HIV-1 infected individuals; the last three classes of autoantibodies all have the
potential to cause a T-cell immune deficit. A change to the efficiency of antigen
processing and presentation also has the ability to dysregulate immune responses in
less predictable ways than the induction of autoimmunity. Loss of specific immune
responses (such as those against Candida albicans and tetanus toxoid, Tassinari et
al., 1995) and skewing of responses (for example away from VH3 utilising
antibodies, Juompan et al., 1998) have been recognised in HIV-1 disease.
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Mechanisms such as immune exhaustion of responses to over-presented antigens,
presentation of antigens in a tolerogenic environment (e.g., in absence of co-
stimulation) and presentation concomitantly to an autoantigen for which a suppressor
cell population exists (leading to bystander suppression, see chapter 5) could be
evoked to explain such phenomena.
Summary
The experiments described in this chapter compare interactions between R5- and
X4-tropic gpl20, with CD4+ monocyte derived macrophages from non-infected
healthy individuals. Evidence is presented for a novel mechanism of R5-tropic
gpl20-induced macrophage surface-CD4 loss and internalisation. This loss is rapid,
substantial and does not occur with X4-tropic gpl20. Confocal microscopy has been
used to follow CD4 loss from the surface, and the kinetics and regulation of surface
CD4 recovery has been investigated by semi-quantitative RT-PCR.
Specific questions
• Is the ability of gpl20 to cause a loss ofCD4 from APC surface influenced by
the cellular tropism of the virus from which the gpl20 was derived?
• Is gpl20-induced CD4 loss due to gpl20 mimicking IL-16 or MlP-la,
physiological ligands of CD4 and CCR-5?
• Is gpl20 induced CD4 loss dependent on CCR-5 expression? Is it observed in
ccr5A32 mutant macrophages, which fail to express CCR-5?
• What is the mechanism of gpl20 induced CD4 loss?
• Where do the lost CD4 and associated gpl20 end up? If it is endocytosed by the
APC, what are the likely consequences of this for the APC and immune system
as a whole?
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• Do CD4 levels recover? By what mechanism?
Materials and methods
See chapter 2 for details.
Reagents and antibodies
Cells were treated with various agents at 8.3nM (equivalent molarity to lpg/ml of
gpl20).
Gpl20niB and R5-gpl20 were obtained from the NIBSC Centralised Facility for
AIDS Reagents. These baculovirus expressed recombinant proteins were derived
from the T-cell line adapted virus strain FHV-Ijiib (Ratner et al., 1985, GenBank
accession number X01762) and from cDNA isolated from a primary macrophage of
paediatric AIDS patient MN (Gurgo et al., 1988, GenBank accession number
U72495). The gene sequences used to generate both rgpl20s were kindly analysed
according to published criteria (DeJong et al., 1992; Fouchier el al., 1992) by Dr
Peter Simmonds (Laboratory for Clinical and Molecular Virology, University of
Edinburgh) and confirmed to be X4-tropic and R5-tropic respectively.
Cytokines. Recombinant IL-16 was obtained from R&D Systems Europe Ltd.
MlP-la was obtained from the NIBSC Centralised Facility for AIDS Reagents.
Anti-CD4. Macrophages were, on occasion, treated with a cross-linking anti-CD4
monoclonal antibody (clone QS4120 from the NIBSC Centralised Facility for AIDS
Reagents). This antibody binds to the gpl20 binding site of CD4 and does not
compete for binding with the MT-310 clone anti-CD4 used to measure CD4 levels
(McKeating et al., 1993; Shotton et al., 1995).
Neutralisation of TNF-a. Neutralising monoclonal anti-TNF-a antibody (clone
1825.121) was obtained from R&D Systems Europe Ltd and added to some
macrophage cultures at 1 pg ml" , a concentration shown by the manufacturer to give
100% neutralisation.
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FITC conjugation of protein. Gpl20 was conjugated to fluorescein isothiocyanate
(FITC) as described in chapter 2. The FITC:gpl20 ratio of the conjugate was
determined using a spectrophotometer and found to be 7:1, similar to a FITC:BSA
ratio of 11.2:1 for FITC conjugated BSA which was used as a control protein
Macrophage Isolation and Culture. Macrophages obtained from Buffy-coats from
single, anonymous, healthy blood donations were cultured for 6 days before the start
of experiments. All the donors were genotyped for the ccr5A32 mutation.
Detection of CD4 and CD18 by Flow Cytometry. To detect alterations in CD4
level an anti-CD4 antibody, MT310, which binds to a different epitope of CD4 from
that which gpl20 binds to was used (McKeating et a!., 1993; Shotton et al., 1995).
Anti-CD 18 (as a control) was also used on occasion. Cultured macrophages were
stained to determine surface marker level as described in chapter 2 after various
treatments. Relative intensities of cell surface staining were determined by
comparing the mean fluorescence intensity of staining, above the background
staining of an isotype control, between samples. Suitable concentrations of
antibodies were determined by titrations, the results ofwhich are presented in figure
4.1. Means and standard errors were calculated for each treatment and means were
compared using unpaired Mann Whitney U tests.
Detection of cell-surface bound gpl20. Six day old macrophages were harvested
from culture flasks and placed at 105 cells per well in a round bottomed 96-well
plate, washed twice with flow buffer and pelleted. 10pi ofR5-gpl20 or gpl20mB at
lpg ml"1 in flow buffer was added to the cell pellet, which was then agitated and
incubated on ice for 2 hours. After washing four times with ice-cold flow-buffer.
lOp.1 of 0.5pg ml"1 polyclonal sheep anti-gpl20 serum was added to the cell pellets
(ARP0734, NIBSC Centralised Facility for AIDS Reagents). Cells were incubated on
ice for a further 2 hours before a single wash in flow buffer, the addition of 1 Opl of
10pg ml"1 of biotinylated donkey anti-sheep serum (Sigma) and incubation on ice for
1 hour. Following another wash. 10pl of lpg ml"' R-PE-conjugated strepavidin was
added to each well and incubated for 1 hour on ice. Cells were then washed twice in
flow buffer and suspended in flow buffer / flow fix, as detailed in chapter 2, for
analysis by flow cytometry.
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Endocytosis of FITC conjugated antibody. Anti-CD4 (clone QS4120) and FITC-
conjugated goat anti-mouse (Fc fragment specific, Sigma) antiserum at lOOpg ml"1
each were incubated together on ice for two hours. The resultant antibody complex
was then added to macrophages at 8.3nM, as was non-pre-incubated FITC-anti-
mouse antiserum. Cells were then treated for confocal microscopy as described
below.
Staining of macrophages for confocal microscopy. Monocyte-derived human
macrophages were grown on sterile glass coverslips for 7 days before treatment with
FITC-gpl20 or FITC-BSA for various lengths of time. Cells were then fixed,
permeabilised, stained for CD4 or FJLA DR, and examined by laser scanning
confocal microscopy and image analysis software.
Macrophage ccr-5A32 Genotyping by RT-PCR. Carried out as described in
chapter 3.
Semi-quantitative RT-PCR. RNA was extracted, and 0.1 pg was reverse transcribed
from each sample as described in chapter 2. A variable cycle number PCR reaction
was carried out to determine the optimum number of cycles required for a near-linear
relationship between the RNA level and resultant DNA band intensity (figure 4.2).
All cDNAs were then amplified by PCR for this number of cycles, and relative
cDNA levels calculated as described in chapter 2. James Logie, a BSc student under
my supervision, did much of this work.
Results
Antibody titration
CD4 and CD18 levels on different macrophage populations were quantified by flow
cytometry. So that increases and decreases could be reproducibly measured, an
appropriate antibody concentration for use in subsequent experiments was
determined by carrying out titrations with different concentrations of primary
antibody as described in chapter 2. A concentration of lOpg ml"1 was chosen for all
subsequent experiments with either antibody, based on these titrations. Figure 4.1
shows data from an anti-CD 18 titration as an example.
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Semi-quantitative RT-PCR optimisation
Figure 4.2 shows data produced from variable cycle RT-PCR experiments. 31 (CD4
and (3-actin) and 29 (ccr5) were chosen as appropriate numbers of cycles for all
future semi-quantitative RT-PCR under similar conditions.
Gpl20 induces a loss ofmacrophage surface CD4
Recombinant gpl20 derived from an M (R5)-tropic primary isolate ofHIV-1 caused
loss of CD4 from the surface of ccr5A32 wildtype macrophages (figure 4.3). The loss
of CD4 was apparent from 1 hour following the addition of gpl20 and reached a
nadir at approximately 3 hours. By 18 hours after gpl20 administration, surface CD4
levels began to recover.
CD4 loss is dependent on gp!20 tropism and cell surface CCR-5
The extent of gpl20-induced surface CD4 loss was dependent on the viral strain
from which the gpl20 was derived (figure 4.4). Gpl20niB induced a maximal 15-
25% surface CD4 loss at 3 hours, which did not reach statistical significance as
judged by the unpaired Mann-Whitney U test at any time-point. R5-tropic gpl20-
induced surface CD4 loss was, however, more substantial (65-75% at both 1 and 3
hours) and statistically significant at all time-points (versus starting CD4 levels
P=0.0411 at 1 hour, P=0.0087 at 3 hours, P=0.0431 at 18 hours). There were also
significant differences between the responses to the two gpl20s (see figure 4.4 for
details). To confirm that substantial CD4 loss was dependent on CCR-5 binding, the
same experiment was repeated twice on macrophages from donors homozygous for
the ccr5A32 homozygous mutation, which fail to express surface CCR-5 (figure 4.5).
On these macrophages neither gpl20uiB nor R5-tropic gpl20 was able to induce a
significant loss of surface CD4.
M- and T-tropic gpl20 can both bind to the macrophage surface
The differences between the R5-tropic gpl20 and gpl20mB in their induction of
surface CD4 loss could be due to differences in their ability to bind to macrophage
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cell surfaces. In order to explore this question ccr5A32 wildtype macrophages were
incubated with either one of the gpl20s used, on ice and in the presence of sodium
azide in order to inhibit endocytosis. Cells were then washed and surface-bound
gpl20 was detected using a polyclonal antibody. Figure 4.6 shows that surface bound
gpl20 was detectable regardless of the HIV-1 strain from which it was derived. It
would be wrong to suggest that figure 4.6 shows R5-tropic gpl20 binding to
macrophage surfaces more strongly than gpl20mB does. This may well have been the
case, but the difference in fluorescence intensity between the two groups of labelled
cells was not large, and could be explained by differences in detection efficiencies by
the polyclonal anti-gpl20 used in this study.
CD4 and CCR-5 ligands IL-16 andMlP-lafail to induce a CD4 loss
In order to further explore the apparent requirement of CD4 and CCR-5 binding for
the surface CD4 loss induced by R5-tropic gpl20, wildtype macrophages were
incubated with the CD4 ligand IL-16 or the CCR-5 ligand MlP-la at 8.3nM (the
molarity at which R5-tropic gpl20 caused a CD4 loss). Figure 4.7 shows that neither
gp 1 20ihb, MlP-la nor IL-16 caused the substantial loss of surface CD4 observed
with R5-tropic gpl20.
Levels ofCD18, a control antigen, remain unchanged
In order to exclude the possibility that gpl20-induced CD4 loss was simply a
symptom of a more generalised loss of macrophage surface antigens in response to
incubation with the possibly cytotoxic R5-tropic gpl20, levels of another
macrophage surface marker, CD 18 were investigated. Neither gpl20inB, R5-tropic
gpl20 nor cross-linking anti-CD4 were able to cause a change in wildtype
macrophage surface CD 18 levels, at 1, 3 or 18 hours following addition of the agent
under test. Figure 4.8 shows CD18 levels on macrophages following 3 hours of
incubation with gpl20 or anti-CD4, a time-point when CD4 levels are at their lowest
on R5-tropic gpl20 treated cells. In all cases treated macrophages displayed similar
CD 18 levels to untreated macrophages.
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Neutralisation ofTNF-adoes not inhibit CD4 loss
There have been reports of gpl20 (Karsten et al., 1996) and LPS (Herbein et al.,
1995) induced losses ofCD4 being mediated by TNF-a production. In order to
investigate this possibility wildtype macrophages were incubated with gpl20mB, R5-
tropic gpl20 or cross-linking anti-CD4 in the presence of a neutralising dose of anti-
TNF-a. Table 4.1 shows that both R5-tropic gpl20 and anti-CD4 were able to induce
substantial surface CD4 losses, but no changes in CD 18 levels. Neutralisation of
TNF-a did not abrogate the CD4 losses observed. Table 4.1 also shows CD 18 levels
measured in the same experiment. None of the cellular treatments caused a change in
CD18 level. ITowever, the data suggests that neutralisation of TNF-a may result in a
slight reduction in CD 18 levels, an observation which was not pursued.
Loss ofsurface CD4 is accompanied by increased levels ofCD4 in an internal MHC
class If pool
One explanation for gpl20-induced CD4 loss is that gpl20 induced the endocytosis
of cell-surface CD4. Following incubation with R5-tropic gpl20, wildtype
macrophages were fixed, permeabilised and stained for surface and intracellular
CD4, before being examined using a fluorescence confocal microscope. Figure 4.9
shows that before gpl20-treatment most cellular CD4 is at the macrophage surface.
Following 3 and 18 hours of incubation with R5-tropic gpl20 there is less CD4
visible at the macrophage surface (this is in agreement with the flow cytometry data)
and more internal, peri-nuclear CD4. It is not clear from this experiment whether the
internal CD4 has been endocytosed from the cell surface, or if it is the product of de
novo CD4 synthesis. Interestingly at the 1 hour time-point there was no noticeable
increase in intracellular CD4 despite flow cytometry reporting a strong decline in
surface CD4 levels (figure 4.4). Double CD4 and HLA DR staining of macrophages
incubated for 3 hours with R5-tropic gpl20 showed that the internal CD4 was
colocalised with HLA DR, suggesting presence in the endoplasmic reticulum or
Golgi apparatus (figure 4.10).
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CCR-5 tropic gpl20 is endocytosed by a pathway resembling receptor mediated
phagocytosis.
Because of the difficulty in identifying the origin of intracellular CD4, the possibility
of gp 120 / CD4 / CCR-5 complex endocytosis was investigated by tracking the
internalisation of FITC-conjugated gpl20. FITC conjugated R5-gpl20 and FITC
conjugated BSA were incubated with macrophages for various times before fixation,
permeabilisation, staining for HLA DR, and confocal imaging. Figure 4.11 shows
images from this experiment and table 4.2 summarises the findings. After 20 minutes
to 1 hour BSA entered the macrophages as numerous small endocytic vesicles, which
resemble pinocytic vesicles. These persisted for at least five hours but by 2 hours
there was evidence of BSA-FITC conjugate breakdown in the form of a more diffuse
green stain, especially noticeable in the nucleoplasm where F1LA DR staining was
absent. In contrast, R5-tropic gpl20 entered cells mostly as one or two larger and
brighter vesicles resembling phagosomes from about 20 minutes; smaller vesicles
only became visible from about 1-2 hours. There was evidence of FITC-gpl20
conjugate breakdown from 2-3 hours. Some of both endocytosed proteins were
detected in HLA DR-containing compartments. FITC-conjugated gpl20mB entered
macrophages in a form resembling the entry ofBSA rather than R5-tropic gpl20
(figure 4.13). To further investigate the differences between pinocytosis of soluble
protein and receptor mediated phagocytosis an additional experiment was
undertaken. Macrophages were incubated for 1 hour with FITC-conjugated
polyclonal goat anti-mouse IgG immunoglobulin. This protein ought to be unable to
bind to the surface of human macrophages; it was endocytosed resulting in the
appearance of about 5 to 30 small fluorescently labelled vesicles per cell (figure
4.12a) resembling those formed by the endocytosis of gpl20mB or BSA (figure 4.11).
In contrast, when macrophages were incubated with pre-formed complexes of (FITC-
conjugated goat anti-mouse IgG / mouse anti-human CD4 antibodies) which are
expected to bind to the surface CD4 of human macrophages, endocytosis resulted in
the appearance of large and usually single fluorescent vesicles resembling those
formed by internalised R5-tropic gp!20 (figure 4.11).
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R5-tropic gpl20 enters macrophages along with CD4, gpl20niB and BSA do not
Figure 4.13 shows results from an experiment in which FITC-gpl20niB, FITC-R5-
tropic gpl20 or FITC-BSA was incubated with wildtype macrophages for 20
minutes, a length of time too short for de novo synthesis of CD4 to confuse the
results. Cells were then fixed, permeabilised and stained for CD4. The large bright
R5-tropic gpl20 containing vesicles also contained CD4 (figure 4.13a). The smaller,
less bright and more numerous BSA or gpl20niB containing vesicles did not contain
CD4, most of which remained on the macrophage cell surface.
R5-tropic gpl20 induces an up-regulation ofmRNA for CCR-5 and CD4
Figures 4.14 and 4.15 show that R5-tropic gpl20 but not gpl20mB induced a
concomitant and significant up-regulation of CD4 and CCR-5 mRNA transcript. The
increased mRNA was detectable from 1 hour after gpl20 incubation and persisted
for about 18 hours when levels started to decline. Variation between donor responses
was greater than in the case of surface CD4 protein decline with significant




Figure 4.1. Anti-CD18 antibody titration. Anti-CD18 or an isotype control
(at 20 pg ml"1) was used to stain 105 macrophages at the concentrations
shown. The R-PE conjugated secondary antibody was applied at a standard
recommended concentration throughout. It can be seen that use of the
primary antibody at a concentration of 1Opg ml"1 gave the greatest staining
intensity, this concentration was chosen for all subsequent experiments.
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Figure 4.2 (previous page). Variable cycle RT-PCR. The
electropherograms show PCR product bands obtained by amplification of an
equal amount of starting material for the number of cycles indicated. Graphs
showing corresponding band intensity values were produced by software
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Figure 4,3, Loss of surface CD4. Flow cytometry histograms showing loss
of surface CD4 from wildtype macrophages in response to incubation with
R5-tropic gp120. The signal obtained from surface CD4 declined within one
hour of incubation with R5-gp120 and reached its maximum extent by about
3 hours. The MnIX (mean fluorescence intensity) for isotype matched
controls remained between 0.5 and 0.7 at all time points.
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Figure 4.4. Surface CD4 levels. Macrophages were incubated with
R5-tropic gp120 or gp120wB for the times indicated. The MnIX values, above
the background fluorescence obtained with isotype control antibody staining,
have been rescaled and expressed as a percentage decrease from the initial
(untreated) staining intensity. Mean data values from experimental replicates
with six different ccr5A32 wildtype donors are shown. Bars show standard










Figure 4.5. Surface CD4 levels. Macrophages were incubated with
R5-tropic gp120 or gp120mB for the times indicated. The MnIX values, above
the background fluorescence obtained with isotype control antibody staining,
have been rescaled and expressed as a percentage change from the initial
(untreated) staining intensity. Mean data values from experimental replicates
with two different homozygous ccr5A32 donors are shown. Bars show




Figure 4.6. Detection of macrophage surface bound gp120. Macrophages
were incubated with a) R5-tropic gp120 or b) gp120mB. The surface bound
gp120s were then detected by flow cytometry using an anti-gp120 polyclonal
antibody, which was linked to FITC-conjugated strepavidin. Incubation of
cells with gp120 resulted in a higher fluorescence signal than cells stained






Figure 4.7. The effects of various CD4 or CCR-5 ligands on CD4 level
Macrophages from a single representative ccr5A32 wildtype donor were
incubated with R5-tropic gp120, gp120niB, recombinant human IL-16 or
recombinant human MIP-1a for the times indicated. The normalised MnIX
values were calculated from the mean fluorescence intensities of the anti-
CD4 labelled cells. The MnIX value, above the background fluorescence
obtained with the isotype control, was then rescaled and expressed as a
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Figure 4.8 (previous page). Macrophage surface CD18 levels do not
change. Monocyte-derived macrophages from a typical ccr5A32 wildtype
donor were incubated for 3 hours with a) gp120mB, b) R5-tropic gp120 or a
cross-linking anti-CD4 (QS4120) at concentrations previously demonstrated
to induce a decline in surface CD4. Cells were then stained with anti-CD18
and showed similar CD18 levels by flow cytometry to those on control
(untreated) cells.
Treatment
CD4 (MnIX) CD 18 (MnIX)
no anti-TNF + anti-TNF no anti-TNF + anti-TNF
Nil - Ohr 11.1 12.5 61.0 45.4
Gpl20niB - lhr 7.93 8.06 58.5 43.8
Gpl20niB - 3hr 8.63 8.68 52.0 44.1
Gpl20ihb - 18hr 8.49 8.75 N.D. 51.5
Nil - Ohr 11.1 12.5 61.0 45.4
R5-gpl20- lhr 6.18 6.57 54.1 53.8
R5-gpl20 - 3hr 4.61 4.63 64.4 49.6
R5-gpl20 - 18hr 4.34 4.33 64.8 48.4
Nil - Ohr 11.1 12.5 61.0 45.4
Anti-CD4- lhr 4.38 4.43 66.7 55.1
Anti-CD4 - 3hr 4.12 3.80 62.2 55.3
Anti-CD4 - 18hr 4.32 4.10 70.7 N.D.
Table 4.1. Effect of TNF-a on macrophage CD4 loss. Ccr5A32 wildtype
macrophages were incubated with gp120mB, R5-tropic gp120 or cross-linking
anti-CD4 for the times indicated above, in the presence or absence of anti-
TNF-a neutralising antibody, before having their surface CD4 and CD18
levels measured by flow cytometry. Surface antigen levels are expressed as

















R5-gp120 - 18hr 0,045915
Figure 4.9. CD4 inside macrophages. Confocal micrographs of ccr5A32
wildtype macrophages which have been incubated with R5-tropic gp120 for
the times indicated, before being fixed, permeabilised and stained for CD4.
At the zero time-point most of the CD4 can be seen on the cell surface. At
the 3 and 18 hour time-points, there is less surface CD4 and more internal
peri-nuclear CD4 visible.
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a) MHC class II (HLA DR, TRITC)
b) CD4 (FITC)
c) overlay
MHC class II (red)
CD4 (green)
Figure 4.10. CD4 and MHC class II colocalise to an internal
compartment. Confocal micrographs of a ccr5A32 wildtype macrophage,
which has been incubated with R5-tropic gp120 for 3 hours and then fixed,
permeabilised and stained red for MHC class II (HLA DR, figure 4.10a) and
green for CD4 (figure 4.10b). CD4 and MHCII are colocalised both at the cell
surface and intracellularly, as indicated by the coincidence of red and green
stains to give a yellow image (figure 4.10c).
142
No treatment I No treatment
BSA - 20 minutes I R5-gp120 - 20 minutes
St
BSA - 40 minutes I R5-gp120 - 40 minutes
Figure 4.11 (continued over).
143




R5-gp120 - 2 hours
S<'»' 7 wwm ,
BSA 3 hours R5-gp120 3 hours
Figure 4.11 (continued over).
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BSA - 4 hours
BSA - 5 hours
BSA - 18 hours
Figure 4.11 (caption over page).
R5-gp120 - 4 hours
R5-gp120 - 5 hours
R5-gp120 - 18 hours
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Figure 4.11 (previous page). Internalised gp120 and BSA. Ccr5A32
wildtype macrophages were incubated with FITC-conjugated R5-tropic gp120
or FITC-conjugated BSA (as a control) for the times indicated, then fixed,
permeabilised and stained red for HLA DR. Internalised protein is visible in
green. Colocalisation of green and red stains is shown as yellow.
Time























start - - N/A N/A - - N/A N/A
20min - + - - + - - -
40min - + - - + - - -
lhr - + - +/- + + - -
2hr - + - + + + + +/-
3hr - + +/- + + + - +
4hr - + + + - + - +
5hr - + - + - + - +
18hr - +/- - + - + - +
Table 4.2. Endocytosis characteristics. Ccr5A32 wildtype macrophages
were incubated with FITC conjugated R5-tropic gp120 or BSA for the times
indicated before being fixed, permeabilised and stained for HLA DR. The
table summarises the characteristics of endocytosed FITC-conjugated
protein in different cell populations. Specimens were scored for the presence
of endocytosed protein giving the appearance of either large or small
intracellular dots, or a diffuse cytoplasmic haze. Colocalisation of
endocytosed protein with MHC class II (HLA DR) was also noted.
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Figure 4.12. Pinocytosis compared with receptor mediated
phagocytosis. Phase contrast micrographs of macrophages superimposed
with confocal immunofluorescence images (green). Figure 4.12a shows
pinocytic vesicles formed after a 1 hour incubation with FITC conjugated
immunoglobulins, which do not have cell surface ligands. Figure 4.12b shows
a large phagocytic vesicle formed by a 1 hour incubation with FITC-
conjugated immunoglobulins which have been pre-complexed to anti-human
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Figure 4.13. Analysis of endocytosed protein. Confocal micrographs show
ccr5A32 wildtype macrophages which have been incubated with FITC-
conjugated R5-tropic gp120 (figure 4.13a), FITC-gp120mB (figure 4.13b), or a
control FITC-conjugated protein (BSA, figure 4.13c) for 20 minutes before
being fixed, permeabilised and stained red for CD4. Internalised protein is
visable in green. Coincidence of red and green labelling is visible as yellow.
The coincidence of endocytosed protein and CD4 in figure 4.11a but not
4.11b or 4.11c was confirmed by software analysis of the images and shown
by the resultant intensity plots, which show the intensity of red and green
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Figure 4.14. CD4 mRNA levels. The graph shows the ratio of CD4 to f.3-actin
gene transcripts in RNA extracted from ccr5A32 wildtype macrophages, pre-
treated with R5-tropic gp120 or gp120inB for the times indicated, as
determined by semi-quantitative RT-PCR. Ratios are expressed as changes
from the ratio obtained for the no-treatment controls. The graph shows the
mean values obtained from six different donors. The bars show standard
error of the means. The P values were calculated using unpaired Mann-
Whitney U tests. The PCR gel picture beneath the graph shows typical raw
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Figure 4.15. CCR-5 mRNA levels. The graph shows the ratio of ccr-5 to
P-actin gene transcripts in RNA extracted from ccr5A32 wildtype
macrophages, pre-treated with R5-tropic gp120 or gp120mB for the times
indicated, as determined by semi-quantitative RT-PCR. Ratios are expressed
as changes from the ratio obtained for the no-treatment controls. The graph
shows the mean values obtained from six different donors. The bars show
standard error of the means. The P values were calculated using unpaired
Mann-Whitney U tests. The PCR gel picture beneath the graph shows typical
raw data obtained from one of the six donors.
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Discussion
It has been reported that HIV-1 gpl20 is able to disrupt the function of immune cells
(Fanci, 1995; Rodriguez and Hard, 1995; Hewson et al., 1999) and one of its actions
is to cause a loss of cell-surface CD4 and the functions associated with this protein
(Wahl et al., 1989; Theodore et al., 1994; DurrbaumLandmann et al., 1994; Karsten
et al., 1996). This thesis identifies a novel, CCR-5-dependent mechanism of CD4
decline. A relatively small (about 25%) surface CD4 decline was induced on
macrophages by gpl20mB (figure 4.4), although this effect did not reach statistical
significance, largely due to the high degree of variability between donors. This
X4-tropic gpl20niB-induced response may be similar to the CD4 loss reported
previously (Wahl et al., 1989; Karsten et al., 1996), although the observation that
neutralisation of TNF-a did not abrogate gpl20mB-induced CD4 loss contradicts the
findings of Karsten et al., 1996.
Although CXCR-4 is expressed on human macrophages and can, under some
circumstances, be utilised for HIV-1 entry by dual-tropic HIV-1 strains (Yi et al.,
1999), it appears to be unusable and possibly inaccessible to many T-cell line
adapted X4-tropic gpl20s including gpl20mB which was used in this study as a
prototypic X4-tropic gpl20. It is therefore proposed that gpl20mB is only able to
interact with macrophages via CD4. Figure 4.6 presents evidence that gpl20niB was
able to bind to the macrophage surface, presumably this interaction was wholly via
CD4.
When R5-tropic gpl20 was incubated with macrophages, a cell-surface CD4
loss that was significantly more substantial than both previous reports of gpl20-
induced CD4 loss and our observations with X4-tropic gpl20mB resulted.
Approximately 75% of the surface CD4 was lost by 3 hrs after addition of gpl20
(figure 4.4). This observation may require a novel mechanism of CD4 loss to be
proposed. Further evidence implicates CCR-5 binding, in addition to CD4 binding as
a requirement for the operation of this novel mechanism.
The requirement for gpl20 to bind to CCR-5 in order to obtain a substantial
CD4 loss is suggested by the strain specificity of the effect, with substantial loss only
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observed when R5-tropic gpl20 is used. Further evidence for a CCR-5 binding
requirement comes from the observation that CD4 loss is not observed in mutant
macrophages, which do not express CCR-5 (figure 4.5). Binding to CD4 only (by
gp 1 20ihb, IL-16 or by R5-tropic gpl20 on ccr5 null cells) or binding to CCR-5 only
(by MlP-la) does not induce substantial CD4 loss (figure 4.7). This observation
supports earlier reports that recombinant IL-16 (Theodore et al., 1996) or
transfection with IL-16 cDNA (Zhou et al., 1997) fail to cause a surface CD4 decline
from T-cells. However, binding of surface CD4 only by an anti-CD4 antibody results
in a substantial surface CD4 loss resembling that induced by R5-tropic gpl20 (table
4.1). The crucial difference between anti-CD4 and R5-tropic gpl20, and IL-16,
MlP-la and gpl20mB may be that the first two proteins are able to cause enough
cross-linking of cell surface antigens for patching, capping and receptor mediated
phagocytosis to result.
R5-tropic gpl20-induced CD4 loss by this newly described mechanism,
therefore requires gpl20 to bind to both CD4 and CCR-5. We propose that the CD4
loss observed be due to cross-linking of CD4 and CCR-5 on the macrophage cell
surface followed by endocytosis of the tri-protein complex (figure 4.16). Single
ligation of CD4 or CCR-5 does not produce sufficient cross-linking to allow
endocytosis and CD4 loss by this mechanism. An assumption of this model is that it
is the same molecule of gpl20 that binds to both cell-surface receptors. CXCR-4 on
the macrophage appears to be inaccessible to X4-tropic gpl20mB binding in this way,
whereas CCR-5 is present on the macrophage cell surface in a form that allows
R5-tropic gpl20 to bind to both it and CD4 (Yi et al., 1999). It may be that CD4 and
CCR-5 are pre-associated in some way on the macrophage cell surface and that this
allows single molecules of R5-tropic gpl20 to bind to these surface proteins and
produce the CD4 loss demonstrated. Such a pre-association could allow CCR-5 to
mediate HIV-1 infection of APCs more efficiently and explain the apparent selection
by HIV-1 of CCR-5 for almost exclusive use as a co-receptor for macrophage
infection. If CD4 loss were indeed the result of phagocytosis of tri-protein
complexes, one would expect to see a loss of macrophage surface CCR-5
concomitant to the CD4 loss. Attempts to show this were frustrated by the lack of
anti-CCR-5 antibodies able to stain CCR-5 brightly enough to allow semi-
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quantitative estimation of receptor densities. The observation that ccr5 mRNA is up-
regulated following CD4 loss (figure 4.15) does however provide indirect evidence
for earlier loss of surface CCR-5.
The analogous in vivo situation may be more complicated. Gpl20 has been
found at high levels in the serum of AIDS and ARC patients (Oh et al., 1992). Serum
antibodies to gpl20 may increase the extent of macrophage surface receptor cross-
linking, bring the Fc receptor into play, and reduce the CCR-5-binding requirement.
It has been observed that most of the gpl20 found in human serum is in the form of
immune complexes (Oh et al., 1992) and that antibodies to gpl20 can enhance cell
infection by increasing virion-to-cell binding (Toth et al., 1994).
Our model of cross-linking-induced endocytosis is strengthened by the
confocal images obtained. Figures 4.11 and 4.13 show that R5-tropic gpl20 enters
macrophages in a form that is different, in terms of size and number of vesicle and
localisation with CD4, from pinocytosis ofBSA, a protein with no specific cell-
surface receptor and endocytosis of gpl20mB, a protein which is unable to use both a
cell-surface receptor and a co-receptor. R5-tropic gpl20 enters cells as a few large
vesicles, possibly by a process of patching and capping. Endocytosed gpl20mB and
BSA appear in macrophages in a form which suggests that they entered by a process
more akin to constitutive pinocytosis (Cohn and Steinman, 1982). Endocytosis of
R5-tropic gpl20 appeared very similar to the entry of cross-linked anti-CD4 (figure
4.12b), and entry ofBSA and gpl20mB resembles the pinocytosis of protein with no
cell surface receptor (figure 4.12a). The presentation efficiency of endocytosed
protein to CD4+ and CD8+ T-cells was not investigated, nor was the context, in terms
of the cytokine environment and co-stimulatory signals. However, endocytosed CD4
(figures 4.11 and 4.13), newly synthesised CD4 (figure 4.10) and endocytosed
R5-gpl20 and endocytosed BSA (figure 4.11) were all detected in MHC class II
containing cellular compartments making presentation of these proteins a possibility.
If our proposed model of cross-linking induced endocytosis operates in vivo,
there are implications for processing and presentation of large amounts of both viral
and self-protein entering an antigen presenting cell. The induction of protective and
autoimmune responses could be influenced if the endocytosed proteins were finding
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their way into antigen presentation pathways and being presented with unusually
high efficiency.
After R5-tropic gpl20-induced cell surface loss of CD4 (and presumably
CCR-5 also) the cellular production of these proteins is stepped up. This is
manifested as an up-regulation ofmRNA transcript (figures 4.14 and 4.15), and at
least in the case ofCD4 at the level of increased translation ofmRNA into
intracellular pools of protein (figure 4.9). Increased levels of intracellular self-protein
must have in vivo implications for the possible breaking of tolerance and the
induction of auto-immune responses to these proteins. There are reports of self
tolerance to CD4 (Chams et al., 1988; Caporossi et al., 1998) and other self antigens
(Magnac et al., 1990; Marchalonis et al., 1997; Strieker et al., 1998) being lost in
HIV-1 infection. There is also potential for immune dysregulation when large
amounts of viral (gpl20) and self (CD4 / CCR-5) antigen are presented by the same
APC. If the immune system is already tolerant of CD4 and CCR-5, this may be due
to the presence of regulatory T-cells specific to these antigens. Bystander
suppression (discussed in chapter 5) could allow tolerance to CD4 and CCR-5 to
spread to the foreign antigen gpl20.
The work discussed in this chapter also has implications for therapeutics
(such as those discussed in chapter 5) designed to block infection by binding to CD4
and CCR-5. It may be that agents which cause too much cell-surface receptor cross-
linking should be avoided because of their potential to produce immune system
dysregulation.
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Figure 4.16. Hypothesis for surface CD4 loss. The observation that
substantial and rapid gp120-induced loss of CD4 is dependent on gp120
being able to bind to both cell-surface CD4 and CCR-5 suggests that the
CD4 loss may be a result of R5-tropic gp120 causing sufficient cross-linking
of membrane components for the cross-linked complexes to be internalised
by receptor mediated phagocytosis.
155
CHAPTER 5: RESULTS
HIV-1, TOLERANCE AND NOTCH
N.B. Many ofthe genes andproteins described in this chapter have multiple
names and different names in different species. To reduce confusion, the same
name will be used here regardless ofthe species. A list ofnames and their
equivalents is given at the start ofthis thesis.
Background
This chapter explores the nature of immunologic tolerance and speculates as to how
the mechanisms of tolerance might be subverted by HIV-1 in order to cause disease.
It will then explain how the Notch signalling pathway, important in embryology,
might be involved in the induction of tolerance. Data showing how HIV-1 gpl20
interacts with the Notch pathway will then be presented and discussed. The central
hypothesis tested is that HIV-1 gpl20 manipulates the Notch signalling pathway in
order to induce inappropriate 'tolerance' which contributes to the immune deficiency
seen in AIDS.
Tolerance
One definition of tolerance is a state of non-responsiveness in the face of
provocation that ought to elicit a response. Immunologic tolerance can be defined as
a state of non-responsiveness to an antigen that ought to elicit a response. Just as it
can be argued that an individual can not be truly tolerant of something ofwhich he is
ignorant, immunologic tolerance differs from immune-ignorance, which is non-
responsiveness to an antigen that the immune system simply has not encountered
(Chen, 1998a; Chen, 1998b; Hausmann et al., 1999). Tolerance of self-antigen is a
central feature of the immune system. Self-antigen ought to elicit a response; indeed,
if the antigen is transferred to another individual (as in a graft), a response does
result.
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Working definitions of tolerance are often along the lines of "tolerance is a
failure to elicit the type of response that we happen to be measuring in our
experiments." If one is only measuring antibody responses, a cell-mediated response
might be missed and mistaken for tolerance. Similarly, the failure of an antigen to
elicit a Thl-type cytokine response may be interpreted as immunologic tolerance of
the antigen, or as an immune-deviation from a Thl to a Th2-type response
(Kuribayashi et al., 1997; Ekerfelt et al., 1999). Defining tolerance as a state of non-
responsiveness implies that it is a passive process - simply the lack of the active
processes of immune-activation. In many situations however, tolerance is actively
mediated, whether by the induction of apoptosis, anergy, or suppressor / regulatory
cells (Wood, 1996). As such tolerance is not truly unresponsiveness, rather it is
different-responsiveness.
Danger
The danger hypothesis (Matzinger, 1994; Pennisi, 1996) states that the function of
the immune system is to discriminate between dangerous and safe antigens, rather
than self and non-self antigens. It proposes that the immune system perceives danger
signals from microbial components and (necrotic) tissue damage and will only mount
a response to antigen encountered in this context. The immune system tolerates
antigens encountered in the absence of a danger signal. The APC is proposed to play
a central role in receiving danger signals (Matzinger, 1994; Ridge et al., 1996). The
danger hypothesis is attractive because it explains how in the absence of complete
deletion of autoreactive lymphocytes (Genain et al., 1994) the immune system is
tolerant of self-antigens encountered in the absence of danger signals. The danger
hypothesis is less successful at explaining autoimmunity; why do lymphocytes start
to attack self-tissue in the apparent absence of danger signals? One explanation for
this is that a transient infection provides the danger signal required to initiate
autoimmunity. This begs the question: how can autoimmune disease be induced
experimentally (Aabakken and Osnes, 1989; Metzler and Wraith, 1993; Powrie,
1999) in the absence of infection? The fact that autoimmune responses to self antigen
can cause disease in some individuals stresses the importance of active self tolerance
in the normal homeostatic regulation of the immune system.
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Mechanisms ofT-cell tolerance
Thymic selection. Not all newly generated thymocytes reach the periphery; many
are deleted by apoptosis in the thymus (Kruisbeek and Amsen, 1996). As well as the
deletion of developing T-cells that do not express a TCR able to recognise peptides
held in self-MHC molecules, T-cells with specificity for self-peptides, or which bind
too tightly to self-MHC are deleted (Janeway, 1994; Jameson and Bevan, 1995;
Kishimoto and Sprent, 2000). IL-4 and IL-7 can inhibit this thymocyte apoptosis
(Kishimoto and Sprent, 1999), and mice which lack pro-apoptotic genes (for Fas and
Fas Ligand), or over-express anti-apoptotic genes (bcl2) develop autoimmune
disease (Strasser et al., 1991; Suda and Nagata, 1997; Weintraub et al., 1998;
Weintraub and Cohen, 1999). Self-peptide / MHC complexes that are absent from
the thymus, or which are present at low density, are unable to trigger the death of
T-cells which can recognise them. These potentially self-reactive T-cells can then
escape to the periphery (Liu et al., 1995; Kawai and Ohashi, 1995).
Peripheral tolerance. Self-reactive T-cells that encounter self-antigen in the
periphery can be induced to undergo apoptosis or become anergic. A variety of
mechanisms can induce this peripheral tolerance. Immune privileged sites such as the
retina, the anterior chamber of the eye, and the testes may express Fas ligand (FasL,
CD140), which can engage Fas (CD95) on T-cells to give them a death signal
(Griffith et al., 1995; Bellgrau et al., 1995; Ferguson and Griffith, 1996a; Ferguson
et al., 1996b; Stuart et al., 1997). Recently, however, some doubt about a general
role for Fas / FasL interactions in immune privilege has emerged because of the
small number of good studies undertaken and the reliability of reagents (Restifo,
2000). Chronic stimulation of the TCR, especially with high-dose antigen can favour
elimination (Sprent and Webb, 1995; Renno et al., 1995) or silencing (Dillon et al.,
1995; Rocha et al., 1995) of T-cells. Activated cells can also become primed for Fas
or TNF mediated activation induced cell death (AICD, Zheng et al., 1995; Bonfoco
et al., 1998; Gao et al., 1998). T-cells may be deleted if they receive a signal through
their TCR at the same time as CTLA-4 engagement by CD28 (Krummel and Allison,
1995; Krummel et al., 1996; Punt et al., 1997). If a T-cell encounters antigen on a
parenchymal cell which is not expressing B7 or an equivalent costimulatory
molecule (only professional APCs express B7 in a non-inflamed site) it will ignore
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the antigen and become anergic (Mueller and Jenkins, 1995; Boise et al., 1995;
MarelliBerg and Lechler, 1999).
Immune deviation. Whether or not immune deviation (the polarisation of a response
towards one that is Thl or Th2 dominated) can be described as a form of tolerance is
largely a semantic argument. Although at a cellular level T-cells are persistently
active, immune deviation can produce functional tolerance at the level of the
organism. In some animal models of autoimmune diseases such as the NOD mouse,
the tissue of non-diseased animals is extensively infiltrated by activated T-cells. This
T-cell response, however, has been skewed to a lineage which does not mediate
disease (Finkelman, 1995; Katz etal., 1995; Liblau etal., 1995;Liblau etal., 1997).
The control of immune deviation and the development of Th-cell subsets is
complicated, but APCs are thought to play an important role by providing an
appropriate environment of cytokines and other signals for T-cell subset
development (Kuchroo et al., 1995; Finkelman, 1995; Carter et al., 1998).
Regulatory / suppressor T-cells. Despite initial controversy over the existence of
regulatory / suppressor T-cells (Moller, 1988), there is mounting evidence that a
subclass of thymus derived, CD4+ T-cells can provide antigen-specific protection
against the potentially damaging effects of other activated T-cells (Groux and
Powrie, 1999; Shevach, 2000). A role for regulatory T cells (Tr-cells) has been
demonstrated in several animal models of autoimmunity, including inflammatory
bowel disease (IBD, Groux and Powrie, 1999) and experimental autoimmune
encephalitis (EAE, Chen et al., 1994; Kumar and Sercarz, 1998). If animals are
depleted of these regulatory cells autoimmune disease develops. Adoptive transfer of
regulatory T-cells can inhibit the disease. The regulatory T-cells that provide
protection from IBD by suppressing T-cells activated against the bacterial flora of a
healthy gut are CD4+, CD45RB10 and are enriched within the CD25+ subset (Groux
and Powrie, 1999; Powrie, 1999). CD4+, CD45RB10 T-cells from IL-10 knockout
mice fail to protect from IBD (Asseman et al., 1999), suggesting that IL-10 has a role
in either the development or action of these regulatory cells (Groux and Powrie,
1999). How regulatory cells are able to suppress other T-cells is poorly understood.
Cytokines, especially TGF-(3 (Prudhomme and Piccirillo, 2000) and IL-10 (Powrie et
al., 1996; Shevach, 2000) are thought to be involved as is CTLA-4 (Powrie, 1999).
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Regulatory T-cells are antigen specific and dependent; cells protecting from IBD will
not develop in animals kept in clean conditions without a gut flora. Despite the
involvement of IL-10 in the control of IBD, regulatory T-cells are distinct from Th2
cells, not least in their independence from IL-4 (Powrie et al., 1996).
Recently a different distinct population of antigen specific double negative
regulatory T-cells with the unique phenotype of a,pTCR+, CD4", CD8", CD25+,
CD28", CD30+, CD44" has been described (Zhang et al., 2000). These cells are able
to acquire alloantigen from APCs and present it to CD8+ activated T-cells along with
a death signal mediated by Fas via cell-to-cell contact (Zhang et al., 2000).
Oral and nasal tolerance
The immune system continuously encounters many harmless but foreign
environmental antigens. Most of these foreign but harmless antigens enter the body
via the nose or mouth, and first encounter the immune system at a mucosal surface.
Pollen, house dust mite (Dermatophagoides pteronyssinus) proteins, and food all
contain potential antigens, but it is unnecessary and damaging to host tissue to mount
an immune response to these antigens. Except in cases of allergy the immune system
is tolerant of them. It is important to remember that not everything that enters via a
mucosal route is harmless -. Many infectious diseases including HIV can be
transmitted across mucosa (Miller et al., 1989). Accordingly, the immune system is
not tolerant of everything delivered to mucosa; the mucosal immune system can be
activated by pathogens. In the case of Chlamydia infection, activation of the mucosal
immune system contributes to pathogenesis (Rasmussen et al., 1997; Stallmach et
al., 1998). However, an immune response to other mucosal pathogens including
herpes simplex virus (Richards et al., 1998), Mycobacterium (Falero-Diaz et al.,
2000), and in some cases HIV-1 (Mazzoli et al., 1997; Kaul et al., 1999; Clerici et
al., 1999) can be protective. Tolerance induced by antigens delivered to a mucosal
surface is known as mucosal (or oral or nasal) tolerance (Wells and Osborne, 1911;
Strobel and Mowat, 1998; Palliser et al., 1998; Lowrey et al., 1998). Just how the
immune system 'knows' whether to ignore or react to a mucosally delivered antigen
is poorly understood. The dose, length of exposure, presence or absence ofmicrobial
components and tissue damage (danger signals) must all play a role (Matzinger,
160
1994; Lowrey et al., 1998; Chin et al., 2000). Mucosal APCs are ideally placed to
integrate these signals, migrate to draining lymphoid tissue, and cause T-cells to
develop into activated Thl or Th2 cells or anergic or regulatory cells by varying the
signals which they give to antigen specific naive T-cells. For example, in the absence
of infection, resident pulmonary alveolar macrophages inhibit T-cell activation
(Thepen et al., 1989) by the production of lymphostatic mediators (Holt, 1986),
inefficient antigen processing and presentation (Holt, 1986), and an absence or
reduction in co-stimulatory molecule expression (Chelen et al., 1995). Other signals
may also be involved.
Experimental intranasal delivery of peptides can induce transient activation of
T-cells followed by the induction of clonal anergy (Tsitoura et al., 1999), and the
activation of regulatory T-cell populations (Palliser et al., 1998).
Linked suppression, bystander suppression andAPCs
Der pi is an antigenic protein of the house-dust mite (Dermatophagoides
pteronyssinus) and a common allergen in man and experimental animals. Antigenic
epitopes of Der pi have been identified in H-2b mice using synthetic peptides
representing short sequences of Der pi. Der pi110"130 produces a peak antigenic
response, and was therefore identified as containing the immunodominant epitope.
Weaker responses were observed to Derpl81"102, Der pl2l"49and Derpl197"212 (Hoyne
et al., 1994). Intranasal administration of Der pi peptides is able to tolerise an animal
to subsequent (2 weeks to 6 months) in vitro T-cell challenges with either the
peptides or full length Der pi. The immunodominant epitope induced the most
profound tolerance (Hoyne et al., 1997). If animals were tolerised with the
immunodominant peptide of Der pi alone, their cells showed a reduced response to
all epitopes of Der pi on subsequent challenge with full length Der pi (Hoyne et al.,
1997). This phenomenon, where induction of tolerance to one epitope induces non-
responsiveness to other epitopes on the same molecule, is known as linked
suppression. If mice in the Der pi model were nasally tolerised with the
immunodominant peptide of Der pi, and 14 days later co-immunised with Der pi
and OVA, their T-cells showed a reduced response to epitopes on both Der pi and
OVA (Hoyne et al., 1997). This phenomenon, where induction of tolerance to one
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antigen spreads to other antigens which are encountered by the immune system
simultaneously to the tolerised antigen, is called bystander suppression.
If nasal tolerance induces regulatory / suppressor T-cells (there is some
controversy over whether this is the case or if nasal tolerance is purely the result of
T-cell anergy Whitacre et al., 1991; Melamed and Friedman, 1993; Garside et al.,
1995), then a mechanism to explain linked and bystander suppression involving
APCs becomes apparent. Recent studies (Yoshida et al., 1997; Krause et al., 2000)
suggest that mucosal administration of high dose antigen results in clonal anergy, and
that low dose antigen tolerises by inducing transient T-cell activation and subsequent
induction of actively suppressing cells. When a regulatory T-cell (Tr-cell; figure 5.1)
encounters its epitope on an APC, naive, potentially reactive, T-cells recognising the
same or other epitopes simultaneously presented by the same APC will also engage
their TCRs. Epitopes which are parts of the same protein or which are endocytosed
by the APC at the same time are most likely to be co-presented. The close proximity
of the T-cells on the same APC allows the regulatory T-cell to give a tolerising signal
to naive T-cells engaged at the same APC. The nature of the tolerising signal that




Figure 5.1. Models of linked and bystander suppression. A regulatory /
suppressor T-cell (Tr-cell) recognises MHC / peptide A complex on an APC
(for clarity CD4 and signal two are not shown). Naive T-cells recognising the
same or a different epitope on the same APC can be tolerised and become
anergic and/or Tr-cells themselves. There are three potential mechanisms by
which the tolerance signal can be delivered to the naive T-cells. The signal
could be propagated through the APC; the most obvious mechanism for this
to occur would be if the APC down-regulated its co-stimulatory molecules on
encountering a Tr-cell. Alternatively, naive T-cells could receive their peptide
in a tolerance-inducing cytokine environment established by the Tr-cell
(and/or the APC); it has been suggested that the Tr-cell could prevent the
expansion of the naive T-cells by 'mopping up' IL-2 (Lombardi etal., 1994;
Lombardi et al., 1995). In a third alternative mechanism, the proximity of the
T-cells could allow a tolerogenic signal to be delivered by T-cell-to-T-cell
contact. One, more or all of these mechanisms may operate in vivo.
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Tolerance induction
The re-establishment of antigen-specific tolerance is the goal of the treatment of
autoimmune disease. In vitro T-cells can be rendered non-responsive (anergic /
regulatory) to antigen stimulation by treatment with very high doses of antigen, or
when given antigen in the presence of non-depleting anti-CD4 or anti-CD8 (Qin et
al., 1993). In vivo oral administration of antigen can also result in clonal anergy.
Experimental autoimmune encephalitis (EAE) is an animal model of multiple
sclerosis (MS). The disease is induced in mice or rats by eliciting a Thl CD4+ T-cell
response against myelin basic protein (MBP) by injection ofMBP and adjuvant,
which results in an MS-like phenotype (Kumar and Sercarz, 1998). Feeding MBP to
affected animals causes oral tolerance and remission of disease (Metzler and Wraith,
1993) by inducing regulatory T-cells, which can be cloned and used to transfer
protection to other animals. The regulatory T-cells are CD44 and have a similar
specificity and epitope recognition to the encephalitogenic Thl-cells. They suppress
the encephalitogenic cells by producing TGF-P and IL-10 (Chen et al., 1994).
Although they can produce varying amounts of IL-4, this cytokine does not appear
important for protection because EAE can be ameliorated by oral administration of
MBP in IL-4 knockout mice (Liblau et al., 1997). In the Lewis Rat model of EAE,
intra-tracheal administration ofMBP induces tolerance with a higher potency than
does oral administration (Pietropaolo et al., 2000).
Tolerance and HIV-1
As reviewed in the introduction to this thesis, HIV-1 induces an immune deficit.
Decline of leukocyte numbers, anergy, changes in APC cytokine production, a Thl
to Th2 switch and inappropriate apoptosis all contribute to the immunodeficiency
seen in AIDS. Tolerance induction involves anergy, apoptosis and changes in
cytokine production. It is therefore possible that some of the molecular signalling
events involved in HIV-1 pathogenesis may be shared with those involved in
tolerance induction. Indeed it could be claimed that HIV-1 has evolved to subvert the
physiological mechanism of tolerance induction and immune regulation to its own
ends in order to escape immune destruction.
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Measurements oftolerance
A major hindrance to in vitro and in vivo tolerance experiments is that they attempt
to measure the absence of a response, which is not always as easy to detect as a
positive response (usually observed as a proliferation). Because tolerance is usually
antigen specific, much work has been done with T-cell clones, T-cell lines and
transgenic T-cells so that the absence of a response of a single specificity is not
swamped by responses of other specificities. The HLA DR1*0101 restricted
influenza haemagglutinin reactive T-cell clone HA1.7 (Eckels et al., 1982; Lamb et
al., 1982a; Lamb et al., 1982b) and the HLA DR 11 restricted Der P II 28-40 reactive
T-cell clone AC 1.1 (Pala et al., 2000) were used in some of the tolerance
experiments described here.
Notch and cell-to-cell interactions
The inner cell mass of a mammalian blastula is a clump of a few hundred cells. All
of these cells are equivalent, genetically identical and totipotent (Walpert, 1991).
The question at the heart of embryology is - "why do some of the descendants of
these early cells differentiate into liver cells, some into skin cells, some into brain
cells and some into blood cells?" When haematopoiesis is considered similar
questions are raised, that is - "why do some blood cells become erythrocytes and
others become lymphocytes?" Equivalent questions in the peripheral immune system
are - "why do some initially equivalent T-cells become Thl as opposed to Th2, or
regulatory cells as opposed to effector cells, and why do some immune cells live
rather than die?" An embryologist's answer to these questions is that pattern
formation can be explained by induction reinforced by differentiation. Induction is
the process where one region of the developing embryo interacts with a second
region in order to influence the second region's differentiation, via cell autonomous
and non-autonomous signalling events. Can this view be extended to our
understanding of how cell fate decisions may be made in the peripheral immune
system? If so, the immune system might be able to utilise many of the conserved
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signalling pathways that are used during embryonic development, to regulate cell
growth and fate decisions in mature lymphocytes.
In embryonic development inductive interactions can set up tissue patterning
from initially equivalent cells due to slight and randomly occurring initial differences
between cells. This is illustrated in figure 5.2. Figure 5.2a represents a tissue
consisting of a single sheet of cells. All cells are equal and can send and receive a
signal from their neighbours. Signal strength is governed by a simple rule - the more
signal a cell receives the less signal it gives to its neighbours. In figure 5.2a all cells
are giving and receiving an equal (medium) amount of signal to and from their
neighbours. A random event perturbs this unstable equilibrium and one cell (starred)
produces slightly more signal than its neighbours. This causes the surrounding cells
to down-regulate their own signal (figure 5.2b). Two additional cells in figure 5.2b
now receive less signal than the others and up-regulate their own signal in response
(figure 5.2c). The pattern of signalling is propagated across the field (figure 5.2d),
resulting in isolated signaller cells surrounded by receivers. This pattern can be made
permanent by differentiation of signallers and receivers, thus giving rise to two
distinct cell fates (figure 5.2e).
a b c d e
Figure 5.2. Establishment of tissue patterning in an equipotential field.
The level of signal produced by each cell is indicated by the intensity of red
shading.
Figure adapted from Gilbert, 1994. © Sinauer Associates Inc. 1994.
The example given in figure 5.2 was proposed to explain the development of the
Drosophila ventral nerve cord (Greenwald and Rubin, 1992). Starting from a field of
about 1800 equivalent ectodermal cells, one quarter will become neuroblasts and the
rest hypodermis (Hartenstein and CamposOrtega, 1984). The initial differences
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between the cell types is created by chance and amplified by induction; the cell types
become arranged in a similar pattern to figure 5.2e (ArtavanisTsakonas et al., 1991).
Inactivating mutations in two Drosophila genes, called notch and delta, result
in embryo death because all the cells in the field become neuroblasts (Lehmann et
al., 1983; ArtavanisTsakonas et al., 1991). Experiments with genetic mosaic
embryos show that notch is needed in the cells that will become epidermis and delta
is needed in the cells that will induce the epidermal phenotype. This is because Delta
is a signalling molecule expressed on the cell-surface and Notch is its receptor.
Could Notch and Delta be involved in signalling between immune cells? Such a
suggestion is theoretically attractive if the immune system is considered as an organ
that develops throughout the lifetime of the organism. Inputs to the system by chance
antigen-encounters influence not just the cell which meets the antigen but the 'organ'
as a whole and future patterns of immunity. Phenomena such as linked suppression,
regulatory cell suppression, original antigenic sin and immune deviation can be
viewed as a dynamic version of pattern formation.
Viewing the immune system as an integrated 'organ' or 'network' is not a
new idea (Matzinger, 1994; Janeway and Travers, 1996). Traditionally
communication between cells of the immune system has been viewed as cell-to-cell
interaction mediated by exclusive 'immune system' signals and soluble cytokines.
However, there is growing interest in the role of pattern formation genes in the
establishment of immune system patterning.
The Notch signalling pathway
Notch genes. The notch locus was first isolated from Drosophila melanogaster
(Welshons, 1971) where heterozygous loss-of-function mutants have wing notches
and homozygous loss-of-function mutants die due to the abnormality in neuronal
induction described above (ArtavanisTsakonas et al., 1995). One Xenopus
homologue (Xotch) and four mammalian homologues (notch-1 to -4) ofDrosophila
notch have been identified (Egan et al., 1998). Other members of the Notch
signalling pathway were identified in Drosophila by their genetic interaction with
notch alleles and have since been found in mammals. Mutations in the HES {hairy
and enhancer ofsplit) genes cause enhancement of notch phenotypes
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(CamposOrtega, 1991). Loss of the deltex gene suppresses the lethality of gain-of-
function notch alleles such as abruptex (Busseau et al., 1991; Busseau et al., 1994).
In Caenorhabditis elegans the notch homologue lin-12 is involved in fate induction,
lateral specification and cell division (Austin and Kimble, 1987; Yochem et al.,
1988; Yochem et al., 1988). Human notch-1 and notch-4 were independently isolated
as the TAN-1 and int-3 oncogenes (Ellisen et al., 1991; Robbins et al., 1992; Joutel
and TournierLasserve, 1998).
Protein structure of mammalian Notches. Mammalian homologues ofNotch are
very large membrane-spanning glycoproteins. They have an N-terminal extracellular
signal peptide and up to 36 EGF-like repeats (Wharton et al., 1985; Kidd et al., 1986;
ArtavanisTsakonas et al., 1995). Six of these repeats are predicted Ca2+ binding
domains (Rao et al., 1995) and in Notch-4 the EGF repeat region is rather different,
suggesting a different ligand specificity (Uyttendaele et al., 1996; Gallahan and
Callahan, 1997; Egan et al., 1998). The EGF repeats are followed by three copies of
a cysteine rich Lin-12 / Notch repeat (LNR, Yochem et al., 1988). Deletion of the
LNRs results in constitutively activated Notch. It has been suggested that the LNRs
prevent the dimerisation of Notch, required for activation, unless a Notch ligand is
present (Kidd et al., 1989; Lieber et al., 1992; Lieber et al., 1993; DeCelis and
GarciaBellido, 1994; Egan et al., 1998). The cytoplasmic domain ofNotch contains a
Ram domain, six ankyrin repeats and a PEST domain involved in protein turnover
(Breeden and Nasmyth, 1987). There is also a cytoplasmic cleavage site, Notch being
cleaved after activation (ArtavanisTsakonas et al., 1995; Egan et al., 1998).
Notch ligands. Several ligands for Notch have been identified (ArtavanisTsakonas et
al., 1995; Fleming et al., 1997); the nomenclature varies across species (see
Lissemore and Starmer, 1999, for a discussion ofNotch ligand phylogeny). The
names used here for all species are based on the names of the original Drosophila
genes. Serrate (also called jagged) and delta (also called delta-like, dll) genes, of
which there are five in mammals, encode proteins which act as Notch ligands (Nye
and Kopan, 1995; Zimrin et al., 1996). Notch ligands all share a cysteine-rich -200
amino acid DSL (Delta / Serrate / Lag-2) conserved domain (Tax et al., 1994). The
DSL domain is important for Notch ligand function because it binds to EGF repeats
11 and 12 ofNotch (DeCelis et al., 1993). Other Notch, Delta and Serrate regions
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may also influence binding events (Lieber et al., 1992). Serrate and Delta are both
membrane-anchored proteins with unrelated cytoplasmic tails (Egan et al., 1998).
They can signal to Notch whilst bound to the surface of the same or different cells,
Serrate and Delta may possibly also be cleaved from their membranes and function
as soluble signalling molecules (ArtavanisTsakonas et al., 1995; Egan et al., 1998).
Ligand specificity. Experiments with Notch and its ligands are complicated by the
fact that the specificity of ligand for receptor is not well understood. Whether all of
the Notches within a single species can bind all of the Serrates and Deltas, and
whether this binding can initiate signalling in all cases is unknown. There is a
confusing array of data in this regard with evidence coming from in vitro adhesion
assays, mutation analysis and co-localisation ofmRNA in tissues at the time of
signalling. In Drosophila neuroblast differentiation (modelled in figure 5.2), Serrate
can compensate for a loss of Delta (Gu et al., 1995). However, in wing development,
Delta and Serrate have distinct and non-overlapping capabilities (Doherty et al.,
1996). In mammals there is evidence for distinct but overlapping ligand pairs. In the
developing rat hindbrain and spinal cord, serrate-1 and delta-1 are expressed in well-
demarcated stripes (Lindsell et al., 1996). Co-localisation ofmRNA with notch
genes suggests that delta-1 interacts with notch-1 and serrate-1 with notch-3 in order
to specify different cell fates (Lindsell et al., 1996). In binding studies with mouse
proteins, Serrate-1 can bind to Notch-1, -2 and -3 (Shimizu et al., 1999). In a mouse
myoblast system (Weinmaster, 1998), Delta-1 activates Notch-1 but not Notch-2, and
Serrate-1 activates both Notch-1 and -2. A cysteine-rich region - unique to Serrate-1
- appeared to be required for Notch-2 signalling. If this region is removed from
Serrate-1, Notch-2, but not Notch-1, signalling is prevented. Conversely, adding a
cysteine rich region to Delta-1 allows it to signal through both Notch-1 and Notch-2
(Weinmaster, 1998). Receptor-ligand pairing in other systems may be completely
different.
Notch activation
Dominant mutant alleles of various notches have been identified in which all or most
of the sequence encoding the extracellular domain is missing (Ellisen et al., 1991;
Robbins et al., 1992; Rohn et al., 1996). Cell-lines have also been transfected with
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constructs based on the intracellular domain ofNotch-1 (Callahan et al., 2000). In all
these cases the intracellular portion of the Notch molecule, in the absence of the
extracellular domain, is constitutively active (Egan et al., 1998). One result of this
activation is (usually) the prevention of apoptosis, which may explain why alleles of
notch with these deletions have been isolated from tumours (Ellisen et al., 1991;
Robbins et al., 1992). EBV nuclear antigen 2 appears to transform B-cells by
interacting with the CBF-1 / RBPJk transcriptional repressor in a similar way to
Notch (Hsieh et al., 1996; Strobl et al., 1997; Callahan et al., 2000).
When Notch binds to its DSL containing ligands there is proteolytic cleavage
of the Notch protein (figure 5.3) which results in the release of the active intracellular
region. The cleavage protease has not yet been identified with certainty; Furin or the
metalloprotease Kuzbanian may be responsible (Pan and Rubin, 1997; Weinmaster,
1998). It is likely that the protease is constitutively present and active but that ligand
binding is required to disrupt Notch dimers and expose the cleavage site. In an
alternative model ofNotch activation (Blaumueller et al., 1997) newly synthesised
Notch is cleaved in the trans-Golgi before reaching the surface. Following cleavage,
the extracellular and transmembrane-intracellular fragments remain non-covalently
associated and travel to the plasmalemma. DSL-ligand binding causes breakdown of
this association and the release of the extracellular domain (a second cleavage may
mediate this). The intracellular domain, (possibly by a second (or third) cleavage
(Schweisguth, 2000)), is then released from membrane anchorage and becomes
active. In this model ready-cleaved Notch is on the cell surface, therefore it is
possible that under certain physiological circumstances (reducing conditions) the
non-covalent association between the two Notch peptides could be disrupted,
releasing soluble Notch fragments which could neutralise Notch ligands
(Blaumueller et al., 1997). According to either model, following signalling the
extracellular domain ofNotch may remain bound to the DSL-ligand expressing cell
or be endocytosed by this cell. This trans-endocytosis can cause confusing
experimental results with Notch ligands being identified by immunocytochemistry in
cells that have not synthesised it.
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Activated Notch targets - HES-1
Activated Notch causes the transcription of nuclear genes including the HES (hairy
and enhancer ofsplit) genes in Drosophila and vertebrates (DeCelis et al., 1996;
Jarriault et al., 1998) by releasing the transcription factor CBF-1 from its association
with membrane anchored Notch allowing it to bind the TGGGAA promoter nuclear
sequence (Knust et al., 1987; Tamura et al., 1995; Lu and Lux, 1996). It is not
known whether activated CBF-1 is associated with an intracellular cleavage fragment
ofNotch when it enters the nucleus. The HES genes encode basic helix-loop-helix
transcription factors (Delidakis et al., 1991). HES proteins complex with the widely
expressed Groucho repressor (Paroush et al., 1994) and can repress genes with
CACNAG promoter sequences (Tietze et al., 1992). Thus, this branch ofNotch
signalling can result in both transcriptional activation and repression. Targets for
activation by HES / CBF-1 include Notch (Weinmaster, 1998) and NF-kB (Oswald et
al., 1998), a transcription factor involved in many immune processes including the
increased expression of inflammatory cytokines, co-stimulatory molecules, and
molecules involved in antigen processing and presentation. Specific targets ofNF-kB
include IL-1, -2, -3, -8, -12, TNF-a, IFN-(3, GM-CSF, M-CSF, G-CSF, TAP1, MHC
class I and II, and P2-microglobulin (May and Ghosh, 1998). NF-kB is also involved
in inducing tolerance to LPS in B-cells (Wedel et al., 1999), monocytes
(Frankenberger and ZieglerHeitbrock, 1997) and endothelium (Lush et al., 2000). In
B-cells at least, NF-kB can cause the up-regulation of serrate (Bash et al., 1999). In
the context of HIV-1 infection, NF-kB is both up-regulated in T-cells by interaction
with gpl20 (Briant et al., 1998) and acts on HIV-1 provirus to increase viral gene
transcription (Alcami et al., 1995). There is also evidence that the NF-kB2 isoform
ofNF-kB (Oswald et al., 1998) and GM-CSF (Cockerill et al., 1996) can be
expressed by the action of CBF-1 in the absence of HES. NF-kB2 activity has been
associated with protection from apoptosis in lymphoid tissues (Osborne and Miele,
1999).
Interestingly HES also binds to a silencer site in the CD4 promoter and acts
to reduce CD4 gene expression in T-cells (Kim and Siu, 1998).
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Activated Notch targets - Deltex
Deltex is a cytosolic protein, present in both Drosophila and vertebrates, which is
able to interact with Notch via the ankyrin repeats ofNotch's intracellular domain
(Diederich et al., 1994). Deltex expression acts as a positive regulator ofNotch
signalling through CBF-1 and HES, possibly by disrupting Notch / CBF-1
interactions and thereby inhibiting the cytoplasmic retention ofCBF-1 and
encouraging its translocation to the nucleus (Matsuno et al., 1995).
When CBF-1 and HES are mutated in Drosophila, some but not all of the
actions ofNotch are inhibited (DeCelis et al., 1996; Matsuno et al., 1997). These
data suggest that not all of the targets ofNotch signalling are influenced via CBF-1 -
mediated signalling. It has been suggested (Matsuno et al., 1995; Matsuno et al.,
1997) that Deltex has a second role in transducing Notch signalling into CBF-1-
independent downstream events via its association with Grb-2. Grb-2 is a molecular
adaptor protein that links receptor tyrosine kinases to ras signalling and ultimately
nuclear transcription events (Lowenstein et al., 1992). Grb-2 is involved in several
immunologically important signalling processes especially in monocytes and
macrophages. Grb-2 (and in some cases a related protein, Mona, Bourette et al.,
1998) is involved in transducing signals from M-CSF and GM-CSF receptors to ras
and other growth and differentiation controlling genes by binding to phosphorylated
signalling molecules such as STAT-5 (Odai et al., 1997; Rohrschneider et al., 1997;
Yeung et al., 1998; Yagisawa et al., 1999). Grb-2 also binds to MAP kinases thereby
mediating macrophage responses to the anaphylatoxin C5a (Torres and Forman,
1999). Fey receptor signalling, leading to macrophage activation and the production
of reactive oxygen species is dependent on the adaptor function of Grb-2
(ErdreichEpstein et al., 1999). Monocyte IL-3 responses (Anderson et al., 1997;
Yagisawa et al., 1999), eosinophil IL-5 responses (Bates et al., 2000) and the
activation of T-cells by CD43 cross-linking (PedrazaAlva et al., 1998) all involve
Grb-2 in their signal transduction pathways. Deltex may also be involved in
suppression of gene transcription. A proposed mechanism of Deltex action is that
Deltex / Grb-2 heterodimers inhibit JNK-mediated activation of the transcription
factor E47 (Ordentlich et al., 1998). E47 is a basic helix-loop-helix protein involved
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in B-cell specific Ig gene transcription and is required for early B-cell development












Figure 5.3. The Notch signalling pathway. Notch ligands Delta and Serrate
(usually on a different cell, rather than the same cell as Notch as shown here)
bearing the DSL domain bind to EGF repeats of the extracellular domain of
Notch. This causes cleavage of Notch, possibly resulting in trans-endocytosis
of the extracellular domain, and nuclear translocation of the intracellular
domain to the nucleus. The intracellular domain is involved in inducing the
transcription of genes such as HES, Deltex and NF-kB.
Integration with otherpathways
The Notch pathway interacts with a variety of other signalling pathways. In addition
to the potential to modulate NF-kB, MAP kinase and STAT signals as discussed
above, the Notch pathway interacts with other proteins which were also first
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described as developmentally important in Drosophila, but have since been identified
in mammals.
Fringe proteins (lunatic, radical and manic) and the neurogenic protein
Brainiac are not DSL-motif containing -Notch ligands, but secreted proteins able to
interact with the extracellular domains ofNotch ligands, possibly by changes to
gylcosylation so as to abrogate Serrate, but potentiate Delta signalling (Fleming et
al., 1997; Wilson et al., 1997;Panin et al., 1997; Egan etal., 1998; Wu and Rao,
1999). Recent studies suggest that fringe is a glycosyltransferase (Bruckner et at,
2000) which exhibits most of its Delta modifying activity in the Golgi apparatus
before it is secreted (Munro and Freeman, 2000). During vertebrate embryogenesis
bursts of Lunatic Fringe expression cause periodic activation ofNotch and regulate
body segmentation, the so called 'segmentation clock' (Pourquie, 1999). The
intracellular adaptor protein Numb can block Notch signalling (CamposOrtega,
1996; Spana and Doe, 1996; Guo et al., 1996) presumably by binding to its
intracellular domain, although studies in cultured cells have failed to demonstrate
Numb blockade of CBF-1 binding (Frise et al., 1996; CamposOrtega, 1996).
Dishevelled is a protein required for the reception of the Wingless signal and is
phosphorylated in response to this signal (Yanagawa et at, 1995). Dishevelled can
also bind to the intracellular domain ofNotch, and inhibit Delta signalling through
Notch (Axelrod et al., 1996). Flairless interferes with Notch signalling by blocking
the association of CBF-1 with its promoter target sequences (Bang et al., 1995); the
phosphorylation state of Hairless may regulate this activity (Christensen et al., 1996).
Bearded may also regulate Notch signalling by modulating Notch / CBF-1
interactions (Leviten and Posakony, 1996). Bone morphogenetic proteins (BMPs)
can cause a reduction in delta transcription by interfering with achaete / scute
transcription factors involved in the regulation of delta expression (Wilson and
HemmatiBrivanlou, 1997). Proteins such as Noggin and Chordin can interfere with
BMP function and therefore may be capable of increasing Delta protein expression
(Lamb et al., 2000).
The rapid expansion of molecules known to interact with Notch signalling
will undoubtedly continue over the coming years as more proteins are identified by
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genetic screens and in vitro binding assays, and assisted by the Human Genome
Project, their mammalian homologues are identified.
Notch in immune system development
Most work on Notch signalling has focused on its roles in embryogenesis where it is
particularly important in neurogenesis (Xu et al., 1990; ArtavanisTsakonas and
Simpson, 1991; ArtavanisTsakonas et al., 1991). Other roles beyond neurogenesis
and wing development include the role of the Notch pathway in immune system
development. Notch and its ligands are widely expressed in immune cells and
tissues. CD34+ haematopoietic precursors express Notch-1 and -2 (VarnumFinney et
al., 1998). Double negative thymocytes express high levels of Notch-1, double
positives express little or no Notch-1, and mature CD4+ and CD8+ T-cells express
intermediate levels ofNotch proteins (Hasserjian et al., 1996; Felli et al., 1999).
Thymus and bone marrow stromal cells express some (but not all) Notch ligands (Li
et al., 1998; VarnumFinney et al., 1998; Felli et al., 1999), and isolated cells in the
periarteriolar sheath but not the germinal centres ofmouse spleens express Delta-1,
Serrate-1 and Notch-1 (Lamb et al., 1998). mRNA for Notch-1 and Serrate-1 has
been detected in splenic CD4+ and CD8+ T-cells, B-cells and DCs (Hoyne et al.,
2000). Taken together these data suggest that the potential for regulation of leukocyte
development by Notch signalling exists. The differentiation stage of the cell
receiving Notch signals appears to be highly important to the outcome of signalling,
and would explain how the same pathway is able to influence many different cell fate
decisions.
Notch and early haematopoiesis. When CD34f haematopoietic precursors were
transfected to express constitutively activated Notch-1, or exposed to a Serrate-2
expressing cell-line, acquisition of granulocytic and myeloid differentiation markers
was delayed (Carlesso et al., 1999). Exposure to Serrate-1 expressing cells led to a
proliferation of undifferentiated precursors (VarnumFinney et al., 1998). These data
suggest that in very early haematopoiesis (the CD34+ precursor stage) the role of
Notch signalling is to maintain and amplify undifferentiated precursor cells.
If notch-1 is inactivated using the Cre-Lox system, bone marrow derived
lymphocyte precursors are unable to develop into T-cells. B-cell development is
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normal suggesting an instructive role for Notch-1 activation in inducing a T-cell
rather than a B-cell fate (Radtke et al., 1999). This observation is in line with
constitutively active alleles ofNotch-1 being responsible for human T lymphoblastic
leukaemia (Ellisen et al., 1991) and bone marrow precursors transfected with
constitutively active Notch-1 producing extra T-cell precursors at the expense of
B-cell precursors (Pui et al., 1999).
Notch and ap versus y5 T-cell development. Transgenes encoding constitutively
active intracellular fragments ofNotch can be transfected into developing
thymocytes where they support differentiation to aP T-cells at the expense of y8
T-cells (Washburn et al., 1997). Expression ofNotch ligands on thymic stromal cells
may promote ap T-cell production (Hayday et al., 1999). In mice reconstituted with
a 1:1 mixture of heterozygous Notch-1 +/- and Notch-1 +/+ haematopoietic
precursors more of the y§ T-cells develop from Notch-1 +/- precursors than from the
Notch-1 +/+ population (Robey and Fowlkes, 1998). ap or y8 lineage commitment
requires the production of a functional (rearranged in-frame and capable of
signalling) TCR; Notch activation does not abrogate this requirement (Hayday et al.,
1999). It may be that Notch signalling is not instructive but acts by selectively
enhancing the survival of aP cells normally destined to die. Alternatively it may be a
'facilitative factor' modulating the cell's capacity to respond to instructive signals.
Notch and CD4 versus CD8 T-cell development. There has been long-running
speculation as to how double positive thymocytes 'choose' CD4 or CD8 expression
and how the choice of coreceptor matches the TCR specificity for MHC class I or II.
Instructive and stochastic models of CD4 versus CD8 lineage decision have been
proposed (Davis et al., 1993; Chan et al., 1993a; Chan et al., 1993b; Suzuki et al.,
1995). Recently a role for Notch has been suggested (Deftos et al., 1998), although
the absence of Notch in double positive thymocytes (Hasserjian et al., 1996) casts
doubt on the physiological significance of this. Constitutively activated Notch-1 in
mouse thymocytes leads to the production of extra CD8+ T-cells and fewer CD4+
T-cells (Robey et al., 1996; Robey, 1999). BrdU labelling experiments in which non-
proliferating double positive thymocytes are followed as they develop into single
positives show that the extra CD8+ cells are not simply the result of inappropriate
single positive proliferation, but that a proportion of T-cells which normally chose
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the CD4 lineage become CD8+ T-cells (Robey, 1999). It appears that inappropriate
Notch-1 signalling causes some MHC class II recognising T-cells, which would
normally develop as CD4+ T-cells to develop as (presumably non-functional) CD8+
T-cells (Robey et al., 1996). Robey, 1999, proposes a model of instructive T-cell
subset commitment based on Notch expression linking coreceptor engagement to
differentiation. Robey suggests that Class I recognition (CD8 engagement) by a
double positive thymocyte leads to enhanced Notch signalling by DSL-containing
Notch ligands on stromal cells and that this reinforces CD8 and suppresses CD4
expression (Robey et al., 1998). Pertussis toxin is able to induce an increase in CD8
lineage selection by an up-regulation ofNotch expression (Takahama et al., 1997).
There is also evidence that the Notch pathway intermediate HES-1 silences CD4
gene expression in CD4+ Th-cells (Kim and Siu, 1998).
Notch and apoptosis. Notch engagement can function as an anti-apoptotic signal
(Miele and Osborne, 1999; Yang and Ashwell, 1999). Evidence for this comes from
the ectopic expression of constitutively active Notch in some neoplasms (Ellisen et
al., 1991; Smith et al., 1995; Gallahan and Callahan, 1997). Notch-1 knockout mice
die before birth, but inducible knockouts have been made using the Cre-Lox system.
Following Notch-1 gene excision mice exhibit overall size reduction, a smaller
thymus and fewer single and double positive thymocytes (Swiatek et al., 1994;
Radtke et al., 1999). Experimental expression of active Notch-1 in primary
thymocytes and thymoma cell-lines results in increased expression of the anti-
apoptotic gene Bcl-2 and resistance to glucocorticoid induced 'death by neglect'.
Elowever, the protection from apoptosis offered by active Notch-1 cannot be so
straightforward as the up-regulation ofBcl-2 because induced expression of this gene
alone does not prevent death by neglect (Deftos et al., 1998). Active Notch-1
expression can also render T-cell lines refractory to TCR-mediated apoptosis by
binding to the pro-apoptotic nuclear hormone, Nur77 and inhibiting its action (Jehn
et al., 1999). It is conceivable that Notch-mediated inhibition of apoptosis in the
peripheral immune system could contribute to the specification ofmemory cell fate.
Little work has been done to study the influence ofNotch on apoptosis of
monocytic cells, and the picture here is complicated by the influence of cytokines.
When primary human monocytes expressing high amounts ofNotch-1 and -2 were
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triggered in vitro with immobilised Delta-1 apoptosis resulted, but only in the
presence ofM-CSF and not GM-CSF (Ohishi et al., 2000). As discussed above,
Notch signalling can induce these cytokines and the G-CSF signalling pathway can
interact with the Notch pathway via Grb-2. G-CSF, GM-CSF and Notch interact in
myeloid differentiation. In 32D myeloid progenitor cells active Notch-1 specifically
inhibits granulocytic differentiation induced by G-CSF, and Notch-2 inhibits
GM-CSF-mediated differentiation (Bigas et al., 1998). Specificity of the Notch
effects is controlled by the Notch cytokine response (NCR) region of the cytoplasmic
Notch protein (Bigas et al., 1998). These results are hard to reconcile with another
study where Notch-1 activation (by transfection with constitutively active notch-], or
co-culture with Serrate-1 expressing fibroblasts) accelerated granulocytic
differentiation of 32D cells (Schroeder and Just, 2000). There is a danger that ectopic
Notch expression experiments may produce artefactual results by inducing
expression ofNotch at non-physiologically high levels. Notch-1 knockout mice show
normal monocyte, granulocyte, NK-cell and B-cell development, and thymic DCs
develop normally despite a deficiency in the thymocyte lineage (Radtke et al., 2000).
Notch and proliferation. As discussed above and in a similar manner to Notch /
Delta interactions maintaining neuronal precursors in Drosophila (Brennan et al.,
1999), Notch / Serrate interactions can contribute to the maintenance of
haematopoietic precursors (Carlesso et al., 1999). However, under different
circumstances, such as the absence of growth factors, Notch activation of human
CD34+ cells by cells expressing Serrate-1 inhibits proliferation (Walker et al., 1999).
The outcome ofNotch signalling is highly dependent on the other signals
present - in many circumstances Notch signalling may simply acts as a 'facilitation
factor'.
"The receptor encoded by the Notch gene plays a central role in preventing
cells from making decisions about their fates until appropriate signals are
present. ... Loss ofNotch... function results in cells making premature and
incorrect cell fate decisions, whilst increases in Notch signalling prevent cells
from making these decisions. "
Brennan et al., 1999.
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Notch and tolerance
About five years ago Lamb, Hoyne and Dallman proposed that Notch signalling
might help to explain the induction of immunologic tolerance (Hoyne et al., 2000).
Invoking the Notch pathway to explain tolerance is theoretically appealing because
all the components of the pathway appear to be expressed in the relevant cells and to
be involved in haematopoiesis and immune system development (see above). Notch
regulated fate specification and lateral inhibition in the embryo can be likened to
processes involved in the induction of tolerance. Immune-dominance, bystander and
linked suppression are all processes in which lymphocytes regulate the activity of
other lymphocytes, either directly or via an APC. Cell proximity at an APC would
allow cell to cell contact signalling, possibly by Notch. The experimental evidence
accumulating in support ofNotch's role in tolerance is summarised below (N.B. not
all of this data has been published in peer-reviewed journals, sources include
personal communications, abstracts, seminars at the University of Edinburgh and the
Scottish Immunology Group 2000 meeting in St. Andrews and UK patent application
GB2335194A).
• Mice were immunised with Der PI110-131 peptide (the immunodominant epitope)
or OVA. A week later the antigen-primed lymph node cells (LNC) were
removed. In vitro proliferation and IL-2 production by the LNC in response to
either recall antigen was reduced by more than 80% if a Der P 1110-131 specific
T-cell hybridoma, transfected to express surface Delta-1 and irradiated to prevent
proliferation or cytokine secretion, was also present in the culture. Control
hybridomas not expressing Delta-1 did not suppress LNC responses (Lamb et al.,
1998). In this experiment the Delta-1 expressing hybridoma did not inhibit T-cell
responses specifically; this contradicts other data (see below) and models of
suppression, and may have been due to the artificially close proximity of the
suppressor and suppressed cells in culture.
• Murine splenic DCs were transfected to express Serrate-1 and pulsed with Der
PI1I0~131 peptide. Mice were then immunised with these DCs and boosted with
Der PI two weeks later. Seven days after boosting LNCs were isolated. LNCs
from mice immunised with the Serrate-1 expressing DCs failed to proliferate or
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secrete IL-2 when challenged in vitro with their recall antigen compared to cells
from mice immunised with control DCs (Lamb et al., 1998; Hoyne et al., 2000).
Potentially reactive T-cells had been tolerised (or deleted) when presented
peptide by Serrate-1 expressing APCs. Further studies (Hoyne et al., 2000) have
shown that this tolerance lasts for at least 12 weeks, the longest time-point tested.
• Mice were injected with a Der PI110-131 reactive, irradiated T-cell hybridoma,
transfected to express Delta-1, at the same time as whole Der PI protein in CFA.
Seven days later LNCs were isolated and stimulated in vitro with Der PI110"131 or
81 102Der P 1 " peptide. No IL-2 or proliferative response was seen in response to
either epitope in LNCs isolated from mice treated with the Delta-1 expressing
hybridoma, LNCs from mice treated with control transfected hybridomas did not
show reduced antigenic responses (Lamb et al., 1998). This experiment
demonstrates Delta-l's role in eliciting linked suppression; although the Delta-1
expressing T-cell was specific for an epitope in Der PI110-131 it was able to induce
tolerance to another, linked epitope. It appears that tolerance induction towards
the Der pj81"102 epitope is a true example of linked suppression and not simply
due to a non-specific inhibitory effect of the Delta-1 transfected hybridoma. A
separate experiment (Lamb et al., 1998) demonstrated that the Der PI-specific
delta-1 transfected hybridoma was unable to inhibit an in vitro recall response to
the unrelated OVA protein (Lamb et al., 1998; Hoyne et al., 2000).
• The HA1.7 human T-cell clone (reactive to influenza haemagglutinin (HA) 306-
318) was transfected to express cell surface Delta-1. These cells were mixed with
normal HA1.7 cells, presentation competent APCs (irradiated HLA DRB1*0101
OA/: t i o
PMBCs) and HA " peptide, and were able to inhibit responses to antigenic
stimulus in the non-transfected T-cells (Lamb et al., 1998). The untreated HA1.7
cells retained a normal ability to proliferate in response to IL-2 (Lamb et al.,
1998). This experiment suggests that the Delta-1 expressing HA1.7 cells acted as
suppressor cells and inhibited the response of other HA1.7 cells by Delta-1
mediated signalling. Presumably the suppressive signal was delivered by cell-cell
contact when T-cells were brought into close proximity by interaction with
APCs.
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• HA1.7 cells proliferate in response to HA306"318 peptide presented on L-cells (a
fibroblast cell line transfected to express HLA-DRB1*0101). When the L-cells
were transfected to express Serrate-1 in addition to HLA-DRB1 *0101 the HA 1.7
proliferative response was poor. The HA1.7 T-cells that had been tolerised by
Serrate-1-expressing L-cells became suppressor T-cells themselves and were able
to inhibit proliferation of fresh HA1.7 cells in response to antigen presented by
normal APCs (irradiated PBMC, Lamb et al., 1998). HA 1.7 cells could act as
suppressors after irradiation, which makes cytokine involvement unlikely and
suggests involvement of signalling by cell-cell contact (Lamb et al., 1998).
• When HA1.7 cells are cultured in the presence of a high dose of HA306"318 peptide
in the absence of APCs, a state of unresponsiveness to subsequent antigenic
challenges is induced (i.e., tolerance). RT-PCR shows that resting HA1.7 cells do
not express any transcript for Delta-1, but that 2 hours from the initiation of the
tolerisation protocol delta-1 mRNA appeared (Lamb et al., 1998). No equivalent
data has been reported to show an increase in Notch ligand expression following
tolerisation by a Delta or Serrate expressing APC.
• Antigen-specific tolerance can be induced in mice by intranasal administration of
the immunodominant Der PI1l0~131 peptide (Hoyne et al., 1993). Mice treated in
this way or with PBS as a control and subsequently rechallenged subcutaneously
with full length Der PI in CFA were killed at various times following rechallenge
and their superficial lymph nodes and spleens harvested for
immunohistochemistry. Mice that received intranasal Der pi110"131 peptide
showed increased spleen and lymph node expression ofNotch-1, Delta-1 and
Serrate-1 from eight days after rechallenge (Lamb et al., 1998). Control, PBS
treated mice showed lower levels of these proteins (Lamb et al., 1998).
• Mice previously immunised with Der PI mount a strong in vitro recall response.
However, a 75% reduction in this recall response was observed if the animals
were immunised as normal and then tolerised with Serrate-1+ Der p 1110-131
pulsed DCs (Hoyne et al., 2000). This experiment shows that Notch signalling is
able to inhibit established immunity, an important demonstration if attempts are
to be made to modulate the Notch pathway as a therapy for allergy or
autoimmunity.
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One criticism of the above experiments is that transfected cells may express
Notch ligands at unusually high levels, which may not be relevant to physiologically
induced tolerance. It would be interesting to see if physiological stimuli (e.g., oral
tolerance, prostaglandins etc) or disease processes (e.g., the HIV-1 induced immune
deficit) were able to induce changes in Notch ligand expression sufficient to see the
tolerisation effects described above.
There is considerable commercial interest in modulating Notch signalling to
therapeutic ends (Montesano et al., 1997; ArtavanisTsakonas and Matsuno, 1997;
Lendahl et al., 1999; ArtavanisTsakonas et al., 2000; Anon., 2000; Lamb et al.,
2000). Notch signalling could be modulated to induce angiogenesis following
ischemia or wounding or to inhibit it in tumours (Uyttendaele and Kitajewski, 1998),
as well as modulating the immune response to pathogens, allergens, xenografts,
allografts or self-tissue in autoimmunity (Lamb et al., 1998).
Semen, prostaglandin and tolerance
An immune response to spermatozoa is a threat to fertility (Kelly, 1999). Sperm
express MHC class I antigens on their surface (Martinvilla et al., 1996), although this
has not been shown definitively (Vince and Johnson, 1995; Kelly, 1997). The
presence of infection in either the male or female genital tract might provide a
'danger signal' (Matzinger, 1994; Medzhitov and Janeway, 1997) to the immune
system and sensitise the female to subsequent sperm exposure in the absence of
infection (Kelly, 1997). The evolutionary strategy adopted by man and other
primates to prevent anti-sperm immune responses is to suppress the immune system
of the female genital tract at the time of insemination (Kelly, 1997). This brings the
risk that the female may not be able to mount an effective response to invading
pathogens, especially sexually transmitted diseases. This risk may be minimised by
secretory IgA and innate immune mechanisms such as macrophage phagocytosis in
the male and female reproductive tracts and, the innate activity of anti-microbial
chemicals in semen (Kelly, 1999).
It has long been recognised that human semen is profoundly
immunosuppressive (see James and Hargreave, 1984; Alexander and Anderson,
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1987, and Kelly, 1995, for reviews). It has also been suggested that semen is
'tolerogenic' and that repeated exposure to sperm antigens in the presence of seminal
plasma will induce antigen-specific anergy and regulatory T-cell populations (Kelly,
1997; Kelly, 1999). Support for this comes from an epidemiological study of the
incidence of preeclampsia, a condition associated with dysfunctional embryo
implantation. The condition is significantly less common in women who have
cohabited with the father of their child for at least 12 months before becoming
pregnant (Robillard et al., 1994). A possible reason for this is that repeated exposure
to their partner's semen before conception had induced tolerance of antigens present
on their partner's sperm and paternally encoded antigens on the embryo. Immune
mediators in semen include spermine, prostaglandins and TGF-P (Kelly, 1999). The
concentration of prostaglandin in human semen is 10,000 fold higher than that found
in any other tissue and represents a considerable evolutionary investment by the male
(Kelly, 1999). Low levels of IL-8, IL-6 and other cytokines are sometimes found in
seminal plasma, but are produced by leukocytes in cases of leukospermia, rather than
being intrinsic components of the ejaculate (Shimoya et al., 1993; Paradisi et al.,
1997).
Prostaglandins (PGs) are usually viewed as pro-inflammatory mediators.
Non-steroidal anti-inflammatory drugs such as indomethacin can inhibit their
production and the resultant inflammation (Kelly, 1999). The pro-inflammatory
action of PG is due to its vasoactive properties (Mossmann, 1973). The E series of
PG (PGE) also have direct immunosuppressive actions on leukocytes by increasing
intracellular cAMP levels so as to raise the threshold for activation (Kelly, 1999).
PGE suppresses human T-cell proliferation (Goodwin et al., 1977) by reducing IL-2
production (Chouaib and Fradelizi, 1982) and the expression of IL-2 receptor
(Krouse and Deutsch, 1991). PGE is also immunosuppressive by other effects on
cytokine release. On whole human blood IL-12 release is inhibited (Kraan et al.,
1995) and IL-10 production enhanced (Kelly et al., 1997a) by PGE and 19-hydroxy-
PGE (19HO-PGE), both major components of semen (Kelly, 1997). Both IL-10
(Chang et al., 1995; Iglesias et al., 1997) and PGE (Iglesias et al., 1997) down
regulate B7 expression on APCs, an addition possible mechanism of tolerance
induction. PGE has an established role in inducing tolerance of gut microflora.
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Transgenic mice engineered to contain only hen egg lysozyme reactive CD4+ T-cells
are tolerant of the orally administered protein. However tolerance cannot be
established, and gut pathology is seen, if indomethacin is concurrently administed to
the mice (Newburry et al., 1999; Morteau, 1999; Murch, 2000). Indomethacin is an
inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in PG production
(Newburry et al., 1999). In humans with IBD COX inhibitors have been shown to
exacerbate intestinal inflammation (Kauffman and Taubin, 1987; Aabakken and
Osnes, 1989; Bjarnason et al., 1993).
HIV-1, gpl20 andprostaglandin
Many viruses are known to manipulate the immune system towards tolerance
(Alcami and Koszinowski, 2000). EBV produces an IL-10 mimic (Viera et al.,
1991). Measles virus inhibits IL-12 production by infected monocytes (Karp et al.,
1996), and CMV stimulates PGE production by host cells (Nokta et al., 1996). Male
to female sexually transmitted HIV-1 may avoid the need to manipulate the immune
system in this way by being delivered in the tolerogenic environment of semen
(Kelly, 1997). Jay Levy has long studied a soluble factor produced by CD8+ T-cells
which blocks HIV-1 infection of cells (Levy et al., 1996). Although the identity of
this factor has yet to be identified, its production is blocked by IL-10 (Barker et al.,
1995). PGE in semen has the potential to abolish production of this potentially
protective factor in the genital mucosa and draining lymphoid tissue.
Gpl20 is reported to directly stimulate the production of PGs. Rats injected
intracerebroventricularly with gpl20 show increased expression ofCOX-2 in the
brain cortex and increased levels of PGE2 in whole-brain homogenates.
Indomethacin administration abolishes PGE2 rises and the accompanying apoptosis
of cortex cells (Bagetta et al., 1998). Cultured neuroblastoma cells also up-regulate
the PGE-synthesising arachidonic acid cascade and undergo apoptosis in response to
gpl20 (Maccarrone et al., 1998). They can be rescued from this death by COX
inhibitors (Corasaniti et al., 1995). Cultured astrocytoma cells release PGE2 in
response to culture with gpl20 (Mollace et al., 1994). None of the above reports of
gpl20 induced PG synthesis identifies the strain ofHIV-1 from which the gpl20 was
derived or its cellular tropism. M- and T-tropic HIV-1 derived gpl20 is reported to
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stimulate phosphorylation of the CD4-p56lck receptor signal transduction pathway
but not PG formation in the THP-1 human monocytic cell line (Hui et al., 1995). In
primary bronchoalveolar lavage macrophages however, gpl20mB induced a
substantial PGE2 secretion. This was blocked by indomethacin (Denis, 1994).
Gpl20mB-induced PGE2 production enhanced the growth of an AIDS-associated
strain ofMycobacterium avium in gpl20-treated macrophages (Denis, 1994).
Prostaglandin signals may be linked to the Notch pathway via NF-kB.
Activated NF-kB can trigger the expression ofNotch ligand (Bash et al., 1999), and
PGs can influence the activation state ofNF-kB (Conte et al., 1997; D'Acquisto et
al., 1998; Rossi et al., 2000), although whether PGs are inhibitory or activatory of
NF-kB is not clear.
Summary oftolerance signals
In addition to Notch, antigen presentation in the context of several other signalling
molecules may induce specific tolerance. The tolerogenic signal can come from
suppressor T-cells or APCs.
IL-10 acts as a growth factor for the suppressor CD4+ T-cells able to protect
against IBD, and IL-10 knockout mice are unable to produce this protective cell
population (Asseman and Powrie, 1998; Fowler and Powrie, 1999; Leach et al.,
1999). IL-10 producing suppressor T-cells are induced in models of oral tolerance
(Krause et al., 2000). PGE, 19HO-PGE and seminal plasma can induce IL-10
production from whole blood (Kelly et al., 1997a). In the eye, lymphoid cells
undergoing Fas-mediated apoptosis produce IL-10 before dying in order to limit the
immune response to their self-antigens (Gao et al., 1998). As well as being anti¬
proliferative to CD8+ T-cells, IL-10 down regulates macrophage endocytosis
(Montaner et al., 1999). Reports of the effects ofHIV-1 infection and incubation
with gpl20 on monocyte / macrophage production of IL-10 are contradictory. Some
authors observe no change in either basal or LPS-stimulated release of IL-10 in
response to HIV-1 infection or the presence of gpl20 (DeReuddreBosquet et al.,
1997; Bergamini et al., 1998). Other reports describe an increased expression of
IL-10 by macrophages and macrophage / T-cell syncytia after HIV-1 infection or
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incubation with gp 120 (Gessani et al., 1997; Taoufik et al., 1997; Hammond et al.,
1998). It seems likely that the maturation state of the monocyte derived macrophages
is important in determining the extent of the IL-10 response. HIV-1-induced
reductions ofmacrophage secreted IL-12 may be the result of inhibition of IL-12
production by IL-10 Taoufik et al., 1997). The outcome of HIV-1-induced IL-10
production is complex; immune-inhibitory properties of IL-10, and CCR-5 up-
regulation in response to the cytokine (Houle et al., 1999) would be expected to
favour viral infection and replication. However, IL-10 acts on infected macrophages
to slow the rate of viral replication, possibly by inhibiting complete macrophage
maturation (Chang et al., 1996).
TGF-p is produced by the regulatory T-cells providing protection from
disease in models of IBD. Neutralising antibodies to TGF-P can ablate the suppressor
cells' protective effect (Powrie et al., 1996). Interestingly, in TGF-P knockout mice,
a protective suppressor T-cell population can still develop (Barone et al., 1998).
When human macrophages ingest apoptotic cells, they produce TGF-p, presumably
to avoid an inflammatory response (McDonald et al., 1999). In the context ofHIV-1,
Tat has been demonstrated to induce TGF-P production by macrophages (Reinhold et
al., 1999; Rubartelli et al., 1999). The role of PGs in tolerance has already been
reviewed above. Other proposed mechanisms of tolerance induction include the
macrophage cell surface expression of a tryptophan metabolising enzyme in order to
prevent lymphocyte proliferation by starving them of a necessary extracellular
precursor molecule (Mellor and Munn, 1999; Mellor and Munn, 2000), and the
removal or reduction in production of pro-response cytokines such as IL-2
(Lombardi et al., 1994; Lombardi et al., 1995) and IL-12 (Taoufik et al., 1997).
The hypothesis that Notch signalling is involved in tolerance induction does
not preclude a role for any other molecule. There is a precedent for Notch signals to
interact with other signals, including cytokine signals, and several components of the
Notch pathway are common with other signalling pathways (see above). There has
been little work examining the interaction of conventional tolerance signals with the
Notch pathway, except that IL-10 has been shown to increase notch-1 transcription in
CD4+ T-cells, and TGF-p up-regulate serrate-1 mRNA in DCs and B-cells (Lamb et
al., 2000). Although experimental systems involving transfection of cells to express
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high levels of Notch ligands result in tolerance induction and point to a way of
inducing tolerance therapeutically, it seems likely that in physiological situations no
one signal will be overriding. The decision that the immune system makes when it
decides between tolerance or immunity is a vital one, and one would expect it to be
made in the light of all the available information. Notch signals may help naive
T-cells to adopt a regulatory cell fate. Furthermore, Notch signals may be used to
allow regulatory T-cells to regulate the activity of other T-cells.
Notch experimental difficulties
The proteins of the Notch signalling pathway are highly conserved between species,
so it is difficult to raise antibodies to them for experimental use. A handful of rather
poor affinity antibodies are now available, but most of these have been raised against
the cytoplasmic region of the proteins. This precludes their use in live cells and
makes it difficult to use them in flow cytometry. The University of Edinburgh's
Centre for Inflammation Research has had some success using an anti-Serrate
antibody in immunohistochemistry on Cytospins and tissue section.
Real-time PCR studies avoid the need to use antibodies and this approach has
been taken to the Notch pathway in this thesis. Results based on measured mRNA
levels need to be interpreted with caution, translational regulation can mean that the
level of a specific mRNA does not always vary in line with its protein (Lie and
MacDonald, 1999; McDonald et al., 1999). Nevertheless, there is a precedent at the
Centre for Inflammation Research and other centres for using Real-time PCR to
study the Notch and related pathways and this supports the contention that the Notch
pathway is principally regulated at the transcription level. Notch is cleaved upon
activation (Kidd et al., 1998; Schweisguth, 2000), so signalling through Notch is
proceeded by an up-regulation of notch mRNA to replenish cell surface Notch. There
is also data (Smith et al., 1995; Robey et al., 1996) which suggest that one of the
transcriptional targets ofNotch is notch itself. Whether each notch locus is
specifically up-regulated in response to activation of its corresponding protein, or all
available notch genes are expressed in response to Notch activation is not known.
Notch cleavage releases the intracellular domain of Notch. This portion of the
receptor is believed to enter the nucleus and promote transcription of HES and deltex
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by interacting with DNA-binding proteins (Schweisguth, 2000). Transcriptional
activation ofNotch target-genes is, therefore, a direct read-out of this signalling
event.
Aims of chapter
Data presented in chapter 4 demonstrate that HIV-1 gpl20 induces changes in APC
cell-surface phenotype. This chapter investigates whether gpl20-induced changes in
phenotype are linked to changes in the functional ability of APCs and T-cells. The
novel and exploratory nature of this work necessitated the investigation of a large
number ofmolecular candidates in order to select those for further study rather than
the investigation a more defined area with greater rigor.
Specific questions
• Does gpl20 cause a defect in antigen presentation and T-cell stimulation by
APCs?
• Could any defect be interpreted as gpl20 induced tolerance?
• Is the Notch pathway, prostaglandin or cytokine signalling involved in this
tolerance induction?
• Which molecules of the Notch pathway are important in gpl20 responses?
• Does seminal plasma induce tolerance via the Notch pathway in a similar manner
to gpl20?




Refer to chapter 2 for details of materials and methods.
Cell culture
Macrophages. Monocytes were isolated from Buffy coats obtained from blood
donations. All cells used in this chapter were homozygous wildtype for the ccr5
locus (see chapter 3). Blood cells known to be positive for HLA DRB1 *0101 were
kindly donated by a colleague and found to be homozygous wildtype for the ccr5A32
mutation. Monocytes were differentiated to macrophages over a period of 7 days and
immuno-phenotyped before use as described in chapter 2.
Langerhans cells. DCs were generated from primary monocytes over a period of 7
days by culture with GM-CSF and IL-4 as described in chapter 2. To better model in
vitro the LCs present in the genital mucosa (Purcell et al., 1996; SaintAndreMarchal
et al., 1998), an LC-type phenotype was induced in all the DCs used in this chapter
by addition of TNF-a one day before use of the cells (Strunk et al., 1996).
T-cells. CD4+ T-cells were isolated from PBMCs obtained from Buffy coats using a
depleting cell-isolation column from R&D Systems. Cells were immuno-phenotyped
to assess purity before use.
HA1.7 T-cell line. This cell line was passaged and stimulated with antigen on a 7-
day cycle. Cells were taken for proliferation experiments at day 7 before
re-stimulation to ensure that cells were quiescent at the start of the experiment.
HA1.7 and AC) .1 activation. This procedure was carried out by Dr Adrienne
Verhoef (Department of Biology, Imperial College, London). Tissue culture plates
were coated with anti-CD3 (lOpg/ml) and anti-CD28 (lpg/ml) for 1 hour at room
temperature. Plates were then washed and 1ml ofHA1.7 or AC1.1 cells added at
2xl06/ml for various times. RNA was extracted from these cells and sent to our lab
on dry ice.
HA1.7 and AC 1.1 anergy induction. This procedure was carried out by Dr
Adrienne Verhoef. 2xl06 F1A1.7 or AC 1.1 cells were incubated respectively with
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25pg/ml of HA306"318 or Der P H28"40 in 1ml of medium for various times. RNA was
then extracted and sent to our lab on dry ice.
Cell treatments
Cultures were stimulated with the agents listed below, at the concentrations and for
the times given in the results section of this chapter.
Gpl20mB and R5-gpl20 were obtained from the NIBSC Centralised Facility for
AIDS Reagents. These baculovirus expressed recombinant proteins were derived
from the T-cell line adapted virus strain HIV-Ihib (Ratner et al., 1985, GenBank
accession number X01762) and from cDNA isolated from a primary macrophage of
paediatric AIDS patient MN (Gurgo et al., 1988, GenBank accession number
U72495). The gene sequences used to generate both recombinant gpl20s were kindly
analysed according to published criteria (DeJong et al., 1992; Fouchier et al., 1992)
by Dr Peter Simmonds (Laboratory for Clinical and Molecular Virology, University
ofEdinburgh) and confirmed to be X4-tropic and R5-tropic respectively.
3.7 peptide is a 44-mer incorporating discontinuous epitopes of gpl20. It was
obtained from Professor Robert Ramage (Department of Chemistry, University of
Edinburgh). The sequence, design and synthesis of 3.7 is described in chapter 6.
FMDV peptide was also obtained from Professor Ramage and used as a control for
3.7. FMDV is a 44-mer peptide based on a sequence derived from a different virus
(bovine Foot and Mouth Disease Virus) and like 3.7 has a C-X-C bond incorporated
in its structure. There is no sequence homology between 3.7 and FMDV.
QS4120 anti-CD4. This mouse monoclonal antibody is directed against the CDR2
region of CD4 and inhibits gp 120 / CD4 binding (Howie et al., 1998).
Sheep IgG was isolated using a protein G column as described in chapter 2 from
non-immunised sheep serum (SAPU). Having a molecular weigh of approximately
150kD but being unable to bind to human cells, it was used as a control for both
gpl20 and QS4120.
Seminal plasma extract (SPE), PGE2 and 19HO-PGE2 were obtained courtesy of
Professor Rodney Kelly (MRC Centre for Reproductive Biology, Edinburgh).
190
Indomethacin, also obtained from Professor Kelly was added at 5pM to some
cultures in order to block prostaglandin synthesis by inhibiting COX-2.
Cell harvesting and analysis
Proliferation assays, flow cytometry, semi-quantitative RT-PCR, Real-time RT-PCR,
prostaglandin determination, immunophenotyping and ELISA were carried out as
described in chapter 2. Vivien Grant (MRC Centre for Reproductive Biology,
Edinburgh) carried out prostaglandin determination. Real-time RT-PCR was carried
out in collaboration with Gail Baldie (MRC Centre for Reproductive Biology,
Edinburgh). James Logie carried out the IL-10 semi-quantitative RT-PCR, under my
supervision as part of his BSc Experimental Pathology final year project.
Results
Cell purities.
Monocyte derived macrophages and LCs, and column purified CD4+ T-cells were
phenotyped by flow cytometry in order to assess their purity. Macrophage cultures
were >90% MHC class II+, >80% CD14+, >85% CD80+ with contaminating T-cells
(CD3+) of <10% and B-cells (CD40+) of <0.5%. LC cultures were >90% CDla+,
>85% CD54+, >80% CD80+ and >85% MHC class II+ (>65% MHC class IIhi).
Contaminating T-cells (CD3+) were <3% and B-cells (CD40+) <10%. Contaminating
monocytes / macrophages (CD14+) were <20%. Column isolated CD4+ T-cell
cultures were 98% CD3+, 93% CD41) 5% CD8+, 0.25% CD14+ (monocytes) and 2%
CD40+ (B-cells).
PCR standard curves
Figure 5.4 shows the data obtained from a variable cycle RT-PCR experiment for
IL-10. 31 cycles were chosen for all future semi-quantitative RT-PCR reactions
under similar conditions. The level of IL-10 mRNA present in each sample was
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expressed relative to the level of the (3-actin housekeeping gene mRNA, determined
as described in chapter 4.
The Notch pathway is involved in experimental T-cell line anergy induction
The antigen specific CD4+ T-cell lines HA 1.7 and AC 1.1 were treated in vitro to
render them anergic or activated. RNA was isolated from these cells at various post
treatment time-points, and mRNA levels for genes of the Notch signalling pathway
determined. Figure 5.5 shows relative levels ofNotch pathway transcripts in HA1.7
cells. Figure 5.6 shows a smaller set of results from AC 1.1 cells. Several mRNAs
were up-regulated in HA1.7 cells in response to activation or anergy (figure 5.5).
However, in general the initially elevated transcript levels in activated cells declined
after about 24 hours, whereas specific mRNA levels in anergic cells continued to rise
until at least 120 hours (5 days). Among the Notch ligands serrate-2 and especially
delta-1 transcripts were most elevated in anergic cells. There is some indication that
notch-1, -2 and -4 mRNA levels may be higher in anergic as opposed to activated
cells. With regard to mRNA for intracellular signalling proteins acting down-stream
ofNotch, deltex levels remained low and unchanged in all samples, and HES-l was
not detectable in any of the HA 1.7 cells (not shown). The picture in AC 1.1 cells is
less complete (figure 5.6), but broadly in agreement with the HA1.7 results, showing
delta-1 mRNA levels varying the most and deltex mRNA remaining constant. HES-l
mRNA was also absent from AC1.1 cells (not shown).
Inhibition ofHA1. 7 antigen specific proliferation
In order to investigate if gpl20 and other agents were able to induce HA1.7 anergy,
HA1.7 cells were incubated with gpl20 or anti-CD4 before being driven to
proliferate by macrophage presentation of HA306"318 peptide. Pre-treatment of HA1.7
cells did not result in a significant reduction in basal proliferation in the absence of
antigen (figure 5.7b), or proliferation in response to 0.5pg/ml (figure 5.7d) or lpg/ml
(figure 5.If) of HA306"318.
However, ifmacrophages were pre-treated with R5-tropic gpl20 or anti-CD4,
but not gp 1 20ihb or sheep IgG, their ability to support antigen specific HA1.7
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proliferation was reduced (figure 5.7a and c). This reduction in ha1.7 proliferation
was not seen when ha306"318 was added at its highest dose of lpg/ml (figure 5.7e).
Pre-treatment of LCs for 48 hours with various agents also caused a reduction
in their ability to support HA1.7 proliferation. R5-tropic gpl20, anti-CD4, PGE2 and
SPE all caused a significant reduction in LC ability to support HA1.7 proliferation in
response to 0.2pg/ml (figure 5.8a) or 0.5p.g/ml (figure 5.8b) of HA306"318. The control
protein sheep IgG did not affect proliferation, nor did gpl20mB. SPE produced the
most profound suppression of proliferation. The presence of indomethacin abrogated
the suppression caused by R5-tropic gpl20 and anti-CD4.
Gpl20 treatment does not cause macrophage apoptosis
In order to investigate the possibility that gpl20 and anti-CD4 treatment of
macrophages lead to the reduced ability of APCs to support T-cell proliferation by
causing APC apoptosis, macrophages were assayed for apoptosis by the annexin V
method following various treatments. R5-tropic gpl20, gpl20mB and anti-CD4
treatment for 48 hours did not induce detectable increases in macrophage apoptosis
above the level present in control cells treated with sheep IgG. Figure 5.9 shows a
background level of 7 to 9% apoptotic cells in macrophages treated with sheep IgG,
gpl20 or anti-CD4. To confirm the ability of the annexin V method to detect
apoptosis, macrophages were starved of medium for 48 hours; this resulted in over
95% of cells becoming apoptotic or secondarily necrotic (figure 5.9a).
Gpl20 can induce serrate mRNA in CD4+ T-cells
In order to investigate the possible role of the Notch pathway genes (induced in
anergic HA1.7 T-cells) in primary CD4+ T-cell responses to gp'l20 treatment, various
concentrations of gpl20 or anti-CD4 were incubated with purified CD4+ T-cells.
Real-time PCR showed an up-regulation of serrate-2 mRNA in response to R5-tropic
gpl20 and anti-CD4 (figure 5.10). These increases in serrate-2 mRNA were dose
dependent. The increase in serrate-2 mRNA in response to gpl20niB was less certain.
No consistent changes in mRNA for notch-1, delta-1 or deltex were observed. In
193
common with HA1.7 and AC1.1 T-cells, HES-1 was not detectable in primary CD4f
T-cells.
The Notch pathway may be involved in reduced macrophage and LC capacity to
supportproliferation
Figure 5.7 and 5.8 show that treatment of APCs with gpl20, SPE or PGE2 reduced
their capacity to support T-cell proliferation. In order to investigate the possible
involvement of the Notch pathway in this phenomenon, mRNA levels of Notch
pathway genes were measured following APC treatment with various agents.
Notch ligands. Following 6 or 48 hours of LC treatment with R5-tropic gpl20,
gpl20hib, SPE or PGE2, serrate-1 and -2 mRNA levels showed some variation but
no consistent pattern of change (figure 5.11a, b and c). However, delta-1 mRNA
levels at 6 hours (figure 5.1 Id) increased in response to treatment with all four
agents. There was no apparent difference between responses to R5-tropic gpl20 and
gpl20hib- Gpl20-induced delta-1 mRNA increases were partly abrogated by the
presence of indomethacin. By 48 hours delta-1 mRNA levels had largely returned to
basal levels. On macrophages convincing delta-1 mRNA increases were not
observed (figure 5.12a and b).
Notch receptors. In general no LC treatments resulted in dramatic notch mRNA
increases. A small dose dependent increase in notch-1 in response to PGE2 (figure
5.1 lg), and an increase in notch-2 in response to gpl20niB are exceptions to this
observation. In macrophages 48 hours of treatment with SPE caused large increases
in notch-1 mRNA (figure 5.12d).
Down-stream signalling molecules. HES-1 and deltex mRNA was detected in LCs,
but not in macrophages. A wider survey of HES-1 and deltex expression showed that
both mRNAs were detected in monocyte-derived LCs from donors A and B, but
were absent from monocyte-derived macrophages from donors B, C and D (data not
shown).
In LCs gpl20-, SPE- and PGE2-induced changes in HES-1 and/or deltex
mRNA levels were larger at 48 hours than 6 hours (this is in contrast to Notch ligand
mRNA increases, which were greatest at 6 hours). HES-1 mRNA expression was
induced in LCs at 48 hours in a dose dependent fashion (figure 5.12m). There was no
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apparent strain specificity of gpl20-induced effects. Little change in HES-1 mRNA
level was seen at 48 hours in response to SPE or PGE2, or at 6 hours in response to
any agent. In LCs , all four agents induced an increase in deltex mRNA (figure 5.1 In
and 0). This increase was greatest at 48 hours, dose dependent, and in the case of
gpl20, non-strain specific and partly abrogated by indomethacin.
Peptide 3. 7 may be able to mimic some ofgp120's actions
The gpl20-based peptide 3.7 (discussed in detail in chapter 6) could potentially
mimic the effects of gpl20 and modulate mRNA levels of Notch pathway genes. In
order to investigate this possibility, 3.7 and an irrelevant (FMDV) peptide were
incubated with LCs for 6 and 48 hours. By 6 hours 3.7 induced an increase in delta-I
(figure 5.13a) and notch-1 (figure 5.13b) mRNA. Responses to 3.7 at 48 hours or
changes to HES-1 (figure 5.13c) or deltex (figure 5.13d) mRNA levels were no larger
than those seen with FMDV peptide.
Prostaglandin may mediate gpl20 effects
The observations that responses to gpl20 may be partly abrogated by the addition of
the COX-2 inhibitor indomethacin, and that some of the responses to gpl20 are
similar to those induced by PGE2, and published reports of gpl20-induced
prostaglandin synthesis by microglia (e.g., Denis, 1994), suggest that the gpl20
effects on Notch pathway mRNA may be mediated via prostaglandin production. In
order to explore this possibility further, PGE2 was measured in the supernatants of
LC and macrophage cultures treated with gpl20 for 6 and 48 hours (the same cells in
which mRNA levels were measured). Both gpl20mB and R5-tropic gpl20 induced
PGE2 release by LCs at 6 hours (figure 5.14). By 48 hours this PGE2 was no longer
detectable in the supernatant. In macrophages gpl20 seemed less able to induce
PGE2 release at the time-points assayed. The apparent PGE2 release by macrophages
in response to lpg/ml of gpl20 at 6 hours (figure 5.14) may have been caused by a
single assay contamination event.
The effects of gpl20 and PG on LC HES-1 transcript induction were not
identical. Both M-tropic and T-tropic gp!20 induced HES-1 mRNA at 48 hours
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(figure 5.11m). This HES-1 induction was abolished by indomethacin, suggesting
that PG mediated it. However 6 or 48 hours of PGE2 treatment did not result in a
similar HES-1 induction (figure 5.111 and m), despite similar effects of PGE2 and
gpl20 on the induction ofNotch ligand mRNA. It appears that PG synthesis (COX-2
activity) is required to mediate gpl20-induced HES-1 up-regulation, but that the
effect may not be mediated solely by PGE2-induced up-regulation ofNotch ligand.
Other signals from, or induced by, gpl20 (for example CD4 ligation or non-PGE2
PGs) may also be required. Alternatively, PGE2 treatment of LCs may cause HES-1
up-regulation at a time point not assayed in these experiments.
In addition to the Notch pathway, cytokines may be involved in APC tolerance
induction
As well as the Notch pathway many other APC-derived signals are involved in
tolerance induction. In order to investigate the possibility that cytokines may have
been involved in the inhibition ofHA1.7 proliferation seen in figures 5.7 and 5.8 (in
addition to or in place ofNotch signals), ELISAs were used to assay TGF-pi, IL-10
and IL-12 in APC supernatants. Selected supernatants from macrophage and LC
cultures treated with gpl20, SPE, PGE2 or LPS for 6 or 48 hours (the same cultures
in which mRNA levels were measured) were assayed for IL-10, IL-12 and TGF-pl.
IL-10 and IL-12 were undetectable in all samples (except the LPS-treated positive
controls, data not shown, limit of detection approximately 50pg/ml). However,
TGF-pi was detected in the supernatant of both macrophages and LCs at both 6 and
48 hours following treatment with SPE, PGE2 and gpl20 (figure 5.15). TGF-pi
release in response to gpl20 was dose dependent (optimum concentration ~0.1p.g/ml)
and non-strain specific.
Because IL-10 production in response to gpl20 has been previously reported
(Borghi et al., 1995), the failure to detect IL-10 by ELISA was of concern. IL-10
mRNA was therefore measured by semi-quantitative RT-PCR (figure 5.16) in
macrophages treated with gpl20 for up to 96 hours. Although gpl20uiB and R5-
tropic gpl20 caused an up-regulation of IL-10 mRNA (and presumably subsequent
cytokine release) by 72 and 96 hours, gpl20 caused an initial decline in IL-10 mRNA
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which may account for the failure to detect IL-10 protein by EL1SA at 6 and 48
hours.
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Number of PCR cycles
Figure 5.4. IL-10 standard curve. The electropherogram shows RT-PCR
IL-10 product bands (328bp) obtained by amplification of 0.1 pg of starting
RNA for the number of cycles indicated. It can be seen that with increasing
cycle number, the band intensity increases and then plateaus. The
accompanying graph shows results of image analysis of the
electropherogram.
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Figure 5.5. mRNA levels in activated and anergised HA1.7 T-cells. Cells
were activated (white bars) or anergised (black bars) in vitro. Levels of
specific mRNAs extracted from these cells were measured by real-time PCR,
and are expressed relative to basal levels in un-stimulated cells (t = 0) given
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Figure 5.6. mRNA levels in activated and anergised AC1.1 T-cells. Cells
were activated (white bars) or anergised (black bars) in vitro. Levels of
specific mRNAs extracted from these cells were measured by real-time PCR,
and are expressed relative to basal levels in un-stimulated cells (t = 0) which
were given a value of 1. Graphs show mRNA levels from a single
experiment. N.D. = not determined.
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Figure 5.7. Antigen specific T-cell proliferation. Either macrophages or
ha1.7 T-cells were pretreated with 0.1pg/ml of gp120mB, R5-tropic gp120,
anti-CD4 (QS4120) or sheep IgG (as a control) for 24 hours (white bars) or
48 hours (shaded bars). T-cells and macrophages were then mixed and
antigen specific T-cell proliferation in response to various doses of ha306"318
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Figure 5.8 (previous page). Antigen specific T-cell proliferation. LCs
were pretreated for 48 hours with 0.1pg/ml of gp120mB, R5-tropic gp120, anti-
CD4 (QS4120) or sheep IgG, or with 1pM PGE2, or with 0.05% seminal
plasma extract, in the presence or absence of indomethacin (indo). HA1.7
T-cells were then added to the LCs, and antigen specific T-cell proliferation in
response to 0.2 or 0.5pg/ml of HA306"318 peptide was measured. P values
(calculated by Mann-Whitney U tests) are shown comparing responses.
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Figure 5.9. Annexin V macrophage apoptosis assay. Scatter plots show
F.S. / S.S. characteristics of the cells and reveal a small (<8%) population of
contaminating lymphocytes. Only those macrophages falling into the large
scatter plot gate are shown in subsequent analysis. Part a) as a positive
control macrophages were driven to apoptosis by culturing them in PBS in
the absence of medium for 48 hours. Staining with P.I. and annexin V shows
95.7% of the cells as annexin V positive (i.e., apoptotic) and 48.6% showing
secondary necrosis. Parts b), c), d), and e) show results from macrophages
incubated for 48 hours with, respectively Ipg/ml of sheep IgG (control









































Figure 5.10. mRNA levels in primary CD4+ T-cells. Primary CD4+ T-cells
were treated with various concentrations of gp120mB, R5-tropic gp120 or
cross-linking anti-CD4 (QS4120) for 48 hours. Levels of specific mRNAs
extracted from these cells were measured by real-time PCR, and are
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+ + + - - - -
notch-1 - - - - - - - -
notch-2 - - - - N.D. N.D. N.D. N.D.
notch-3 - - - - - - - -
notch-4 - - - - N.D. N.D. N.D. N.D.











= abrogated by indomethacin, N.D. = not determined
Only substantial specific mRNA increases observed over a range of
concentrations are indicted in the above summary table. Smaller and less
consistent increases have been excluded, see preceding graphs for complete
unedited data.
Figure 5.11. mRNA levels in LCs. Primary LCs were treated for 6 or 48
hours with various concentrations of R5-tropic gp120, gp120wB, SPE or
PGE2, in the presence or absence of indomethacin (indo). Levels of specific
mRNAs, extracted from these cells, were measured by real-time PCR, and
are expressed relative to basal levels in untreated cells (given a value of 1).
Graphs show data from a single experiment, which was partly repeated to





0.01ug/ml R5 0.1ug/ml R5 1ug/mlR5 0.01ug/ml 1MB 0.1ug/ml 1MB
I


















0.01ug/ml R5 0.1ug/ml R5 1ug/mlR5 0.01ug/ml NIB 0.1ug/ml 1MB





































_ _ ■ n r i
■













































Notch-1 macrophage 48 hr
Figure 5.12. mRNA levels in macrophages. Primary macrophages were
treated for 6 or 48 hours with various concentrations or R5-tropic gp120,
gp1 20ihb, SPE, PGE2 or 19HO-PGE2, in the presence or absence of
indomethacin (indo). Levels of specific mRNAs extracted from these cells
were measured by real-time PCR, and are expressed relative to basal levels
in un-stimulated cells (given a value of 1).
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Figure 5.13. mRNA levels in LCs following peptide treatment. Primary
LCs were treated for 48 hours with various concentrations of the gp120-
based peptide 3.7 (black bars) or the irrelevant FMDV-based control peptide
(white bars). Levels of specific mRNAs extracted from these cells were
measured by real-time PCR, and are expressed relative to basal levels in
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Figure 5.14. APC production of PGE2. LCs or macrophages were treated
for 6 or 48 hours with gp120niB (black bars) or R5-tropic gp120 (white bars) at
the concentrations indicated. Cell culture supernatants were then assayed for
PGE2. Absolute PGE2 concentrations are expressed as a change from that
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Figure 5.15 (previous page). APC production of TGF-pi. Macrophages or
LCs were treated for 6 or 48 hours with 0.05% seminal plasma extract and
indomethacin (SP + indo), 1pM PGE, 1pg/ml LPS, or various concentrations
of R5-tropic gp120 or gpl20mib- Cell culture supernatants were then assayed
for TGF-pi. TGF-pi concentrations are expressed as changes from the































Figure 5.16. IL-10 mRNA production by macrophages. Macrophages
were treated with R5-tropic gp120 (white bars) or gp120mB (shaded bars) for
the times indicated. Levels of IL-10 mRNA extracted from these cells were
measured by semi-quantitative RT-PCR relative to p-actin mRNA, and are
expressed in proportion to basal levels in untreated cells (given a value of 1).
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Discussion
HIV-1 induced immune deficits = tolerance?
HIV-1 infection and HIV-1 proteins, especially gpl20, can induce dysregulation of
T-cells and APCs (Hewson et al., 1999). Altered cytokine production (Romagnani et
al., 1994a; Gessani et al., 1997; Bornemann et al., 1997), changes in cell surface
molecules (Oberg et al., 1997; Stent and Crowe, 1997a; Hewson and Howie, 1998),
and reduced presentation efficiency (Chelen et al., 1995) by APCs can all result in a
reduced lymphocyte response to both HIV-l's antigens and the antigens of other
invading pathogens (Wang et al., 1994; Heinkelein et al., 1997; Bouhdoud et al.,
2000). This reduced immune response can be interpreted as the induction of
inappropriate tolerance, and not just an overall immune system decline, because loss
of protective responses is at least partially antigen specific (Bouhdoud et al., 2000).
The role of cytokines in HIV-1 induced tolerance induction has been studied for
many years. The Notch signalling pathway has recently been implicated in tolerance
induction in certain experimental systems (Lamb et al., 1998; Hoyne et al., 2000;
Hoyne et al., 2000), but no previous work has studied the Notch pathway in relation
to immune defects induced by HIV-1 or any other infectious pathogen.
Notch and HA1. 7 T-cells
T-cell lines such as HA1.7 and AC1.1 can be activated or tolerised in vitro by
CD3/CD28 cross-iinking or high dose antigen respectively (Pala et al., 2000). It is
not known how closely these experimental manipulations reflect physiological
situations, but tolerised HA 1.7 cells are both anergic and regulatory (Lamb et al.,
1998). Notch ligand mRNA is up-regulated when HA1.7 cells are activated or
anergised (figure 5.5). However, whereas in activated cells ligand mRNA quickly
returns to resting levels, anergised HA1.7 cells maintain elevated levels of serrate-2
and especially delta-1 mRNA for at least 120 hours. Anergic / regulatory HA1.7 cells
could therefore potentially express elevated surface levels ofNotch ligands
indefinitely (or for as long as they remain anergic / regulatory). This suggests a
mechanism by which regulatory HA1.7 cells can spread their anergic phenotype to
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other HA1.7 cells, as has been previously observed (Lamb et al., 1998). Resting
HA1.7 cells express mRNA for all the Notch proteins and, if we assume that this
mRNA is translated, they ought to be able to receive anergising signals from
regulatory HA1.7 cells through these receptors. Indeed, notch mRNA appears to be
up-regulated following anergy induction (figure 5.5) - possibly due to Notch
engagement and cleavage necessitating replenishment of surface Notch protein.
However, because HA1.7 cells (in common with primary CD4+ T-cells,
figure 5.10) do not express HES-1 and do not modulate deltex mRNA levels in
response to Notch signalling, the ability of T-cells to modulate down-stream cellular
events subsequent to receiving Notch-mediated signals is cast in doubt. It may be
that signalling events down-stream ofNotch engagement are mediated in T-cells by
as yet unidentified molecules, not examined in these experiments. An alternative
explanation is that although regulatory T-cells can express Notch ligand, they are
unable to deliver a tolerisation signal directly to other T-cells. The spreading of an
anergic phenotype from a regulatory T-cell to a naive T-cell may require to be
mediated via a DC. LCs (a DC subclass) could transduce Notch signals from a
regulatory T-cell via HES-1 and Deltex (figure 5.11), and then, possibly, induce
anergy in naive T-cells by more traditional tolerising signals (conceivably cytokines,
CTLA-4, lack of co-stimulation).
HA1.7 T-cell proliferation, gp!20 and Notch
HA1.7 T-cells proliferate in response to peptide antigen presented by macrophages
or LCs (figures 5.7 and 5.8). Although gpl20 or anti-CD4 treatment of primary
T-cells can induce serrate-2 expression (figure 5.10), and anti-CD4 has been used to
induce regulatory T-cells able to prevent graft rejection (Qin et al., 1993), gpl20
treatment ofHA1.7 cells did not result in a reduction in the proliferative capacity of
these cells (figure 5.7). Treatment of APCs with gpl20, SPE or PGE2 caused a
reduction in their capacity to support HA1.7 cell proliferation (figures 5.7 and 5.8),
which was not due to APC apoptosis (figure 5.9).
One explanation for the reduction in the proliferation driven by R5-tropic
gpl20 and anti-CD4 treated APCs could be that receptor-mediated internalisation of
these proteins (as discussed in chapter 4) caused increased presentation of anti-CD4,
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CD4, gpl 20 and CCR-5 derived peptides at the expense of HA306"318 presentation.
This mechanism would explain why gpl20mB treatment of APCs did not result in a
lack of proliferation, but would not explain the actions of PGE2 and SPE.
The observation that gpl20 induces prostaglandin production by LCs (figure
5.14), and that indomethacin abrogates the effects ofR5-tropic gpl20 and anti-CD4
on HA 1.7 proliferation (figure 5.8) suggests that the gpl20 and anti-CD4 induced
reduction in HA1.7 proliferation may be the result of immunosuppressive
prostaglandin release. However, this cannot be the whole story because prostaglandin
is released in response to gpl20 in a non-strain specific fashion (figure 5.14), and
other immunosuppressive cytokines including TGF-pi (figure 5.15) are present.
Gpl 20 induces the expression of Notch ligand mRNA, especially that for
Serrate-2 (figure 5.11). It is possible, therefore, that the Notch pathway is involved in
the inhibition ofHA 1.7 proliferation, although this explanation on its own it unable
to account for the lack of strain specificity in gpl 20 induction ofNotch pathway
molecules. Because prostaglandin treatment of LCs inhibits HA1.7 proliferation
(figure 5.8), and gpl20 induces prostaglandin release in a non-strain specific manner
(figure 5.14), it is likely that gpl20 is immunosuppressive because it stimulates
prostaglandin release, which in turn stimulates the expression ofNotch ligands.
Expression ofNotch ligand mRNA is partly abrogated by the presence of
indomethacin. Neither prostaglandin release (figure 5.14), nor delta-1 mRNA up-
regulation (figure 5.12) in response to gpl20 was seen on macrophages. There is no
direct evidence presented here that prostaglandin-induced expression ofNotch
ligands on APCs induces an anergic / regulatory phenotype in the HA1.7 cells (as
opposed to just a reduction in proliferation), although transfection of APCs to
express Notch ligand is known to do this (Lamb et al., 1998).
As well as expressing Notch ligand in response to tolerising agents, LCs
express mRNA for Notch proteins (figure 5.11) and therefore ought to be able to
receive, as well as give, Notch-mediated signals. HES-1 (figure 5.11m) and deltex
(figure 5.1 lo) mRNA is up-regulated in LCs in response to gpl20, SPE and PGE2.
This is evidence for these cells receiving Notch signals, something macrophages may
be unable to do due to the absence of HES-1 or deltex mRNA. The timing of the
mRNA expression of members of the Notch pathway in LCs is interesting. Notch
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ligand mRNA is up-regulated from 6 hours, but changes in HES-1 and deltex levels
are first measured at 48 hours. The delay in HES-1 and deltex expression may
represent the time taken for intervening signalling steps.
Viewed as a whole, the data in this thesis do not point to a single mechanism
of gpl20-induced immunosuppression, which is able to account for the strain
specificity of gpl20-induced proliferation defects, gpl20-induced reduction in the
proliferation-supporting capacity of both macrophages and DCs, and the effects of
indomethacin. It therefore seems likely that presentation efficiency, prostaglandin,
Notch ligands, and possibly TGF-pi are all involved in gpl20 induced immune
dysregulation.
Semen and Notch
Semen is profoundly immunosuppressive, largely due to its high prostaglandin
concentration (Kelly, 1999). SPE and PGE2 induced the production of TGF-pi by
APCs (figure 5.15). An additional mechanism of immunosuppression by semen may
be the induction of APCs to express Notch ligands (figures 5.11 and 5.12). The
induction ofNotch ligands by SPE and PGE2 has important implications for the
initiation of protective immune responses against sexually transmitted pathogens
(including HIV-1) delivered in the immunosuppressive seminal environment (Kelly,
1997; Kelly and Critchley, 1997b).
DCs are special
F1A1.7 cells, primary CD41" T-cells, macrophages and LCs all express Notch ligand
mRNA and presumably Notch ligand surface protein. However only LCs express the
complete machinery (HES-1 and deltex) for transduction of an incoming Notch
signal along all known intracellular pathways. Macrophages express neither HES-1
nor deltex, and T-cells express deltex only but do not appear to modulate its mRNA
level upon reception of a Notch signal (at least not in the studies presented here). The
difference between macrophages and LCs in this regard is especially startling when it
is remembered that the LCs and macrophages used in the experiments presented here
were both differentiated from the same population of peripheral blood monocytes. It
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would be interesting to correlate the acquisition of dendritic/Langerhans surface
markers with deltex and HES-1 rnRNA expression during LC differentiation. The
discovery that only LCs (and presumably other DCs) express HES-1 and deltex may
point to a unique role of DCs in immune regulation. All immune system cell types
can potentially receive tolerisation signals from pathogens or cytokines and change
their own phenotype accordingly (this would include up-regulation of Notch
ligands). However, if DCs are the only cell type able to receive Notch mediated
signals in a complete form able to cause the up-regulation of their own Notch
ligands, DCs will be required for the reception ofNotch signals from regulatory
T-cells. If regulatory T-cells principally regulate the activity of other lymphocytes
via the expression of Notch ligands, it follows that DCs may be required for the
activity of regulatory T-cells. T-cell to T-cell tolerance inducing signals would have
to be mediated via a DC (figure 5.1). Such a requirement may have evolved as a way
of strictly controlling the antigen specificity of tolerance induction, and limiting the
spread of epitope specificity during linked and bystander suppression to those
epitopes presented by the same APC. However, under some circumstances T-cells
can be rendered anergic by Notch ligand expression on APCs (Lamb et al., 1998), so
they must be able to transduce signals from Notch without the help of HES-1,
possibly solely by the use of deltex, although in the studies presented here T-cell






HIV-1 is the most sought after drug target ever, but after almost 20 years of effort
there is still no cure for AIDS. Academic and commercial research groups have
found many interesting molecules, from diverse sources, which have exhibited anti-
HIV-1 properties in vitro. However, only 14 drugs (in just three classes) have been
licensed (in the UK, Parfitt, 1999) for treatment ofHIV-1 infection. None of these
drugs is satisfactory due to toxicity problems, the rapid evolution of resistance and
the failure to produce a complete and permanent cure (Moyle, 2000).
Current anti-HIV-1 drugs
The replicative cycle ofHIV-1 can be split into 10 stages (Mohan and Baba, 1995),
adsorption (initial virion binding to the cell surface), fusion of the envelope and
plasmalemma (these first two stages comprise entry), uncoating of the viral genome,
reverse transcription, integration of provirus into the host genome, DNA replication,
transcription of viral mRNA, translation of viral genes, maturation of viral proteins
and budding (assembly and release of virus from the cell surface). A drug could
potentially block any stage of the replicative cycle. There may be advantages in
treating HIV-1-infected individuals with a combination of drugs; each targeted to a
different stage in the viral replicative cycle, to reduce the likelihood of viral
resistance to the complete treatment protocol from developing. Drugs currently in
use include reverse-transcriptase inhibitors such as AZT and protease inhibitors such
as Indinvar, which target the viral protease needed to insure correct maturation of
viral proteins. Targeting the fusion stage with peptides and plant lectins (Matsui et
al, 1990; Balzarini et al., 1992), the uncoating stage with bicyclams (DeClercq et
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al., 1992), and the integration, DNA replication, transcription and translation stages
with antisense oligonucleotides (Zamecnik et al., 1986; Sarin et al., 1988; Goodchild
et al., 1988; McShan et al., 1992) has also been attempted but has not yet resulted in
widely-used clinical drugs.
HIV-1 entry inhibitors
Within the past year a dendritic cell (DC) specific protein, DC-SIGN (Geijtenbeek et
al., 1999; Steinman, 2000; Geijtenbeek et al., 2000b) has been identified as an HIV-1
receptor (Geijtenbeek et al., 2000a) which mediates the very first interactions
between HIV-1 and the DC. There have been suggestions that disrupting this
interaction might be an effective drug target. No work has yet been published on
DC-SIGN inhibitors but they may be promising because the DC-SIGN interaction is
of high affinity and its expression is restricted to DCs. However, DC-SIGN-mediated
interactions with T-cells are important in supporting primary immune responses
(Geijtenbeek et al., 2000b) so there is a danger that a therapy aimed at blocking the
function ofDC-SIGN could cause an immune deficit (extremely undesirable in an
AIDS patient) as a side effect.
A more promising and better-studied target for intervention is the gp 120 /
gp41 / CD4 / chemokine receptor interaction. Targeting this early step in the viral
replication cycle is attractive because it will prevent the spread of virus before
cellular entry thereby allowing HIV-1 the least opportunity to do harm. Because
binding ofHIV-1 to cells involves host proteins that do not mutate during the course
of infection and corresponding viral proteins that have their variability constrained at
key residues by their need to bind to these host proteins, there may be less of a
problem with viral resistance to drugs targeted to the entry stage ofHIV-l's
replication cycle.
Even if absorption or entry inhibitors fail to function successfully as a
treatment for established HIV-1 infection, they may have a role as 'morning after',
post exposure drugs aimed at stopping the establishment of a new infection. Because
such drugs ought to require just a few doses given under medical supervision, it
would not be necessary to deliver them orally; this might overcome problems with
the oral bioavailability of some drugs candidates (especially protein or peptide based
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treatments). The World Health Organization has identified an urgent need for
tropically applied HIV entry inhibitors suitable for use by women to block sexual
transmission ofHIV-1 (Lange et al., 1993; The International Working Group on
Vaginal Microbicides, 1996; Elias and Coggins, 1996). Entry inhibitors that fall short
of curing HIV-1 infection might prolong life and increase its quality by reducing the
rate of cellular dissemination ofHIV-1 and by interfering with the CD4 / chemokine
receptor / gpl20 / gp41 interactions involved in syncytium formation (Levy, 1994).
A reduction of the syncytia inducing ability ofHIV-1 would be beneficial to the
patient by reducing the opportunity for viral recombination (Burke, 1997),
decreasing HIV-1 replication dynamics (Connor and Ho, 1994; GranelliPiperno et
al., 1995) and slowing the loss of immune cells. Because most (but not all)
syncytium inducing (SI) HIV-1 strains use CXCR-4 as a coreceptor (Zhang et al.,
1998; Horuk, 1999; Abebe et al., 1999), drugs targeted to inhibit syncytium
formation would be better targeted to block CXCR-4 than CCR-5.
Absorption inhibitors have five main targets, CD4, gpl20, gp41 and the
CXCR-4 or CCR-5 coreceptor. Targeting an inhibitor to a host protein might avoid
the problem of resistance evolving. However, a drug that binds to host proteins might
produce unwanted side effects by disrupting the physiological roles of these proteins
as receptors for MHC class II, IL-16 and chemokines respectively. Studies of the
ccr5A32 mutation (see chapter 3) show that loss of CCR-5 function is not harmful
(Berger, 1997); this suggests that drugs designed to specifically block CCR-5 would
be well tolerated. CCR-5 might be a better target than CXCR-4 (particularly for a
drug to be given shortly after exposure). Protecting APCs from infection might be
more important than protecting T-cells because APCs have a longer life span and less
capacity for renewal than T-cells, and because APCs are the first cells to be infected
after virus transmission (Miller et al., 1989; Spira et al., 1996). One side effect of the
use of CCR-5 inhibitors might be the selection for new and more pathogenic HIV-1
strains using CXCR-4 (Michael and Moore, 1999) or possibly another, currently
rarely used, chemokine receptor (Landau, 1997).
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Current HIV-1 entry inhibitors
Several different groups of chemical entities have been demonstrated to be HIV-1
entry inhibitors. These potential drugs have arisen from the screening of natural and
synthetic chemicals, variations of the proteins involved in HIV-1 absorption
(chemokine receptors, CD4 and gpl20) and their natural ligands (chemokines such
as MlP-la) and from rational design based on knowledge of the molecular
interactions. This last approach has been made easier by the crystallographic
elucidation of the structure of gpl20 (Wyatt and Sodroski, 1998b) and gp41 (Chan et
al., 1997). There is evidence that some HIV-1 exposed but uninfected individuals
may gain protection by their ability to produce high levels ofCC chemokines
(Paxton et al., 1996; Zagury et al., 1998), these observations support the strategy of
using chemokine-based molecules to block infection.
One of the best-described natural entry inhibitors is cyanovirin-N, an 11 kD
protein originally extracted from the cyanobacterium Nostoc ellipsosporum but since
produced by recombinant DNA expression techniques (Boyd et al., 1997; Gustafson
et al., 1997; Mori et al., 1997a; Mori et al., 1997b; Mariner et al., 1998; Bewley et
al., 1998; Mori et al., 1998; Yang et al., 1999; Esser et al., 1999). It appears that
cyanovirin-N acts by disrupting post-absorption fusion events. Other entry inhibitors
include the bis-azo compound FP-21399, which binds to gpl20 (Zhang et al., 1998),
and a soluble galactosylceramide analogue (Fantini et al., 1997). However, most
entry inhibitors so far designed have been proteins, or peptides, based on one of the
viral or host proteins involved in HIV-1 entry. There has been some success with
peptides targeted to interfere with the conformational changes required for the
fusogenic portion of gp41 to interact with the target cell membrane (Jiang et al.,
1993; Kilby et al., 1998; Nisole et al., 1999), most notably with the peptide T-20
which has entered clinical trials (Rizzardi and Pantaleo, 1999). For a time, soluble (s)
CD4 and derivatives such as truncated CD4 molecules and CD4-immunoglobulin
fusion proteins were promising drug candidates. These proteins were demonstrated to
block infection of T-cell lines in vitro (Capon et al., 1989; ShapiraNahor et al., 1990;
Rausch et al., 1992; Yeh et al., 1992; Meshcheryakova et al., 1993) and prevent the
infection of chimpanzees by the T-cell adapted HIV-1 strain IIIB (Ward et al., 1991).
However, when tested on macrophages, M-tropic HIV-1 strains and primary virus
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isolates, sCD4-based therapies were much less effective (Daar et al., 1990; Gomatos
et al., 1990). The misleadingly encouraging results from the T-cell adapted HIV-1
experiments might have been because these HIV-1 strains require an especially
strong (and therefore more prone to disruption) interaction with cellular CD4. The
sCD4 experience demonstrates how important it is to choose an appropriate assay
system for in vitro drug screening. Most recent attempts at protein / peptide
inhibitors have focused on gpl20 mimics. Gpl20 may be a better target than a
cellular protein because HIV-1 is unlikely to be able to evolve a reduced requirement
for gpl20 use in the same way that a reduced requirement for CD4 or chemokine
receptor binding could evolve. Many short peptides (Wang, 1989; Nehete et al.,
1993; Mabrouk et al., 1995; Delezay et al., 1996; Murakami et al., 1997; Donzella et
al., 1998; Barbouche et al., 1998; Ferrer and Harrison, 1999) and several branched
peptides (Fantini et al., 1993; Yahi et al., 1994; Benjouad et al., 1994; Yahi et al.,
1995; Benjouad et al., 1995; Sabatier et al., 1995; Fantini et al., 1996) have been
shown to inhibit HIV-1 infection in vitro. Most of these peptides incorporate either
CD4 binding domains or the V3 loop, although all of them are based on either
consensus sequences from North American and European HIV-1 isolates or from
T-cell tropic viral sequences. Most synthetic gpl20 peptides so far investigated have
contained continuous gpl20 sequences.
The use of gpl20 / gp41-binding peptides in therapy must be approached
with caution, both soluble CD4 and certain peptides derived from the V3 loop of
gpl20 have been shown to enhance HIV-1 infection under certain in vitro
circumstances (Demaria and Bushkin, 1996; Dettin et al., 1998), presumably by
mediating conformational changes in viral gpl20 or host receptor which allow for
more efficient binding. Other possible side effects might be caused by artificial
peptides mimicking the toxic or immunoregulatory properties of gp 120/ gp41
(Werner et al., 1991; Garry and Koch, 1992; Miller etal., 1993).
Manufacture ofpeptides
Traditionally, therapeutic peptides and proteins such as insulin (Keefer et al., 1981)
have been made by using recombinant DNA to engineer the expression of large
amounts of product in microbial, insect or mammalian cell culture. Therapeutic
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peptides have also been expressed in the milk of farm animals (Colman, 1999).
These genetic engineering approaches which have also been used to produce peptides
for vaccination have the advantage of production of large amounts of peptide at
relatively low cost. They may also allow for protein glycosylation which may (or
may not) be identical to the naturally produced protein. Branched peptides cannot be
made by conventional genetic engineering. Modified or non-protein amino acids and
other modifications needed to increase the bioavailability or stability of the peptide
cannot be made by genetic engineering. Branched peptides have the advantage of
recreating more effectively the three-dimensional structure of the whole protein on
which they are modelled. Three-dimensional structure may be important for binding
function and for antigenicity, especially in the case of B-cell epitopes, which are
often discontinuous (Janeway and Travers, 1996).
F-moc chemistry in automatedpeptide synthesis
Several chemical methods are available to produce completely synthetic peptides.
The F-moc (9-fluorenylmethoxycarbonyl) automated synthesis technique depends on
adding 1 -hydroxybenzotriazole-activated esters of the required amino acids one at a
time to a growing peptide chain, which is immobilised to a solid-phase
4-benzyloxybenzyl alcohol resin. The amino terminals (and any amino side groups)
of the amino acids to be added are protected by F-moc, so the only available amino
groups are on the immobilised peptide. Such a method allows efficient synthesis
from the C-terminal to the N-terminal of peptides up to several dozen residues long
(Ramage et al., 1994). Branch points can be added to the linear chain by stopping the
automated synthesis and adding a protected lysine, arginine or histidine ester by hand
(Bycroft et al., 1993; Howie et al., 1998). Selective protection of the a-amino group
on this residue at the end of the nascent peptide allows automated synthesis to be
restarted from a side-chain amino group along one of the peptide branches. The
protection can then be removed from the a-amino group and automated synthesis
down the second branch started. F-moc chemistry is not limited to the synthesis of
peptides solely from the amino acids used in nature.
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Anti-HIV vaccines
Although treatment for HIV-1 infected people is an important goal, a successful
treatment is likely to be unaffordable in the Developing World, where most HIV-1
infections and deaths occur. Although simple, preventative measures such as the
promotion of safer-sex which has recently yielded very encouraging results in
Thailand (Phoolcharoen, 1998) are needed, a cheap and effective AIDS vaccine is
the only realistic hope that most of the Third World has of solving its HIV problem.
The vaccine approach may be more effective in preventing infection than anti-
retroviral therapy ever is at eradicating infection because of HIV-l's ability to hide
as a provirus in the host genome, invisible to the immune system and drug treatments
(McCune, 1995). It has recently been estimated that the half-life of this latent viral
reservoir is about 44 months (Finzi et al., 1999; Persaud et a!., 2000); this would
mean that even a small reservoir of 1 x 105 cells would take at least 60 years to clear
(Gotch and Hardy, 2000) unless virus were forced out of hiding by immunotherapy
such as IL-2 administration (Davey et al., 1999). Alternatively, therapeutic vaccines
may be useful adjuncts to existing anti-viral therapies (Gotch et al., 1999).
The immune system is strongly activated against HIV-1 in infected people.
The emergence of immune-escape HIV-1 variants (Goulder et al., 1997; Harcourt et
al., 1998) is evidence that the immune system places HIV-1 under selective pressure
at least as great as that from anti-retroviral drugs (Borrow et al., 1997; Price et al.,
1997; Gotch and Hardy, 2000). B-cell immunity to HIV-1 is seen in infected people;
this can control HIV-1 by blocking infection, opsonisation or by complement-
mediated lysis (Gotch and Hardy, 2000). CD8+ CTL and CD4+ Th-cell responses are
also seen in HIV-1 infection (Berzofsky, 1991). As well as causing lysis of infected
cells, T-cells can produce CCR-5-blocking chemokines such as MlP-la and
RANTES (Park et al., 1999; Polo et al., 1999) and the distinct CD8+ T-cell antiviral
factor (Hsueh et al., 1994; Mackewicz et al., 1994; Levy et al., 1996). There are
several unknowns as to which responses offer significant protection from disease and
ought to be strengthened by prophylactic vaccination. Anti-gpl20 IgG antibodies can
block infection in vitro (Ugolini et al., 1997), and when infused into Rhesus
macaques (Macaca mulatto) they can protect against vaginal transmission of
pathogenic SIV / HIV-1 chimeric (SHIV) virus. However, epidemiological studies
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have suggested that an overall high anti-gpl20 antibody response correlates with
rapid disease progression (Rusconi et al., 1998) although the presence of antibodies
to the V3 loop of gpl20 correlate with protection from progression (Juompan et al.,
1998). Slow disease progression is predicted by a strong CTL response and
antibodies to the Gag proteins (Klein et al., 1995; Rusconi et al., 1998). Many
vaccines currently being developed and tested (for example, Kelleher et al., 1997)
are based on the V3 loop of gpl20 because this area of gpl20 contains the principle
neutralisation domains (Juompan et al., 1998) and can be antigenically mimicked by
synthetic peptides (Hart et al., 1990). Attempts at mimicking antigenic epitopes in
gpl20-based peptides have focused on continuous epitopes with relatively little work
on discontinuous epitopes.
IgA-mediated mucosal immunity may prove to be more important in
protection from sexual transmission than IgG seroconversion (Mazzoli et al., 1997;
Zagury et al., 1998; Kaul et al., 1999). It would be expected that a vaccine against
sexual transmission ofHIV-1 would be required to induce a mucosal response, so the
use ofmucosal vaccine delivery and mucosal adjuvants such as cholera toxoid need
to be investigated (Velin et al., 1998).
Using peptides as vaccines has the advantage that the induced immune
response can be closely tailored to defined epitopes. Recombinant peptides have
been used successfully as vaccines against hepatitis B (Parfitt, 1999) and several
trials of recombinant AIDS vaccines are currently taking place (Kelleher et al., 1997;
Boily et al., 1999).
Early work on synthetic gpl20 peptides
The interaction of CD4 and gpl20 is complex and leads to conformational changes in
gpl20, gp41 and possibly CD4 (Verrier et al., 1997). Point mutation and epitope
mapping studies (Olshevsky et al., 1990; Thali et al., 1991) identified five conserved
discontinuous residues of gpl20, which form part of the CD4 binding site. More
recent evidence (Wyatt and Sodroski, 1998b) from crystallographic studies confirms
the importance of these residues in CD4 interactions and shows that they surround a
deep cavity, which interacts with F43 on CD4. D368 and E370 in the C3 domain of
gpl20 and D457 in the C4 domain (some authorities place D457 just inside the V5
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domain) are critically important for CD4 binding. Because these residues are near
conserved cysteine residues (C378 and C445) it was suspected, long before
crystallographic confirmation, that although discontinuous, these residues would be
spatially proximal. Figure 6.1 shows the structure of gpl20 in this region and how
the important residues become close.
The work on discontinuous gpl20 peptide sequences reviewed below was
carried out in the University ofEdinburgh's Departments ofPathology and
Chemistryfrom 1996 to 1998 (Cotton et al., 1996; Heslop, 1997; Howie et
al., 1998). See figure 6.1 and table 6.1 for details ofpeptides discussed and
the abbreviation list at the start ofthis thesis for the standard, single letter
amino acid abbreviations used here.
The synthesis of GC-1 (figure 6.1) represented the first deliberate attempt to
mimic, within a linear peptide, the structure of a discontinuous region of a protein by
anchoring the structure around a disulphide bond. Circular dichroism measurements
indicate that the configuration ofGC-1 and the related GC-2 peptide is dependent on
oxidation of the cysteines and probably involves a hydrophobic association between
residues 376, 377, 446 and 447 (Cotton et al., 1996). The observation that antibodies
raised in mice against GC-1 fail to recognise GC-2, but do recognise reduced GC-1
and linear peptides representing single continuous 'arms' of GC-1 (Cotton et al.,
1996) supports the theory that the hydrophobic region close to the C-C bond is not
exposed on the peptide surface. Anti-GC-1 is able to bind GC-1 better than mixtures
of peptides representing the 'arms' either side of the C-C bond. This suggests that
some of the epitopes recognised by anti-GC-1 contained components from both
'arms' of GC-1, that is, they are discontinuous. Anti-GC-1 is able to bind to shared
epitopes on gpl20 indicating at least partial mimicking of gpl20 conformation
(Cotton et al., 1996). GC-1 is able to bind to CD4on transfected HeLa cells much
better than either of the peptide 'arms' or GC-2 (Cotton et al., 1996), indicating that
as well as retaining some of gpl20's discontinuous antigenic epitopes discontinuous
CD4 binding motifs are also retained. GC-1 is able to block CD4 / gp 120
interactions, giving the first indication of its possible therapeutic role.
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GC-1 analogues
In order to confirm their importance in GC-l's antigenicity and CD4 binding
properties, the E370 and D457 residues of GC-1 were replaced by alanines in
analogues ofGC-1. Analogue 3.5 contains a D—»A457 substitution and analogue 3.6
contains a D—>A457 and an E—»A370 substitution. These substitutions resulted in
peptides that could not efficiently bind CD4 or be recognised by anti-GC-1 (Howie et
al., 1998). A further peptide, 3.7 (originally called IH-1), was prepared (figure 6.1,
Howie et al., 1998). 3.7 incorporates an additional 12-residue branch, which was also
synthesised separately as peptide 4.3 (figure 6.1). This extra branch is an additional
region of gpl20's C4 domain which contains residue W427, important for CD4
binding and Q422 and K421, involved in CCR-5 binding and M-tropism (Howie et
al., 1998). Although peptide 4.3 does not have any sequence homology with a
chemokines, 4.3's Hopp and Wood hydropathy values and residue molecular weights
are similar to those for RANTES, MlP-la and MIP-ip, suggesting that 4.3 could be
CCR-5 binding (Howie et al., 1999). Antibody cross-reactivity studies show that 3.7
shares epitopes with GC-1 but also contains additional immune reactivity. 3.7 binds
to the CD4+CCR5+ T-cell line H9, better than GC-1 (Howie et al., 1998). This data
suggests that 3.7 is a better R5-tropic gpl20 mimic than GC-1. 3.7 binds to the
monocytic cell line MM6 and colocalises with CD4 (Howie et al., 1999). 3.7 is also
able to bind to CCR-5 on MM6 cells, as shown by its inhibition of fluoresceinated
MlP-la binding (Howie et al., 1999). 3.7 is likely to bind to the same CDR2 site on
CD4 domain 1 as gpl20, because it is able to inhibit the binding to H9 cells of
gpl20-competing anti-CD4 monoclonal antibody (clone QS4120), but not non-
gpl20-completing anti-CD4 (clone L120) (Howie et al., 1999). QS4120's epitope
has been mapped to CDR2 of CD4, whereas LI20 binds to domain 4 of CD4 (Wyatt
et al., 1998a; Chen, 1998a).
Biological activities ofsynthetic peptides
Gpl20 is able to cause activation-induced cell death (AICD) in CD4+ T-cells
(Meyaard et al., 1992; Groux et al., 1992; Gougeon et al., 1993a; Gougeon and
Montagnier, 1993b; Howie et al., 1994). AICD is mediated by the transduction of
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signals through CD4 (LaurentCrawford et al., 1993; Wang et al., 1994; Maldarelli et
al., 1995; Corbeil and Richman, 1995). The signal from gpl20 is usually only strong
enough to induce apoptosis when the gpl20 is cross-linked by antibodies (Howie et
al., 1998). GC-1 was able to mimic gpl20 by inducing H9 cell apoptosis when cross-
linked by anti-GC-1. GC-1 alone was able to inhibit gpl 20 / anti-gpl20-induced
apoptosis by competing with gpl20 for CD4 binding (Howie et al., 1998). Work
presented in this thesis tested some of these synthetic peptides in an HIV-1 infection
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Figure 6.1. Schematic representation of an area of gp120 and synthetic
peptides based on its structure. Boxed residues are critical for CD4
binding. Circled residues are involved in M-tropism and CCR-5 binding. The
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first diagram shows an area of gp120mB. The sequence and to some extent
the secondary structure of this part of gp1 20wb has been reconstructed in the
peptide GC-1, which also has an extra lysine residue (K363) to give the
option of coupling to a carrier protein. GC-2 represents a small part of GC-1.
Peptide 4.3 is based on another part of gp120, this time incorporating
residues required for CD4 and CCR-5 binding. GC-1 and 4.3 are combined in
3.7, this requires the central valine to be substituted by a lysine. Residue
numbering is based on that for the HIV-1wB sequence (SwissProt accessions
P03376 and P04624, Crowl eta!., 1985; Muesing et al., 1985).
Figure adapted from Howie et al., 1999, and Cotton et al., 1996. ©The
FASEB Journal, 1999 and © Elsevier Science Ltd, 1996.









Table 6.1. Properties of gp120 and gp120 derived peptides. PSS023 is a
random linear 34-mer control peptide.
HIV-1 infectivity assays
Several different in vitro assay systems have been used to test potential anti-HIV-1
drugs (Mohan and Baba, 1995). These include:
• protection of target cells from cytotoxic effect of HIV-1 (Mitsuya et al., 1985)
• inhibition of HIV-1 induced syncytia formation / syncytial plaque forming assay
(Colligan et al., 1993)
• inhibition of p24 (Gag) protein production (Mohan and Baba, 1995)
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• inhibition of reverse transcriptase production (Mohan and Baba, 1995)
• inhibition of production of viral DNA ofRNA (Mitsuya et al., 1987).
Several factors influence the choice of assay, not least the ease of carrying it
out under category-three pathogen-containment conditions. The choice of cell type to
use in the assay is important; the work described below used primary macrophages as
the HIV-1 target cell. Although earlier work on GC-1 and 3.7 used cell lines, it was
felt that a primary cell culture might model in vivo APC infection more closely. With
an interest in APCs in general, either macrophages or dendritic cells could have been
used. Macrophages were chosen as they could be grown from blood monocytes more
easily and cheaply and without the need for the exogenous cytokine GM-CSF which
is known to effect HIV-1 replication rates (Crowe and Lopez, 1997; Kedzierska et
al, 1998) and could complicate the assay. It was decided to use HIV-Ibal as the
viral strain to test the peptides against. BAL is an M-tropic, CCR-5 utilising HIV-1
strain (Gartenhaus et al., 1991) and because some of the peptides to test had CCR-5
binding activity, this was thought to be most appropriate. Primary isolates ofHIV-1
could have been used in the assay, but these would not have been available in large
amounts and would have introduced an additional source of variability. The use of
HIV-Ibal avoids the problems associated with T-cell line adapted HIV-1 strains
which have been shown to give misleading results in some studies due to their
unusually high CD4 binding affinity (Daar et al., 1990).
It has been reported (Mohan and Baba, 1995) that the viral inoculum size
(expressed as MOI or TCID50) used in an assay can influence the results. The need to
calculate MOI precisely was removed in the studies presented here by using
HIV-Ibal from the same single supernatant batch in each experiment and by adding
a large amount ofHIV-1 to the cells in each case so that a ratio of virus particles to
target cells of at least 100:1 and a correspondingly high MOI could be assumed.
Using an excess of virus brings the danger that subtle anti-viral effects could be
missed. This problem was not fully addressed in our studies. However, allowing the
peptides to be pre-incubated with the target cells in the absence ofHIV-1 gave them
a 'head start' on the virus and enabled them to demonstrate anti-viral properties
which might otherwise have been swamped by HIV-1 excess.
246
High tissue culture protein concentrations (from high concentrations of
human or bovine serum) have been shown to affect the anti-viral activities of some
experimental compounds (Kageyama et al., 1994). Therefore, the assay system in the
studies described here used medium containing only 5% human serum as required
for macrophage survival. The assay system used also allowed the peptides tested to
pre-incubate with the macrophages for a period in the absence of serum.
The IIIV-1 infection assay chosen for these studies identifies infection of
target cells by using semi-quantitative RT-PCR to specifically detect HIV-1 mRNA.
The RT-PCR reaction used was designed not to detect either HIV-1 genomic RNA or
DNA provirus, but only appropriately spliced mRNA. Such a RT-PCR based assay
would be ideally suited to the real-time PCR techniques used elsewhere in this thesis.
However, PE Biosystems (manufacturer of the TaqMan™ real-time PCR system and
holders of exclusive patent rights to this technology, Gelfand et al., 1993) prohibit
the use of their system for the detection ofHIV-1, even for pure research purposes.
An RT-PCR based infection assay has the advantage over some other
techniques in that a minimum of time needs to be spent in the category-three
containment facilities because the extracted DNase treated RNA is considered safe to
handle in an ordinary laboratory if good laboratory practice (GLP) is observed. RT-
PCR is more rapid than techniques which involve counting cells by eye, and unlike
plaque-forming assays it can be used with NSI HIV-1 strains. When interpreting
results from an assay which measures mRNA it needs to be born in mind that in
addition to measuring infection efficiency, transcription efficiency may also
influence results.
Aims of chapter
• To validate, by variable cycle RT-PCR the infection assay system chosen for this
study and to determine the optimum number of cycles to use.
• To investigate if the gpl20 based peptides described above are able to block
HIV-1 infection ofmacrophages.
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• To use infection assay data to comment on possible improvements to the design
of these peptides.
Methods
See chapter 2 for details of procedures.
Synthesis ofpeptides
Peptides GC-1, 3.7, PSS023 and 4.3 were synthesised by Albachem Ltd (Edinburgh)
and the University of Edinburgh Department of Chemistry using the F-moc system
as described above, in Cotton et al., 1996, and Howie et al., 1998. The reactions
were carried out on an Applied Biosynthesis 43OA automated peptide synthesiser
(Parke-Davis, Warner-Lambert, Eastleigh, Hampshire, UK) fitted with an Applied
Biosystems 757 UV monitoring system (PE Biosystems) allowing real-time
monitoring of coupling efficiencies. Briefly, GC-1, PSS023 and 4.3 were synthesised
entirely automatedly from the carboxyl to amino terminals. The cysteine residues in
GC-1 were oxidised in air to form the disulphide bridge between residues 378 and
443. The synthesis of 3.7 was more complex and involved automated G459 to C445
synthesis, lysine that had been protected at its Na amino function by 4,4-dimethyl-
2,6-dioxocyvlohex-l-ylidine (Dde) was then manually coupled and automated
synthesis restarted from the N£ amino function to K421. After removal of Dda in
hydrazine, synthesis was continued from the N" amino function to K363. The
cysteines were then oxidised in air.
Infectivity assay
The agent under test was added at 30pM (except gpl20, which was used at 0.3pM)
to the infection assay system described in chapter 2. Peptide PSS023 was used as a
control and has no sequence homology to gpl20. It is a random 34-mer peptide
(Howie et al., 1999).
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The semi-quantitative RT-PCR reaction used to detect HIV-1 mRNA must be
optimised and validated before it can be used to generate meaningful results. The
appropriate number of PCR cycles for the reaction needs to be chosen so that an
HIV-1 and fd-actin housekeeping control signal can both be detected, but neither
signal becomes saturated. This allows both increases and decreases of starting
mRNA to be detected as increases or decreases in band intensity. Briefly, the
RT-PCR reaction described in chapter 2 was run with a known positive for HIV-1.
0.1 jug of positive control RNA was used for each reaction tube because this was the
amount ofRNA reverse-transcribed for the test samples. The PCR reaction was set to
run for 50 cycles and individual tubes were removed from the thermal cycler after
undergoing 25 to 50 cycles each (see figure 6.2 for exact number of cycles used).
The samples were then electrophoresed on an agarose gel, stained with ethidium
bromide and UV illuminated. The band intensity was assessed visually and using the
Enhanced Analysis System (EASY, version 4.19, Scotlab).
Results
RT-PCR validation
Figure 6.2 shows the data obtained from the variable cycle RT-PCR experiment. 32
was chosen as the number of cycles for all future semi-quantitative RT-PCR under
similar conditions.
Infectivity assay
Recombinant R5-tropic gpl20 at 0.3pM completely blocked detectable in vitro
infection ofmacrophages after challenge with HIV-1Bal for both 72 and 94 hours
(figure 6.3). The irrelevant peptide PSS023 at 30pM had no effect on the
infectability of macrophages (data not shown). At this concentration 3.7 and its
analogues blocked infection to varying extents. Figure 6.3c shows the infection
levels detected in macrophages that were pre-treated with various peptides before
HIV-Ibal challenge, expressed relative to cells treated with PSS023. 3.7 and 4.3
were approximately equally effective at blocking HIV-1 infection, showing a 71%
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and 83% respective reduction in infection level of macrophages after 72 hours of
HIV-Ibal challenge. The protective effect of 4.3 was, however, substantially lost by
94 hours with only an approximately 29% reduction in infection observed. The
protection offered by 3.7 was more long lasting, by 94 hours the reduction in
macrophage infection caused by this peptide only fell from 71% to 62%.
GC-1 treatment of cells caused an enhancement of infection. At 72 hours this
enhancement was slight with an infection level of 121% of the control value. By 94
hours the macrophage infection level was enhanced to 243% of the control value.
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Figure 6.2. Variable cycle RT-PCR. The electropherogram shows PCR
product bands (fi-actin at 661 bp and HIV-1 at 215 bp) obtained by
amplification of an equal amount of starting material for the number of cycles
and primer sets indicated. It can be seen that with increasing cycle number
the band intensity at first increases and then declines as non-specific
reactions, nucleic acid degradation and enzyme denaturation increase.
Accompanying graphs show results of image analysis on the
electropherogram, band intensity and its base-two logarithm is plotted
against number of cycles. 32 cycles is found on a region of the graphs where
















































Figure 6.3. Results of infectivity assay. RT-PCR was carried out on RNA
from cells treated with the proteins or peptides indicated and then challenged
with HIV-1 bal for 72 hours (left panels) or 94 hours (right panels) in order to
semi-quantify mRNA for the j3-actin housekeeping gene (part b) and HIV-1
(part a). The electropherograms show raw data from a typical experiment.
The graphs (part c) show the mean band intensity ratios from two similar
experiments. MM = master mix (negative control).
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Discussion
Because 3.7 can bind to both CD4 and CCR-5 we tested the ability of 3.7 and two of
its analogues to inhibit infection by an M-tropic HIV-1 strain. Using primary,
peripheral blood-derived macrophages we found that 3.7 could indeed inhibit
infection with HIV-Ibal whereas the irrelevant peptide PSS023 had no effect. This is
promising if 3.7 is to be considered as a therapeutic candidate. However experiments
with GC-1 and 4.3 highlight some important issues and potential pitfalls of
therapeutic peptide design which must be addressed and could be important in
guiding the design of future generations of synthetic peptides.
Stability ofpeptides
The protective effect of full length R5-tropic gpl20 lasted for at least 94 hours; the
protection from infection offered by 4.3 and 3.7 declined from 72 to 94 hours (by
65% and 13% respectively). Gpl20 was assayed at a different molarity to the
peptides and this could have influenced the longevity of the infection inhibition
effect. Additionally gpl20 may have been protective against infection by inducing a
decline in macrophage surface CD4 and CCR-5 as described in chapter 4. An
alternative and plausible explanation is offered by differential peptide and protein
stability in tissue culture condition, and may be related to the in vivo stability of these
molecules. In tissue culture conditions (and in vivo) proteins will be exposed to the
degradative effects of extracellular proteases and the endocytic properties of
macrophages. The peptides and proteins in this study may have been protected from
breakdown by their secondary structure or by complexing with CD4 or CCR-5. In
this study gpl20 was the most stable molecule, followed by 3.7 and then 4.3. The
greater stability of 3.7 over 4.3 may have been due to its higher affinity for cellular
receptors (Howie et al., 1998), or its increased gpl20-mimicing secondary structure.
It would be possible to assay peptides in cell culture supernatant and in the
circulation of human volunteers in order to measure their half-life. Using novel,
branched peptide synthesis techniques to allow the retention ofmore protein
secondary structure may not only be beneficial from a therapeutic viewpoint by
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preserving the biological activity of the parent protein, it may also increase the
molecular stability of the peptide.
Blocking efficiency
Although 4.3 appears to be less stable in culture than 3.7 (see above and figure 6.3)
72 hours after HIV-Ibal challenge, 4.3 was able to block infection just as well, if not
better than 3.7. This is despite the fact that 4.3 contains none of the three
CD4-binding residues of GC-1 (figure 6.1). The reason for 4.3's greater activity
could be that the K363-C378 and C445-G459 arms of 3.7 spatially hindered the
important infection-blocking K421-K433 residues, which were freer to interact with
cellular targets in 4.3. An alternative explanation, partially supported by observations
of the effect of GC-1, is that the K363-C378 and C445-G459 arms of 3.7 may
enhance infection (see below). It is theoretically possible that instead of blocking
infection, the peptides were simply killing the cells thereby removing potential
infection targets. This seems highly unlikely as no noticeable difference was
observed between treated and untreated cells when closely examined by phase-
contrast microscopy. A more vigorous approach to assessing cell death was taken in
chapter 5 where it was shown, by annexin V staining, that in the absence of infection
R5-gpl20 did not induce apoptosis in macrophage cultures.
Infection enhancement
GC-1 enhanced the infection ofmacrophages by HIV-1Bal- There is a precedent for
anti-CD4 (Stamatatos et al., 1997), sCD4 (Demaria and Bushkin, 1996) and CD4
binding synthetic peptides based on the V3 loop of gp20 (Dettin et al., 1998)
enhancing infection. The mechanism of infection enhancement by GC-1 is likely to
be the induction of conformational changes in CD4 or gpl20 which result in gpl20
being able to bind to CD4 and CCR-5 with greater efficiency (Jones et al., 1998;
Choe et al., 1998; Dettin et al., 1998). An alternative explanation is that GC-1 did
not enhance HIV-1 entry, but rather the action of this molecule on already infected
cells increased the transcription rate of HIV-1 mRNA, giving an increased signal in
the assay used (Tremblay et al., 1994; Morio et al., 1997; Briant et al., 1998). The
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observation that GC-1 can enhance HIV-1 infection highlights a serious risk in the
design and use of viral entry inhibitors. Previous studies have shown that GC-1 is
able to bind to CD4 but not with the same affinity as 3.7 (Howie et al., 1998; Howie
et al., 1999). One might imagine that weakly binding peptides (e.g., GC-1, 3.5, 3.6)
might be more likely to cause infection enhancement than more strongly interacting
peptides (e.g., 3.7). Weakly binding ligands would be able to 'coax' the target
proteins into conformational changes but then fall off their targets rather than bind so
tightly so as to block gpl20 / host protein interactions. The data in figure 6.3 could
also be interpreted to suggest that infection enhancement is a risk when a peptide
contains CD4-binding residues alone (e.g., GC-1) but not when both CD4 and
CCR-5 binding residues are present (e.g., 4.3, 3.7, and gpl20). It is important to
remember that infection enhancement in vitro may not accurately model the potential
in vivo situation; viral tropism, viral and peptide concentration and cellular activation
states may be different.
3. 7 as an vaccine
Experiments described in this chapter's introduction have demonstrated that 3.7 and
GC-1 contain discontinuous and continuous BALB/C murine B-cell epitopes (Chen,
1998a; Howie et al., 1999). The fact that antibody to these peptides was all of the
IgG class (Weissman et al., 1995) means that there must have been isotype switching
during the anti-peptide immune response. This implicates T-cell involvement and is
evidence that the peptides contain murine T-cell epitopes. Whether or not 3.7
contains human T- and B-cell epitopes is not demonstrated by its immunogenicity in
mice because of species differences between the two immune systems. However, the
mouse studies at least show that the peptides are capable of being processed into an
immune stimulatory form. Predicting immunogenicity in humans is complicated by
different class I and II MHC restriction of T-cell epitopes in individuals of an
outbred population. However, comparisons of the 3.7 sequence with published
epitopes from the HIV molecular immunology database (figure 6.2 and Katz et al.,
1995) shows that 3.7 contains several previously identified T- and B-Cell epitopes.
On consideration of the above data, it seems likely that 3.7 would be immunogenic if
humans were vaccinated with it. If 3.7 were administered as a vaccine, its
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immunogenicity would be advantageous, especially if 3.7 contains neutralising
epitopes (the B-cell epitope listed in table 6.2 is neutralising, Lasky et al., 1987).
However, if 3.7 were to be used as a post-exposure prophylactic to block infection of
cells after an individual had exposed themselves to risk, the induction of B-cell
immunity would be disadvantageous. An antibody produced against the prophylactic
peptide could bind to the peptide and neutralise its action; this would reduce the
effectiveness of the peptide if used a second time.
3.7 region and sequence
Reference
364 to 378 421 to 433 445 to 459
KSSGGDPEIVTHSFNC KQFINMWQEVGG CSSNITGLLLTRDGG
Continuous antibody epitopes
QFINMWQEVK Lasky et at, 1987
T-helper epitopes
QSSGGDPEIV Schrier et at., 1989
SSGGKPEIVTHSFNC Wahren et at, 1989
SSNITGLLLTRDGGTC Manca et al., 1995
CTL epitopes
PEIVTHS Dadaglio et at, 1991
Table 6.2. Alignment of 3.7 with human T- and B-cell epitopes. Details of
epitopes were obtained from the H!V molecular immunology database
(Korber et al., 1998) and references cited in the table. Discontinuous B-cell
epitopes are not shown. Imperfect residue matches are underlined.
Future directions
That the synthetic peptide 3.7 derived from three discontinuous sequence stretches of
conserved regions can adopt a structure which allows it to interact with cell surface
ligands of native gpl20 and partially inhibit infection of primary macrophages has
implications for the development of both therapeutic interventions and a synthetic
vaccine. The approach of using synthetic chemistry to bring together in a peptide
regions of a protein around a C-C bond in order to preserves discontinuous antigenic
epitopes or binding motifs also has more general implications for the synthesis of
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novel peptides representing complex, sequence discontinuous, ligand binding sites of
important biological proteins.
The HIV-1 infection enhancing effect of GC-1 serves as an important
reminder of this risk when considering the design of therapeutic peptides. It would be
useful to investigate this phenomenon more closely in an attempt to define which
gpl20 regions are involved in enhancement and which in inhibition of infection. This
information would be useful in guiding the design of future peptide-based HIV-1
entry inhibitors.
The observation that 4.3 is able to show similar anti-infection properties to
3.7 raises the possibility that the complex and expensive synthesis of branched
peptides may not be necessary. 4.3 is a short linear peptide and as such can be made
cheaply by synthetic or genetic engineering techniques. Since 4.3 was designed, the
residues of gpl20 involved in CCR-5 binding have been better defined (see figure
6.4 and Rizzuto et al., 1998). Additional residues in the C4 region of gpl20 on which
4.3 was based have been identified as important for CCR-5 binding. These residues
include R419, Q422,1423,1424, M426 and E429 (Rizzuto et al., 1998). It would be
possible to produce a series of peptides based on the success of 4.3 but incorporating
these recently identified residues. A combinatorial chemistry approach could be used
to generate a large series of 4.3-based molecules for testing in an infectivity assay. If
the therapeutic target of this work is to produce a peptide for use as a post-exposure
prophylactic, or a vaginal microbicide (The International Working Group on Vaginal
Microbicides, 1996) it is important to use a peptide with low immunogenity. Only
one immunogenic epitope has been described in 4.3 (see Lasky et al., 1987, and
figure 6.3). It is possible that if combinatorial chemistry were used to produce a
series of 4.3 analogues, peptides would be found that efficiently blocked infection
but did not result in the production of anti-peptide antibody which would neutralise










Figure 6.4. Structure of HIV-1 gp120 showing residues implicated in
CCR-5 binding. A) Ribbon diagram of gp120 and gp41 (blue). B) Molecular
surface diagram of gp120 from the same perspective as A). Coloured
residues are associated with CCR-5 binding, yellow indicates residues which
when changed result in a > 75% decrease in CCR-5 binding, changes to red
residues cause a > 90% decrease in binding and changes to green residues
cause a > 50% increase in CCR-5 binding.
Figure from Rizzuto et at., 1998. © The American Association for the












SUMMARY, GENERAL DISCUSSION AND CONCLUSIONS
"And that was the day that we knew, oh! In the world there is a new disease
calledAIDS. I thought surely this will be the greatest war we have ever
fought. Surely many will die. And surely we will be frustrated, unable to help.
But I also thought the Americans willfind a treatment soon. This will not be
forever."
Dr Jayo Kidenya, Bukoba, Tanzania, 1985 (Garrett, 1994).
Summary
This final thesis chapter will re-examine the problems posed by HIV-1, summarise
results presented in each of the earlier chapters, and attempt to bring them together
and place them in the context of past work and future possibilities.
The major results arising from this work are summarised below:
• Many previous studies have reported the incidence of the ccr5A32 allele. Few
have statistically analysed the distribution of this allele. Chapter 3 reports a
significant correlation between ccr5A32 allele frequency and northerly latitude,
and predicts an allele frequency of 12.61% (8.42% to 16.80% at the 95%
confidence level) for a population at the latitude of south east Scotland.
• In a group of 94 anonymous blood donors in the south east of Scotland, the
frequency of the ccr5A32 allele was 14.89%. I believe that this is the first report
of ccr5A32 incidence in a healthy Scottish population. The allele's incidence fits
with that predicted for the population's latitude (chapter 3).
• The M-tropic HIY-1 strain BAL uses CCR-5 as an entry co-receptor. HIV-Ibal
was unable to infect homozygous ccr5A32 monocyte-derived macrophages,
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which fail to express surface CCR-5. This finding demonstrates that HIV-Ibal
macrophage infection requires the use of CCR-5 (chapter 3).
Gpl20 induces loss of macrophage surface CD4 (chapter 4).
Substantial gpl20-induced loss ofmacrophage surface CD4 is CCR-5 dependent,
as it only occurs with M-tropic gpl20, not T-tropic gpl20, and it does not occur
on macrophages homozygous for the ccr5A32 mutation, which fail to express
surface CCR-5 (chapter 4).
Macrophage surface CD4 loss is due to CD4 internalisation by a process
resembling receptor-mediated phagocytosis (chapter 4).
Exposure to M-tropic, but not T-tropic, gpl20 reduces an APC's capacity to
support T-cell proliferation (chapter 5). This may be because CD4 internalisation
(chapter 4) alters antigen processing and presentation efficiencies. Several
alternative explanations for reduced T-cell proliferation, involving the Notch
pathway and cytokines, were also investigated (see below).
In addition to M-tropic gpl20, seminal plasma extract (SPE) and prostaglandin
(PG) treatment of APCs inhibits their ability to support T-cell line proliferation
(chapter 5).
Anergised T-cell lines express elevated levels ofNotch ligand mRNA, suggesting
the involvement of the Notch pathway in anergy induction (chapter 5), and the
possibility that the Notch pathway is involved in the gpl20-induced T-cell
proliferation defect.
M-tropic and T-tropic gpl20, SPE and PG induce Notch ligand mRNA and
down-stream Notch signalling events in APCs. Gpl20 induces PG release; this,
together with the abolition of gpl20-mediated effects by indomethacin, suggests
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that the gpl20 effects on Notch ligand mRNA expression are mediated (at least
in part) by PG (chapter 5).
• mRNA for the Notch pathway signal transduction molecules HES-1 and deltex is
found in LC-like DCs but not macrophages. mRNA levels change in LCs
following putative Notch signalling. Deltex, but not HES-1, is expressed in
T-cells, but is only modulated in response to gpl20-induced events in LCs
(chapter 5).
• In addition to the Notch pathway, there is evidence that cytokines and other
soluble mediators may be involved in gpl20-induced T-cell proliferation defects.
TGF-p is released by macrophages and monocyte-derived LCs in response to
M-tropic and T-tropic gpl20, PG and SPE (chapter 5). An increase in IL-10
mRNA is also induced by M- and T-tropic gpl20, but only after 72 hours - not
soon enough to account for gpl20 inhibition of T-cell proliferation (chapter 5).
• Synthetic branched peptides based on discontinuous sequences of M-tropic
gpl20, and retaining some of the antigenic and binding properties of gpl20 block
M-tropic HIV-Ibal infection ofmacrophages, and are therefore potential drug
candidates (chapter 6).
• However, using gpl20-based peptides as an HIV-1 vaccine or other therapeutic
agent brings potential dangers. One gpl20-based peptide tested caused infection
enhancement (chapter 6), and evidence from chapter 5 demonstrates that another
gpl20-based peptide retains the Notch ligand inducing property of gpl20, and
therefore, the potential to induce inappropriate tolerance.
Discussion
HIV-1
HIV-1 is a retrovirus which causes AIDS (BarreSinoussi et al., 1983), and infects 40
million people worldwide (WHO 1999 estimate). Following HIV-1 infection, host
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immunity declines over several years until the host is killed by a succession of
opportunistic infections and/or malignancies (Castro et al., 1993). HIV-1 infects
CD4+ T-cells, macrophages and DCs. The first stage of infection is the binding of
cell surface CD4 by HIV-l's envelope glycoprotein, gpl60 (consisting of gpl20 and
gp41, Dalgleish et al., 1984). Following CD4 engagement, a conformational change
in gpl20 reveals residues that bind to one of the chemokine receptors (D'Souza and
Harden, 1996). Further conformational changes take place and the viral envelope
fuses with the target cell plasmalemma (Pereira et al., 1997; Ji et al., 1999). The
range of cell types that an isolate of HIV-1 is able to target is known as its cellular
tropism. Cellular tropism is determined by which chemokine receptors a particular
isolate's gpl20 is able to bind to, and the availability of these receptors on the
surface of various cell types (Hoffman and Doms, 1999). HIV-1 can be broadly
classified as M-tropic, T-tropic or dual tropic (Berger, 1997). M-tropic virus can
infect macrophages, DCs, LCs and T-cells, and utilises CCR-5 as an entry co-
receptor. T-tropic virus uses CXCR-4, and can only infect T-cells. Dual tropic HIV-1
has the ability to infect T-cells, macrophages, LCs and DCs via CCR-5 and CXCR-4
(Doranz et al., 1996). Because M-tropic HIV-1 strains such as HIV-Ibal are limited
to using CCR-5 as a co-receptor, individuals who are homozygous for the ccr5A32
mutation and fail to express cell surface CCR-5 are protected from infection by
M-tropic strains ofHIV-1 (Paxton et al., 1998, and chapter 3). The ccr5A32 mutation
confers no phenotype on healthy individuals (Magierowska et al., 1998). It arose
approximately 700 years ago (Stephens et al., 1998; Nasioulas et al., 1998) and is
common in white Europeans. New results presented in chapter 3 show that the
ccr5A32 mutation becomes more common in Europe with increasing northerly
latitude, and report the allele frequency for the south east of Scotland, which is
predicted by Scotland's northerly latitude. The reasons for the geographic
distribution of ccr5A32 are discussed in chapter 5, but remain obscure.
Antigen presenting cells
APCs have a central co-ordinating role in the immune system. Phagocytic APCs act
as effectors of the innate immune system. APCs also have a role in regulating the
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activity of lymphocytes of the adaptive immune system. In order to be fully
activated, T-cells must be presented with MHC-complexed antigenic peptides, and
given appropriate co-stimulatory and cytokine signals (Janeway and Travers, 1996).
Antigen specific signals delivered to T-cells in the absence of co-stimulation, or in
the presence of 'tolerogenic' signals may lead to T-cell anergy (Frauwirth et al.,
2000), and/or a regulatory T-cell phenotype (Chen et al., 1994). Any disease that
dysregulates APC function, therefore has the potential to disrupt both innate and
acquired immunity.
HIV-1, gp!20 andAPC dysregulation
HIV-1 disease is characterised by a dramatic fall in CD4+ T helper cells, which
parallels disease progression. However, the loss ofHIV-1 infected CD4+ T-cells does
not completely explain the immunodeficiency seen in HIV-1 disease. Immune
defects are seen in HIV-1+ patients before a significant CD4+ T-cell decline, and
uninfected T lymphocytes and APCs can be killed or have their function disrupted
(Hewson et al., 1999).
Gpl20 is arguably the most damaging HIV-1 protein because it is secreted by
infected cells, and found in the plasma ofHIV-1+ patients (Oh et al., 1992), where it
has the potential to dysregulate the function of uninfected cells. Soluble gpl20
retains its ability to bind to the cellular receptors, CD4, CXCR-4 and CCR-5 (Oh et
al., 1992), and the tropism of soluble gpl20 influences the range of cell types to
which it can bind. HIV-1 infected APCs show a reduced capacity to support T-cell
proliferation (Knight et al., 1997a). Chapter 5 shows that treatment of uninfected
APCs with M-tropic, but not T-tropic, gpl20 reduces their capacity to support the
proliferation of a T-cell line. SPE or PGE2 treatment results in a similar proliferation
deficit. Several mechanism (discussed below) could account for this. HIV-1 is able to
cause changes to APC cytokine production (Ankel et al., 1996; Gessani et al., 1997),
and can influence the Thl - Th2 balance of an immune response (Clerici and
Shearer, 1993). HIV-1 proteins can mimic and antagonise cytokines (Idziorek et al.,
1998; Howie et al., 1999) and change MHC (Peter, 1998), CD4 (Willey et al., 1992;
Rhee and Marsh, 1994), Fas ligand (Badley et al., 1996; Dockrell et al., 1998), and
Fc receptor (De et al., 1998) cell surface levels. Data in this thesis (chapter 5) shows
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that from 3 days onwards IL-10 mRNA in macrophages is up-regulated by exposure
to gpl20. It is possible that gpl20-induced IL-10 could lead to immune deviation.
However, no gpl20-induced IL-10 release was detected by ELISA at earlier time-
points. This rules out IL-10 mediated immune deviation as a cause of the observed
gpl20-induced T-cell proliferation deficiency.
Gpl20 and CD4
There are several reports of T-tropic gpl20 inducing a decline in surface CD4 from
T-cells (Theodore et al., 1994) and macrophages (Karsten et al., 1996). Research
presented in chapter 4 compares the effects ofT-tropic and M-tropic gpl20 on
macrophage surface CD4 levels. It was discovered that M-tropic gpl20 induced a far
greater CD4 loss than T-tropic gpl20 (Hewson and Howie, 1998, chapter 4). Chapter
4 presents results from experiments comparing only two gpl 20s, that from the
prototypic T-tropic HIV-Ihib, and one from a primary M-tropic patient isolate. It
would be interesting to compare a wider range of gpl20 samples in order to
strengthen the hypothesis that differential chemokine receptor usage by gpl20
determines the extent of induced CD4 loss. Further proof that CCR-5 binding is
required for substantial CD4 loss comes from the observations that CD4 loss was not
observed in ccr5 null macrophages, and ccr5 mRNA is up-regulated in response to
CD4 loss (implying replenishment following a concomitant CCR-5 loss). It seems
likely that substantial M-tropic gpl20-induced surface CD4 loss is due to the
triggering of receptor mediated phagocytosis. Confocal microscopy (chapter 4)
showed that M-tropic but not T-tropic gpl20 was internalised as large vesicles
resembling those formed during receptor-mediated phagocytosis. Further work could
confirm this hypothesis by investigating the effect of pharmacological phagocytosis
inhibitors on CD4 loss. It would also be interesting to know if the receptor mediated
phagocytosis of CD4 / gpl 20 / CCR-5 complexes is macrophage specific, and what
signal transduction events are involved in triggering it. It is not known to what extent
CD4 and CCR-5 mediated phagocytosis of gpl20 occurs in vivo. One indirect
method ofmeasuring this would be to obtain lymph node biopsies from AIDS
patients and look for increased levels of intracellular CD4 protein or mRNA, which
would indicate chronic CD4 loss and renewal.
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Surface CD4 and CCR-5 loss has several potential consequences for
macrophage function. Chemotactic responses to IL-16 and MlP-la may be lost.
M-tropic gpl20 endocytosis leads to increased intracellular pools of CD4, gpl20
(and presumably CCR-5, chapter 4). Although these proteins have been detected in
HLA DR-containing intracellular compartments, the compartments in which they are
located could be defined in more detail in order to deduce the likely fate of these
potentially antigenic proteins. Increased efficiency of processing and MHC
presentation of these host and viral proteins could have consequences for the
production of protective and autoimmune responses. There is also the danger that
chronically increased levels of MHC-loading with CD4, gpl20 or CCR-5 may
prevent other antigenic peptides being presented at sufficiently high densities to
trigger T-cell activation. Such a mechanism could explain the reduction in the
capacity to support T-cell proliferation seen in APCs incubated with M-tropic gpl20.
M-tropic gpl20 induced surface CD4 loss within 1 hour, fast enough to account for
the proliferation defect. The strain specificity of the CD4 loss fits with the
observation that gpl20-induced T-cell proliferation decreases are also strain specific
(chapter 5).
Gpl20 and inappropriate tolerance
An alternative explanation for the immune deficit seen in uninfected T-cells of
HIV-1+ patients, and the actions of M-tropic gpl20 on the ability of APCs to support
T-cell proliferation could be that HIV-1 subverts the physiological mechanisms of
tolerance induction so that APCs give tolerogenic, rather than activatory, signals to
T-cells concomitant to an antigen-specific signal. It is known that gpl20 can trigger
APCs to produce the immunosuppressive mediators IL-10 (Borghi et al., 1995) and
PGE (Denis, 1994). There is a precedent for human viruses to induce inappropriate
immune tolerance and suppression (Karp et al., 1996; Nokta et al., 1996; Alcami and
Koszinowski, 2000), and it may be easier for HIV-1 to do this when transmitted in
semen because of the immunosuppressive / tolerogenic cytokines and other soluble
mediators contained in seminal plasma (Kelly, 1997). New data in chapter 5 show
that gp!20 is able to induce TGF-pi and PGE2 production by LCs and macrophages
265
in a non-strain specific way, and that PGE2- and SPE-treated APCs show a reduced
capacity to support T-cell proliferation. Indomethacin, a cycloxygenase-2 (COX-2)
inhibitor which prevents PG production, can abolish the M-tropic gpl20-induced
defect in APCs' T-cell proliferation supporting capacity. These observations suggest
that the reduced ability ofM-tropic gpl20-treated APCs to support T-cell
proliferation is due to PG (and possibly also TGF-P) release by the APCs. However,
PGE2 is released by APCs in response to gpl20 in a non-strain specific fashion, so
PGE2 on its own is unable to account for all features of the APC defect.
HIVprostaglandin andNotch
The Notch pathway has recently been implicated in tolerance induction (Hoyne et
al., 2000), and chapter 5 contains data showing that the induction of anergy in T-cell
lines causes Notch ligand mRNA to be induced. Chapter 5 presents the first data to
show the interaction between Notch signalling and immune modulation by semen or
a pathogen. M-tropic gpl20 treatment of APCs reduces their capacity to support
T-cell proliferation. As discussed above this may be due to gpl20's ability to induce
TGF-P 1 and prostaglandin release. Prostaglandin, whether added directly, in seminal
plasma or induced by gpl20, caused an up-regulation ofNotch ligand mRNA
(chapter 5), and may have acted to reduce T-cell proliferation by signalling through
the Notch pathway. Changes in antigen processing and presentation efficiency
caused by surface CD4 internalisation, TGF-P, PGE2 and induction of Notch ligands
may all contribute to the reduced capacity of gpl20-treated APCs to support T-cell
proliferation. Changes in antigen processing and presentation efficiencies caused by
CD4 loss could account for the gpl20 strain specificity of the proliferation defect,
but not the abolition of the defect by indomethacin treatment. The action of
indomethacin suggests a role for APC-derived PG in reduced T-cell proliferation.
Indeed gpl20 induces PGE2 release by APCs, and direct PGE2 treatment of APCs
causes a reduction in their ability to support T-cell proliferation. PGE2 may act to
reduce T-cell proliferation via its induction ofNotch ligands on APCs. It seems
likely that all of the signals discussed above will influence the extent to which
gpl20-treated APCs (and perhaps APCs in general) will drive T-cell proliferation.
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There is data emerging to show that the Notch pathway can interact with more
'tradition' immunologic signals. Chapter 5 shows an interaction between the Notch
pathway and PG, and other workers have demonstrated that TGF-(3 and IL-10 act
individually and in synergy to induce Notch ligands on murine APC (Lynn Forsyth
and Gerry Ployne, unpublished observations). Alternatively APC-expressed Notch
ligands may simply provide T-cells with APC-derived survival signals, so that they
stays alive long enough to be influenced by other signals such as cytokines.
Of course, it is possible that gpl20-induced PGE2 may be directly
immunosuppressive / tolerogenic, and that a role for Notch does not need to be
proposed in order to explain gpl20-induced proliferation deficits. However, the
PGE2 concentrations induced by gpl20 in cell culture and in vivo in HIV-1 infection
are not likely to approach the extremely high PGE2 levels responsible for the
immunosuppression caused by seminal plasma (Kelly, 1994; Kelly, 1997). Lower
PGE2 concentrations are likely to induce a Thl to Th2 switch (Clerici and Shearer,
1993) rather than immunosuppression or tolerance per se. Such immune deviation is
seen in pregnancy, a state which results in immune modulation (certain autoimmune
diseases are aggravated whilst others are abrogated, Koch et al., 1999; Huizinga et
al., 1999), but no overall immunosuppression (Kelly, 1994; Piccinni and Romagnani,
2000). A recent review ofHIV-1 infection in pregnancy (DeRuiter and Brocklehurst,
1998; Bessinger et al., 1998) concluded that the immune modulation caused by
pregnancy in HIV-1+ women did not change HIV-1 disease progression rates.
New data regarding the distribution ofHES-1 and deltex mRNA expression
among various cell types is also presented in chapter 5. Whilst lymphocytes and
macrophages may be able to transduce Notch / Notch ligand signals via alternative
intracellular pathways, only LCs were shown to have the ability to transduce a
Notch-mediated tolerisation signal via both HES-1 and deltex (as indicated by
changes to HES-1 and deltex mRNA levels). The implications of this finding are
unknown but could point to a central role for LCs / DCs in the induction of anergic /
regulatory T-cells. With regard to the gpl20 induced T-cell proliferation defect
reported in chapter 5, it may be that we are looking at a complicated system
involving different signals being used to communicate between different cell types.
If it were assumed that T-cells do not have the requisite signal transduction
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machinery to receive a Notch ligand mediated signal (the absence of HES-1 and
deltex mRNA would suggest this), then the role of Notch mediated signalling would
be confined to propagating the 'anti-proliferation supporting' phenotype between
APCs (monocyte derived LCs appear able to transduce incoming Notch ligand
signals via HES-1 and deltex, as evidenced by changes to mRNA levels in response
to receiving Notch signals). Cytokines and changes in antigen presentation might be
the only signals being fully transduced from APCs to T-cells.
Antigen specific (re)establishment of tolerance is the goal of treatments for
autoimmunity and the prevention of graft rejection. Delivery of antigens in an
environment that cause the up-regulation ofNotch ligands may be sufficient to
establish tolerance, or increase the potency of other tolerising signals.
PGE2, semen and gpl20 (or isolated components of the latter two) may all contribute
to a tolerogenic environment for antigen presentation by the induction ofNotch
ligand expression. Although Notch-mediated tolerance of pathogens is deleterious,
the induction ofNotch ligands by the agents investigated in this thesis could
potentially be used to treat autoimmune disease.
Semen and tolerance
It has long been known that PG in seminal plasma establishes an immunosuppressive
(and probably a tolerogenic) environment in the female reproductive tract which can
prevent an immune response being mounted to allogenic sperm antigens (Kelly and
Critchley, 1997b). Changes in IL-10 and IL-12 have been proposed as a mechanism
of PG action (Kelly, 1999). Induction of Notch ligand and the immunosuppressive
cytokine TGF-P (chapter 5) may also be involved, and contribute to female tolerance
of sperm antigens. As an unavoidable consequence of semen's tolerogenicity,
inappropriate tolerance to sexually transmitted infections may also appear.
Gpl20 mimicking peptides
Chapter 6 describes the production of synthetic peptides, including branched
peptides, based on discontinuous gpl20 epitopes. These peptides were better able to
retain the three-dimensional structure and binding properties of their parent protein
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than unbranched linear peptides were. Several of these synthetic peptides were able
to block HIV-Ibal infection ofmacrophages. In addition to this, important
observations as to the consequences of peptide stability, and the danger of infection
enhancement by gpl20-mimics, were made. Since the peptides used in chapter 6
were synthesised by colleagues in the Department of Chemistry new data on the
crystallographic structure of gpl20 (Kwong et al., 1998) and the regions responsible
for determination of viral tropism and chemokine receptor binding (Hoffman and
Doms, 1999; Verrier et al., 1999) have emerged. This information will allow the
design of future generations of peptides better able to mimic gpl20. Several novel
therapeutic approaches to HIV-1 disease could be made with gpl20-mimicking
peptides. In addition to use as vaccines and infection-blocking drugs, gpl20-mimics
could be used to investigate and combat the gpl2.0-induced immune dysregulation
uncovered by work presented here. There is a danger that peptides, such as 4.3 and
3.7, engineered to bind to both CD4 and a chemokine receptor, could cause sufficient
cross-linking of cell surface molecules to lead to a macrophage surface CD4 loss
similar to that described in chapter 4. Whether this CD4 loss would be damaging (by
inducing APC dysregulation and altering presentation efficiencies) or beneficial (by
reducing infection of APCs by down-regulating HIV-l's cellular receptors) is not
known. Preliminary studies (data not shown) suggest that 3.7 does not cause
macrophage surface CD4 loss to the extent seen with R5-tropic gpl20. Peptide
engineering technology could conceivably be used to link antigenic vaccine epitopes
to motifs designed to bind to APC surface receptors (CD4, mannose receptor, Fc
receptor) in order to trigger receptor-mediated phagocytosis of the peptide and
increased presentation efficiency of the vaccine epitopes. If the induction ofNotch
ligands by gpl20 induces inappropriate in vivo tolerance, therapeutic peptides could
be used to block gpl20 binding and Notch ligand induction. 3.7 has been shown to
block gpl20 induced T-cell apoptosis by disrupting CD4 / gp 120 interactions (Howie
et al., 1998). However, 3.7 induced an up-regulation of delta-1 mRNA in LCs in a
similar way to gpl20, so may be inappropriate for use in this context.
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Peptide antigenicity
It is likely that at least some of the gpl20 mimicking peptides in chapter 6 are
antigenic in humans, although HLA-restriction will greatly influence individual
immune responses. The desirability of this depends on the type of therapeutic
intervention being contemplated for the peptides. Obviously, a vaccine candidate
needs to be antigenic. For other therapeutic uses (e.g., receptor blockade) peptide
antigenicity may be disadvantageous, especially if the peptide is to be given in
repeated doses. If an antibody response is mounted to a therapeutic peptide, there is
the danger that its properties will be neutralised. A synthetic approach to peptide
engineering allows antigenicity to be manipulated with precision. It ought to be
possible to closely target immune responses either towards, or away from, defined
epitopes. A combinatorial chemistry approach would allow the quick and easy
generation of a large library of peptides for efficacy and antigenicity testing. Such an
approach might be successful in producing peptides retaining biological (infection
blocking) activity but lacking antigenicity, or vaccine peptides capable of inducing
an immune response to neutralising epitopes only.
Conclusions
HIV and AIDS have been the subjects of unprecedented research intensity over
almost 20 years. A vaccine or cure for AIDS may still be many years away. The
research presented in this thesis serves to remind us that despite containing only nine
genes, HIV-1 and its interaction with the human immune system is extremely
complicated. However, there is cause for optimism in HIV research because new
avenues of research are appearing all the time. Data presented here uncover new
ways in which HIV-1 can interact with the immune system via its envelope
glycoprotein. The cellular tropism of the envelope glycoprotein is shown to be vital
in determining its uptake by antigen presenting cells. Functional consequences of
gpl20 exposure and uptake have also been explored.
The Notch signalling pathway, recently shown to be involved in tolerance
induction, is also influenced by gpl20. The precise importance of gpl20-induced up-
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regulation ofNotch ligands, the mechanism by which this leads to immune defects,
and the interaction between Notch signals and those mediated by more 'traditional'
molecules is poorly understood. However, I believe that this thesis presents the first
evidence for the possible involvement ofNotch signalling in any infectious disease.
Once an understanding of both the molecular interactions of gpl20 with
APCs, and the functional consequences of these interactions has been gained, the
next step forward is to develop the capability to modulate these interactions to
therapeutic ends. Recent advances in branched peptide synthesis methods allow the
production of peptides that are able to retain a greater amount of the three-
dimensional structure of their parent proteins. The three dimensional structure of a
region of gpl20 was recreated by combining discontinuous gpl20 regions around a
cysteine-cysteine bond in a branched synthetic peptide. The manufacture of GC-1
and 3.7 were the first applications of this new approach to peptide synthesis. Data
showing the HIV-1 infection-blocking properties of 3.7 presented in this thesis are
the first to show that peptides made in this way can retain a biological function of
their parent protein. If branched synthetic discontinuous-epitope-containing peptides
can be made with non-natural amino acids or other modifications to increase their
bio-availability, or linked to motifs causing increased phagocytosis or abrogation or
increases in Notch signalling, they represent a new class of therapeutics which can be
adapted to a range of molecular targets, ever expanding as we enter the post-
genomics age.
Insights into human immunology gained by HIV-1 research may have
significance that stretches beyond the current AIDS epidemic. The 20th century has
seen the emergence ofHIV-1, HIV-2, HTLV-I, HTLV-II, Lassa fever, Muerto
Canyon virus, and Ebola (Garrett, 1994). Increased immunologic knowledge and
new weapons to manipulate the immune response may help mankind outwit more




I wish to express my deep gratitude to my supervisor, Sarah Howie, for her patience,
encouragement, expertise, ideas and enthusiasm.
Many thanks also to Marilyn Moore, Donald Innes, Peter Simmonds, Jonathan
Lamb, Margaret Dallman, Adrienne Verhoef, Gail Baldie, Vivien Grant and Rodney
Kelly for additional help, ideas, material, training, collaboration and supervision.
Many thanks to the undergraduate students who have worked with me, Nazir Lone,
Ashok Rebello and James Logie, for their hard work and help.
Many thanks to the staff at the Centre for HIV Research, especially Sarah Lockett,
for allowing me to use their HIV containment facility and for training me to do this.
Many thanks to Angus McGregor, Tim Andrews, Susannah Lindy, Mairi Stewart and
Sharon White for samples of cells to genotype, and to Jonathan Lamb for the
occasional arm-full of blood.
Many thanks to Linda Sharp for help with capturing confocal images, Stewart
McKenzie and Steven Haig for assistance with preparing illustrations and Bill
Adams for statistical advice.
Many thanks to everyone in the labs of the Departments of Pathology and
Respiratory Medicine, especially, Jane Sadler, Kim Midwood, Helen Caldwell,
Marta Corsin-Jimenez, Susannah Lindy, Steve MacKell, Gill Hall, Lynn Forsyth,
Gareth Stewart, Sharon Ahmad, Georgia Perona-Wright, Matthias Dollinger, Gerry
Hoyne, Su Hayley, Linda Stewart, Nigel Savage, Mairi Stewart, Karen Wahl and
Karen Tan for assistance with techniques from cell culture to PCR. A special thanks
to Francis Rae for patiently answering so many questions in the lab.
A big thank you to John Horton, Gary Coulton, Val Cox, Colin Jahoda, Barbara
Leyland, Stewart Lawson, Max Dobbyn, Geoff Milburn and other great teachers for
getting me interested in science in the first place
Thanks to my flatmates, Jason, Niall, Andrew, Christian, Anita, Kirsty and Andrew
for support, communal suffering and more than a few drinks.
272
Loads of thanks to Niall, Liz, Jen, Malcolm, Gen, Karen, Mat, Dave, Ian, Mel,
Duncan and Karl, and Al, Chris, Katrina, Cathryn and the rest of DUSA for allowing
me to escape down South every so often.
Loads of thanks to my parents and Robert, my brother, for their love and support;
you're not expected to read it all, just look at the pictures!
Finally, all my love and thanks to Jill for patience, proof reading and for being so
special to me.
Organisations
I am very grateful to AVERT for funding my research project and to the
Cunningham Trust for supplementary funding. I am also grateful to the British
Society for Immunology for awarding me a travel grant to allow me to present some
of this work in the USA and UK. The Scottish National Blood Transfusion Service
made available a ready supply of human blood and serum without which this work
would have been impossible. Many of the reagents used were made available thought
the National Institute for Biological Standards and Controls Centralised Facility for
AIDS Reagents supported by European Union programme EVA [contract BMH4
97/2515] and the UK Medical Research Council as a UNAIDS initiative. The
Scottish Antibody Production Unit (SAPU) provided animal serum and Albachem





Anon. (1981) Kaposi's sarcoma and Pneumocytis pneumonia among homosexual men - New York
and California. Morbid.Mortal. Weekly Rep. 30:305-8.
Anonymous inventor. University of Yale (US), (assignee). Binding Domains in Delta Proteins.
[Patent] EP;US. EP0930366. 2000.
Aabakken L., Osnes M. (1989) Non-steroidal anti-inflammatory drug-induced disease in the distal
ileum and large bowel. Scan.J.Gastroenterol. 163 (S):48-55.
Abebe A., Demissie D., Goudsmit J., Brouwer M., Kuiken C.L., Pollakis G., Schuitemaker H.,
Fontanet A.L., DeWit T.F.R. (1999) HIV-1 subtype C syncytium- and non-syncytium-inducing
phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13:1305-11.
Agace W.W., Amara A., Roberts A.I., Pablos J.L., Thelen S., Uguccioni M., Li X.Y., Marshal J.,
ArenzanaSeisdedos F., Delaunay T., et al. (2000) Constitutive expression of stromal derived factor-
1 by mucosal epithelia and its role in HIV transmission and propagation. Cur.Biol. 10:325-8.
Aiba S., Terunuma A., Manome H., Tagami H. (1997) Dendritic cells differently respond to
haptens and irritants by their production of cytokines and expression of co-stimulatory molecules.
Euro.J.Immunol. 27:3031-8.
Aiberolalla J., Takaki S., Kerner J.D., Perlmutter R.M. (1997) Differential signaling by
lymphocyte antigen receptors. Ann.Rev.Immunol. 15:125-54.
Albright A.V., Shieh J.T.C., Itoh T., Lee B., Pleasure D., O'Connor M.J., Doms R.W.,
Gonzalezscarano F. (1999) Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the
principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 73:205-13.
Alcami A., Koszinowski U.H. (2000) Viral mechanisms of immune evasion. Immunol. Today
21(9):447-55.
Alcami J., Delera T.L., Folgueira L., Pedraza M.A., Jacque J.M., Bachelerie F., Noriega A.R.,
Hay R.T., Harrich D., Gaynor R.B., et al. (1995) Absolute dependence on kappa-B responsive
elements for initiation and Tat-mediated amplification ofHIV transcription in blood CD4 T-
lymphocytes. EMBO J. 14:1552-60.
Alexander N.J., Anderson D.J. (1987) Immunology of semen. Fertil.Steril. 47(192):205.
Allison, Kurts, Kamradt, Mitchison, Stockinger, Hammerling, Jenkins, Lechler, Hafler, Allen,
et al. (1998) Cross-presentation of self antigens to CD8(+) T cells: the balance between tolerance and
autoimmunity - Discussion. Ciba Found.Symp. 215:181-5.
Alter H.J. (1987) Transmission of LAV/HTLV-III by blood products. Annales De L'lnstitut Pasteur-
Virology 138:31-8.
Alvarez V., LopezLarrea C., Coto E. (1998) Mutational analysis of the CCR5 and CXCR4 genes
(HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug
users. Hum.Gen. 102:483-6.
Ameisen J.C., Estaquier J., Idziorek T. (1994) From AIDS to parasite infection - pathogen-
mediated subversion of programmed cell-death as a mechanism for immune dysregulation.
Immunol.Rev. 142:9-51.
274
Ameisen J.C., Estaquier J., Idziorek T., Debels F. (1995) The relevance of apoptosis to AIDS
pathogenesis. Trends Cell Biol. 5:27-32.
Anderson S.M., Burton E.A., Koch B.L. (1997) Phosphorylation of Cbl following stimulation with
interleukin-3 and its association with Grb2, Fyn, and phosphatidylinositol 3-kinase. J.Biol.Chem.
272:739-45.
Ankel H., Capobianchi M.R., Frezza F., Castiiletti C., Dianzani F. (1996) Interferon induction by
HIV-l-infected cells: A possible role of sulfatides or related glycolipids. Virology 221:113-9.
AnsariLari M.A., Liu X.M., Metzker M.L., Rut A.R., Gibbs R.A. (1997) The extent of genetic
variation in the CCR5 gene. Nat.Gen. 16:221-2.
Arimilli S., Mumm J.B., Nag B. (1996) Antigen-specific apoptosis in immortalized T cells by
soluble MHC class II-peptide complexes. Immunol.Cell Biol. 74:96-104.
ArtavanisTsakonas S., Delidakis C., Fehon R.G. (1991) The Notch locus and the cell biology of
neuroblast segregation. Ann.Rev.Cell Biol. 7:427-52.
ArtavanisTsakonas, S., Matsuno, K., (inventors). University of Yale (US), (assignee). Vertebrate
deltex proteins, nucleic acids, and antibodies, and related methods and compositions. [Patent]
WO;US. W09718822. 1997.
ArtavanisTsakonas S., Matsuno K., Fortini M.E. (1995) Notch signaling. Science 268:225-32.
ArtavanisTsakonas, S., Qi, H.L., Rand, M.D., (inventors). University of Yale (US), (assignee).
Delta cleavage products and methods based thereon. [Patent] WO;US. W00002897. 2000.
ArtavanisTsakonas S., Simpson P. (1991) Choosing a cell fate - a view from the Notch locus.
Trends Gen. 7:403-8.
Ashwell J.D., DeFranco A.L., Paul W.E., Schwartz R.H. (1984) Antigen presentation by resting B-
cells. Radiosensitivity of the antigen-presentation function and two distinct pathways of T-cell
activation. J.Exp.Med. 159:881-905.
Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. (1999) An essential role for
interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J.Exp.Med.
190:995-1003.
Asseman C., Powrie F. (1998) Interleukin 10 is a growth factor for a population of regulatory T cells.
Gut 42:157-8.
Austin J., Kimble J. (1987) Glp-1 is required in the germ line for regulation of the decision between
mitosis and meiosis in C. elegans. Cell 51:589-99.
Axelrod J.D., Matsuno K., ArtavanisTsakonas S., Perrimon N. (1996) Interaction between
wingless and notch signaling pathways mediated by dishevelled. Science 271 :1826-32.
Bachmann M.F., Barner M., Viola A., Kopf M. (1999) Distinct kinetics of cytokine production and
cytolysis in effector and memory T cells after viral infection. Euro.J.Immunol. 29:291-9.
Bachmann M.F., Oxenius A., Pircher H., Hengartner H., Ashton-Richardt P.A., Tonegawa S.,
Zinkernagel R.M. (1995) TAPl-independent loading of class-I molecules by exogenous viral
proteins. Euro.J.Immunol. 25:1739-43.
275
Badley A.D., McElhinny J.A., Leibson P.J., Lynch D.H., Alderson M.R., Paya C.V. (1996)
Upregulation of fas ligand expression by human immunodeficiency virus in human macrophages
mediates apoptosis of uninfected T lymphocytes. J. Virol. 70:199-206.
Bagasra O., Kajdacsy-Balla A., Lischner H.W., Pomerantz R.J. (1993a) Alcohol intake increases
human-immunodeficiency-virus type-1 replication in human peripheral-blood mononuclear-cells.
J. Infect.Dis. 167:789-97.
Bagasra O., Pomerantz R.J. (1993b) Human-immunodeficiency-virus type-1 replication in
peripheral-blood mononuclear-cells in the presence of cocaine. J. Infect.Dis. 168:1157-64.
Bagasra O., Wright S.D., Seshamma T., Oakes J.W., Pomerantz R.J. (1992) CD 14 is involved in
control of human-immunodeficiency-virus type-1 expression in latently infected-cells by
lipopolysaccharide. Proc.Nat.Acad.Sci.USA 89:6285-9.
Bagetta G., Corasaniti M.T., Paoletti A.M., Berliocchi L., Nistico R., Giammarioli A.M.,
Malorni W., FinazziAgro A. (1998) HIV-1 gpl20-induced apoptosis in the rat neocortex involves
enhanced expression of cyclo-oxygenase type 2 (COX-2). Biochem.Biophys.Res.Comm. 244:819-24.
Baggiolini M., Dewald B., Moser B. (1997) Human chemokines: An update. Ann.Rev.Immunol.
15:675-705.
Bain G., Maandag E.C.R., Izon D.J., Amsen D., Kruisbeek A.M., Weintraub B.C., Krop 1.,
Schlissel M.S., Feeney A.J., VanRoon M., et al. (1994) E2A proteins are required for proper B-cell
development and initiation of immunoglobulin gene rearrangements. Cell 79:885-92.
Balfour B.M., Drexhage H.A., Kamperdijk E.W., Hoefsmit E.C. (1981) Antigen presenting cells,
including Langerhans cells, veiled cells and interdigitating cells. Ciba Found.Symp. 84:281-301.
Balotta C., Bagnarelii P., Violin M., Ridolfo A.L., Zhou D., Berlusconi A., Corvasce S.,
Corbellino M., Clementi M., Clerici M., et al. (1997) Homozygous Delta 32 deletion of the CCR-5
chemokine receptor gene in an HIV-1-infected patient. AIDS 11:F67-F71.
Balzarini J., Neyts J., Schols D., Hosoya M., VanDamme E., Peumans W., DeClercq E. (1992)
The mannose-specific plant-lectins from Cymbidium hybrid and Epipactis helleborine and the (N-
acetylglucosamine) N-specific plant lectin from Urtica dioica are potent and selective inhibitors of
human-immunodeficiency-virus and cytomegalovirus replication in vitro. Antiviral Research 18:191-
207.
Banda N.K., Bernier J., Kurahara D.K., Kurrle R., Haigwood N., Sekaly R.P., Finkel T.H.
(1992) Cross-linking CD4 by human immunodeficiency virus-gpl20 primes T-cells for activation-
induced apoptosis. J.Exp.Med. 176:1099-106.
Bang A.G., Bailey A.M., Posakony J.W. (1995) Hairless promotes stable commitment to the sensory
organ precursor cell fate by negatively regulating the activity of the Notch signaling pathway.
Dev.Biol. 172:479-94.
Barbouche R., Miquelis R., Sabatier J.M., Fenouillet E. (1998) SPC3, an anti-HIV peptide
construct derived from the viral envelope, binds and enters HIV target cells. J.Peptide Sci. 4:479-85.
Barker E., Mackewicz C.E., Levy J.A. (1995) Effects ofTh(l) and Th(2) cytokines on CD8(+) cell
response against human-immunodeficiency-virus - implications for long term survival.
Proc.Nat.A cad.Sci. USA 92:1 1135-9.
Barone K.S., Tolarova D.D., Ormsby 1., Doetschman T., Michael J.G. (1998) Induction of oral
tolerance in TGF-beta 1 null mice. J.Immunol. 161:154-60.
276
BarreSinoussi F. (1988) HIV target-cells - effect of their infection by HIV on the pathogenesis of
AIDS. Lymphology 21:11-4.
BarreSinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C.,
AxIerBIin C., Vezinetbrun F., Rouzioux C., et al. (1983) Isolation of a T-lymphotropic retrovirus
from a patient at risk for acquired immune-deficiency syndrome (AIDS). Science 220:868-71.
Bash J., Zong W.X., Banga S., Rivera A., Ballard D.W., Ron Y., Gelinas C. (1999) Rel/NF-kappa
B can trigger the Notch signaling pathway by inducing the expression of Jagged 1, a ligand for Notch
receptors. EMBOJ. 18:2803-1 1.
Bates M.E., Green V.L., Bertics P.J. (2000) ERK1 and ERK2 activation by chemotactic factors in
human eosinophils is interleukin 5-dependent and contributes to leukotriene C-4 biosynthesis.
J.Biol.Chem. 275:10968-75.
Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. (1995) A role for CD95
ligand in preventing graft-rejection. Nature 377:630-2.
Benjouad A., Chapuis F., Fenouillet E., Gluckman J.C. (1995) Multibranched peptide constructs
derived from the V3 loop of envelope glycoprotein gpl20 inhibit human-immunodeficiency-virus
type-1 infection through interaction with CD4. Virology 206:457-64.
Benjouad A., Fenouillet E., Gluckman J.C., Sabatier J.M. (1994) Multibranched peptide
constructs (MBPC) of the V3 loop of envelope glycoprotein gp 120 inhibit human immunodeficiency
virus-induced syncytium formation. Antivir.Chem.Chemotherap. 5 :195-6.
Bennett S., Breit S.N. (1994) Variables in the isolation and culture of human monocytes that are of
particular relevance to studies ofHIV. J.Leuk.Biol. 56:236-40.
Bennetts B.H., Teutsch S.M., Buhler M.M., Heard R.N.S., Stewart G.J. (1997) The CCR5
deletion mutation fails to protect against multiple sclerosis. Hum.Immunol. 58 :52-9.
Bergamini A., Bolacchi F., Faggioli E., Placido R., Vendetti S., Cappannoli L., Ventura L.,
Cerasari G., Uccella I., Andreoni M., et al. (1998) HIV-1 does not alter in vitro and in vivo IL-10
production by human monocytes and macrophages. Clin.Exp.Immunol. 112:105-11.
Berger E.A. (1997) HIV entry and tropism: the chemokine receptor connection. AIDS 11 :S3-S 16.
Berzofsky J.A. (1991) Progress toward an artificial vaccine for HIV: identification of helper and
cytotoxic T-cell epitopes and methods of immunization. Biotechnol.Ther. 2( 1 -2): 123-35.
Bessinger R., Clark R., Kissinger P., Rice J., Coughlin S. (1998) Pregnancy is not assosiated with
the progression ofHIV disease in women attending an HIV outpatient program. Am.J. Epidemiol.
147(5):434-40.
Bewley C.A., Gustafson K.R., Boyd M.R.. Covell D.G., Bax A., Clore G.M., Gronenborn A.M.
(1998) Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat.Struct.Biol. 5:571-
8.
Bigas A., Martin D.I.K., Milner L.A. (1998) Notch 1 and Notch2 inhibit myeloid differentiation in
response to different cytokines. Molec.Cell.Biol. 18:2324-33.
Bird D.A., Gillotte K.L., Horkko S., Friedman P., Dennis E.A., Witztum J.L., Steinberg D.
(1999) Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can
recognize both the modified lipid moieties and the modified protein moieties: Implications with
respect to macrophage recognition of apoptotic cells. Proc.Nat.Acad.Sci. USA 96:6347-52.
277
Biti R., French R.F., Young J., Bennetts B., Stewart G., Liang T. (1997) HIV-1 infection in an
individual homozygous for the CCR5 deletion allele. Nat.Med. 3:252-3.
Bjarnason I., Hayllar J., MacPherson A.I., Russell A.S. (1993) Side effects of nonsteroidal anti¬
inflammatory drugs on the small and large intestine in humans. Gastroenterology 104:1832-47.
Blanc M. (1986) L'autre virus du SIDA (French Language - "The other AIDS virus"). La Recherche
17:974-6.
Blanche S. (1996) Time-course of pediatric HIV disease and the 1994 classification. Annates De
Pediatrie 43:7-13.
Blanche S., Newell M.L., Mayaux M.J., Dunn D.T., Teglas J.P., Rouzioux C., Peckham C.S.
(1997) Morbidity and mortality in European children vertically infected by HIV-1 - The French
pediatric HIV infection study group and European collaborative study. J.AIDS Hum.Retrovirol.
14:442-50.
Blaumueller C.M., Qi H.L., Zagouras P., ArtavanisTsakonas S. (1997) Intracellular cleavage of
notch leads to a heterodimeric receptor on the plasma membrane. Cell 90:281-91.
Blumenthal R., Pak C., Krumbiegel M., Dimitrov D.S., Puri A. (1994) Interactions ofCD4 bearing
plasma-membrane vesicles with gpl20-gp41 expressing cells. AIDS Res.Hum.Retrovir. 10:S28.
Boehme S.A., Zheng L.X., Lenardo M.J. (1995) Analysis of the CD4 coreceptor and activation-
induced costimulatory molecules in antigen-mediated mature T-lymphocyte death. J.Immunol.
155:1703-12.
Boily M.C., Masse B.R., Desai K., Alary M., Anderson R.M. (1999) Some important issues in the
planning of phase III HIV vaccine efficacy trials. Vaccine 17:989-1004.
Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., Thompson C.B. (1995)
CD28 costimulation can promote T-cell survival by enhancing the expression of Bcl-x(L). Immunity
3:87-98.
Bonfoco E., Stuart P.M., Brunner T., Lin T., Griffith T.S., Gao Y., Nakajima H., Henkart P.A.,
Ferguson T.A., Green D.R. (1998) Inducible nonlymphoid expression of Fas ligand is responsible
for superantigen-induced peripheral deletion of T cells. Immunity 9:711-20.
Borghi P., Fantuzzi L., Varano B., Gessani S., Puddu P., Conti L., Capobianchi M.R., Ameglio
F., Belardelii F. (1995) Induction of interleukin-10 by human-immunodeficiency-virus type-1 and its
gpl20 protein in human monocytes macrophages. J. Virol. 69(2): 1284-7.
Bornemann M.A.C., Verhoef J., Peterson P.K. (1997) Macrophages, cytokines, and HIV.
J.Lab.Clin.Invest. 129:10-6.
Borrow P., Lewicki H., Wei X.P., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E.,
Hahn B.H., Oldstone M.B.A., et al. (1997) Antiviral pressure exerted by HIV-l-specific cytotoxic T
lymphocytes (CTLs) during primary infection demonstrated by rapid selection ofCTL escape virus.
Nat.Med. 3:205-11.
Bouhdoud L., Villain P., Merzouki A., Arella M., Couture C. (2000) T-cell receptor-mediated
anergy of a human immunodeficiency virus (HIV) gpl20-specific CD4(+) cytotoxic T-cell clone,
induced by a natural HIV type-1 variant peptide. J. Virol. 74:2121-30.
Bour S., Geleziunas R., Wainberg M.A. (1995) The human-immunodeficiency-virus type-1 (HIV-1)
CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol.Rev. 59:63-93.
278
Bourette R.P., Arnaud S., Myles G.M., Blanchet J.P., Rohrschneider L.R., Mouchiroud G.
(1998) Mona, a novel hematopoietic-specific adaptor interacting with the macrophage colony-
stimulating factor receptor, is implicated in monocyte/macrophage development. EMBO J. 17:7273-
81.
Bowers K., Pitcher C., Marsh M. (1997) CD4: a co-receptor in the immune response and HIV
infection. Int. J.Biochem.Cell Biol. 29(6):871-5.
Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T.,
Gulakowski R.J., Wu L., Rivera M.I., Laurencot C.M., et al. (1997) Discovery of cyanovirin-N, a
novel human immunodeficiency virus-inactivating protein that binds viral surface envelope
glycoprotein gpl20: Potential applications to microbicide development. Antimicrob.Agents
Chemother. 41:1521-30.
Bratt G., Leandersson A.C., Albert J., Sandstrom E., Wahren B. (1998) MT-2 tropism and CCR-5
genotype strongly influence disease progression in HIV-l-infected individuals. AIDS 12:729-36.
Breeden L., Nasmyth K. (1987) Similarity between cell-cycle genes of budding yeast and fission
yeast and the Notch gene ofDrosophila. Nature 329:651-4.
Breese E.J., Wood E.G., Curtis M.J., Warner T.D., Mitchell J.A. (1999) Effects ofCOX-1 and
COX-2-selective NSAIDs on prostaglandin E-2 and GM-CSF production by human synoviocytes.
Brit.J.Phamacol. 126:155.
Brennan K., Tateson R., Lieber T., Couso J.P., Zecchini V., Arias A.M. (1999) The Abruptex
mutations ofNotch disrupt the establishment of proneural clusters in Drosophila. Dev.Biol. 216:230-
42.
Breslauer K.J., Frank R., Blocker H., Marky L.A. (1986) Predicting DNA duplex stability from the
base sequence. Proc.Nat.Acad.Sci.USA 83:3746-50.
Brewton R.G., Maccabe J.A. (1988) In vitro effects of calmodulin antagonists on macrophage
function in the posterior necrotic zone of the chick wing. J.Exp.Zool. 246:103-7.
Briant L., RobertHebmann V., Sivan V., Brunet A., Pouyssegur J., Devaux C. (1998)
Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling
activation of nuclear factor-kappa B and AP-1 transcription factors. J.Immunol. 160:1875-85.
Brinkman B.M.N., Keet I.P.M., Miedema F., Verweij C.L., Klein M.R. (1997) Polymorphisms
within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type
1-seropositive persons. J.Infect.Dis. 175:188-90.
Bruckner K., Perez L., Clausen H., Cohen S. (2000) Glycosyltransferase activity of Fringe
modulates Notch-Delta interactions. Nature 406:411-5.
Buchbinder S.P., Katz M.H., Hessol N.A., O'Malley P.M., Holmberg S.D. (1994) Long-term HIV-
1 infection without immunological progression. AIDS 8:1123-8.
Buelens C., Verhasselt V., DeGroote D., Thielemans K., Goldman M., Willems F. (1997)
Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear
cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor.
Euro.J.Immunol. 27:756-62.
Bukrinsky M.I., Nottet H.S.L.M., Schmidtmayerova H., Dubrovsky L., Flanagan C.R., Mullins
M.E., Lipton S.A., Gendelman H.E. (1995) Regulation of nitric-oxide synthase activity in human-
immunodeficiency-virus type-1 (HlV-l)-lnfected monocytes - implications for HIV-associated
neurological disease. J.Exp.Med. 181:735-45.
279
Burke D. (1997) Recombination in HIV: An Important Evolutionary Strategy. Emer.Infect.Dis.
3(3): 1-9.
Buseyne P., Janvier G., Teglas J.P., Ivanoff S., Burgard M., Bui E., Mayauk M.J., Blanche S.,
Rouzioux C., Riviere Y. (1998) Impact of heterozygosity for the chemokine receptor CCR5 32-bp
deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency
virus-infected children at 8 years of age. J.Infect.Dis. 178:1019-23.
Busseau 1., Diederich R.J., Xu T., ArtavanisTsakonas S. (1991) Deltex, a locus interacting with the
neurogenic genes notch, delta, and mastermind. J.Neurogenet. 7:118.
Busseau I., Diederich R.J., Xu T., ArtavanisTsakonas S. (1994) A member of the notch group of
interacting loci, deltex encodes a cytoplasmic basic-protein. Genetics 136:585-96.
Buttke T.M., Sandstrom P.A. (1994) Oxidative stress as a mediator of apoptosis. Immunol. Today
15:7-10.
Bycroft B.W., Chan W.C., Chhabra S.R., Hone N.D. (1993) A novel lysine-protecting procedure
for continuous-flow solid-phase synthesis of branched peptides. J.Chem.Soc-Chem.Commun. 9:778-
9.
Callahan J., Aster J., Sklar J., Kieff E., Robertson E.S. (2000) Intracellular forms of human
NOTCH 1 interact at distinctly different levels with RBP-Jkappa in human B and T cells. Leukemia
14:84-92.
Cameron P.U., Mallal S.A., French M.A.H., Dawkins R.L. (1990) Major histocompatibility
complex genes influence the outcome of HIV-infection - ancestral haplotypes with C4 null alleles
explain diverse HLA associations. Hum.Immunol. 29:282-95.
CamposOrtega J.A. (1991) Genetic mechanisms of early neurogenesis in Drosophila melanogaster.
Int. Rev. Cytol. -Survey Cell Biol. 124:1-41.
CamposOrtega J.A. (1996) Numb diverts notch pathway off the Tramtrack. Neuron 17:1-4.
Camus A. (1989) The Plague (English translation, Penguin 20th Centuiy Classics series).
Harmondsworth: Penguin; ISBN: 0-14-018020-6.
Capon D.J., Chamow S.M., Mordenti J., Marsters S.A., Gregory T., Mitsuya H., Byrn R.A.,
Lucas C., Wurm F.M., Groopman J.E., et al. (1989) Designing CD4 immunoadhesins for AIDS
therapy. Nature 337:525-31.
Caporossi A.P., Bruno G., Salemi S., Mastroianni C., Falciano M., Salotti A., Bergami N.,
Santilio I., Nisini R., Barnaba V. (1998) Autoimmune T-cell response to the CD4 molecule in HIV-
infected patients. Vir.Immunol. 11:9-17.
Carlesso N,, Aster J.C., Sklar J., Scadden D.T. (1999) Notch 1-induced delay of human
hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood
93:838-48.
Carter L.L., Zhang X.H., Dubey C., Rogers P., Tsui L., Swain S.L. (1998) Regulation of T cell
subsets from naive to memory. J.Immunotherap. 21:181-7.
Castro K.G., Ward J.W., Slutsker L., Buehler J.W., Jaffe H.W., Berkelman R.L., Curran J.W.
(1993) 1993 Revised classification-system for HIV-infection and expanded surveillance case-
definition for AIDS among adolescents and adults (Reprinted from MMWR, vol 41, pg rr 17, 1992).
Clin.Infect.Dis. 17:802-10.
280
Center D.M., Berman J.S., Kornfeld H., Theodore A.C., Cruikshank W.W. (1995) The
lymphocyte chemoattractant factor. J.Lab.Clin.Invest. 125:167-72.
Center D.M., Kornfeld H., Cruikshank W.W. (1996) Interleukin 16 and its function as a CD4
ligand. Immunol. Today 17:476-81.
Chalmers A.K. (1901) Report on certain cases ofPlague occuring in Glasgow in 1900 (Medical
Officer ofHealth report). Glasgow: Corporation of Glasgow; ISBN: not assigned.
Chamat S., Nara P., Berquist L., Whalley A., Morteau O., Kohler H., Kang C.Y. (1992) Two
major groups of neutralizing anti-gpl20 antibodies exist in HIV-infected individuals: Evidence of
epitope diversity around the CD4 attachment site. J.Immunol. 149:649-54.
Chambers C.A., Allison J.P. (1997) Co-stimulation in T cell responses. Current Opinion In
Immunology 9:396-404.
Chams V., Jouault T., Fenouillet E., Gluckman J.C., Klatzmann D. (1988) Detection of anti-CD4
autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules. AIDS
2:353-61.
Chan D.C., Fass D., Berger J.M., Kim P.S. (1997) Core structure of gp41 from the HIV envelope
glycoprotein. Cell 89:263-73.
Chan S.H., Benoist C., Mathis D. (1993a) A challenge to the instructive model of positive selection.
Immunol.Rev. 135:119-31.
Chan S.H., Cosgrove D., Waltzinger C., Benoist C., Mathis D. (1993b) Another view of the
selective model of thymocyte selection. Cell 73:225-36.
Chang C.H., Furue M., Tamaki K. (1995) B7-1 expression of Langerhans cells is up-regulated by
proinflammatory cytokines, and is down regulated by interferon-gamma or interleukin-10.
Euro.J.Immunol. 25:394-8.
Chang J., Naif H.M., Li S., Jozwiak R., HoShon M., Cunningham A.L. (1996) The inhibition of
HIV replication in monocytes by interleukin 10 is linked to inhibition of cell differentiation. AIDS
Res.Hum.Retrovir. 12:1227-35.
Chapuis F., Rosenzwajg M., Yagello M., Ekman M., Biberfeld P., Gluckman J.C. (1997)
Differentiation ofhuman dendritic cells from monocytes in vitro. Euro.J.Immunol. 27:431-41.
Chatila T.A., Schwartz D.H., Miller R., Geha R.S. (1987) Requirement for mitogen, T-cell
accessory cell contact, and interleukin-1 in the induction of resting T-cell proliferation.
Clin. Immunol.Immunopathol. 44:235-47.
Chehimi J., Trinchieri G. (1994) Interleukin-12: a bridge between innate resistance and adaptive
immunity with a role in infection and acquired immunodeficiency. J.Clin.Immunol. 14(3): 149-61.
Chelen C.J., Fang Y., Freeman G.J., Secrist H., Marshall J.D., Hwang P.T., Frankel L.R.,
DeKruyff R.H., Umetsu D.T. (1995) Human alveolar macrophages present antigen ineffectively due
to defective expression of B7 costimulatory cell-surface molecules. J.Clin.Invest. 95:1415-21.
Chen L.P. (1998a) Immunological ignorance of silent antigens as an explanation of tumor evasion.
Immunol.Today 19:27-30.
Chen L.P. (1998b) Overcoming T cell ignorance by providing costimulation - Implications for the
immune response against cancer. Advan.Exp.Med.Biol. 451:159-65.
281
Chen Y.H., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. (1994) Regulatory T-cell clones
induced by oral tolerance - suppression of autoimmune encephalomyelitis. Science 265:1237-40.
Chen Z.W., Kwon D., Jin Z.Q., Monard S., Telfer P., Jones M.S., Lu C.Y., Aguilar R.F., Ho
D.D., Marx P.A. (1998) Natural infection of a homozygous Delta 24 CCR5 red-capped mangabey
with an R2b-tropic simian immunodeficiency virus. J.Exp.Med. 188:2057-65.
Chin J., Turner B., Barchia I., Mullbacher A. (2000) Immune response to orally consumed
antigens and probiotic bacteria. Immunol.Cell Biol. 78:55-66.
Chirmule N., Pahwa S. (1996) Envelope glycoproteins of human immunodeficiency virus type 1:
Profound influences on immune functions. Microbiol.Rev. 60:386.
Choe H. (1998) Chemokine receptors in HIV-1 and SIV infection. Arch.Pharm.Res 21:634-9.
Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L.J., MacKay C.R.,
LaRosa G., Newman W., et al. (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate
infection by primary HIV-1 isolates. Cell 85:1135-48.
Choe H., Martin K.A., Farzan M., Sodroski J., Gerard N.P., Gerard C. (1998) Structural
interactions between chemokine receptors, gpl20 Env and CD4. Semin.lmmunol. 10:249-57.
Chouaib S., Fradelizi D. (1982) The mechanism of inhibition of human IL-2 production. J.Immunol.
129:2463-8.
Christensen S., Kodoyianni V., Bosenberg M., Friedman L., Kimble J. (1996) lag-1, a gene
required for lin-12 and glp-1 signaling in Caenorhabditis elegans, is homologous to human CBF1 and
Drosophila Su(H). Development 122:1373-83.
Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., Davey R.T., Dybul M.,
Kovacs J.A., Metcalf J.A., et al. (1999) Effect of interleukin-2 on the pool of latently infected,
resting CD4(+) T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
Nat.Med. 5:651-5.
Chung C.D., Lewis L.A., Miceli M.C. (1997) T cell antigen receptor-induced IL-2 production and
apoptosis have different requirements for Lck activities. J.Immunol. 159:1758-66.
Clapham P.R., Blanc D., Weiss R.A. (1991) Specific cell surface requirements for the infection of
CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency
virus. Virology 181(2):703-15.
Clapham P.R., McKnight A., Talbot S., Wilkinson D. (1996) HIV entry into cells by CD4-
independent mechanisms. Perspec.Drug Dis.Des. 5:83-92.
Clavel F., BrunVezinet F., Guetard D. (1986) LAV type II: A second retrovirus associated with
AIDS in West Africa. Centre Recherche Academie Science Paris 302:485-8.
Clavel F., Mansinho K,, Chamaret S. (1987) Human immunodeficiency virus type 2 infection
associated with AIDS in West Africa. New.Eng.J.Med. 316:1180-5.
Clemens D.L., Lee B.Y., Horwitz M.A. (2000) Deviant expression of Rab5 on phagosomes
containing the intracellular pathogens Mycobacterium tuberculosis and Legionella pneumophila is
associated with altered phagosomal fate. Infect.Immunity 68:2671-84.
Clerici M., Salvi A., Trabattoni D., LoCaputo S., Seinplici F., Biasin M., Ble C., Meacci F.,
Romeo C., Piconi S., et al. (1999) A role for mucosal immunity in resistance to HIV infection.
Immunol.Lett. 66:21-5.
282
Clerici M., Shearer G.M. (1993) A Thl-Th2 Switch is a critical step in the etiology of HIV infection.
Immunol. Today 14:107-10.
Clotet B., Junca J., Salinas I., Herrero M. (1986) Heterosexual transmission ofHTLV-I1I/LAV.
Medicina Clinica 86:131 -2.
Clumeck N., Hermans P. (1996) The complications of survival: haematological and oncological
features of AIDS. Helix. 5: 20-27.
Cockerill P.N., Osborne C.S., Bert A.G., Grotto R.J.M. (1996) Regulation of GM-CSF gene
transcription by core-binding factor. Cell Growth Differential. 7:917-22.
Cohen D.A., Kaplan A.M. (1983) Adherent Ia+ murine cell-lines with characteristics of dendritic
cells: II. Characteristics of I region-restricted antigen presentation. Cell.Immunol. 80:349-62.
Cohen O.J., Kinter A., Fauci A.S. (1997a) Host factors in the pathogenesis ofHIV disease.
Immunol.Rev. 159:31-48.
Cohen O.J., Vaccarezza N., Lam G.K., Baird B.F., Wildt K., Murphy P.M., Zimmerman P.A.,
Nutman T.B., Fox C.H., Hoover S., et al. (1997b) Heterozygosity for a defective gene for CC
chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of
HIV-infected long-term nonprogressors. J.Clin.Invest. 100:1581-9.
Cohn Z.A., Steinman R.M. (1982) Phagocytosis and fluid-phase pinocytosis. Ciba Found.Symp.
92:15-34.
Colligan J.E.; Kruisbeek A.M.; Margulies D.H.; Shevach E.M.; Strober W. (1993) Current
protocols in immunology (Volume I).
Colman A. (1999) Dolly, Polly and other 'ollys': likely impact of cloning technology on biomedical
uses of livestock. Gen.Anal.-Biomolec.Eng. 15:167-73.
Combadiere C., Ahuja S.K., Tiffany H.L., Murphy P.M. (1996) Cloning and functional expression
of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 alpha, MIP-1 beta, and
RANTES. J.Leuk.Biol. 60:147-52.
Connor J.M.; FergusonSmith M.A. (1993) Essential medical genetics. 4 ed. Oxford: Blackwell
Scientific; ISBN: 0-632-03228-6.
Connor R.I., Ho D.D. (1994) Human-immunodeficiency-virus type-1 variants with increased
replicative capacity develop during the asymptomatic stage before disease progression. J. Virol.
68:4400-8.
Conte E., Bonaiuto C., Nesci C., Crimi N., Vancheri C., Messina A. (1997) Nuclear factor-kappa B
activation in human monocytes stimulated with lipopolysaccharide is inhibited by fibroblast
conditioned medium and exogenous PGE(2). FEBS Let. 400 (3):315-8.
Corasaniti M.T., Melino G., Navarra M., Garaci E., FinazziAgro A., Nistico G. (1995) Death of
cultured human neuroblastoma-cells induced by HIV-1 gpl20 is prevented by NMDA receptor
antagonists and inhibitors of nitric-oxide and cyclooxygenase. Neurodegeneration 4:315-21.
Corbeil J., Richman D.D. (1995) Productive infection and subsequent interaction ofCD4-gpl20 at
the cellular membrane is required for HIV-induced apoptosis ofCD4(+) T-cells. J.General. Virol.
76:681-90.
283
Cota M., Mengozzi M., Vicenzi E., PaninaBorignon P., Sinigaglia F., Transidico P., Sozzani S.,
Mantovani A., Poli G. (2000) Selective inhibition ofHIV replication in primary macrophages but not
T lymphocytes by macrophage-derived chemokine. Proc.Nat.Acad.Sci. USA 97(16):9162-7.
Cotton G.J., Howie S.E.M., Heslop I., Ross J.A., Harrison D.J., Ramage R. (1996) Design and
synthesis of a highly immunogenic, discontinuous epitope ofHIV-1 gpl20 which binds to CD4+ve
transfected cells. Molec.Immunol. 33:171-8.
Cottrez F., Manca F., Dalgleish A.G., ArenzanaSeisdedos F., Capron A., Groux H. (1997)
Priming of human CD4(+) antigen-specific T cells to undergo apoptosis by HIV-infected monocytes -
A two-step mechanism involving the gpl20 molecule. J.Clin.Invest. 99:257-66.
Coulaud J.P., Matheron S., Ancelle R. (1986) Mother to child transmission of the LAV/HTLV-III.
Contraception Fertilite Sexualite 14:151-4.
Craig H.M., Pandori M.W., Guatelli J.C. (1998) Interaction of HIV-1 Nef with the cellular
dileucine-based sorting pathway is required forCD4 down-regulation and optimal viral infectivity.
Proc.Nat.Acad.Sci. USA 95:11229-34.
Crane I.J., Kuppner M.C., McKillopSmith S., Wallace C.A., Forrester J.V. (1999) Cytokine
regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production by human
retinal pigment epithelial cells. Clin.Exp.Immunol. 115:288-93.
Croft M. (1994) Activation of naive, memory and effector T-cells. Current Opinion In Immunology
6:431-7.
Croft M., Dubey C. (1997) Accessory molecule and costimulation requirements for CD4 T cell
response. Crit.Rev.Immunol. 17:89-118.
Crowe S.M., Lopez A. (1997) GM-CSF and its effects on replication ofHIV-1 in cells of
macrophage lineage. J.Leuk.Biol. 62:41-8.
Crowl R., Ganguly K., Gordon M., Conroy R., Schaber M., Kramer R., Shaw G., Wongstaal F.,
Reddy E.P. (1985) HTLV-III env gene-products synthesized in Escherichia coli are recognized by
antibodies present in the sera of AIDS patients. Cell 41:979-86.
Cullen B.R. (1998) HIV-1 auxiliary proteins: Making connections in a dying cell. Cell 93:685-92.
Cumberbatch M., Illingworth I., Kimber I. (1991) Antigen-bearing dendritic cells in the draining
lymph-nodes of contact sensitized mice - cluster formation with lymphocytes. Immunology 74:139-
45.
D'Acquisto F., Sautebin L., luvone T., DiRosa M., Carnuccio R. (1998) Prostaglandins prevent
inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappa B activation in
J774 macrophages. FEBSLet. 440(l-2):76-80.
D'Souza M.P., Harden V.A. (1996) Chemokines and HIV-1 second receptors - Confluence of two
fields generates optimism in AIDS research. Nat.Med. 2:1293-300.
Daar E.S., Li X.L., Moudgil T., Ho D.D. (1990) High-concentrations of recombinant soluble CD4
are required to neutralize primary human-immunodeficiency-virus type-1 isolates.
Proc.Nat.Acad.Sci. USA 87:6574-8.
Dadaglio G., Leroux A., Langladedemoyen P., Bahraoui E.M., Traincard F., Fisher R., Plata F.
(1991) Epitope recognition of conserved HIV envelope sequences by human cytotoxic lymphocytes-
T. J.Immunol. 147:2302-9.
284
Dalgleish A.G., Beverley P.C.L., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A.
(1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
Nature 312:763-7.
Davey R.T., Chaitt D.G., Albert J.M., Piscitelli S.C., Kovacs J.A., Walker R.E., Falloon J., Polis
M.A., Metcalf J.A., Masur H., et al. (1999) A randomized trial of high- versus low-dose
subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1
infection. J.Infect.Dis. 179:849-58.
Davis C.B., Dikie I., Unutmaz D., Hill C.M., Arthos J., Siani M.A., Thompson D.A., Schlessinger
J., Littman D.R. (1997) Signal transduction due to HIV-1 envelope interactions with chemokine
receptors CXCR4 or CCR5. J.Exp.Med. 186:1793-8.
Davis C.B., Killeen N., Crooks M.E.C., Raulet D., Littman D.R. (1993) Evidence for a stochastic
mechanism in the differentiation of mature subsets of T-lymphocytes. Cell 73:237-47.
De S.K., Venkateshan C.N.S., Seth P., Gajdusek D.C., Gibbs C.J. (1998) Adenovirus-mediated
human immunodeficiency virus-1 Nef expression in human monocytes/macrophages and effect ofNef
on downmodulation of Fc gamma receptors and expression ofmonokines. Blood 91:2108-17.
Deacon N.J., Tsykin A., Solomon A., Smith K., Ludfordmenting M., Hooker D.J., McPhee D.A.,
Greenway A.L., Ellett A., Chatfield C., et al. (1995) Genomic structure of an attenuated quasi-
species ofHIV-1 from a blood-transfusion donor and recipients. Science 270:988-91.
Dean M., Carrington M., Goedert J., O'Brien S.J, (1996) Genetic restriction of HIV-1 infection
and progression to AIDS by a deletion allele of the CKR5 structural gene (vol 273, pg 1856, 1996).
Science 274:1069.
Dean M., Jacobson L.P., McFarlane G., Margolick J.D., Jenkins F.J., Howard O.M.Z., Dong
H.F., Goedert J.J., Buchbinder S., Gomperts E., et al. (1999) Reduced risk ofAIDS lymphoma in
individuals heterozygous for the CCR5-Delta32 mutation. Can.Res. 59:3561-4.
DeCelis J.F., Barrio R., Delarco A., GarciaBellido A. (1993) Genetic and molecular
characterization of a notch mutation in its delta-binding and serrate-binding domain in Drosophila.
Proc.Nat.Acad.Sci. USA 90:4037-41.
DeCelis J.F., DeCelis J., Ligoxygakis P., Preiss A., Delidakis C., Bray S. (1996) Functional
relationships between Notch, Su(H) and the bHLH genes of the E(spl) complex: The E(spl) genes
mediate only a subset ofNotch activities during imaginal development. Development 122:2719-28.
DeCelis J.F., GarciaBellido A. (1994) Modifications of the notch function by abruptex mutations in
Drosophila melanogaster. Genetics 136:183-94.
DeClercq E., Yamamoto N., Pauwels R., Baba M., Schols D., Nakashima H., Balzarini J.,
Debyser Z., Murrer B.A., Schwartz D., et al. (1992) Potent and selective-inhibition of human-
immunodeficiency-virus (HlV)-l And HIV-2 replication by a class of bicyclams interacting with a
viral uncoating event. Proc.Nat.Acad.Sci. USA 89 :5286-90.
Defoe D. (1960) A journal of the plague year: being observations or memorials of the most
remarkable occurrences, as wellpublic as private, which happened in London duriung the last great
visitation in 1665. London: The Folio Society; ISBN: not assigned.
Deftos M.L., He Y.W., Ojala E.W., Bevan M.J. (1998) Correlating notch signaling with thymocyte
maturation. Immunity 9:777-86.
285
DeJong J.J., Deronde A., Keulen W., Tersmette M., Goudsmit J. (1992) Minimal requirements for
the human-immunodeficiency-virus type-1 V3 domain to support the syncytium-inducing phenotype -
analysis by single amino-acid substitution. J. Virol. 66:6777-80.
Delezay O., Hammache D., Fantini J., Yahi N. (1996) SPC3, a V3 loop-derived synthetic peptide
inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. Biochemistry 35:15663-71.
Delidakis C., Preiss A., Hartley D.A., ArtavanisTsakonas S. (1991) Two genetically and
molecularly distinct functions involved in early neurogenesis reside within the Enhancer of split locus
ofDrosophila melanogaster. Genetics 129:803-23.
Demaria S., Bushkin Y. (1996) Soluble CD4 induces the binding of human immunodeficiency virus
type 1 to cells via the V3 loop of glycoprotein 120 and specific sites in glycoprotein 41. AIDS
Res.Hum.Retrovir. 12:281-90.
Deng H.K., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., DiMarzio P., Marmon S.,
Sutton R.E., Hill C.M., et al. (1996) Identification of a major co-receptor for primary isolates of
HIV-1. Nature 381:661-6.
Denis M. (1994) Envelope glycoprotein (gpl20) from HIV-1 enhances Mycobacterium avium growth
in human bronchoalveolar macrophages - an effect mediated by enhanced prostaglandin synthesis.
Clin.Exp.Immunol. 98:123-7.
DeReuddreBosquet N., Clayette P., Martin M., Benveniste O., Fretier P., Jaccard P., Vaslin B.,
Lebeaut A., Dormont D. (1997) Lack of interleukin 10 expression in monocyte-derived macrophages
in response to in vitro infection by HIV type 1 isolates. AIDS Res.Hum.Retrovir. 13:961-6.
Dermine J.F., Desjardins M. (1999) Survival of intracellular pathogens within macrophages.
Protoplasma 210:11-24.
Derossi A., Ometto L., Roncella S., Dandrea E., Menin C., Calderazzo F., Rowe M., Ferrarini
M., Chiecobianchi L. (1994) HIV-1 induces down-regulation ofbcl-2 expression and death by
apoptosis of EBV-immortalized B-cells - a model for a persistent self-limiting HIV-1 infection.
Virology 198:234-44.
DeRuiter A., Brocklehurst P. (1998) HIV infection and pregnancy. Int.J.STD AIDS 9:647-55.
Desbarats J., Freed J.H., Campbell P.A., Newell M.K. (1996) Fas (CD95) expression and death-
mediating function are induced by CD4 cross-linking on CD4(+) T cells. Proc.Nat.Acad.Sci. USA
93:11014-8.
DeSimone C., Famularo G., Cifone G., Mitsuya H. (1996) HIV-1 infection and cellular
metabolism. Immunol.Today 17:256-8.
Desjarlais D.C., Friedman S.R., Stoneburner R.L. (1988) HIV infection and intravenous drug-use -
critical issues in transmission dynamics, infection outcomes, and prevention. Rev.Infect.Dis 10:151-
8.
Dettin M., Scarinci C., Zanotto C., Roncon R., Derossi A., DiBello C. (1998) Biological and
conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection. J.Peptide Sci.
4:436-48.
Dezube B.J., Pardee A.B., Beckett L.A., Ahlers C.M., Ecto L., Allenryan J., Anisowicz A., Sager
R., Crumpacker C.S. (1992) Cytokine dysregulation in AIDS - in vivo overexpression of messenger-
RNA of tumor-necrosis-factor-alpha and its correlation with that of the inflammatory cytokine Gro.
J.AIDS Hum.Retrovirol. 5:1099-104.
286
Diederich R.J., Matsuno K., Hing H., ArtavanisTsakonas S. (1994) Cytosolic interaction between
Deltex and Notch ankyrin repeats implicates Deltex in the Notch signaling pathway. Development
120:473-81.
Dillon S.R., MacKay V.L., Fink P.J. (1995) A functionally compromised intermediate in
extrathymic CD8(+) T-cell deletion. Immunity 3:321 -33.
Dimitrov D.S. (1996) Fusin - a place for HIV-1 and T4 cells to meet: Identifying the coreceptor
mediating HIV-1 entry raises new hopes in the treatment of AIDS. Nat.Med. 2(6):640-l.
Dockrell D.H., Badley A.D., Villacian J.S., Heppelmann C.J., Algeciras A., Ziesmer S., Yagita
H., Lynch D.H., Roche P.C., Leibson P.J., et al. (1998) The expression of Fas ligand by
macrophages and its upregulation by human immunodeficiency virus infection. J.Clin.Invest.
101:2394-405.
Doenhoff M.J. (1999) Granulomatous inflammation and transmission of infection - reply.
Immunol. Today 20:338.
Doherty D., Feger G., YoungerShepherd S., Jan L.Y., Jan Y.N. (1996) Delta is a ventral to dorsal
signal complementary to Serrate, another Notch ligand in Drosophila wing formation. Gene.Dev.
10:421-34.
Donaldson Y.K., Bell J.E., Holmes E.C., Hughes E.S., Brown H.K., Simmonds P. (1994) In vivo
distribution and cytopathology of variants of human-immunodeficiency-virus type-1 showing
restricted sequence. J.Virol. 68:5991-6005.
Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P.,
Sakmar T.P., Henson G., DeClercq E., et al. (1998) AMD3100, a small molecule inhibitor of H1V-
1 entry via the CXCR4 co-receptor. Nat.Med. 4:72-7.
Doranz B.J., Rucker J., Yi Y.J., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Coilman
R.G., Doms R.W. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine
receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-58.
Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y.X., Nagashima K.A., Cayanan C.,
Maddon P.J., Roup R.A., Moore J.P., et al. (1996) HIV-1 entry into CD4(+) cells is mediated by
the chemokine receptor CC-CKR-5. Nature 381:667-73.
Dubey C., Croft M. (1996) Accessory molecule regulation of naive CD4 T cell activation.
Immunol.Res. 15:114-25.
Durie F.H., Foy T.M., Masters S.R., Laman J.D., Noelle R.J. (1994) The role ofCD40 in the
regulation of humoral and cell-mediated-immunity. Immunol. Today 15:406-11.
DurrbaumLandmann I., Kaltenhauser E., Flad H.D., Ernst M. (1994) HIV-1 envelope protein
gpl20 affects phenotype and function ofmonocytes in vitro. J.Leuk.Biol. 55:545-51.
Ebner S., Lenz A., Reider D., Fritsch P., Schuler G., Romani N. (1998) Expression of maturation-
/migration-related molecules on human dendritic cells from blood and skin. Immunobiology
198(5):568-87.
Eckels D.D., Lamb J.R., Lake P., Woody J.N., Johnson A.H., Hartzman R.J. (1982) Antigen-
specific human lymphocyte-T clones - genetic restriction of influenza virus-specific responses to
HLA-D region genes. Hum.Immunol. 4:313-24.
287
Edelstein R.E., Arcuino L.A.M., Hughes J.P., Melvin A.J., Mohan K.M., King P.D., McLellan
C.L., Murante B.L., Kassman B.P., Frenkel L.M. (1997) Risk of mother-to-infant transmission of
HIV-1 is not reduced in CCR5/Delta 32ccr5 heterozygotes. J.AIDS Hum.Retrovirol. 16:243-6.
Egan P.J., Kimpton YV., Seow H.F., Bowles V.M., Brandon M.R., Nash A.D. (1996)
Inflammation-induced changes in the phenotype and cytokine profile of cells migrating through skin
and afferent lymph. Immunology 89:539-46.
Egan S.E., StPierre B., Leow C.C. (1998) Notch receptors, partners and regulators: From conserved
domains to powerful functions. Cur. Top.Microbiol.Immunol. 228:273-324.
Ekerfelt C., Matthiesen L., Berg G., Ernerudh J. (1999) Th2-deviation of fetus-specific T cells.
Immunol. Today 20:534.
Elias C.J., Coggins C. (1996) Female-controlled methods to prevent sexual transmission of HIV.
AIDS 10.S43-S51.
Ellis J., Chain B.M., Davies D.H., Ibrahim M.A.A., Katz D.R., Kaye P.M., Lightstone E. (1991)
Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin
(IL)2,1L4 and interferon-gamma by allogeneic T-cells. Euro.J.Immunol. 21:2803-9.
Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., Sklar J. (1991) TAN-1,
the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T-
lymphoblastic neoplasms. Cell 66:649-61.
ErdreichEpstein A., Liu M., Kant A.M., Izadi K.D., Nolta J.A., Durden D.L. (1999) Cbl functions
downstream of Src kinases in Fc gamma R1 signaling in primary human macrophages. J.Leuk.Biol.
65:523-34.
Esser M.T., Mori T., Mondor I., Sattentau Q.J., Dey B., Berger E.A., Boyd M.R., Lifson J.D.
(1999) Cyanovirin-N binds to gp 120 to interfere with CD4-dependent human immunodeficiency virus
type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gpl20 or
soluble CD4-induced conformational changes in gpl20. J. Virol. 73(5):4360-71.
EugenOIsen J., Iversen A.K.N., Benfield T.L., Koppelhus U., Garred P. (1998) Chemokine
receptor CCR2b 641 polymorphism and its relation to CD4 T-cell counts and disease progression in a
Danish cohort of HIV-infected individuals. J.AIDS Hum.Retrovirol. 18:110-6.
Falero-Diaz G., Challacombe S., Banerjee D., Douce G., Boyd A., Ivanyi, J. (2000) Intranasal
vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18(28):3223-9.
Fan L.J., Peden K. (1992) Cell-free transmission of vifmutants of HIV-1. Virology 190:19-29.
Fanci A.S. (1995) AIDS - newer concepts in the immunopathogenic mechanisms of human-
immunodeficiency-virus disease. Proc.Assoc.Am.Physic. 107:1-7.
Fang W., Weintraub B., Goodnow C., Jenkins M., Mueller D., Behrens T. (i997) Self-reactive B
cells that escape negative selection are rendered anergic in the periphery. Arth.Rheumat. 40:465.
Fantini J., Hammache D., Delezay O., Yahi N., AndreBarres C., RicoLattes I., Lattes A. (1997)
Synthetic soluble analogs of galactosylceramide (GaiCer) bind to the V3 domain ofHIV-1 gpl20 and
inhibit HIV-1-induced fusion and entry. J.Biol.Chem. 272:7245-52.
Fantini J., Yahi N., Mabrouk K., Rochat H., VanRietschoten J., Sabatier J.M. (1996) V3 loop-
derived multibranched peptides as inhibitors of HIV infection in CD4(+) and CD4(-) cells.
Perspec.Drug Dis.Des. 5:243-50.
288
Fantini J., Yahi N., Mabrouk K., VanRietschoten J., Rochat H., Sabatier J.M. (1993)
Multibranched peptides based on the HIV-1 V3 loop consensus motif inhibit H1V-1 and HIV-2
infection in CD4(+) and CD4(-) Cells. Comptes Rendus De L'Academie Des Sciences Serie Ill-
Sciences De La Vie-Life Sciences 316(11): 1381-7.
Farrar J.J., Howard M., Fullerfarrar J., Paul W.E. (1983) Biochemical and physicochemical
characterization of mouse B-cell growth-factor - a lymphokine distinct from interleukin-2.
J. Immunol. 131:1838-42.
Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M., Gerard N.P., Gerard C.,
Sodroski J., Choe H. (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1
entry. Cell 96:667-76.
Fathalla S.E., Aljama A.A., Badawy M.S., EIRifaei A.N.M., Younis Y.S. (1996) Epstein-Barr virus
(EBV) antibody patterns among the healthy population and the EBV-associated patients in Eastern
Saudi Arabia (1990-1994). Saudi Med. J. 17:608-13.
Felli M.P., Maroder M., Mitsiadis T.A., Campese A.F., Bellavia D., Vacca A., Mann R.S., Frati
L., Lendahl U., Gulino A., et al. (1999) Expression pattern of Notch 1, 2 and 3 and Jagged 1 and 2
in lymphoid and stromal thymus components: distinct ligand-receptor interactions in intrathymic T
cell development. Int.Immunol. 11:1017-25.
Ferguson T.A., Griffith T.S. (1996a) Fas/Fas ligand-mediated apoptosis as a mechanism of immune
privilege. FASEB J. 10:1588.
Ferguson T.A., Herndon J.M., Griffith T.S. (1996b) Fas/Fas-ligand interactions modulate immune
privilege and immune deviation in the eye. Invest.Ophthalmol. Vis.Sci. 37:5202.
Ferrer M., Harrison S.C. (1999) Peptide ligands to human immunodeficiency virus type 1 gpl20
identified from phage display libraries. J. Virol. 73(7):5795-802.
Ferres M., Prado P., Ovalle J., Fuentes R., Villarroel L., Ferreccio C., Vial P. (1995) Prevalence
of Epstein Barr virus infection in healthy individuals in Santiago, Chile. Revista Medica De Chile
123:1447-52.
Fidler S.J., Rees A.D.M. (1999) Antigen presenting cell function in HIV-1 infected patients.
Immunol.Lett. 66:129-34.
Filler S.G., Pfunder A.S., Spellberg B.J., Spellberg J.P., Edwards J.E. (1996) Candida albicans
stimulates cytokine production and leukocyte adhesion molecule expression by endothelial ceils.
Infect.Immunity 64:2609-17.
Finkelman F.D. (1995) Relationships among antigen presentation, cytokines, immune deviation, and
autoimmune-disease. J.Exp.Med. 182:279-82.
Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K.,
Lisziewicz J., Lori F., Flexner C., et al. (1999) Latent infection of CD4(+) T cells provides a
mechanism for lifelong persistence ofHIV-1, even in patients on effective combination therapy.
Nat.Med. 5:512-7.
Finzi D., Siliciano R.F. (1998) Viral dynamics in HIV-1 infection. Cell 93:665-71.
Flamand L., Crowley R.W., Lusso P., ColombiniHatch S., Margolis D.M., Gallo R.C. (1998)
Activation ofCD8(+) T lymphocytes through the T cell receptor turns on CD4 gene expression:
Implications for HIV pathogenesis. Proc.Nat.Acad.Sci. USA 95:3111-6.
289
Fleming R.J., Purcell K., ArtavanisTsakonas S. (1997) The NOTCH receptor and its ligands.
Trends Cell Biol. 7:437-41.
Follis K.E., Trahey M., LaCasse R.A., Nunberg J.H. (1998) Continued utilization of CCR5
coreceptorby a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.
J. Virol. 72:7603-8.
Fortis C., Biswas P., Soldini L., Veglia F., Careddu A.M., Delfanti F., Mantelli B., Murone M.,
Lazzarin A., Poli G. (1999) Dual role of TNF-alpha in NK/LAK cell-mediated lysis of chronically
HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-
mediated lysis. Euro.J.Immunol. 29:3654-62.
Fouchier R.A.M., Groenink M., Kootstra N.A., Tersmette M., Huisman H.G., Miedema F.,
Schuitemaker H. (1992) Phenotype-associated sequence variation in the 3rd variable domain.
J.Virol. 66:3183-7.
Fowler S., Powrie F. (1999) Control of immune pathology by IL-10-secreting regulatory T cells.
Springer Semin.Immunopathol. 21:287-94.
Fox R., Eldred L.J., Fuchs E.J., Kaslow R.A., Visscher B.R., Ho M., Phair J.P., Polk B.F. (1987)
Clinical manifestations of acute infection with human-immunodeficiency-virus in a cohort of gay
men. AIDS 1:35-8.
Franchini G., Bosch M.L. (1989) Genetic relatedness of the human immunodeficiency viruses type-1
and type-2 (HIV-1, HIV-2) And the simian immunodeficiency virus (SIV). Ann.New York Acad.Sci.
554:81-7.
Frankel A.D., Pabo C.O. (1988) Cellular uptake of the Tat protein from human immunodeficiency
virus. Cell 55:1189-93.
Frankenberger M., ZieglerHeitbrock H.W.L. (1997) LPS tolerance in monocytes/macrophages:
Three 3' cytosins are required in the DNA binding motif for detection of upregulated NF-kappa B p50
homodimers. Immunobiology 198:81-90.
Frauwirth K.A., Alegre M.L., Thompson C.B. (2000) Induction of T cell anergy in the absence of
CTLA-4/B7 interaction. J.Immunol. 164:2987-93.
Friedland G., Saltzman B., Kahl P., Lesser M., Mayers M., Feiner C., Klein R., Rogers M.
(1986) Risk of HTLV III/LAV transmission to household contacts - reply. New.Eng.JMed. 315:258-
9.
Friedland G.H., Saltzman B.R., Rogers M.F., Kahl P.A., Lesser M.L., Mayers M.M., Klein R.S.
(1986) Lack of transmission of HTLV III LAV infection to household contacts of patients with AIDS
or AIDS-related complex with oral candidiasis. New.Eng.J.Med. 314:344-9.
Frise E., Knoblich J.A., YoungerShepherd S., Jan L.Y., Jan Y.N. (1996) The Drosophila Numb
protein inhibits signaling of the Notch receptor during cell-cell interaction in sensory organ lineage.
Proc.Nat.Acad.Sci. USA 93:11925-32.
Fu D.X., Jinno A., Shimizu N., Haraguchi Y., Hoshino H. (1999) Isolation and characterization of a
monoclonal antibody that inhibits HIV-1 infection. Microb.Infect. 1:677-84.
Fukasawa M., Miura T., Hasegawa A., Morikawa S., Tsujimoto H., Miki K., Kitamura T.,
Hayami M. (1988) Sequence of simian immunodeficiency virus from African-green monkey, a new
member of the HIV/SIV group. Nature 333:457-61.
290
Gabrilovich D.I., Woods G.M., Patterson S., Harvey J.J., Knight S.C. (1994) Retrovirus-induced
immunosuppression via blocking of dendritic cell-migration and down-regulation of adhesion
molecules. Immunology 82:82-7.
Galeeva A.R., Khusnutdinova E.K., Slominskii P.A., Limborskaya S.A. (1998) Distribution of the
CCR5 chemokine receptor-gene 32-bp deletion in populations of the Volga-Ural region (Russian
Language). Genetika 34:1160-2.
Gallahan D., Callahan R. (1997) The mouse mammary tumor associated gene 1NT3 is a unique
member of the NOTCH gene family (NOTCH4). Oncogene 14:1883-90.
Gao Y.K., Herndon J.M., Zhang H., Griffith T.S., Ferguson T.A. (1998) Antiinflammatory effects
ofCD95 ligand (FasL)-induced apoptosis. J.Exp.Med. 188:887-96.
Garred P. (1998) Chemokine-receptor polymorphisms: clarity or confusion for H1V-1 prognosis?
Lancet 351:2-3.
Garred P., Madsen H.O., Balslev U., Hofmann B., Pedersen C., Gerstoft J., Svejgaard A. (1997)
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles ofmannose-
binding lectin. Lancet 349:236-40.
Garred P., Madsen H.O., Petersen J., Marquart H., Hansen T.M., Sorensen S.F., Volck B.,
Svejgaard A., Andersen V. (1998) CC chemokine receptor 5 polymorphism in rheumatoid arthritis.
J.Rheumatol. 25:1462-5.
Garrett L. (1994) The coming plague: newly emerging diseases in a world out ofbalance. London:
Penguin; ISBN: 0-14-025091-3.
Garry R.F., Koch G. (1992) Tat contains a sequence related to snake neurotoxins. AIDS 6:1541-2.
Garside P., Steel M., Liew F.Y., Mowat A.M. (1995) CD4(+) But not CD8(+) T-cells are required
for the induction of oral tolerance. Int. Immunol. 7:501-4.
Gartenhaus R., Michaels F., Hall L., Gallo R.C., Reitz M.S. (1991) Relative activities of HIV-1-
IIIB and HIV-l-BaL LTR and Tat in primary monocytes and lymphocytes. AIDS Res.Hum.Retrovir.
7:681-8.
Gaynor R. (1992) Cellular transcription factors involved in the regulation of HIV-1 gene-expression.
AIDS 6:347-63.
Geijtenbeek T.B.H., Kwon D.S., Torensma R., VanVIiet S.J., VanDuijnhoven G.C.F., Middel J.,
Cornelissen I.L.M.H.A., Nottet H.S.L.M., Kewalramani V.N., Littman D.R., et al. (2000a) DC-
SIGN, a dendritic cell-specific HIV-l-binding protein that enhances trans-infection of T cells. Cell
100:587-97.
Geijtenbeek T.B.H., Torensma R., VanVIiet S.J., VanDuijnhoven G.C.F., Adema G.J.,
VanKooyk Y., Figdor C.G. (2000b) Identification of DC-SIGN, a novel dendritic cell-specific
ICAM-3 receptor that supports primary immune responses. Cell 100:575-85.
Geijtenbeek T.B.H., Torensma R., VanVIiet S.J., VanDuijnhoven G.C.F., Middel J., Cornelissen
I.L.M.H.A., Adema G.J., Nottet H.S.L.M., Figdor C.G., VanKooyk Y. (1999) DC-SIGN, a novel
dendritic cell-specific adhesion receptor for ICAM-3 mediates DC-T cell interactions and HIV-1
infection of DC. Blood 94:1928.
Gelfand, D.H., Holland, P.M., Saiki, R.K., Watson, R., (inventors). Hoffman-La Roche Inc.(US),
(assignee). Homogeneous assay system using the nuclease activity of a nucleic acid polymerase.
[Patent] US;EP. US5210015. 1993.
291
Cenain C.P., Leeparritz D., Nguyen M.H., Massacesi L., Joshi N., Ferrante R., Hoffman K.,
Moseley M., Letvin N.L., Hauser S.L. (1994) In healthy primates, circulating autoreactive T-cells
mediate autoimmune-disease. J.Clin.lnvest. 94:1339-45.
Gessani S., Borghi P., Fantuzzi L., Varano B., Conti L., Puddu P., Belardelli F. (1997) Induction
of cytokines by HIV-1 and its gpl20 protein in human peripheral blood monocyte/macrophages and
modulation of cytokine response during differentiation. J.Leuk.Biol. 62:49-53.
Gilbert S.F. (1994) Developmental biology. 4 ed. Sunderland, Massachusetts: Sinauer Associates;
ISBN: 0-87893-249-6.
Gluckman E., Spire B., Gluckman J.C., BarreSinoussi F., Vilmer E., Devergie A., Benbunan M.,
Rabian C., BrunVezinet F., Rouzioux C., et al. (1985) 2 Cases of acquired immuno deficiency
syndrome (AIDS) after allogeneic bone-marrow transplant (BMT) = Transmission of LAV by healthy
marrow donors. Exp.Hematol. 13:325.
Goh W.C., Markee J., Akridge R.E., Meldorf M., Musey L., Karchmer T., Krone M., Collier A.,
Corey L., Emerman M., et al. (1999) Protection against human immunodeficiency virus type 1
infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited
CCR5 coreceptor defects. J.Infect.Dis. 179:548-57.
Gomatos P.J., Stamatos N.M., Gendelman H.E., Fowler A., Hoover D.L., Kalter D.C., Burke
D.S., Tramont E.C., Meltzer M.S. (1990) Relative inefficiency of soluble recombinant CD4 for
inhibition of infection by monocyte-tropic HIV in monocytes and T-cells. J.Immunol. 144:4183-8.
GomezReino J.J., Pablos J.L., Carreira P.E., Santiago B., Serrano L., Vicario J.L., Balsa A.,
Figueroa M., Dejuan M.D. (1999) Association of rheumatoid arthritis with a functional chemokine
receptor, CCR5. Arth.Rheumat. 42:989-92.
Goodchild J., Agrawal S., Civeira M.P., Sarin P.S., Sun D., Zamecnik P.C. (1988) Inhibition of
human immunodeficiency virus-replication by antisense oligodeoxynucleotides.
Proc.Nat.Acad.Sci. USA 85:5507-1 1.
Goodwin J.S., Bankhurst A.D., Messner R.P. (1977) Suppression of human T cell mitogenesis by
prostaglandin. J.Exp.Med. 146(1719): 1734.
Gotch F., Hardy G. (2000) The immune system: our best antiretroviral. Cur.Op.Infect.Dis. 13:13-7.
Gotch F., Hardy G., Imami N. (1999) Therapeutic vaccines in HIV-1 infection. Immunol.Rev.
170:173-82.
Gougeon M.L., Garcia S., Heeney J., Tschopp R., Lecoeur H., Guetard D., Rame V., Dauguet
C., Montagnier L. (1993a) Programmed cell-death in AIDS-related HIV and SIV infections. AIDS
Res.Hum.Retrovir. 9:553-63.
Gougeon M.L., Montagnier L. (1993b) Apoptosis in AIDS. Science 260:1269-70.
Goulder P.J.R., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P.,
Luzzi G., Morgan B., Edwards A., et al. (1997) Late escape from an immunodominant cytotoxic T-
lymphocyte response associated with progression to AIDS. Nat.Med. 3:212-7.
GranelliPiperno A., Pope M., Inaba K., Steinman R.M. (1995) Coexpression of NF-kappa-B/Rel
and Spl transcription factors in human-immunodeficiency-virus 1-induced, dendritic cell T-cell
syncytia. Proc.Nat.Acad.Sci. USA 92:10944-8.
292
Graziosi C., Pantaleo G., Gantt K.R., Fortin J.P., Demarest J.F., Cohen O.J., Sekaly R.P., Fauci
A.S. (1994) Lack of evidence for the dichotomy of T(h)l And T(h)2 Predominance in HIV-infected
individuals. Science 265:248-52.
Greenspan H.C., Aruoma O.I. (1994) Oxidative stress and apoptosis in HIV-infection - a role for
plant-derived metabolites with synergistic antioxidant activity. Immunol. Today 15:209-13.
Greenwald I., Rubin G.M. (1992) Making a difference - the role of cell-cell interactions in
establishing separate identities for equivalent cells. Cell 68:271 -81.
Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. (1995) Fas ligand-induced
apoptosis as a mechanism of immune privilege. Science 270:1189-92.
Grossman Z., Polis M., Feinberg M.B., Levi I., Jankelevich S., Yarchoan R., Boon J., DeWoIf F.,
Lange J.M.A., Goudsmit J., et al. (1999) Ongoing HIV dissemination during HAART. Nat.Med.
5:1099-104.
Groux H., Powrie F. (1999) Regulatory T cells and inflammatory bowel disease. Immunol. Today
20:442-6.
Groux H., Torpier G., Monte D., Mouton Y., Capron A., Ameisen J.C. (1992) Activation-induced
death by apoptosis in CD4+ T-cells from human-immunodeficiency-virus infected asymptomatic
individuals. J.Exp.Med. 175:331-40.
Gruneberg U., Rich T., Roucard C., VanHam S.M., Charron D., Trowsdale J. (1997) Two
widely used anti-DR alpha monoclonal antibodies bind to an intracellular C-terminal epitope.
Hum.Immunol. 53:34-8.
Gu Y., Hukriede N.A., Fleming R.J. (1995) Serrate expression can functionally replace delta-
activity during neuroblast segregation in the Drosophila embryo. Development 121:855-65.
Guo H.G., Franchini G., Collalti E., Beaver B., Gurgo C., Gallo R.C., Wongstaal F., Reitz M.S.
(1987) Structure of the long terminal repeat of simian lymphotropic virus type-Ill (African-green
monkey) and its relatedness to that ofHIV. AIDS Res. Hum.Retrovir. 3:177-85.
Guo M., Jan L.Y., Jan Y.N. (1996) Control of daughter cell fates during asymmetric division:
Interaction of numb and notch. Neuron 17:27-41.
Gurgo C., Guo H.G., Franchini G., Aldovini A., Collalti E., Farrell K., Wongstaal F., Gallo R.C.,
Reitz M.S. (1988) Envelope sequences of2 new United-States H1V-1 isolates. Virology 164:531-6.
Gustafson K.R., Sowder R.C., Henderson L.E., Cardellina J.H., McMahon J.B., Rajamani U.,
Pannell L.K., Boyd M.R. (1997) Isolation, primary sequence determination, and disulfide bond
structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the
cyanobacterium Nostoc ellipsosporum. Biochem.Biophys.Res.Comm. 238:223-8.
Hallsworth M.P., Smith P.I., Lee T.H., Hirst S.I. (1999) Phorbol ester attenuates dexamethasone-
induced inhibition ofGM-CSF production by human airway smooth muscle cells.
Am.J.Resp.Crit.Care Med. 159:A400.
Hammache D., Delezay O., Fantini J., Yahi N. (1996) Suramin: A polysulfonated compound that
inhibits the binding of HIV-1 gpl20 to GalCer/sulfatide and blocks the CD4-independent pathway of
HIV-1 infection in mucosal epithelial cells. Perspec.Drug Dis.Des. 5:225-33.
Hammond E.M., Brunet C.L., Johnson G.D., Parkhill J., Milner A.E., Brady G., Gregory C.D.,
Grand R.J.A. (1998) Homology between a human apoptosis specific protein and the product of
APG5, a gene involved in autophagy in yeast. FEBS Let. 425:391-5.
293
Harcourt G.C., Garrard S., Davenport M.P., Edwards A., Phillips R.E. (1998) HIV-1 variation
diminishes CD4 T lymphocyte recognition. J.Exp.Med. 188:1785-93.
Harris C., Small C.B., Klein R.S., Friedland G.H., Moll B., Emeson E.E., Spigland I., Steigbigel
N.H. (1983) Immunodeficiency in female sexual partners ofmen with the acquired immunodeficiency
syndrome. New.Eng.J.Med. 308:1181-4.
Hart M.K., Palker T.J., Matthews T.J., Langlois A.J., Lerche N.W., Martin M.E., Scearce R.M.,
McDanal C., Bolognesi D.P., Haynes B.F. (1990) Synthetic peptides containing T-cell and B-cell
epitopes from human-immunodeficiency-virus envelope gpl20 induce anti-HlV proliferative
responses and high titers of neutralizing antibodies in rhesus-monkeys. J.Immunol. 145:2677-85.
Hartenstein V., CamposOrtega J.A. (1984) Early neurogenesis in wild-type Drosophila
melanogaster. Wilhelm Rouxs Arch.Dev.Biol. 193:308-25.
Hashimoto F., Oyaizu N., Kalyanaraman V.S., Pahwa S. (1997) Modulation of Bcl-2 protein by
CD4 cross-linking: A possible mechanism for lymphocyte apoptosis in human immunodeficiency
virus infection and for rescue of apoptosis by interleukin-2. Blood 90:745-53.
Hasserjian R.P., Aster J.C., Davi F., Weinberg D.S., Sklar J. (1996) Modulated expression of
NOTCH 1 during thymocyte development. Blood 88:970-6.
Hausmann J., Hallensleben W., DeLaTorre J.C., Pagenstecher A., Zimmermann C., Pircher H.,
Staheli P. (1999) T cell ignorance in mice to Borna disease virus can be overcome by peripheral
expression of the viral nucleoprotein. Proc.Nat.Acad.Sci.USA 96:9769-74.
Hausser G., Ludewig B., Gelderblom H.R., TsunetsuguYokota Y., Akagawa K., Meyerhans A.
(1997) Monocyte-derived dendritic cells represent a transient stage of differentiation in the myeloid
lineage. Immnnobiology 197(5):534-42.
Hayday A.C., Barber D.F., Douglas N., Hoffman E.S. (1999) Signals involved in gamma/delta T
cell versus alpha/beta T cell lineage commitment. Semin.lmmunol. 11:239-49.
He J.L., Chen Y.Z., Farzan M., Choe H.Y., Ohagen A., Gartner S., Busciglio. (1997) CCR3 and
CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385:645-9.
Heiken H., Becker S., Bastisch I., Schmidt R.E. (1999) HIV-1 infection in a heterosexual man
homozygous for CCR-5 Delta 32. AIDS 13:529-30.
Heinkelein M., Muller M., Kutsch O., Sopper S., Jassoy C. (1997) Rapid and selective depletion of
CD4(+) T lymphocytes and preferential loss ofmemory cells on interaction of mononuclear cells with
HIV-1 glycoprotein-expressing cells. J.AIDS Hum.Retrovirol. 16:74-82.
Hentges F., Hoffmann A., Dearaujo F.O., Hemmer R. (1992) Prolonged clinically asymptomatic
evolution after HIV-1 infection is marked by the absence of complement-C4 null alleles at the MHC.
Clin.Exp.Immunol. 88:237-42.
Herbein G., Doyle A.G., Montaner L.J., Gordon S. (1995) Lipopolysaccharide (LPS) down-
regulates CD4 expression in primary human macrophages through induction of endogenous tumor-
necrosis-factor (TNF) and IL-1-beta. Clin. Exp.Immunol. 102:430-7.
Heslop, I. Synthetic approaches to discontinous epitope mapping of HIV-1. [Thesis] University of
Edinburgh. University of Edinburgh Main Library; University of Edinburgh Chemistry Library. PhD.
1997.
Hewlett L.J., Prescott A.R., Watts C. (1994) The coated pit and macropinocytic pathways serve
distinct endosome populations. J.Cell Biol. 124:689-703.
294
Hewson T., Lone N., Moore M., Howie S. (1999) Interactions of HIV-1 with antigen-presenting
cells. Immunol.Cell Biol. 77:289-303.
Hewson T.J., Howie S.E.M. (1998) The Effects of HIV gp 120 on the expression of antigen
presenting cell (APC) surface molecules. Immunology 95(S1):86.
Higuchi R., Dollinger G., Walsh P.S., Griffith R. (1992) Simultaneous amplification and detection
of specific DNA-sequences. Bio-Technol. 10:413-7.
Higuchi R., Fockler C., Dollinger G., Watson R. (1993) Kinetic PCR analysis - real-time
monitoring of DNA amplification reactions. Bio-Technol. 11:1026-30.
Hilkens C., Snijders A., Vermeulen H., VanDerMeide P., Wierenga E., Kapsenberg M. (1996)
Accessory cell-derived interleukin-12 and prostaglandin E-2 determine the level of interferon-gamma
produced by activated human CD4(+) T cells. Ann.New York Acad.Sci. 795:349-50.
Hirschberg H., Braathen L.R., Thorsby E. (1982) Antigen presentation by vascular endothelial-
cells and epidermal langerhans cells - the role ofHLA-DR. Immunol.Rev. 66:57-77.
Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. (1995) Rapid
turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-6.
Hoffman T.L., Doms R.W. (1999) HIV-1 envelope determinants for cell tropism and chemokine
receptor use. Molec.Memb.Biol. 16:57-65.
Hoffman T.L., MacGregor R.R., Burger H., Mick R., Doms R.W., Collman R.G. (1997) CCR5
genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection
status. J.Infect.Dis. 176:1093-6.
Hogg N., MacDonald S., Slusarenko M., Beverley P.C.L. (1984) Monoclonal-antibodies specific
for human-monocytes, granulocytes and endothelium. Immunology 53:753-67.
Holland P.M., Abramson R.D., Watson R., Gelfand D.H. (1991) Detection of specific polymerase
chain-reaction product by utilizing the 5'-3' Exonuclease activity of Thermus aquaticus DNA-
polymerase. Proc.Nat.Acad.Sci. USA 88:7276-80.
Holmes K.L., Cuntz L.M., Ress W. (1997) Robinson J.P., Darzynkeiwicz Z., Dean P.N., el al.,
(editors). Current Protocols in Cytometry. 1 ed. New York: John Wiley and Sons; ISBN: 0-471-
16131-4. 4, Cell labelling, p. 4.2.1
Holt P.G. (1986) Down-regulation of immune responses in the lower respiratory tract: The role of
alveolar macrophages. Clin.Exp.Immunol. 63:1415-21.
Horuk R. (1999) Chemokine receptors and HIV-1: the fusion of two major research fields.
Immunol. Today 20(2):89-94.
Houle M., Thivierge M., LeGouill C., Stankova J., RolaPleszczynski M. (1999) IL-10 up-regulates
CCR5 gene expression in human monocytes. Inflammation 23:241-51.
Howard M., Matis L., Malek T.R., Shevach E., Kell W., Cohen D., Nakanishi K., Paul W.E.
(1983) Interleukin-2 induces antigen-reactive T-cell lines to secrete BCGF1. J.Exp.Med. 158:2024-
39.
Howie S.E., Harrison D.J., Wyllie A.H. (1994) Lymphocyte apoptosis - mechanisms and
implications in disease. Immunol.Rev. 142:141-56.
295
Howie S.E.M., Cotton G.J., Heslop I., Martin N.J., Harrison D.J., Ramage R. (1998) Synthetic
peptides representing discontinuous CD4 binding epitopes of HIV-1 gpl20 that induce T cell
apoptosis and block cell death induced by gp 120. FASEB J. 12:991-8.
Howie S.E.M., Fernandes M.L., Heslop I., Hewson T.J., Cotton G.J., Moore M.J., Innes D.,
Ramage R., Harrison D.J. (1999) A functional, discontinuous HIV-1 gpl20 C3/C4 domain-derived,
branched, synthetic peptide that binds to CD4 and inhibits MIP-1 alpha chemokine binding. FASEB J.
13:503-11.
Howie S.E.M., Sommerfield A.J., Gray E., Harrison D.J. (1994) Peripheral T-lymphocyte
depletion by apoptosis after CD4 ligation in vivo: selective loss of CD44(-) and "activating" memory
T-cells. Clin.Exp.Immunol. 95 :195-200.
Hoyne G.F., Callow M.G., Kuo M.C., Thomas W.R. (1994) Inhibition of T-cell responses by
feeding peptides containing major and cryptic epitopes - studies with the Der p 1-allergen.
Immunology 83:190-5.
Hoyne G.F., Dallman M.J., Lamb J.R. (2000) T-cell regulation of peripheral tolerance and
immunity: the potential role for Notch signalling. Immunology 100(2):281-8.
Hoyne G.F., Jarnicki A.G., Thomas W.R., Lamb J.R. (1997) Characterization of the specificity and
duration of T cell tolerance to intranasally administered peptides in mice: a role for intramolecular
epitope suppression. Int.Immunol. 9:1165-73.
Hoyne G.F., LeRoux I., CorsinJimenez M., Tan K., Dunne J., Forsyth L.M.G., Dallman M.J.,
Owen M.J., IshHorowicz D., Lamb J.R. (2000) Serrate 1-induced Notch signalling regulates the
decision between immunity and tolerance made by peripheral CD4(+) T cells. Int.Immunol. 12:177-
85.
Hoyne G.F., Ohehir R.E., Wraith D.C., Thomas W.R., Lamb J.R. (1993) Inhibition of T-cell and
antibody-responses to house-dust mite allergen by inhalation of the dominant T-cell epitope in naive
and sensitized mice. J.Exp.Med. 178:1783-8.
Hsieh J.J.D., Henkel T., Salmon P., Robey E., Peterson M.G., Hayward S.D. (1996) Truncated
mammalian Notch 1 activates CBFl/RBPJK-repressed genes by a mechanism resembling that of
Epstein-Barr virus EBNA2. Molec.Cell.Biol. 16:952-9.
Hsueh F.W., Walker C.M., Blackbourn D.J., Levy J.A. (1994) Suppression ofHIV replication by
CD8(+) cell clones derived from HIV-infected and uninfected individuals. Cell.Immunol. 159:271-9.
Huang Y.X., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L.Q., He T., Kang S.,
Ceradini D., Jin Z.Q., Yazdanbakhsh K., et al. (1996) The role of a mutant CCR5 allele in HIV-1
transmission and disease progression. Nat.Med. 2:1240-3.
Huang Y.X., Zhang L.Q., Ho D.D. (1998) Characterization of gag and pol sequences from long-term
survivors of human immunodeficiency virus type 1 infection. Virology 240:36-49.
Hubert P., Bismuth G., Korner M., Debre P. (1995) HIV-1 glycoprotein gpl20 disrupts CD4-
p56(Lck)/CD3-T cell-receptor interactions and inhibits CD3 signaling. Euro.J.Immunol. 25:1417-25.
Hui R., Curtis J.F., Sumner M.T., Shears S.B., Glasgow W.C., Eling T.E. (1995) Human-
immunodeficiency-virus type-1 envelope protein does not stimulate either prostaglandin formation or
the expression of prostaglandin-H synthase in THP-1 human monocytes macrophages. J. Virol.
69(12):8020-6.
296
Huizinga T.W.J., VanDerLinden M.W., DeneysLaporte V., Breedveld F.C. (1999) lnterleukin-10
as an explanation for pregnancy-induced flare in systemic lupus erythematosus and remission in
rheumatoid arthritis. Rheumatology 38:496-8.
Hurst S.D., Cooper C.J., Sitterding S.M., Choi J.H., Jump R.L., Levine A.D., Barrett T.A.
(1999) The differentiated state of intestinal lamina propria CD4(+) T cells results in altered cytokine
production, activation threshold, and costimulatory requirements. J.Immunol. 163:5937-45.
Husain S., Goila R., Shahi S., Banerjea A.C. (1998) First report of a healthy Indian heterozygous
for Delta 32 mutant of HIV-1 co-receptor-CCR5 gene. Gene 207:141-7.
Husman A.M.D., Koot ML, Cornelissen M., Keet I.P.M., Brouwer M., Broersen S.M., Bakker
M., Roos M.T.L., Prins M., DeWolf F., et al. (1997) Association between CCR5 genotype and the
clinical course of HIV-1 infection. Ann.Int.Med 127:882.
Husman A.M.D., Schuitemaker H. (1998) Chemokine receptors and the clinical course of HIV-1
infection. Trends Microbiol. 6:244-9.
Idziorek T., Khalife J., BillautMulot O., Hermann E., Aumercier M., Mouton Y., Capron A.,
Bahr G.M. (1998) Recombinant human 1L-16 inhibits HIV-1 replication and protects against
activation-induced cell death (AICD). Clin.Exp.Immunol. 112:84-91.
Iglesias B.M., Cerase J., Ceracchini C., Levi G., Aloisi F. (1997) Analysis of B7-1 and B7-2
costimulatory ligands in cultured mouse microglia: Upregulation by interferon-gamma and
lipopolysaccharide and downregulation by interleukin-10, prostaglandin E (2) and cyclic AMP-
elevating agents. J.Neuroimmunol. 72:83-93.
Itescu S., Rose S., Dwyer E., Winchester R. (1994) Certain HLA-DR5 and HLA-DR6 major
histocompatibility complex class-II alleles are associated with a CD8 lymphocytic host response to
human-immunodeficiency-virus type-1 characterized by low lymphocyte viral strain heterogeneity
and slow disease progression. Proc.Nat.Acad.Sci. USA 91:11472-6.
Ito M., Ishida T., He L.M., Tanabe F., Rongge Y., Miyakawa Y., Terunuma H. (1998) HIV type 1
Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells. AIDS
Res.Hum.Retrovir. 14:845-9.
Iyengar S., Schwartz D.H., Hildreth J.E.K. (1999) T cell-tropic HIV gpl20 mediates CD4 and CD8
cell chemotaxis through CXCR4 independent ofCD4: Implications for HIV pathogenesis. J.Immunol.
162:6263-7.
James K., Hargreave T.B. (1984) Immunosuppression by seminal plasma and its possible clinical
significance. Immunol. Today 5(357):363.
Jameson S.C., Bevan M.J. (1995) T-cell receptor antagonists and partial agonists. Immunity 2:1-11.
Janewav C.A. (1994) Thymic selection - two pathways to life and two to death. Immunity 1:3-6.
Janeway C.A.; Travers P. (1996) Immunobiology - the immune system in health and disease. 2 ed.
Edinburgh: Churchill Livingstone; ISBN: 0-443-05658-7.
Jarriault S., LeBail O., Hirsinger E., Pourquie O., Logeat F., Strong C.F., Brou C., Seidah N.G.,
Israel A. (1998) Delta-1 activation ofNotch-1 signaling results in HES-1 transactivation.
Molec. Cell. Biol. 18:7423-31.
Jasny B.R., Clery D. (1998) AIDS Research-1998. Science. 280: 1855-1855.
297
Jehn B.M., Bielke W., Pear W.S., Osborne B.A. (1999) Cutting edge: Protective effects ofNotch-1
on TCR-induced apoptosis. J.Immunol. 162:635-8.
Ji H., Shu W., Burling F.T., Jiang S.B., Lu M. (1999) Inhibition of human immunodeficiency virus
type 1 infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion.
J. Virol. 73:8578-86.
Jiang S.B., Lin K., Strick N., Neurath A.R. (1993) Inhibition of HIV-1 infection by a fusion domain
binding peptide from the HIV-1 envelope glycoprotein-gp41. Biochem.Biophys.Res.Comm. 195:533-
8.
Johnston L.J., Halliday G.M., King N.J.C. (1996) Phenotypic changes in Langerhans' cells after
infection with arboviruses: A role in the immune response to epidermally acquired viral infection?
J. Virol. 70:4761-6.
Jones P.L.S., Korte T., Blumenthal R. (1998) Conformational changes in cell surface HIV-1
envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors.
J.Biol.Chem. 273:404-9.
Jonuleit H., Knop J., Enk A.H. (1996) Cytokines and their effects on maturation, differentiation and
migration of dendritic cells. Arch.Dermatol.Res 289:1-8.
Joseph S.B., Miner K.T., Croft M. (1998) Augmentation of naive, Thl and Th2 effector CD4
responses by IL-6, IL-1 and TNF. Euro.J.Immunol. 28:277-89.
Joutel A., TournierLasserve E. (1998) Notch signalling pathway and human diseases. Semin.Cell
Dev.Biol. 9:619-25.
June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. (1994) The B7 and CD28 receptor
families. Immunol.Today 15:321-31.
Juompan L., Lambin P., Zouali M. (1998) Selective deficit in antibodies specific for the
superantigen binding site of gpl20 in HIV infection. FASEB J. 12:1473-80.
Kageyama S., Anderson B.D., Hoesterey B.L., Hayashi H., Kiso Y., Flora K.P., Mitsuya H.
(1994) Protein-binding of human-immunodeficiency-virus protease inhibitor KNI-272 and alteration
of its in vitro antiretroviral activity in the presence of high-concentrations of proteins.
Antimicrob.Agents Chemother. 38:1107-11.
Kaneko H., Hishikawa T., Sekigawa I., Hashimoto H., Okumura K., Kaneko Y. (1997) Role of
tumour necrosis factor-alpha (TNF-alpha) in the induction of HIV-1 gpl20-mediated CD4(+) T cell
anergy. Clin.Exp.Immunol. 109:41-6.
Kanki P., Barin F., Allan J., Lee T.H., Mboup S., Essex M. (1986) Simian T-lymphotropic virus
type-Ill (STLV-IIIAgm) in African-green monkeys and its relationship to human retroviruses in Africa.
J.Cell Biochem. 191.
Kanki P.J., Barin F., Mboup S., Allan J.S., Rometlemonne J.L., Marlink R., McLane M.F., Lee
T.H., Arbeille B., Denis F., et al. (1986) New human T-lymphotropic retrovirus related to simian T-
lymphotropic virus type-Ill (STLV-IIIAgm)- Science 232:238-43.
Kantor R., Gershoni J.M. (1999) Distribution ofthe CCR5 gene 32-base pair deletion in Israeli
ethnic groups. J.AIDS Hum.Retrovirol. 20:81-4.
Kaplan J.E., Oleske J.M., Getchell J.P., Kalyanaraman V.S., Minnefor A.B., Zabalaablan M.,
Joshi V., Denny T., Cabradilla C.D., Rogers M.F., et al. (1985) Evidence against transmission of
298
human T-lymphotropic virus lymphadenopathy-associated virus (HTLV-III/LAV) in families of
children with the acquired immunodeficiency syndrome. Ped.Infect.Dis.J. 4:468-71.
Kapsenberg M.L., Teunissen Stiekema F.E.M., Keizer H.G. (1986) Antigen-presenting
cell-function of dendritic cells and macrophages in proliferative T-cell responses to soluble and
particulate antigens. Euro.J.Immunol. 16:345-50.
Karp C.L., Wysocka M., Wahl L.M., Ahearn J.M., Cuomo P.J., Sherry B., Trinchieri G.,
Griffin D.E. (1996) Mechanism of suppression of cell-mediated-immunity by measles-virus. Science
273:228-31.
Karray S., Zouali M. (1997) Identification of the B cell superantigen-binding site of HIV-1 gpl20.
Proc. Nat.Acad.Sci. USA 94:1356-60.
Karsten V., Gordon S., Kirn A., Herbein G. (1996) HIV-1 envelope glycoprotein gpl20 down-
regulates CD4 expression in primary human macrophages through induction of endogenous tumour
necrosis factor-alpha. Immunology 88:55-60.
Katz J.D., Benoist C., Mathis D. (1995) T-helper cell subsets in insulin-dependent diabetes. Science
268:1185-8.
Katzenstein T.L., EugenOlsen J., Hofmann B., Benfield T., Pedersen C., Iversen A.K.N.,
Sorensen A.M., Garred P., Koppelhus U., Svejgaard A., et al. (1997) HIV-infected individuals
with the CCR5 Delta 32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in
the early years of the infection than do patients with the wild type. J.AIDS Hum.Retrovirol. 16:10-4.
Kauffman H.J., Taubin H.L. (1987) Nonsteroidal anti-inflammatory drugs activate quiescent
inflammatory bowel disease. Ann.Int.Med. 107:513-6.
Kaul R., Trabattoni D., Bwayo J.J., Arienti D., Zagliani A., Mwangi F.M., Kariuki C., Ngugi
E.N., MacDonald K.S., Ball T.B., et al. (1999) HIV-1-specific mucosal IgA in a cohort ofHIV-1 -
resistant Kenyan sex workers. AIDS 13:23-9.
Kawai K., Ohashi P.S. (1995) Immunological function of a defined T-cell population tolerized to
low-affinity self-antigens. Nature 378:419.
Kedzierska K., Rainbird M.A., Lopez A.F., Crowe S.M. (1998) Effect ofGM-CSF on HIV-1
replication in monocytes/macrophages in vivo and in vitro: A review. Vet.Immunol.Immunopathol.
63:111-21.
Keefer L.M., Piron M.A., Demeyts P. (1981) Human insulin prepared by recombinant DNA
techniques and native human insulin interact identically with insulin-receptors.
Proc. Nat.A cad. Sci. USA-Biol.Sci. 78:1391-5.
Kelleher A.D., Emery S., Cunningham P., Duncombe C., Carr A., Golding H., Forde S., Hudson
J., Roggensack M., Forrest B.D., et al. (1997) Safety and immunogenicity ofUBI HIV-l(MN)
octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res.Hum.Retrovir.
13:29-32.
Kelly R.W. (1994) Pregnancy maintenance and parturition - the role of prostaglandin in manipulating
the immune and inflamatory response. Endocrine Rev. 15(5):684-706.
Kelly R.W. (1995) Immunosuppressive mechanisms in semen: implications for contraception.
Hum.Repro. 10(1686): 1693.
Kelly R.W. (1997) Prostaglandins in primate semen: biasing the immune system to benefit
spermatozoa and virus? Prost.Leukotrienes Essent.Fatty Acids 57:113-8.
299
Kelly R.W. (1999) Immunomodulators in human seminal plasma: a vital protection for spermatozoa
in the presence of infection? Int.J.Androl. 22:2-12.
Kelly R.W., Carr G.G., Critchley H.O.D. (1997a) A cytokine switch induced by human seminal
plasma: An immune modulation with implications for sexually transmitted disease. Hum.Repro.
12:677-81.
Kelly R.W., Critchley H.O.D. (1997b) Immunomodulation by human seminal plasma: a benefit for
spermatozoon and pathogen? Hum.Repro. 12:2200-7.
Kestler H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., Desrosiers R.C.
(1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell 65:651-62.
Keydar I., Chen L., Karby S., Weiss F.R., Delarea J., Radu M., Chaitcik S., Brenner H.J. (1979)
Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer
15(5):659-70.
Khoo S.H., Pepper L., Snowden N., Hajeer A.H., Vallely P., Wilkins E.G.L., Mandal B.K., Oilier
W.E.R. (1997) Tumour necrosis factor c2 microsatellite allele is associated with the rate ofHIV
disease progression. AIDS 11:423-8.
Kibber C.C. (1997) Morgan D.R., (editor). Managing biological and chemical risks. 1 ed. London:
Institute of Biology; ISBN: 0-900-490-34-9. Indroducing 'Universal Precautions' into clinical and
laboratory environments.
Kidd S., Baylies M.K., Gasic G.P., Young M.W. (1989) Structure and distribution of the notch
protein in developing Drosophila. Gene.Dev. 3:1113-29.
Kidd S., Kelley M.R., Young M.W. (1986) Sequence of the Notch locus of Drosophila melanogaster
- relationship of the encoded protein to mammalian clotting and growth-factors. Molec. Cell. Biol.
6:3094-108.
Kidd S., Lieber T., Young M.W. (1998) Ligand-induced cleavage and regulation of nuclear entry of
Notch in Drosophila melanogaster embryos. Gene.Dev. 12:3728-40.
Kiertscher S.M., Roth M.D. (1996) Human CD14(+) leukocytes acquire the phenotype and function
of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J.Leuk.Biol. 59:208-18.
Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L.,
Hunter E., Lambert D., Bolognesi D., et al. (1998) Potent suppression of HIV-1 replication in
humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat.Med. 4:1302-7.
Kim A., PettoelloMantovani M., Goldstein H. (1998) Decreased susceptibility of peripheral blood
mononuclear cells from individuals heterozygous for a mutant CCR5 allele to HIV infection. J.AIDS
Hum.Retrovirol. 19:145-9.
Kim H.K., Siu G. (1998) The notch pathway intermediate HES-1 silences CD4 gene expression.
Molec.Cell.Biol. 18:7166-75.
Kim M.K., Schreiber A.D. (1999) Phagocytosis by human Fc gamma RI: The 11 C-terminal amino
acids of the Fc gamma RI transmembrane domain are required for Fc gamma Rl/gamma association
and phagocytic signaling. Blood 94:2598.
Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., Desrosiers R.C. (1995) Brief report -
absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
New.Eng.J.Med. 332:228-32.
300
Kishimoto H., Sprent J. (1999) Several different cell surface molecules control negative selection of
medullary thymocytes. J.Exp.Med. 190:65-73.
Kishimoto H., Sprent J. (2000) The thymus and central tolerance. Clin.Immunol. 95:S3-S7.
Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend. (1984)
Lymphocyte-T T4 molecule behaves as the receptor for human reterovirus LAV. Nature 312:767-8.
Klein M.R., VanBaalen C.A., Holwerda A.M., Kerkhofgarde S.R., Bende R.J., Keet I.P.M.,
Eeftinckschattenkerk J.K.M., Osterhaus A.D.M.E., Schuitemaker H., Miedema F. (1995)
Kinetics ofGag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1
infection - a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp.Med.
181:1365-72.
Klein M.R., VanDerBurg S.H., Pontesilli O., Miedema F. (1998) Cytotoxic T lymphocytes in HIV-
1 infection: a killing paradox? Immunol. Today 19:317-24.
Klein S.A., Dobmeyer J.M., Dobmeyer T.S., Pape M., Ottmann O.G., Helm E.B., Hoelzer D.,
Rossol R. (1997) Demonstration of the Thl to Th2 cytokine shift during the course of HIV-1 infection
using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 11:1111-8.
Knight S.C., Elsley W., Wang H. (1997a) Mechanisms of loss of functional dendritic cells in HIV-1
infection. J.Leuk.Biol. 62:78-81.
Knight S.C., Patterson S. (1997b) Bone marrow-derived dendritic cells, infection with human
immunodeficiency virus, and immunopathology. Ann.Rev.Immunol. 15:593-615.
Knust E., Tietze K., CamposOrtega J.A. (1987) Molecular analysis of the neurogenic locus
Enhancer of split of Drosophila melanogaster. EMBOJ. 6:4113-23.
Koch C.A., Robyn J.A., Pacak K. (1999) How do levels of (endogenous) glucocorticoids,
interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after
pregnancy? Clin.Endocrinol. 50:815-6.
Korber B.; Moore J.; Brander C.; Koup R.; Haynes B.; Walker B. (1998) HIV molecular
immunology database. Los Alamos: Los Alamos National Laboratory; ISBN: not assigned
(publication number LAUR 99-586) (also available at http://hiv-web.lanl.gov.immunology).
Kostrikis L.G., Huang Y.X., Moore J.P., Wolinsky S.M., Zhang L.Q., Guo Y., Deutsch L., Phair
J., Neumann A.U., Ho D.D. (1998) A chemokine receptor CCR2 allele delays HIV-1 disease
progression and is associated with a CCR5 promoter mutation. Nat.Med. 4:350-3.
Kraan T.C.T.M.V., Boeije I.C.M., Smeenk R.J.T., Wijdenes J., Aarden L.A. (1995)
Prostaglandin-E2 is a potent inhibitor of human interleukin-12 production. J. Exp.Med. 181:775-9.
Krause I., Blank M., Shoenfeld Y. (2000) Immunomodulation of experimental autoimmune diseases
via oral tolerance. Crit.Rev.Immunol. 20:1-16.
Krieger J.I., Grammer S.F., Grey H.M., Chesnut R.W. (1985) Antigen presentation by splenic B-
cells - resting B-cells are ineffective, whereas activated B-cells are effective accessory cells for T-cell
responses. J.Immunol. 135:2937-45.
Krouse D.S., Deutsch C. (1991) cyclic AMP directly inhibits IL-2 receptor expression in human T
cells: expression of both p55 and p75 subunits are affected. J.Immunol. 146:2285-94.
301
Kruger M., VanDeWinkel J.G.J., Dewit T.P.M., Coorevits L., Ceuppens J.L. (1996) Granulocyte-
macrophage colony-stimulating factor down-regulates CD 14 expression on monocytes. Immunology
89:89-95.
Kruisbeek A.M., Amsen D. (1996) Mechanisms underlying T-cell tolerance. Current Opinion In
Immunology 8:233-44.
Krummel M.F., Allison J.P. (1995) CD28 and CTLA-4 have opposing effects on the response ofT-
cells to stimulation. J.Exp.Med. 182:459-65.
Krummel M.F., Sullivan T.J., Allison J.P. (1996) Superantigen responses and co-stimulation: CD28
and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int.Immunol. 8:519-23.
Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L.,
Nabavi N., Glimcher L.H. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the
Thl/Th2 developmental pathways - application to autoimmune-disease therapy. Cell 80:707-18.
Kuipers H., Workman C., Dyer W., Geczy A., Sullivan J., Oelrichs R. (1999) An HIV-1-infected
individual homozygous for the CCR-5 Delta 32 allele and the SDF-1 3' A allele. AIDS 13:433-4.
Kumar V., Sercarz E. (1998) Induction or protection from experimental autoimmune
encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4
T cells. J.Immunol. 161:6585-91.
Kupfer B., Kaiser R., Brackmann H.H., Effenberger W., Rockstroh J.K., Matz B., Schneweis
K.E. (1999) Protection against parenteral HIV-1 infection by homozygous deletion in the C-C
chemokine receptor 5 gene. AIDS 13:1025-8.
Kuribayashi K., Tsukiyama M., Takenaka T. (1997) Secretion patterns ofThl- and Th2-type
cytokines in immune deviation caused by dendritic cells. Int.Arch.AIlerg.Immunol. 114:30-7.
Kurts C., Heath W.R., Carbone F.R., Kosaka H., Miller J.F.A.P. (1998) Cross-presentation of self
antigens to CD8(+) T cells: the balance between tolerance and autoimmunity. Ciba Found.Symp.
215:172-81.
Kusner D.J., Hall C.F. (1996) Complement receptor-mediated phagocytosis of Mycobacterium
tuberculosis or opsonized zymosan by human macrophages is associated with activation of SRC-
family tyrosine kinases. J.Invest.Med. 44:A320.
Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. (1998)
Structure of an HIV gpl20 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 393:648-59.
Lamb, J.R., Dallman, M.J., Hoyne, G.F., (inventors). Lorantis Limited (GB), (assignee). Notch.
[Patent] GB;WO;EP. GB 2335194A. 1998.
Lamb, J.R., Dallman, M.J., Hoyne, G.F., (inventors). Lorantis Limited (GB), (assignee).
Methods of immunosuppression. [Patent] WO;GB. WO 00/36089. 2000.
Lamb J.R., Eckels D.D., Lake P., Woody J.N., Green N. (1982a) Human T-cell clones recognize
chemically synthesized peptides of influenza hemagglutinin. Nature 300:66-9.
Lamb J.R., Woody J.N., Hartzman R.J., Eckels D.D. (1982b) In vitro influenza virus-specific
antibody-production in man - antigen-specific and HLA-restricted induction of helper activity
mediated by cloned human lymphocytes-T. J.Immunol. 129:1465-70.
302
Landau N.R. (1997) HIV co-receptor identification: good or bad news for drug discovery? Current
Opinion In Immunology 9:628-30.
Lane B.R., Markovitz D.M., Woodford N.L., Rochford R., Strieter R.M., Coffey M.J. (1999)
TNF-alpha inhibits H1V-1 replication in peripheral blood monocytes and alveolar macrophages by
inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression.
J.Immunol. 163:3653-61.
Lange J.M.A., Karam M., Piot P. (1993) Boost for vaginal microbicides against HIV. Lancet
342:1356.
Lapham C.K., Zaitseva M.B., Lee S., Romanstseva T., Golding H. (1999a) CORRECTION -
Fusion ofmonocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4
andCCR5. Nat.Med. 5:590.
Lapham C.K., Zaitseva M.B., Lee S., Romanstseva T., Golding H. (1999b) Fusion ofmonocytes
and macrophages with HIV-1 correlates with biochemical properties ofCXCR4 and CCR5. Nat.Med.
5:303-8.
Lasky L.A., Nakamura G., Smith D.H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory
T., Capon D.J. (1987) Delineation of a region of the human-immunodeficiency-virus type-1 gp 120
glycoprotein critical for interaction with the CD4 receptor. Cell 50:975-85.
Laurence J., Hodtsev A.S., Posnett D.N. (1992) Superantigen implicated in dependence of HIV-1
replication in T-cells on TCR V-beta expression. Nature 358:255-9.
LaurentCrawford A.G., Krust B., Riviere Y., Desgranges C., Muller S., Kieny M.P., Dauguet C.,
Hovanessian A.G. (1993) Membrane expression ofHIV envelope glycoproteins triggers apoptosis in
CD4 cells. AIDS Res.Hum.Retrovir. 9:761-73.
Leach M.W., Davidson N.J., Fort M.M., Powrie F., Rennick D.M. (1999) The role of IL-10 in
inflammatory bowel disease: "Of mice and men". Toxicologic Pathol. 27:123-33.
Leboute A.P.M., DeCarvalho M.W.P., Simoes A.L. (1999) Absence of the Delta ccr5 mutation in
indigenous populations of the Brazilian Amazon. Hum.Gen. 105:442-3.
Ledru E., Lecoeur H., Garcia S., Debord T., Gougeon M.L. (1998) Differential susceptibility to
activation-induced apoptosis among peripheral Thl subsets: Correlation with Bcl-2 expression and
consequences for AIDS pathogenesis. J.Immunol. 160:3194-206.
Lee B., Doranz B.J., Rana S., Yi Y.J., Mellado M., Frade J.R., Martinez C., O'Brien S.J., Dean
M., Collman R.G., et al. (1998) Influence of the CCR2-V64I polymorphism on human
immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function ofCCR2b,
CCR3, CCR5, and CXCR4. J.Virol. 72:7450-8.
Lehmann R., Jimenez F., Dietrich U., CamposOrtega J. A. (1983) On the phenotype and
development ofmutants of early neurogenesis in Drosophila melanogaster. Wilhelm Rouxs
Arch.Dev.Biol. 192:62-74.
Lendahl, U., Zhao, M., Clarke, D., Frisen, J., Johansson, C., Momma, S., Delfani, K., Janson,
A.M., (inventors). Lendahl, U., Zhao, M., Clarke, D., Frisen, J., Johansson, C., Momma, S.,
Delfani, K., Janson, A.M., Neuronova AB. (assignees). Ependymal neural stem cells and method
for their isolation. [Patent] SE;WO. W09967363. 1999.
Leviten M.W., Posakony J.W. (1996) Gain-of-function alleles of Bearded interfere with alternative
cell fate decisions in Drosophila adult sensory organ development. Dev.Biol. 176:264-83.
303
Levy J.A. (1994) HIV and the Pathogenesis ofAIDS. Washington DC, USA: American Society for
Microbiology; ISBN: 1-55581-076-4.
Levy J.A., Mackewicz C.E., Barker E. (1996) Controlling HIV pathogenesis: The role of the
noncytotoxic anti-HIV response ofCD8(+) T cells. Immunol. Today 17:217-24.
Li C., Yan Y.P., Shieh B., Lee C.M., Lin R.Y., Chen Y.M.A. (1997) Frequency of the CCR5 Delta
32 mutant allele in HIV-1-positive patients, female sex workers, and a normal population in Taiwan.
J.Formosan.Med.Assoc 96:979-84.
Li L.H., Milner L.A., Deng Y., Iwata M., Banta A., Graf L., Marcovina S., Friedman C., Trask
B.J., Hood L., et al. (1998) The human homolog of rat Jagged I expressed by marrow stroma
inhibits differentiation of 32D cells through interaction with Notch 1. Immunity 8:43-55.
Libert F., Cochaux P., Beckman G., Samson M., Aksenova M., Cao A., Czeize! A., Claustres M.,
DeLaRua C., Ferrari M., et al. (1998) The Delta ccr5 mutation conferring protection against HIV-1
in Caucasian populations has a single and recent origin in Northeastern Europe. Hum.Molec.Gen.
7:399-406.
Liblau R., Steinman L., Brocke S. (1997) Experimental autoimmune encephalomyelitis in IL-4-
deficient mice. Int.Immunol. 9:799-803.
Liblau R.S., Singer S.M., McDevitt H.O. (1995) Thl and Th2 CD4(+) T-cells in the pathogenesis of
organ-specific autoimmune-diseases. Immunol. Today 16:34-8.
Lie Y.S., MacDonald P.M. (1999) Translational regulation of oskar mRNA occurs independent of
the cap and poly(A) tail in Drosophila ovarian extracts. Development 126:4989-96.
Lieber T., Kidd S., Alcamo E., Corbin V., Young M.W. (1993) Antineurogenic phenotypes induced
by truncated notch proteins indicate a role in signal-transduction and may point to a novel function for
notch in nuclei. Gene.Dev. 7:1949-65.
Lieber T., Wesley C.S., Alcamo E., Hassel B., Krane J.F., CamposOrtega J.A., Young M.W.
(1992) Single amino-acid substitutions in EGF-like elements of notch and delta-modify Drosophila
development and affect cell-adhesion in vitro. Neuron 9:847-59.
Lindsell C.E., Boulter J., DiSibio G., Gossler A., Weinmaster G. (1996) Expression patterns of
Jagged, Deltal, Notchl, Notch2, and Notch3 genes identify ligand-receptor pairs that may function in
neural development. Molec.Cell.Neuroscience 8:14-27.
Lissemore J.L., Starmer W.T. (1999) Phylogenetic analysis of vertebrate and invertebrate
Delta/Serrate/LAG-2 (DSL) proteins. Molec.Phylogen.Evol. 11:308-19.
Liu G.Y., Fairchild P.J., Smith R.M., Prowle J.R., Kioussis D., Wraith D.C. (1995) Low avidity
recognition of self-antigen by T-cells permits escape from central tolerance. Immunity 3:407-15.
Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E.,
Stuhlmann H., Koup R.A., Landau N.R. (1996) Homozygous defect in HIV-1 coreceptor accounts
for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-77.
Livak K.J., Flood S.J.A., Marmaro J., Giusti W., Deetz K. (1995) Oligonucleotides with
fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product
and nucleic-acid hybridization. PCR-Meth.Applic. 4:357-62.
Livingstone W.J., Moore M., Innes D., Bell J.E., Simmonds P., Whitelaw J., Wyld R., Robertson
J.R., Brettle R.P. (1996) Frequent infection of peripheral blood CD8-positive T-lymphocytes with
HIV-1. Lancet 348:649-54.
304
Loegering D.J. (1985) Time course of the recovery of hepatic macrophage complement receptor
clearance function and host defense following erythrocyte phagocytosis. J.Leuk.Biol. 38:102.
Lombardi G., Sidhu S., Batchelor R., Lechler R. (1994) Anergic T-cells as suppressor cells in vitro.
Science 264:1587-9.
Lombardi G., Warrens A.N., Lechler R.I. (1995) Anergic T-cells act as suppressor cells in vitro.
Transplantation Proceedings 27:235-6.
London C.A., Lodge M.P., Abbas A.K. (2000) Functional responses and costimulator dependence of
memory CD4(+) T cells. J.Immunol. 164:265-72.
Lowenstein E.J., Daly R.J., Batzer A.G., Li W., Margolis B., Lammers R., Ullrich A., Skolnik
E.Y., Barsagi D., Schlessinger J. (1992) The SH2 and SH3 domain containing protein GRB2 links
receptor tyrosine kinases to ras signaling. Cell 70:431-42.
Lowrey J.A., Savage N.D.L., Palliser D., CorsinJimenez M., Forsyth L.M.G., Hall G., Lindey S.,
Stewart G.A., Tan K.A.L., Hoyne G.F., et al. (1998) Induction of tolerance via the respiratory
mucosa. Int.Arch.Allerg.Immunol. 116:93-102.
Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. (1951) Protein measurement with the Folin
phenol reagent. J.Biol.Chem. 193:265-75.
Lu F.M., Lux S.E. (1996) Constitutively active human Notch 1 binds to the transcription factor CBF1
and stimulates transcription through a promoter containing a CBF1-responsive element.
Proc.Nat.Acad.Sci. USA 93:5663-7.
Lucotte G. (1997) Frequencies of the CC chemokine receptor 5 Delta 32 allele in various populations
of defined racial background. Biomed.Pharmacotherap. 51:469-73.
Lucotte G., Mercier G. (1998a) Distribution of the CCR5 gene 32-bp deletion in Europe. J.AIDS
Hum.Retrovirol. 19:174-7.
Lucotte G., Mercier G. (1998b) Frequences de la mutation delta 32 du gene du corecepteur CCR5
dans les differentes regions franijaises (French Language - "Delta 32 mutation frequencies of the
CCR5 coreceptor in different French regions"). Comptes Rendus De L'Academie Des Sciences Serie
Ill-Sciences De La Vie-Life Sciences 321(5):409-13.
Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N.J., Trapani J., Cebon J. (1998) Type I IFNs
enhance the terminal differentiation of dendritic cells. J. Immunol. 161:1947-53.
Lush C.W., Cepinskas G., Kvietys P.R. (2000) LPS tolerance in human endothelial cells: reduced
PMN adhesion, E-selectin expression, and NF-kappa B mobilization. Am. J. Physiol.-Heart
Circulat.Physiol. 278:H853-H861.
Lusso P., Malnati M.S., Garzinodemo A., Crowley R.W., Long E.O., Gallo R.C. (1993) Infection
of natural-killer-cells by human herpesvirus-6. Nature 362:458-62.
Mabrouk K., VanRietschoten J., Rochat H., Loret E.P. (1995) Correlation of antiviral activity with
beta-turn types for V3 synthetic multibranched peptides from HIV-1 gpl20. Biochemistry 34:8294-8.
Maccarrone M., Navarra M., Corasaniti M.T., Nistico G., Agro A.F. (1998) Cytotoxic effect of
HIV-1 coat glycoprotein gpl20 on human neuroblastoma CHP100 cells involves activation of the
arachidonate cascade. Biochem.J. 333:45-9.
Mackewicz C.E., Ortega H., Levy J.A. (1994) Effect of cytokines on HIV replication in CD4(+)
lymphocytes - lack of identity with the CD8(+) cell antiviral factor. Cell.Immunol. 153:329-43.
305
Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., Axel R. (1986) The T4
gene encodes the AIDS virus receptor and is expressed in the immune-system and the brain. Cell
47:333-48.
Maggi E., Mazzetti M., Ravina A., Annunziato F., DeCarli M., Piccinni M.P., Manetti R.,
Carbonari M., Pesce A.M., DelPrete G., et al. (1994) Ability ofHIV to promote a T(h)l To T(h)0
Shift and to replicate preferentially in T(h)2 And T(h)0 Cells. Science 265:244-8.
Magierowska M., Lepage V., Boubnova L., Carcassi C., DeJuan D., Djoulah S., ElChenawi F.,
Grunnet N., Halle L., Ivanova R., et al. (1998) Distribution of the CCR5 gene 32 base pair deletion
and SDF1-3'A variant in healthy individuals from different populations. Immunogenetics 48:417-9.
Magierowska M., Theodorou L., Debre P., Sanson F., Autran B., Riviere Y., Charron D., Alt F.,
Costagliola D. (1999) Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the
long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood
93:936-41.
Magnac C., Desaintmartin J., Pidard D., Legrand C., Dighiero G. (1990) Platelet antibodies in
serum of patients with human-immunodeficiency-virus (HIV) infection. AIDS Res.Hum.Retrovir.
6:1443-9.
Maier C.C., Greene M.I. (1998) Biochemical features of anergic T cells. Immunol. Res. 17:133-40.
Malcomson R.D.G., Clarke A.R., Peter A., Coutts S.B., Howie S.E.M., Harrison D.J. (1997)
Apoptosis induced by gamma-irradiation, but not CD4 ligation, of peripheral T lymphocytes in vivo is
p53-dependent. J.Pathol. 181:166-71.
Maldarelli F., Sato H., Berthold E., Orenstein J., Martin M.A. (1995) Rapid induction of
apoptosis by cell-to-cell transmission of human-immunodeficiency-virus type-1. J. Virol. 69:6457-65.
Malo A., Rommel F., Bogner J., Gruber R., Schramm W., Goebel F.D., Riethmuller G., Wank
R. (1998) Lack of protection from HIV infection by the mutant HIV coreceptor CCR5 in
intravenously HIV infected hemophilia patients. Immunobiology 198:485-8.
Malur A., Raychaudhuri B., Buhrow I., Dinakar C., Kavuru M., Thomassen M.J. (1999) Nitric
oxide (NO) differentially regulates tumor necrosis factor-alpha (TNF), granulocyte macrophage-
colony stimulating factor (GM-CSF) and macrophage inflammatory protein-1-alpha (MIP) production
by human blood monocytes. Am.J.Resp.Crit.Care Med. 159:A860.
Manca F., Fenoglio D., Valle M.T., Lipira G., Kunkl A., Ferraris A., Saverino D., Lancia F.,
Mortara L., Lozzi L., et al. (1995) Human CD4(+) T-cells can discriminate the molecular and
structural context of T-epitopes of HIV p66. J.AIDS Hum.Retrovirol. 9:227-37.
Manfredi R., Re M.C., Furlini G., Gorini R., Chiodo F. (1997) In vivo effects of recombinant
human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF), alone and associated with
zidovudine, on HIV-1 replication. Microbiological^-.345-50.
Mangano A., Prada F., Roldan A., Picchio G., Bologna R., Sen L. (1998) Distribution ofCCR-5
Delta 32 allele in Argentinian children at risk of HIV-1 infection: its role in vertical transmission.
AIDS 12:109-10.
Mange A.P.; Mange E.J. (1989) Genetics: human aspects. 2 ed. Sunderland, MA, USA: Sinauer
Associates Inc.; ISBN: 0-87893-501-0.
Marchalonis J.J., Ampel N.M., Schluter S.F., Garza A., Lake D.F., Galgiani J.N., Landsperger
W.J. (1997) Analysis of autoantibodies to T-cell receptors among HIV-infected individuals: epitope
analysis and time course. Clin.Immunol.Immunopathol. 82(2): 174-89.
306
MarelliBerg F.M., Lechler R.I. (1999) Antigen presentation by parenchymal cells: a route to
peripheral tolerance? Immunol.Rev. 172:297-314.
Mariani R., Kirchhoff F., Greenough T.C., Sullivan J.L., Desrosiers R.C., Skowronski J. (1996)
High frequency of defective nef alleles in a long-term survivor with nonprogressive human
immunodeficiency virus type 1 infection. J. Virol. 70:7752-64.
Mariani R., Wong S., Mulder L.F., Wilkinson D.A., Reinhart A.L., LaRosa G., Nibbs R.,
O'Brien T.R., Michael N.L., Connor R.I., et al. (1999) CCR2-64I polymorphism is not associated
with altered CCR5 expression or coreceptor function. J. Virol. 73:2450-9.
Mariner J.M., McMahon J.B., O'Keefe B.R., Nagashima K., Boyd M.R. (1998) The HIV-
inactivating protein, cyanovirin-N, does not block gpl20-mediated virus-to-cell binding.
Biochem.Biophys.Res. Comm. 248:841 -5.
Marshall J.D., Chehimi J., Gri G., Kostman J.R., Montaner L.J., Trinchieri G. (1999) The
interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency
virus-infected individuals. Blood 94(3): 1003-11.
Marshall K.W., Liu A.F., Canales J., Perahia B., Jorgensen B., Gantzos R.D., Aguilar B.,
Devaux B., Rothbard J.B. (1994) Role of the polymorphic residues in HLA-DR molecules in allele-
specific binding of peptide ligands. J. Immunol. 152:4946-57.
Martin M.P., Carrington M., Dean M., O'Brien S.J., Sheppard H.W., Wegner S.A., Michael
N.L. (1998a) CXCR4 polymorphisms and HIV-1 pathogenesis. J.AIDS Hum.Retrovirol. 19:430.
Martin M.P., Dean M., Smith M.W., Winkler C., Gerrard B., Michael N.L., Lee B., Doms R.W.,
Margolick J., Buchbinder S., et al. (1998b) Genetic acceleration ofAIDS progression by a promoter
variant ofCCR5. Science 282:1907-11.
Martinson J.J., Chapman N.H., Rees D.C., Liu Y.T., Clegg J.B. (1997) Global distribution of the
CCR5 gene 32-basepair deletion. Nat.Gen. 16:100-3.
Martinvilla J.M., Luque I., MartinezQuiles N., Corell A., Regueiro J.R., Timon M.,
Arnaizvillena A. (1996) Diploid expression of human-leujocyte antigrn class-I and class-II molecules
on spermatozoa and their cyclic inverse correlation with inhibin concentration. Biol.Repro. 55:620-9.
Mashikian M.V., Cruikshank W., Brazer W., Ryan T., Center D. (1999) IL-16, through
interaction with CD4, inhibits CCR5b and CXCR4 but not CCR3 signaling. FASEB J. A13:A317.
Matsui T., Kobayashi S., Yoshida O., Ishii S., Abe Y., Yamamoto N. (1990) Effects of
succinylated concanavalin A on infectivity and syncytial formation of human-immunodeficiency-
virus. Medical Microbiology And Immunology 179:225-35.
Matsuno K., Diederich R.J., Go M.J., Blaumueller C.M., ArtavanisTsakonas S. (1995) Deltex
acts as a positive regulator of notch signaling through interactions with the Notch ankyrin repeats.
Development 121:2633-44.
Matsuno K., Go M.J., Sun X., Eastman D.S., ArtavanisTsakonas S. (1997) Suppressor of
Hairless-independent events in Notch signaling imply novel pathway elements. Development
124:4265-73.
Matzinger P. (1994) Tolerance, danger, and the extended family. Ann.Rev.Immunol. 12 :991-1045.
May M.J., Ghosh S. (1998) Signal transduction through NF-kappa B. Immunol. Today 19:80-8.
307
May R.C., Caron E., Hall A., Machesky L.M. (2000) Involvement of the Arp2/3 complex in
phagocytosis mediated by Fc gamma R or CR3. Nat.Cell Biol. 2:246-8.
Mazzoli S., Trabattoni D., Caputo S.L., Piconi S., Ble C., Meacci F., Ruzzante S., Salvi A.,
Semplici F., Longhi R., et al. (1997) HIV-specific mucosal and cellular immunity in HIV-
seronegative partners of HIV-seropositive individuals. Nat.Med. 3:1250-7.
McCartney S.A., Mitchell J.A., Warner T.D., Farthing M.G. (1999) GM-CSF is produced in high
concentrations by colonic mucosa from patients with ulcerative colitis and is down regulated by co-
incubation with dexamethasone. Gastroenterology 116:G3095.
McCune J.M. (1995) Viral latency in HIV disease. Cell 82:183-8.
McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M.
(1998) CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 352 :866-70.
McDonald C.J., Rogers M.P. (1986) Risk ofHTLV III/LAV transmission to household contacts.
New.Eng.J.Med. 315:258.
McDonald P.P., Fadok V.A., Bratton D., Henson P.M. (1999) Transcriptional and translational
regulation of inflammatory mediator production by endogenous TGP-beta in macrophages that have
ingested apoptotic cells. J.Immunol. 163:6164-72.
McKay I.A., Leigh I.M. (1991) Epidermal cytokines and their roles in cutaneous wound-healing.
Brit.J.Dermatol. 124:513-8.
McKeating J.A., Shotton C., Cordell J., Graham S., Balfe P., Sullivan N., Charles M., Page M.,
Bolmstedt A., Olofsson S., et al. (1993) Characterization of neutralizing monoclonal-antibodies to
linear and conformation-dependent epitopes within the 1st and 2nd variable domains of human-
immunodeficiency-virustype-1 gpl20. J.Virol. 67:4932-44.
McKnight A., Wilkinson D., Simmons G., Talbot S., Picard L., Ahuja M., Marsh M., Hoxie J.A.,
Clapham P.R. (1997) Inhibition of human immunodeficiency virus fusion by a monoclonal antibody
to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 71(2): 1692-6.
McShan W.M., Rossen R.D., Laughter A.H., Trial J., Kessler D.J., Zendegui J.G., Hogan M.E.,
Orson F.M. (1992) Inhibition of transcription of HIV-1 in infected human-cells by
oligodeoxynucleotides designed to form DNA triple helices. J.Biol.Chem. 267:5712-21.
Medzhitov R., Janeway C.A. (1997) Innate immunity: impact on the adaptive immune response.
Current Opinion In Immunology 9(4):9.
Melamed D., Friedman A. (1993) Direct evidence for anergy in T-lymphocytes tolerized by oral-
administration of ovalbumin. Euro.J.Immunol. 23:935-42.
MeliefC.J.M., Goudsmit J. (1986) Transmission of lymphotropic retroviruses (HTLV-1 and
LAV/HTLV-III) by blood-transfusion and blood products. Vox Sanguinis 50:1-11.
Mellado M., RodriguezFrade J.M., VilaCoro A.J., DeAna A.M., Martinez C. (1999) Chemokine
control of HIV-1 infection. Nature 400:723-4.
Mellman I.S. (1982) Endocytosis, membrane recycling and Fc receptor function. Ciba Found.Symp.
92:35-51.
Mellor A.L., Munn D.H. (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by
starvation? Immunol. Today 20:469-73.
308
Mellor A.L., Munn D.H. (2000) Immunology at the maternal-fetal interface: Lessons for T cell
tolerance and suppression. Ann.Rev.Immunol. 18:367-91.
Menzo S., Sampaolesi R., Vicenzi E., Santagostino E., Liuzzi G., Chirianni A., Piazza M., Cohen
O.J., Bagnarelli P., Clementi M. (1998) Rare mutations in a domain crucial for V3-loop structure
prevail in replicating HIV from long-term non-progressors. AIDS 12:985-97.
Meshcheryakova D., Andreev S., Tarasova S., Sidorova M., Vafina M., Kornilaeva G., Karamov
E., Khaitov R. (1993) CD4-derived peptide and sulfated polysaccharides have similar mechanisms of
anti-HIV activity-based on electrostatic interactions with positively charged gpl20 fragments.
Molec.Immunol. 30:993-1001.
Metzler B., Wraith D.C. (1993) Inhibition of experimental autoimmune encephalomyelitis by
inhalation but not oral-administration of the encephalitogenic peptide - influence ofMHC binding-
affinity. Int.Immunol. 5:1159-65.
Meyaard L., Hovenkamp E., Keet I.P.M., Hooibrink B., DeJong I.H., Otto S.A., Miedema F.
(1996) Single-cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected
individuals - Decreased IFN-gamma in the presence of preserved IL-4 production. J. Immunol.
157:2712-8.
Meyaard L., Otto S.A., Jonker R.R., Mijnster M.J., Keet R.P.M., Miedema F. (1992)
Programmed death of T-cells in HIV-1 infection. Science 257:217-9.
Meyer L., Magierowska M., Hubert J.B., Mayaux M.J., Misrahi M., LeChenadec J., Debre P.,
Rouzioux C., Delfraissy J.F., Theodorou 1. (1999) CCR5 Delta 32 deletion and reduced risk of
toxoplasmosis in persons infected with human immunodeficiency virus type 1. J.Infect.Dis. 180:920-
4.
Michael N.L., Chang G., Darcy L.A., Ehrenberg P.K., Mariani R., Busch M.P., Birx D.L.,
Schwartz D.H. (1995a) Defective accessory genes in a human-immunodeficiency-virus type 1-
infected long-term survivor lacking recoverable virus. J. Virol. 69:4228-36.
Michael N.L., Chang G., Darcy L.A., Tseng C.J., Birx D.L., Sheppard H.W. (1995b) Functional-
characterization of human-immunodeficiency-virus type-1 nef genes in patients with divergent rates
of disease progression. J. Virol. 69:6758-69.
Michael N.L., Chang G., Louie L.G., Mascola J.R., Dondero D., Birx D.L., Sheppard H.W.
(1997) The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease
progression. Nat.Med. 3:338-40.
Michael N.L., Moore J.P. (1999) HIV-1 entry inhibitors: Evading the issue. Nat.Med. 5:740-2.
Michael N.L., Nelson J.A.E., Kewalramani V.N., Chang G., O'Brien S.J., Mascola J.R., Volsky
B., Louder M., White G.C., Litman D.R., et al. (1998) Exclusive and persistent use of the entry
coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5
Delta 32. J. Virol. 72:6040-7.
Miedema F., Meyaard L., Koot M., Klein M.R., Roos M.T.L., Groenink M., Fouchier R.A.M.,
VanTwout A.B., Tersmette M., Schellekens P.T.A., et al. (1994) Changing virus-host interactions
in the course of HIV-1 infection. Immunol.Rev. 140:35-72.
Miele L., Osborne B. (1999) Arbiter of differentiation and death: Notch signaling meets apoptosis.
J.Cell.Physiol. 181:393-409.
Miller C.J., Alexander N.J., Sutjipto S., Lackner A.A., Gettie A., Hendrickx A.G., Lowenstine
L.J., Jennings M., Marx P.A. (1989) Genital mucosal transmission of simian immunodeficiency
309
virus - animal-model for heterosexual transmission of human immunodeficiency virus. J. Virol.
63(10):4277-84.
Miller M.A., Cloyd M.W., Liebmann J., Rinaldo C.R., Islam K.R., Wang S.Z.S., Mietzner T.A.,
Montelaro R.C. (1993) Alterations in cell-membrane permeability by the lentivirus lytic peptide
(LLP-1) ofHIV-1 transmembrane protein. Virology 196:89-100.
Misrahi M., Teglas J.P., Ngo N., Burgard M., Mayaux M.J., Rouzioux C., Delfraissy J.F.,
Blanche S. (1998) CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and
disease progression in children. J.Am.Med.Assoc. 279:277-80.
Misse D., Cerutti M., Noraz N., Jourdan P., Favero J., Devauchelle G., Yssel H., Taylor N., Veas
F. (1999) A CD4-Independent interaction of human immunodeficiency virus-1 gpl20 with CXCR4
induces their cointernalization, cell signaling, and T-cell chemotaxis. Blood 93:2454-62.
Mitchell S., Harvey K., Fokin V.V., Petasis N.A., Godson C., Brady H.R. (1999) Lipoxins
stimulate macrophage phagocytosis of apoptotic neutrophils. FASEB J. 13:A557.
Mitsuya H., Jarrett R.F., Matsukura M., Veronese F.D., Devico A.L., Sarngadharan M.G.,
Johns D.G., Reitz M.S., Broder S. (1987) Long-term inhibition of human T-lymphotropic virus
type-111 lymphadenopathy-associated virus (human-immunodeficiency-virus) DNA-synthesis and
RNA expression in T-cells protected by 2',3'-dideoxynucleosides in vitro. Proc.Nat.Acad.Sci.USA
84:2033-7.
Mitsuya H., Weinhold K.J., Furman P.A., Stclair M.H., Lehrman S.N., Gallo R.C., Bolognesi D.,
Barry D.W., Broder S. (1985) 3'-Azido-3'-deoxythymidine (Bw a509u) - An antiviral agent that
inhibits the infectivity and cytopathic effect of human lymphotropic-T virus type-Ill
lymphadenopathy-associated virus in vitro. Proc.Nat.Acad.Sci.USA 82:7096-100.
Moffatt O.D., Devitt A., Bell E.D., Simmons D.L., Gregory C.D. (1999) Macrophage recognition of
ICAM-3 on apoptotic leukocytes. J.Immunol. 162:6800-10.
Mohan P.; Baba M. (1995) Anti-AIDS drug development: Challenges, strategies andprospects.
Chur, Switzerland: Harwood Academic; ISBN: 3-7186-5698-1.
Mollace V., Colasanti M., Rodino P., Lauro G.M., Nistico G. (1994) HIV coating gpl20
glycoprotein-dependent prostaglandin-!^ Release by human cultured astrocytoma-cells is regulated by
nitric-oxide formation. Biochem.Biophys. Res.Comm. 203:87-92.
Moller G. (1988) Do suppressor T-cells exist. Scan.J.Immunol. 27:247-50.
Montagnier L. (1995) Nef vaccination against HIV disease. Lancet 346:1170.
Montaner L.J., DaSilva R.P., Sun J.W., Sutterwala S., Hollinshead M., Vaux D., Gordon S.
(1999) Type 1 and type 2 cytokine regulation of macrophage endocytosis: Differential activation by
IL-4/IL-13 as opposed to IFN-gamma or IL-10. J.Immunol. 162:4606-13.
Montesano, R., Pepper, M.S., Maciag, T., Zimrin, A.B., Wong, M.K.K., (inventors). Montesano,
R., Pepper, M.S., Maciag, T., Zimrin, A.B., Wong, M.K.K., University of Geneva (CH), National
American Red Cross (US), (assignees). Therapeutic and diagnostic methods and compositions based
on Jagged/Notch proteins and nucleic acids. [Patent] WO;US. W09745143. 1997.
Moore J.P., Trkola A., Dragic T. (1997) Co-receptors for HIV-1 entry. Current Opinion In
Immunology 9:551-62.
310
Mori T., Gustafson K.R., Pannell L.K., Shoemaker R.H., Wu L., McMahon J.B., Boyd M.R.
(1998) Recombinant production of cyanovirin-N, a potent human immunodeficiency virus
inactivating protein derived from a cultured Cyanobacterium. Prot.Expres.Purif. 12:151-8.
Mori T., Shoemaker R.H., Gulakowski R.J., Krepps B.L., McMahon J.B., Gustafson K.R.,
Pannell L.K., Boyd M.R. (1997a) Analysis of sequence requirements for biological activity of
cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
Biochem.Biophys.Res.Comm. 238:218-22.
Mori T., Shoemaker R.H., McMahon J.B., Gulakowski R.J., Gustafson K.R., Boyd M.R. (1997b)
Construction and enhanced cytotoxicity of a [Cyanovirin-N]-[Pseudomonas exotoxin] conjugate
against human immunodeficiency virus-infected cells. Biochem.Biophys.Res.Comm. 239:884-8.
Morio T., Chatila T., Geha R.S. (1997) HIV glycoprotein gpl20 inhibits TCR-CD3-mediated
activation offyn and Ick. Int.Immunol. 9:53-64.
Morrow W.J.W., Wharton M., Lau D., Levy J.A. (1987) Small animals are not susceptible to
human immunodeficiency virus infection. J.General. Virol. 68:2253-7.
Morteau O. (1999) COX-2: promoting tolerance. Nat.Med. 5(8):867-8.
Mosier D., Sieburg H. (1994) Macrophage-tropic HIV - critical for AIDS pathogenesis.
Immunol.Today 15:332-9.
Mossmann T.R. (1973) Prostaglandins, asprin-like drugs and the oedoma of inflamation. Nature
246:217-8.
Moyle G.J. (2000) Fresh starting points for HIV's second century. Cur.Op.Infect.Dis. 13:1-3.
Mueller D.L., Jenkins M.K. (1995) Molecular mechanisms underlying functional T-cell
unresponsiveness. Current Opinion In Immunology 7:375-81.
Muesing M.A., Smith D.H., Cabradilla C.D., Benton C.V., Lasky L.A., Capon D.J. (1985)
Nucleic-acid structure and expression of the human AIDS lymphadenopathy retrovirus. Nature
313:450-8.
Mummidi S., Ahuja S.S., Gonzalez E., Anderson S.A., Santiago E.N., Stephan K.T., Craig F.E.,
O'Connell P., Tryon V., Clark R.A., et al. (1998) Genealogy of the CCR5 locus and chemokine
system gene variants associated with altered rates of HIV-1 disease progression. Nat.Med. 4:786-93.
Munro S., Freeman M. (2000) The Notch signalling regulator Fringe acts in the Golgi apparatus and
requires the glycosyltransferase signature motif DxD. Cur.Biol. 10:813-20.
Murakami T., Nakajima T., Koyanagi N., Tachibana K., Fujii N., Tamamura H., Yoshida N.,
Waki M., Matsumoto A., Yoshie O., et al. (1997) A small molecule CXCR4 inhibitor that blocks T
cell line-tropic HIV-1 infection. J.Exp.Med. 186:1389-93.
Murch S.H. (2000) Immunologic tolerance and dietary antigens - A review of: Newberry RD,
Stenson WF, Lorenz RG 1999 cyclooxygenase-2-dependent arachidonic acid metabolites are essential
modulators of the immune response to dietary antigen. Nature Med 5:900-906. Ped.Res. 47:430.
Murphy E.E., Terres G., Macatonia S.E., Hsieh C.S., Mattson J., Lanier L., Wysocka M.,
Trinchieri G., Murphy K., O'Garra A. (1994) B7 and interleukin-12 cooperate for proliferation and
interferon-gamma production by mouse T-helper clones that are unresponsive to B7 costimulation.
J.Exp.Med. 180:223-31.
311
Nasioulas G., Dean M., Koumbarelis E., Paraskevis D., Gialeraki A., Karafoulidou A.,
Mandalaki T., Hatzakis A. (1998) Allele frequency of the CCR5 mutant chemokine receptor in
Greek Caucasians. J.AIDS Hum.Retrovirol. 17:181-2.
Nehete P.N., Arlinghaus R.B., Sastry K.J. (1993) Inhibition of human-immunodeficiency-virus
type-1 infection and syncytium formation in human-cells by V3 loop synthetic peptides from gpl20.
J.Virol. 67(11 ):6841-6.
Newburry R.D., Stenson W.F., Lorenz R.G. (1999) Cyclooxygenase-2-dependent arachidonic acid
metabolites are essential modulators of the intestinal immune response to dietry antigen. Nat.Med.
5:900-6.
Ng T.C.C., Pinching A.J., Guntermann C., Morrow W.J.W. (1996) Molecular
immunopathogenesis ofHIV infection. Genitourinary Med. 72:408-18.
Nikiforuk A. (1992) The fourth horseman - a short history ofepidemics, plagues and other scourges.
London: Orion Books; ISBN: 1-85799-091-9.
Nisole S., Krust B., Callebaut C., Guichard G., Muller S., Briand J.P., Hovanessian A.G. (1999)
The anti-HIV pseudopeptide HE-19 forms a complex with the cell-surface-expressed nucleolin
independent of heparan sulfate proteoglycans J.Biol.Chem. 274:27875-84.
Nokta M.A., Hassan M.I., Loesch K., Pollard R.B. (1996) Human cytomegalovirus-induced
immunosuppression - relationship to tumor necrosis factor-dependent release of arachidonic acid and
prostaglandin E(2) in human monocytes. J.Clin.Invest. 97:2635-41.
Nye J.S., Kopan R. (1995) Developmental signaling - vertebrate Iigands for notch. Cur.Biol. 5:966-
9.
Nygard N.R., Klohe E., Giacoletto K., Gorka J., Schwartz B.D., Karr R.W. (1992) Identification
ofHLA class-II beta-chain residues significant for antigen peptide binding. Arth.Rheumat. 35:S 181.
O'Brien T.R., Winkler C., Dean M., Nelson J.A.E., Carrington M., Michael N.L., White G.C.
(1997) HIV-1 infection in a man homozygous for CCR5 Delta 32. Lancet 349:1219.
Oberg H.H., Lengl-Janssen B., Kabelitz D., Janssen O. (1997) Activation-induced T cell death:
Resistance or susceptibility correlate with cell surface Fas ligand expression and T helper phenotype.
Cell.Immunol. 181:93-100.
Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., ArenzanaSeisdedos F., Schwartz
O., Heard J.M., ClarkLewis I., Legler D.F., et al. (1996) The CXC chemokine SDF-1 is the ligand
for LESTR/fiisin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833-5.
Oda N., Minoguchi K., Tanaka A., Yokoe T., Adachi M. (2000) Induction of selective antigen-
specific Th2 cell anergy. J.Aller.Clin.Immunol. 105:326.
Odai H., Sasaki K., lwamatsu A., Nakamoto T., Ueno H., Yamagata T., Mitani K., Yazaki Y.,
Hirai H. (1997) Purification and molecular cloning of SH2- and SH3-containing inositol
polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage
colony-stimulating factor, erythropoietin, and Bcr-Abl. Blood 89:2745-56.
Oh S.K., Cruikshank W.W., Raina J., Blanchard G.C., Adler W.H., Walker J., Kornfeld H.
(1992) Identification ofHIV-1 envelope glycoprotein in the serum of AIDS and ARC patients.
J.AIDS Hum.Retrovirol. 5:251-6.
312
Ohishi K., VarnumFinney B., Flowers D., Anasetti C., Myerson D., Bernstein I.D. (2000)
Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following
interaction with the Notch ligand, Delta-1. Blood 95:2847-54.
Ojcius D.M., Niedergang F., Subtil A., Hellio R., DautryVarsat A. (1996) Immunology and the
confocal microscope. Res.Immunol. 147:175-88.
Olshevsky U., Helseth E., Furman C., Li J., Haseltine W., Sodroski J. (1990) Identification of
individual human-immunodeficiency-virus type-1 gpl20 amino-acids important for CD4 receptor-
binding. J.Virol. 64:5701-7.
Operskalski E.A., Mosley J.W. (1986) Risk of HTLV III/LAV transmission to household contacts.
New.Eng.J.Med. 315:257.
Ordentlich P., Lin A., Shen C.P., Blaumueller C., Matsuno K., ArtavanisTsakonas S., Kadesch
T. (1998) Notch inhibition of E47 supports the existence of a novel signaling pathway.
Molec.Cell.Biol. 18:2230-9.
Osborne B., Miele L. (1999) Notch and the immune system. Immunity 11:653-63.
Oswald F., Liptay S., Adler G., Schmid R.M. (1998) NF-kappa B2 is a putative target gene of
activated Notch-1 via RBP-J kappa. Molec.Cell.Biol. 18:2077-88.
Pala P., Verhoef A., Lamb J.R., Openshaw P.J.M. (2000) Single cell analysis of cytokine
expression kinetics by human CD4+ T-cell clones during activation or tolerance induction.
Immunology 100:209-16.
Palacios E., Digilio L., McClure H.M., Chen Z.W., Marx P.A., Goldsmith M.A., Grant R.M.
(1998) Parallel evolution ofCCR5-null phenotypes in humans and in a natural host of simian
immunodeficiency virus. Cur.Biol. 8:943-6.
Palliser D., Lowrey J.A., Lamb J.R., Hoyne G.F. (1998) T-cell response to inhaled antigen.
Chem. Immunol. 71:161-77.
Palucka K.A., Taquet N., SanchezChapuis F., Gluckman J.C. (1998) Dendritic cells as the
terminal stage ofmonocyte differentiation. J. Immunol. 160:4587-95.
Pan D.J., Rubin G.M. (1997) Kuzbanian controls proteolytic processing ofNotch and mediates
lateral inhibition during Drosophila and vertebrate neurogenesis. Cell 90:271-80.
Panin V.M., Papayannopoulos V., Wilson R., Irvine K.D. (1997) Fringe modulates notch ligand
interactions. Nature 387:908-12.
Paradisi R., Mancini R., Bellavia E., Beltrandi E., Pession A., Venturoli S., Flamigni C. (1997)
T-helper 2 type cytokine and soluable interleukin-2 receptor levels in seminal plasma of fertile men.
Am.J.Repro.Immunol. 38:94-9.
Parfitt K. (1999) Martindale: The complete drug reference (3e). 3 ed. London: Parmaceutical Press;
ISBN: 0-85369-429-X.
Park I.W., Koziel H., Hatch W., Li X.H., Du B., Groopman J.E. (1999) CD4 receptor-dependent
entry of human immunodeficiency virus type-1 env-pseudotypes into CCR5-, CCR3-, and CXCR4-
expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor.
Am.J.Resp.Cell Molec.Biol. 20:864-71.
313
Paroush Z., Finley R.L., Kidd T., Wainwright S.M., Ingham P.W., Brent R., IshHorowicz D.
(1994) Groucho is required for Drosophila neurogenesis, segmentation, and sex determination and
interacts directly with hairy-related bHLH proteins. Cell 79:805-15.
Passos G.A.S., Picanco V.P. (1998) Frequency of the Delta ccr5 deletion allele in the urban Brazilian
population. Immunol.Lett. 61:205-7.
Paxton W.A., Kang S., Koup R.A. (1998) The HIV type 1 coreceptor CCR5 and its role in viral
transmission and disease progression. AIDS Res. Hum.Retrovir. 14:S89-S92.
Paxton W.A., Kang S., Liu R., Landau N.R., Gingeras T.R., Wu L.J., MacKay C.R., Koup R.A.
(1999) HIV-1 infectability ofCD4(+) lymphocytes with relation to beta-chemokines and the CCR5
coreceptor. Immunol.Lett. 66:71-5.
Paxton W.A., Martin S.R., Tse D., O'Brien T.R., Skurnick J., VanDevanter N.L., Padian N.,
Braun J.F., Kotler D.P., Wolinsky S.M., et al. (1996) Relative resistance to HIV-1 infection ofCD4
lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures.
Nat.Med. 2:412-7.
PedrazaAIva G., Merida L.B., Burakoff S.J., Rosenstein Y. (1998) T cell activation through the
CD43 molecule leads to Vav tyrosine phosphorylation and mitogen-activated protein kinase pathway
activation. J.Biol.Chem. 273:14218-24.
PelchenMatthews A., Armes J.E., Griffith G., Marsh M. (1991) Differential endocytosis ofCD4 in
lymphocytic and nonlymphocytic cells. J.Exp.Med. 173(3):575-87.
PelchenMatthews A., Boulet I., Littman D.R., Fagard R., Marsh M. (1992) The protein tyrosine
kinase p561ck inhibits CD4 endocytosis by preventing entry ofCD4 into coated pits. J.Cell Biol.
117(2):279-90.
Pennisi E. (1996) Teetering on the brink of danger. Science 271:1665-7.
Pereira F.B., Goni F.M., Muga A., Nieva J.L. (1997) Permeabilization and fusion of uncharged
lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: Dose and
sequence effects. Biophys.J. 73:1977-86.
Perno C.F., Baseler M.W., Broder S., Yarchoan R. (1990) Infection ofmonocytes by human-
imntunodeficiency-virus type-1 blocked by inhibitors of CD4-gpl20 binding, even in the presence of
enhancing antibodies. J.Exp.Med. 171:1043-56.
Persaud D., Pierson T., Ruff C., Finzi D., Chadwick K.R., Margolick J.B., Ruff A., Hutton N.,
Ray S., Siliciano R.F. (2000) A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in
infected children. J.Clin.Invest. 105:995-1003.
Peter F. (1998) HIV nef: The mother of all evil? Immunity 9:433-7.
Peterson D.A., Kanagawa O., Unanue E.R. (1999) T cells specific for self-peptides that are not
tolerized by presentation of self antigen. FASEB J. 13:A625.
Philipson L.H., Lorincz A.L. (1986) Risk ofHTLV III/LAV transmission to household contacts.
New.Eng.J.Med. 315:257-8.
Philpott S., Burger H., Charbonneau T., Grimson R., Vermund S.H., Visosky A., Nachman S.,
Kovacs A., Tropper P., Frey H., et til. (1999) CCR5 genotype and resistance to vertical
transmission ofHIV-1. J.AIDS Hum. Retrovirol. 21:189-93.
314
Phoolcharoen W. (1998) HIV/AIDS prevention in Thailand: Success and challenges. Science
280:1873-4.
Piccinni M.P., Romagnani S. (2000) Role of hormone-controlled T-cell cytokines in the maintenance
of pregnancy. Biochem.Soc. Trans. 28(2):212-5.
Pietropaolo M., Olson C.D., Reiseter B.S., Kasaian M.T., Happ M.P. (2000) Intratracheal
administration to the lung enhances therapeutic benefit of an MBP peptide in the treatment ofmurine
experimental autoimmune encephalomyelitis. Clin.Immunol. 95:104-16.
Plummer F.A., Ball T.B., Kimani J., Fowke K.R. (1999) Resistance to H1V-1 infection among
highly exposed sex workers in Nairobi: what mediates protection and why does it develop?
Immunol.Lett. 66:27-34.
Poli G., Fauci A.S. (1993) Cytokine modulation and HIV expression. Semin. Immunol. 5 (3): 165-73.
Polo S., Veglia F., Malnati M.S., Gobbi C., Farci P., Raiteri R., Sinicco A., Lusso P. (1999)
Longitudinal analysis of serum chemokine levels in the course ofHIV-1 infection. AIDS 13:447-54.
Pope M., Ho D.D., Moore J.P., Weber J., Dittmar M.T., Weiss R.A. (1997) Different subtypes of
HIV-1 and cutaneous dendritic cells. Science 278:786-7.
Pourquie O. (1999) Notch around the clock. Cur.Op.Gen.Dev 9:559-65.
Powrie F. (1999) Regulatory T cells in the control of inflammatory bowel disease. Immunology
98(S1):7-.
Powrie F., Carlino J., Leach M.W., Mauze S., Coffman R.L. (1996) A critical role for transforming
growth factor-beta but not interleukin 4 iri the suppression of T helper type 1-mediated colitis by
CD45RB(low) CD4(+)T cells. J.Exp.Med. 183:2669-74.
Pratten M.K., Lloyd J.B. (1986) Pinocytosis and phagocytosis - the effect of size of a particulate
substrate on its mode of capture by rat peritoneal-macrophages cultured in vitro. Biochimica Et
Biophysica Acta 881:307-13.
Premkumar D.R.D., Ma X.Z., Maitra R.K., Chakrabarti B.K., Salkowitz J., YenLieberman B.,
Hirsch M.S., Kestier H.W. (1996) The nef gene from a long-term HIV type 1 nonprogressor. AIDS
Res.Hum.Retrovir. 12:337-45.
Preston B.D., Poiesz B.J., Loeb L.A. (1988) Fidelity of HIV-1 reverse-transcriptase. Science
242:1168-71.
Price D.A., Goulder P.J.R., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., Bangham
C.R.M., Phillips R.E. (1997) Positive selection ofHIV-1 cytotoxic T lymphocyte escape variants
during primary infection. Proc.Nat.Acad.Sci.USA 94:1890-5.
Prohaszka Z., Nemes J., Hidvegi T., Toth F.D., Kerekes K., Erdei A., Szabo J., Ujhelyi E.,
Thielens N., Dierich M.P., et al. (1997) Two parallel routes of the complement-mediated antibody-
dependent enhancement of HIV-1 infection. AIDS 11:949-58.
Prudhomme G.J., Piccirillo C.A. (2000) The inhibitory effects of transforming growth factor-beta-1
(TGF-beta 1) in autoimmune diseases. J.Autoimmun. 14:23-42.
Pui J.C., Allman D., Xu L.W., DeRocco S., Karnell F.G., Bakkour S., Lee J.Y., Kadesch T.,
Hardy R.R., Aster J.C., et al. (1999) Notch 1 expression in early lymphopoiesis influences B versus
T lineage determination. Immunity 11:299-308.
315
Punt J.A., Havran W., Abe R., Sarin A., Singer A. (1997) T cell receptor (TCR)-induced death of
immature CD4(+)CD8(+) thymocytes by two distinct mechanisms differing in their requirement for
CD28 costimulation: Implications for negative selection in the thymus. J.Exp.Med. 186:1911-22.
Purcell C.A., Frankel S.S., Nelson A.M., Tavassoli F.A. (1996) Dendritic (Langerhans) cells of the
human vaginal mucosa. Lab.Invest. 74:763.
Qin S.X., Cobbold S.P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. (1993)
Infectious transplantation tolerance. Science 259:974-7.
Quillent C., Oberlin E., Braun J., Rousset D., GonzalezCanali G., Metais P., Montagnier L.,
Virelizier J.L., ArenzanaSeisdedos F., Beretta A. (1998) HIV-1-resistance phenotype conferred by
combination of two separate inherited mutations of CCR5 gene. Lancet 351:14-8.
Rabbi M.F., AlHarthi L., Roebuck K.A. (1997) TNF alpha cooperates with the protein kinase A
pathway to synergistically increase HIV-1 LTR transcription via downstream TRE-like cAMP
response elements. Virology 237:422-9.
Radtke F., Ferrero I., Wilson A., Lees R., Aguet M., MacDonald H.R. (2000) Notch 1 deficiency
dissociates the intrathymic development of dendritic cells and T cells. J.Exp.Med. 191(7): 1085-93.
Radtke F., Wilson A., Stark G., Bauer M., VanMeerwijk J., MacDonald H.R., Aguet M. (1999)
Deficient T cell fate specification in mice with an induced inactivation of Notch 1. Immunity 10:547-
58.
Ramage R., Green J., Muir T.W., Ogunjobi O.M., Love S., Shaw K. (1994) Synthetic, structural
and biological studies of the ubiquitin system - the total chemical synthesis of ubiquitin. Biochem.J.
299:151-8.
Ramsdell F., Seaman M.S., Miller R.E., Picha K.S., Kennedy M.K., Lynch D.H. (1994)
Differential ability of Thl And Th2 T-cells to express Fas ligand and to undergo activation-induced
cell. Int.Immunol. 6:1545-53.
Rana S., Besson G., Cook D.G., Rucker J., Smyth R.J., Yi Y.J., Turner J.D., Guo H.H., Du J.G.,
Peiper S.C., et a!. (1997) Role of CCR5 in infection of primary macrophages and lymphocytes by
macrophage-tropic strains of human immunodeficiency virus: Resistance to patient-derived and
prototype isolates resulting from the Delta ccr5 mutation. J. Virol. 71:3219-27.
Rao Z., Handford P., Mayhew M., Knott V., Brownlee G.G., Stuart D. (1995) The structure of a
Ca2+-binding epidermal growth factor-like domain - its role in protein-protein interactions. Cell
82:131-41.
Rappaport J., Cho Y.Y., Hendel H., Schwartz E.J., Schachter F., Zagury J.F. (1997) 32 bp CCR-
5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet 349:922-3.
Rasmussen S.J., Eckmann L., Quayle A.J., Shen L.. Zhang Y.X., Anderson D.J., Fierer J.,
Stephens R.S., Kagnoff M.F. (1997) Secretion of proinflammatory cytokines by epithelial cells in
response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis.
J.Clin.Invest. 99:77-87.
Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich B., Josephs S.F., Doran E.R., Rafalski
J.A., Whitehorn E.A., Baumeister K., et al. (1985) Complete nucleotide-sequence of the AIDS
virus, HTLV-III. Nature 313:277-84.
Rattis F.M., PeguetNavarro J., Staquet M.J., DezutterDambuyant C., Courtellemont P.,
Redziniak G., Schmitt D. (1996) Expression and function of B7-1 (CD80) and B7-2 (CD86) on
human epidermal Langerhans cells. Euro.J.Immunol. 26:449-53.
316
Rausch D.M., Lifson J.D., Padgett M.P., Chandrasekhar B., Lendvay J., Hwang K.M., Eiden
L.E. (1992) CD4 (81-92)-Based peptide derivatives - structural requirements for blockade of HIV-
infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro.
Biochem.Pharmacol. 43:1785-96.
Reinhold D., Wrenger S., Kahne T., Ansorge S. (1999) HIV-1 Tat: immunosuppression via TGF-
beta 1 induction. Immunol. Today 20:384.
Renno T., Hahne M., MacDonald H.R. (1995) Proliferation is a prerequisite for bacterial
superantigen-induced T-cell apoptosis in vivo. J.Exp.Med. 181:2283-7.
Restifo N.P. (2000) Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor
escape. Nat.Med. 6:493-5.
Rhee S.S., Marsh J.W. (1994) Human-immunodeficiency-virus type-1 nef-induced down-modulation
ofCD4 is due to rapid internalization and degradation of surface CD4. J. Virol. 68:5156-63.
Richards C.M., Shimeld C., Williams N.A., Hill T.J. (1998) Induction of mucosal immunity against
herpes simplex virus type 1 in the mouse protects against ocular infections and establishment of
latency. J.Infect.Dis. 177(6): 1451-7.
Ridge J.P., Fuchs E.J., Matzinger P. (1996) Neonatal tolerance revisited: Turning on newborn T
cells with dendritic cells. Science 271(1723): 1726.
Rigby W.F.C., Waugh M., Graziano R.F. (1990) Regulation of human monocyte HLA-DR and
CD4 antigen expression, and antigen presentation by 1, 25-dihydroxy vitamin-D3. Blood76:189-97.
Rizzardi G.P., Pantaleo G. (1999) Therapeutic perspectives in HIV-1 infection from recent advances
in HIV-1 pathogenesis: it is time to move on. J. Biol. Reg.And Homeostat.Agents 13:151-7.
Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A.,
Sodroski J. (1998) A conserved HIV gpl20 glycoprotein structure involved in chemokine receptor
binding. Science 280:1949-53.
Robbins J., Blondel B.J., Gallahan D., Callahan R. (1992) Mouse mammary-tumor gene-int-3 - a
member of the notch-gene family transforms mammary epithelial-cells. J. Virol. 66:2594-9.
Roberts M., Compels M., Pinching A.J., Knight S.C. (1994) Dendritic cells from HIV-1-infected
individuals show reduced capacity to stimulate autologous T-cell proliferation. Immunol.Lett. 43:39-
43.
Robey E. (1999) Regulation ofT cell fate by Notch. Ann.Rev.Immunol. 17:283-95.
Robey E., Chang D., Baldez P. (1998) Regulation ofT cell development by Notch. Dev.Biol.
198:160.
Robey E., Chang D., Itano A., Cado D., Alexander H., Lans D., Weinmaster G., Salmon P.
(1996) An activated form ofNotch influences the choice between CD4 and CD8 T cell lineages. Celt
87:483-92.
Robey E., Fowlkes B.J. (1998) The alpha beta versus gamma delta T-cell lineage choice. Current
Opinion In Immunology 10:181-7.
Robillard P.Y., Hulsey T.C., Perianin J., Janky E., Miri E.H., Papiernik E. (1994) Association of
pregnancy induced hypertension with duration of sexual cohabitation before conception. Lancet
344(973):975.
317
Rocha B., Grandien A., Freitas A.A. (1995) Anergy and exhaustion are independent mechanisms of
peripheral T-cell tolerance. J.Exp.Med. 181:993-1003.
Rochester C.L., Ackerman S.J., Zheng T., Elias J.A. (1996) Eosinophil-fibroblast interactions -
Granule major basic protein interacts with JL-1 and transforming growth factor-beta in the stimulation
of lung fibroblast IL-6-type cytokine production. J.Immunol. 156:4449-56.
Rodriguez G.E., Hard R.C. (1995) Immunopathogenesis of AIDS. Immunol.Allergy Clin.N.Am.
15:225-60.
Roebuck K.A., Saifuddin M. (1999) Regulation of HIV-1 transcription. Gene Expres. 8 :67-84.
Roger M. (1998) Influence of host genes on HIV-1 disease progression. FASEB J. 12:625-32.
Rohn J.L., Lauring A.S., Linenberger M.L., Overbaugh J. (1996) Transduction ofNotch2 in feline
leukemia virus-induced thymic lymphoma. J.Virol. 70:8071-80.
Rohrschneider L.R., Bourette R.P., Lioubin M.N., Algate P.A., Myles G.M., Carlberg K. (1997)
Growth and differentiation signals regulated by the M-CSF receptor. Molec.Repro.Dev. 46:96-103.
Romagnani S., DelPrete G., Manetti R., Ravina A., Annunziato F., DeCarli M., Mazzetti M.,
Piccinni M.P., Delios M.M., Parronchi P., et al. (1994a) Role of T(h)l/T(h)2 cytokines in HIV-
infection. Immunol.Rev. 140:73-92.
Romagnani S., Maggi E., DelPrete G. (1994b) HIV can induce a T(h)l To T(h)0 Shift, and
preferentially replicates in CD4(+) T-cell clones producing T(h)2-Type cytokines. Res.Immunol.
145:611-8.
Ross T.M., Bieniasz P.D., Cullen B.R. (1999) Role of chemokine receptors in HIV-1 infection and
pathogenesis. Advan.Vir.Res. 52:233-67.
Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., Santoro M.G. (2000) Anti¬
inflammatory cyclopentenone prostaglandins are direct inhibitors of 1 kappa B kinase. Nature
403(6765): 103-8.
Rottman J.B., Ganley K.P., Williams K., Wu L.J., MacKay C.R., Ringler D.J. (1997) Cellular
localization of the chemokine receptor CCR5 - Correlation to cellular targets ofHIV-1 infection.
Am.J.Pathol. 151:1341-51.
Rousseau C.M., Just J.J., Abrams E.J., Casabona J., Stein Z., King M.C. (1997) CCR5delta32 in
perinatal HIV-1 infection. J.AIDS Hum.Retrovirol. 16:239-42.
Rousseau M.C., Moreau J., Delmont J. (1999) Vaccination and HIV: a review of the literature.
Vaccine 18:825-31.
Rubartelli A., Poggi A., Sitia R., Zocchi M.R. (1999) HIV-1 Tat: immunosuppression via TGF-beta
1 induction - Reply to Reinhold et al. Immunol.Today 20:384-5.
Rusconi S., Santambrogio S., DiMarco A., Colombo M.C., Citterio P., Adorni F., Galli M. (1998)
Lack of in vitro anti-gpl60 antibody production is a correlate of nonprogression among HIV type 1-
infected individuals. AIDS Res.Hum.Retrovir. 14:1341-3.
Saah A.J., Hoover D.R., Weng S.G., Carrington M., Mellors J., Rinaldo C.R., Mann D., Apple
R., Phair J.P., Detels R., et al. (1998) Association ofHLA profiles with early plasma viral load,
CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS 12:2107-13.
318
Sabatier, J.M., Benjouad, A., Yahi, N., Fenouillet, E., Mabrouk, K., Gluckman, J.C.,
VanRietschoten, J., Rochat, H., (inventors). Armel SA (FR), (assignee). Multiple branch peptide
constructions for use against HIV. [Patent] GB;EP;WO. WO 95/07929. 1995.
Sabatier J.M., Vives E., Mabrouk K., Benjouad A., Rochat H., Duval A., Hue B., Bahraoui E.
(1991) Evidence for neurotoxic activity of Tat from human-immunodeficiency-virus type-1. J. Virol.
65:961-7.
SaintAndreMarchal I., Martin J.P., Kirn A., Magnol J.P., DezutterDambuyant C., Schmitt D.,
Marchai T. (1998) Feline Langerhans cells migrate from skin and vaginal mucosa to regional lymph
nodes during experimental contact sensitization with fluorescein isothiocyanate. Vet.Dermatol. 9:9-
17.
Sakaguchi S., Toda M., Asano M., Itoh M., Morse S.S., Sakaguchi N. (1996) T cell-mediated
maintenance of natural self-tolerance: Its breakdown as a possible cause of various autoimmune
diseases. J.Autoimmun. 9:211-20.
Sakihama T., Smolyar A., Reinherz E.L. (1995) Oligomerization ofCD4 is required for stable
binding to class-II major histocompatibility complex proteins but not for interaction with human-
immunodeficiency-virus gpl20. Proc.Nat.Acad.Sci.USA 92 :6444-8.
SalasAlanis J.C., Mellerio J.E., Ashton G.H.S., McGrath J.A. (1999) Frequency of the CCR5 gene
32-basepair deletion in Hispanic Mexicans. Clin.Exp.Dermatol. 24:127-9.
Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S.,
Lapoumeroulie C., Cognaux J., Forceille C., et al. (1996) Resistance to HIV-1 infection in
Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature
382:722-5.
Sanders S.P., Connolly K.R., Porter J.D., Proud D. (1999) Nitric oxide inhibits rhinovirus-induced
GM-CSF production in a human bronchial epithelial cell line. Am.J.Resp.Crit.Care Med. 159:A437.
Saparov A., Wagner F.H., Zheng R., Oliver J.R., Maeda H., Hockett R.D., Weaver C.T. (1999)
Interleukin-2 expression by a subpopulation of primary T cells is linked to enhanced memory/effector
function. Immunity 11:271 -80.
Sarin P.S., Agrawal S., Civeira M.P., Goodchild J., Ikeuchi T., Zamecnik P.C. (1988) Inhibition
of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates.
Proc.Nat.Acad.Sci. USA 85:7448-51.
Sasaki T., Horiuchi S., Yamazaki M., Yui S. (1999) Induction ofGM-CSF production of
macrophages by advanced glycation end products of the Maillard reaction.
Biosci.Biotechnol.Biochem. 63:2011-3.
Savill J., Hogg N., Ren Y., Haslett C. (1996) Croquemort, a novel Drosophilia
hemocyte/macrophage receptor that recognizes apoptotic cells (vol 90. pg 1513, 1992). Immunity
5:U8.
Schattner A., Ragerzisman B. (1990) Virus-induced autoimmunity. Rev.Infect.Dis 12:204-22.
Schinkel J., Langendam M.W., Coutinho R.A., Krol A., Brouwer M., Schuitemaker J. (1999) No
evidence for an effect of the CCR5 Delta 32/+ and CCR2b 64I/+ mutations on human
immunodeficiency virus (HIV)-l disease progression among HIV-1-infected injecting drug users.
J. Infect. Dis. 179:825-31.
319
Schrier R.D., Gnann J.W., Landes R., Lockshin C., Richman D., Maccabe J.A., Kennedy C.,
Oldstone Nelson J.A. (1989) T-cell recognition ofHIV synthetic peptides in a natural
infection. J.Immunol. 142:1166-76.
Schroeder T., Just U. (2000) Notch signalling via RBP-J promotes myeloid differentiation. EMBO
J. 19(1 1):2558-68.
Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., Degoede R.E.Y., VanSteenwijk R.P.,
Lange J.M.A., Schattenkerk J.K.M.E., Miedema F., Tersmette M. (1992) Biological phenotype of
human-immunodeficiency-virus type-1 clones at different stages of infection - progression of disease
is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66:1354-60.
Schwartz O., Marechal V., LeGall S., Lemonnier F., Heard J.M. (1996) Endocytosis ofmajor
histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat.Med. 2:338-
42.
Schweisguth F. (2000) Fonctions et regulation de 1'activite de signalisation du recepteur Notch
(French language - "Function and regulation ofNotch receptor signalling activity"). Medecine
Sciences 16:186-91.
Scully C., Porter S. (2000) HIV topic update: oro-genital transmission of HIV. Oral.Dis. 6:92-8.
ShapiraNahor O., Golding H., Vujcic L.K., Restoruiz S., Fields R.L., Robey F.A. (1990) CD4-
derived synthetic peptide blocks the binding ofHIV-1 gpl20 to CD4-bearing cells and prevents HIV-
1 infection. Cell.Immunol. 128:101-17.
Shevach E. (2000) Regulatory T cells in autoimmunity. Ann.Rev.Immunol. 18:423-49.
Shimizu K., Chiba S., Kumano K., Hosoya N., Takahashi T., Kanda Y., Hamada Y., Yazaki Y.,
Hirai H. (1999) Mouse Jagged 1 physically interacts with Notch 2 and other Notch receptors -
Assessment by quantitative methods. J.Biol.Chem. 274:32961-9.
Shimojo N., Anderson R.W., Mattson D.H., Turner R.V., Coligan J.E., Biddison W.E. (1990)
The kinetics of peptide binding to HLA-A2 and the conformation of the peptide A2 complex can be
determined by amino-acid side-chains on the floor of the peptide binding groove. Int.Immunol. 2:193-
200.
Shimoya K., Matsuzaki N., Tsutui T., Taniguchi T., Saji F., Tanizawa O. (1993) Detection of
interleukin-8 (IL-8) in seminal plasma and elevated IL-8 in seminal plasma of infertile patients with
leukospermia. Fertil.Steril. 59(885):888.
Shotton C., Arnold C., Sattentau Q., Sodroski J., McKeating J.A. (1995) Identification and
characterization ofmonoclonal-antibodies specific for polymorphic antigenic determinants within the
V2 region of the human-immunodeficiency-virus type-1 envelope glycoprotein. J. Virol. 69:222-30.
Simmons G., Reeves J.D., McKnight A., Dejucq N., Hibbitts S., Power C.A., Aarons E., Schols
D., De Clercq E., Proundfoot A.E., Clapham P.R (1998) CXCR4 as a functional coreceptor for
human immunodeficiency virus type 1 infection of primary macrophages. J.Virol. 72(10):8453-7.
Simon F., Mauclere P., Roques P., LoussertAjaka I., Muller-Trutwin M.C., Saragosti S.,
GeorgesCourbot M.C., BarreSinoussi F., BrunVezinet F. (1998) Identification of a new human
immunodeficiency virus type 1 distinct from group M and group O. Nat.Med. 4:1032-7.
Skeyne G. (1969) Ane breve description ofthe peste (the English experience). Amsterdam: Walter
Johnson; ISBN: not assigned.
320
Smith G.H., Gallahan D., Diella F., Jhappan C., Merlino G., Callahan R. (1995) Constitutive
expression of a truncated int3 gene in mouse mammary epithelium impairs differentiation and
functional-development. Cell Growth Differential. 6:563-77.
Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., Goedert J.J.,
O'Brien T.R., Jacobson L.P., Kaslow R., et al. (1997) Contrasting genetic influence of CCR2 and
CCR5 variants on HIV-1 infection and disease progression. Science 277:959-65.
Soares M., Finn O.J. (1998) Phenotypic versus functional maturation of in vitro derived human
dendritic cells. Can.Res.Therap.Cont. 5:77-85.
SotoRamirez L.E., Renjifo B., McLane M.F., Marlink R., O'Hara C., Sutthent R., Wasi C.,
Vithayasai P., Vithayasai V., Apichartpiyakul C., et al (1996) HIV-1 Langerhans' cell tropism
associated with heterosexual transmission ofHIV. Science 271:1291-3.
Spana E.P., Doe C.Q. (1996) Numb antagonizes notch signaling to specify sibling neuron cell fates.
Neuron 17:21-6.
Spicer L.D., DeLorimier R., Staats H.F., Haynes B.F. (1999) Modification of anti-HIV antibody
response and peptide solution conformations by point substitutions in chimeric GP120 C4-V3
immunogenic peptides. Abst.Paper.Am. Chem.Soc 218:286-.
Spira A.I., Marx P.A., Patterson B.K., Mahoney J., Koup R.A., Wolinsky S.M., Ho D.D. (1996)
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian
immunodeficiency virus into rhesus macaques. J.Exp.Med. 183:215-25.
Spoelstra F.M., Postma D.S., Hovenga H., Noordhoek J.A., Kauffman H.F. (1999) Budesonide
and formoterol exert an additive effect on the inhibition of ICAM-1 and VCAM-1 upregulation and
GM-CSF production of human lung fibroblasts. Am.J.Resp.Crit.Care Med. 159:A197.
Sprent J., Webb S.R. (1995) Intrathymic and extrathymic clonal deletion of T-cells. Current
Opinion In Immunology 7:196-205.
Stallmach A., Strober W., MacDonald T.T., Lochs H., Zeitz M. (1998) Induction and modulation
of gastrointestinal inflammation. Immunol.Today 19:438-41.
Stamatatos L., ZollaPazner S., Gorny M.K., ChengMayer C. (1997) Binding of antibodies to
virion-associated gpl20 molecules of primary-like human immunodeficiency virus type 1 (HIV-1)
isolates: Effect on HIV-1 infection ofmacrophages and peripheral blood mononuclear cells. Virology
229:360-9.
Steinbach F., Krause B., Blass S., Burmester G.R., Hiepe F. (1998) Development of accessory
phenotype and function during the differentiation of monocyte-derived dendritic cells. Res.Immunol.
149(7-8):627-32.
Steinman R.M. (2000) DC-SIGN: A guide to some mysteries of dendritic cells. Cell 100:491-4.
Stent G., Crowe S.M. (1997a) Effects of HIV-1 on the surface expression of LFA-1 on cultured
monocytes. J.AIDS Hum.Retrovirol. 15:95-103.
Stent G., Joe G.B., Kierulf P., Asjo B. (1997b) Macrophage tropism: Fact or fiction? J.Leuk.Biol.
62:4-11.
Stephens J.C., Reich D.E., Goldstein D.B., Shin H.D., Smith M.W., Carrington M., Winkler C.,
Huttley G.A., Ailikmets R., Schriml L., et al. (1998) Dating the origin of the CCR5-Delta 32 A1DS-
resistance allele by the coalescence of haplotypes. Am.J.Hum.Gen. 62:1507-15.
321
Stern M., Savill J., Haslett C. (1992) Vitronectin receptor mediates macrophage phagocytosis of
apoptotic eosinophils. Thorax 47:240.
Stevenson M., Haggerty S., Lamonica C.A., Meier C.M., Welch S.K., Wasiak A.J. (1990)
Integration is not necessary for expression of human-immunodeficiency-virus type-1 protein products.
J.Virol. 64(5):2421-5.
Stoiber H., Frank I., Spruth M., Schwendinger M., Mullauer B., Windisch J.M., Schneider R.,
Katinger H., Ando I., Dierich M.P. (1997) Inhibition ofHIV-1 infection in vitro by monoclonal
antibodies to the complement receptor type 3 (CR3): An accessory role for CR3 during virus entry?
Molec.Immunol. 34:855-63.
Stoll G., Trapp B.D., Griffin J.W. (1989) Macrophage function during wallerian degeneration of rat
optic-nerve - clearance of degenerating myelin and IA expression. J.Neurosci. 9:2327-35.
Strasser A., Whittingham S., Vaux D.L., Bath M.L., Adams J.D., Cory S., Harris A.W. (1991)
Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune
disease. Proc.Nat.Acad.Sci.USA 88:8661-5.
Streilein J.W., Grammer S.F., Yoshikawa T., Demidem A., Vermeer M. (1990) Functional
dichotomy between langerhans cells that present antigen to naive and to memory effector
lymphocytes-T. Immunol.Rev. 117:159-83.
Strieker K., Knipping E., Bohler T., Benner A., Krammer P.H., Debatin K.M. (1998) Anti-CD95
(APO-l/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-
infected children. Cell.Death.Differ. 5(3):222-30.
Strobel S., Mowat A.M. (1998) Immune responses to dietary antigens: oral tolerance.
Immunol.Today 19:173-81.
Strobl L.J., Hofelmayr H., Stein C., Marschall G., Brielmeier M., Laux G., Bornkamm G.W.,
ZimberStrobl U. (1997) Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notchl
transactivate genes by interacting with the cellular protein RBP-Jk. Immunobiotogy 198:299-306.
Strunk D., Rappersberger K., Egger C., Strobl H., Kromer E., Elbe A., Maurer D., Stingl G.
(1996) Generation of human dendritic cells Langerhans cells from circulating CD34(+) hematopoietic
progenitor cells. Blood 87:1292-302.
Stuart P.M., Griffith T.S., Usui N., Pepose J., Yu X.H., Ferguson T.A. (1997) CD95 ligand
(FasL)-induced apoptosis is necessary for corneal allograft survival. J.Clin.Invest. 99:396-402.
Su B., Jin L., Hu F., Xiao J.H., Luo J.C., Lu D.R., Zhang W.L., Chu J.Y., Du R.F., Geng Z.C., et
al. (1999) Distribution of two HIV-1-resistant polymorphisms (SDFl-3'A and CCR2-641) in east
Asian and world populations and its implication in AIDS epidemiology. Am.J.Hum.Gen. 65:1047-53.
Suda T., Nagata S. (1997) Why do defects in the Fas-Fas ligand system cause autoimmunity?
J.Aller.Clin.Immunol. 100:S97-S101.
Sun Y., Pinchuk L.M., Agy M.B., Clark E.A. (1997) Nuclear import of HIV-1 DNA in resting
CD4(+) T cells requires a cyclosporin A-sensitive pathway. J.Immunol. 158:512-7.
Suzuki H., Punt J.A., Granger L.G., Singer A. (1995) Asymmetric signaling requirements for
thymocyte commitment to the CD4(+) versus CD8(+) T-cell lineages - a new perspective on thymic
commitment and selection. Immunity 2:413-25.
Suzuki Y., Koyanagi Y., Tanaka Y., Murakami T., Misawa N., Maeda N., Kimura T., Shida H.,
Hoxie J.A., O'Brien W.A., et al. (1999) Determinant in human immunodeficiency virus type 1 for
322
efficient replication under cytokine-induced CD4+ T-helper 1 (Thl)- and Th2-type conditions.
J. Virol. 73(1 ):316-24.
Swiatek P.J., Lindsell C.E., Delamo F.F., Weinmaster G., Gridley T. (1994) Notchl is essentia!
for postimplantation development in mice. Gene.Dev. 8:707-19.
Szalai C., Csaszar A., Czinner A., Szabo T., Panczel P., Madacsy L., Falus A. (1999) Chemokine
receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus.
Ped.Res. 46:82-4.
Szalai C., Csaszar A., Czinner A., Szabo T., Falus A. (1998) High frequency of the CCR5 deletion
allele in Gypsies living in Hungary. Immunol.Lett. 63:57-8.
Szalay F.S.; Delson E. (1979) Evolutionary history ofthe primates. London: Academic Press; ISBN:
0-12680150-9.
Takahama Y., Tokoro Y., Sugawara T., Negishi I., Nakauchi H. (1997) Pertussis toxin can replace
T cell receptor signals that induce positive selection ofCD8 T cells. Euro.J.Immunol. 27:3318-31.
Tamma S.M.L., Chirmule N., Yagura H., Oyaizu N., Kalyanaraman V., Pahwa S. (1997) CD4
cross-linking (CD4XL) induces RAS activation and tumor necrosis factor-alpha secretion in CD4(+)
T cells. Blood90:1588-93.
Tamura K., Taniguchi Y., Minoguchi S., Sakai T., Tun T., Furukawa T., Honjo T. (1995)
Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J
kappa/Su(H). Cur.Biol. 5:1416-23.
Taoufik Y., Lantz O., Wallon C., Charles A., Dussaix E., Delfraissy J.F. (1997) Human
immunodeficiency virus gpl20 inhibits interleukin-12 secretion by human monocytes: an indirect
interleukin-10-mediated effect. Blood 89(8):2842-8.
Tassinari P., Deibis L., Blanca I., Bianco N.E., Deperez G.E. (1995) Decreased T-cell proliferative
response to common environmental antigens could be an indicator of early human immunodeficiency
virus-mediated lymphocyte lesions. Clin.Diag.Lab.Immunol. 2:404-7.
Tax F.E., Yeargers J.J., Thomas J.H. (1994) Sequence of C. elegans lag-2 reveals a cell-signaling
domain shared with delta and serrate ofDrosophila. Nature 368:150-4.
Terada N., Hamano N., Maesako K.I., Hiruma K., Hohki G., Suzuki K., Ishikawa K., Konno A.
(1999) Diesel exhaust particulates upregulate histamine receptor mRNA and increase histamine-
induced IL-8 and GM-CSF production in nasal epithelial cells and endothelial cells. Clin.Exp.Allergy
29:52-9.
Thali M., Olshevsky U., Furman C., Gabuzda D., Posner M., Sodroski J. (1991) Characterization
of a discontinuous human-immunodeficiency-virus type-1 gpl20 epitope recognized by a broadly
reactive neutralizing human monoclonal-antibody. J. Virol. 65:6188-93.
The International Working Group on Vaginal Microbicides. (1996) Recomendations for the
development of vaginal microbicides. AIDS 10:UNA1DS Sl-UNAIDS S6.
Theodore A.C., Center D.M., Nicoll J., Fine G., Kornfeld H., Cruikshank W.W. (1996) CD4
ligand 1L-16 inhibits the mixed lymphocyte reaction. J.Immunol. 157:1958-64.
Theodore A.C., Kornfeld H., Wallace R.P., Cruikshank W.W. (1994) CD4 modulation of
noninfected human T-lymphocytes by HIV-1 envelope glycoprotein gpl20 - contribution to the
immunosuppression seen in HIV-1 infection by induction ofCD4 and CD3 unresponsiveness. J.AIDS
Hum.Retrovirol. 7:899-907.
323
Theodorou I., Meyer L., Magierowska M., Katlama C., Rouzioux C. (1997) HIV-1 infection in an
individual homozygous forCCR5 Delta 32. Lancet 349:1219-20.
Thepen T., VanRooijen N., Kraal G. (1989) Alveolar macrophage elimination in vivo is associated
with an increase in pulmonary immune-response in mice. J.Exp.Med. 170:499-509.
Thornton A.M., Buller R.M.L., Devico A.L., Wang I.M., Ozato K. (1996) Inhibition of human
immunodeficiency virus type 1 and vaccinia virus infection by a dominant negative factor of the
interferon regulatory factor family expressed in monocytic cells. Proc.Nat.Acad.Sci. USA 93:383-7.
Tiegs S.L., Evavold B.D., Yokoyama A., Stec S., Quintans J., Rowley D. (1990) Delayed antigen
presentation by epidermal langerhans cells to cloned Thl and Th2 cells. J.Invest.Dermatol. 95:446-9.
Tietze K., Oellers N., Knust E. (1992) Enhancer of split(D), a dominant mutation ofDrosophila, and
its use in the study of functional domains of a helix loop helix protein. Proc.Nat.Acad.Sci. USA
89:6152-6.
Till J.E., McCulloch E.A. (1961) A direct measurement of the radiation sensitivity of normal mouse
bone marrow cells. Radiat.Res. 14:213-22.
Tomaso H., Reisinger E.C., Grasmug E., Ramschak II., Krejs G.J. (1995) Transmission ofHIV.
Wiener Klinische Wochenschrift 107:85-90.
Tomiyama H., Miwa K., Shiga H., Moore Y.I., Oka S., Iwamoto A., Kaneko Y., Takiguchi M.
(1997) Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501
molecules that are associated with the accelerated progression of AIDS. J.Immunol. 158:5026-34.
Torres M., Forman H.J. (1999) Activation of several MAP kinases upon stimulation of rat alveolar
macrophages: Role of the NADPH oxidase. Arch.Biochem.Biophys. 366:231-9.
Toth F.D., Mosborg-Petersen P., Kiss J., Aboagyemathiesen G., Zdravkovic M., Hager H.,
Aranyosi J., Lampe L., Ebbesen P. (1994) Antibody-dependent enhancement ofHIV-1 infection in
human term syncytiotrophoblast cells cultured in vitro. Clin.Exp.Immunol. 96:389-94.
Tremblay M., Meloche S., Gratton S., Wainberg M.A., Sekaly R.P. (1994) Association of
p56(Lck) with the cytoplasmic domain of CD4 modulates HIV-1 expression. EMBO J. 13:774-83.
Tscherning C., Alaeus A., Fredriksson R., Bjorndal A., Deng H.K., Littman D.R., Fenyo E.M.,
Albert J. (1998) Differences in chemokine coreceptor usage between genetic subtypes of HIV-1.
Virology 241:181-8.
Tsitoura D.C., DeKruyff R.H., Lamb J.R., Umetsu D.T. (1999) Intranasal exposure to protein
antigen induces immunological tolerance mediated by functionally disabled CD4(+) T cells.
J.Immunol. 163:2592-600.
TucekSzabo C.L., Andjelic S., Lacy E., Elkon K.B., Nikolic-Zugic J. (1996) Surface T cell Fas
receptor/CD95 regulation, in vivo activation, and apoptosis - Activation-induced death can occur
without Fas receptor. J.Immunol. 156:192-200.
Twigg H.L., Soliman D.M., Spain B.A. (1994) Impaired alveolar macrophage accessory cell-
function and reduced incidence of lymphocytic alveolitis in HIV-infected patients who smoke. AIDS
8:611-8.
Udey M.C. (1997) Cadherins and Langerhans cell immunobiology. Clin.Exp.Immunol. 107 :6-8.
324
Ugolini S., Mondor I., Parren P.W.H.I., Burton D.R., Tilley S.A., Klasse P.J., Sattentau Q.J.
(1997) Inhibition of virus attachment to CD4(+) target cells is a major mechanism ofT cell line-
adapted HIV-1 neutralization. J.Exp.Med. 186:1287-98.
Uyttendaele, H., Kitajewski, J., (inventors). Uyttendaele, H., University of Columbia (US),
Kitajewski, J., (assignees). Angiogenic modulation by Notch signal transduction. [Patent] WO;US.
W09857621. 1998.
Uyttendaele H., Marazzi G., Wu G.Y., Yan Q.Y., Sassoon D., Kitajewski J. (1996) Notch4/int-3, a
mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development
122:2251-9.
Valentin A., VonGegerfelt A., Matsuda S., Nilsson K., Asjo B. (1991) In vitro maturation of
mononuclear phagocytes and susceptibility to HIV-1 infection. J.AIDS Hum. Retrovirol. 4:751-9.
Valitutti S., Muller S., Cella M., Padovan E., Lanzavecchia A. (1995) Serial triggering ofmany T-
cell receptors by a few peptide-MHC complexes. Nature 375:148-51.
VanDerGraaf M., Diepersloot R.J.A. (1986) Transmission of human-immunodeficiency-virus
(HIV/HTLV-III/LAV) - A review. Infection 14:203-11.
VanRij R.P., Broersen S., Goudsmit J., Coutinho R.A., Schuitemaker H. (1998) The role of a
stromal cell-derived factor-1 chemokine gene variant in the clinical course of H1V-1 infection. AIDS
12:F85-F90.
VanRij R.P., Portegies P., Hallaby T., Lange J.M.A., Visser J., Husman A.M.D., VanTwout
A.B., Schuitemaker H. (1999) Reduced prevalence of the CCR5 Delta 32 heterozygous genotype in
human immunodeficiency virus-infected individuals with AIDS dementia complex. J.Infect.Dis.
180:854-7.
VanWilsem E.J., Breve J., Kleijmeer M., Kraal G. (1994) Antigen-bearing langerhans cells in skin
draining lymph-nodes - phenotype and kinetics of migration. J.Invest.Dermatol. 103:217-20.
Varmus H. (1988) Retroviruses. Science 240:1427-35.
VarnumFinney B., Purton L.E., Yu M., BrashemStein C., Flowers D., Staats S., Moore K.A.,
LeRoux I., Mann R., Gray G., et al. (1998) The Notch ligand, Jagged-1, influences the development
of primitive hematopoietic precursor cells. Blood 91:4084-91.
Veillette A., Bookman M.A., Horak E.M., Bolen J.B. (1988) The CD4 and CD8 T-cell surface-
antigens are associated with the internal membrane tyrosine-protein kinase p561ck. Cell 55:301-8.
Velin D., Hopkins S., Kraehenbuhl J.P. (1998) Delivery systems and adjuvants for vaccination
against HIV. Pathobiology 66:170-5.
Verani A., Pesenti E., Polo S., Tresoldi E., Scarlatti G., Lusso P., Siccardi A.G., Vercelli D.
(1998) CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent
primary HIV-1 isolates. J.Immunol. 161 (5):2084-8.
Verrier F., Borman A.M., Brand D., Girard M. (1999) Role of the HIV type 1 glycoprotein 120 V3
loop in determining coreceptor usage. AIDS Res.Hum.Retrovir. 15:731-43.
Verrier F.C., Charneau P., Altmeyer R., Laurent S., Borman A.M., Girard M. (1997) Antibodies
to several conformation-dependent epitopes of gpl20/gp41 inhibit CCR-5-dependent cell-to-cell
fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
Proc.Nat.Acad.Sci. USA 94:9326-31.
325
Vicenzi E., Biswas P., Mengozzi M., Poli G. (1997) Role of pro-inflammatory cytokines and beta-
chemokines in controlling HIV replication. J.Leuk.Biol. 62:34-40.
Viera P., DeWaalMalefyt R., Dang M.N. (1991) Isolation and expression of human cytokine
synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1.
Proc.Nat.Acad.Sci. USA 88:1172-6.
Vigano A., Vella S., Principi N., Bricalli D., Sala N., Salvaggio A., Saresella M., VanZulli A.,
Clerici M. (1999) Thymus volume correlates with the progression of vertical HIV infection. AIDS
13:F29-F34.
Vigano A., Vella S., Saresella M., VanZulli A., Bricalli D., DiFabio S., Ferrante P., Andreotti M.,
Pirillo M., Dally L.G., et al. (2000) Early immune reconstitution after potent antiretroviral therapy in
HIV-infected children correlates with the increase in thymus volume. AIDS 14:251-61.
Vilmer E., Fischer A., Griscelli C., BarreSinoussi F., Vie V., Chermann J.C., Montagnier L.,
Rouzioux C., BrunVezinet F., Rosenbaum W. (1984) Possible transmission of a human
lymphotropic retrovirus (LAV) from mother to infant with AIDS. Lancet 2:229-30.
Vince G.S., Johnson P.M. (1995) Materno-fetal immunobiology in normal pregnancy and its
possible failure in recurrent spontaneous abortion? Hum.Repro. 10 (S2): 107-13.
Vink A., Uyttenhove C., Wauters P., VanSnick J. (1990) Accessory factors involved in murine T-
cell activation - distinct roles of interleukin-6, interleukin-1 and tumor-necrosis-factor.
Euro.J.Immunol. 20:1-6.
Vyakarnam A., Matear P.M., Martin S.J., Wagstaff M. (1995) Thl cells specific for HIV-1 gag
p24 are less efficient than ThO cells in supporting HIV replication, and inhibit virus-replication in ThO
cells. Immunology 86:85-96.
Wagner R.P., Levitz S.M., Tabuni A., Kornfeld H. (1992) HIV-1 envelope protein (gpl20) inhibits
the activity of human bronchoalveolar macrophages against Cryptococcus neoformans.
Am.Rev.Resp.Dis. 146:1434-8.
Wahl S.M., Allen J.B., Gartner S., Orenstein J.M., Popovic M., Chenoweth D.E., Arthur L.O.,
Farrar W.L., Wahl L.M. (1989) HIV-1 and its envelope glycoprotein down-regulate chemotactic
ligand receptors and chemotactic function of peripheral-blood monocytes. J.Immunol. 142:3553-9.
Wahl S.M., Orenstein J.M. (1997) Immune stimulation and HIV-1 viral replication. J.Leuk.Biol.
62:67-71.
Wahren B., Rosen J., Sandstrom E., Mathiesen T., Modrow S., Wigzell H. (1989) HIV-1 peptides
induce a proliferative response in lymphocytes from infected persons. J.AIDS Hum.Retrovirol. 2:448-
56.
Walker L., Lynch M., Silverman S., Fraser J., Boulter J., Weinmaster G., Gasson J.C. (1999)
The Notch Jagged pathway inhibits proliferation of human hematopoietic progenitors in vitro. Stem
Cells 17:162-71.
Walker L.S.K., McLeod J.D., Boulougouris G., Patel Y.I., Hall N.D., Sansom D.M. (1998) Down-
regulation of CD28 via Fas (CD95): Influence of CD28 on T-cell apoptosis. Immunology 94:41-7.
Walpert L. (1991) The triumph ofthe embryo. Oxford: Oxford University Press; ISBN: 0-19-854799-
4.
Wang A.M., Doyle M.V., Mark D.F. (1989) Quantitation ofmessenger-RNA by the polymerase
chain-reaction. Proc.Nat.Acad.Sci. USA 86:9717-21.
326
Wang B., Ge Y.C., Palasanthiran P., Xiang S.H., Ziegler J., Dwyer D.E., Randle C., Dowton D.,
Cunningham A., Saksena N.K. (1996) Gene defects clustered at the C-terminus of the vpr gene of
H1V-1 in long-term nonprogressing mother and child pair: In vivo evolution of vpr quasispecies in
blood and plasma. Virology 223:224-32.
Wang, C.Y., (inventor). United Biomedical Inc.(US), (assignee). Synthetic peptides related to the
HIV-GP120-env-protein, and their use. [Patent] US;EP. EP 0 328 403 A2. 1989.
Wang Z.Q., Orlikowsky T., Dudhane A., Mittler R., Blum M., Lacy E., Riethmuller G.,
Hoffmann M.K. (1994) Deletion of T-lymphocytes in human CD4 transgenic mice induced by HIV-
gpl20 and gpl20-specific antibodies from AIDS patients. Euro.J.Immunol. 24:1553-7.
Ward R.H.R., Capon D.J., Jett C.M., Murthy K.K., Mordenti J., Lucas C., Frie S.W., Prince
A.M., Green J.D., Eichberg J.W. (1991) Prevention of HIV-1 IIIB infection in chimpanzees by CD4
immunoadhesin. Nature 352:434-6.
Washburn T., Schweighoffer E., Gridley T., Chang D., Fowlkes B.J., Cado D., Robey E. (1997)
Notch activity influences the alpha beta versus gamma delta T cell lineage decision. Cell 88:833-43.
Webster S.D., Yang A.J., Margol L., GarzonRodriguez W., Glabe C.G., Tenner A.J. (2000)
Complement component Clq modulates the phagocytosis ofA beta by microglia. Exp.Neurol.
161:127-38.
Wedel A., Frankenberger M., Sulski G., Petersmann I., Kuprash D., Nedospasov S.,
ZieglerHeitbrock H.W.L. (1999) Role of p52 (NF-kappa B2) in LPS tolerance in a human B cell
line. Biol.Chem. 380:1193-9.
Weinberg J.B., Matthews T.J., Cullen B.R., Malim M.H. (1991) Productive human-
immunodeficiency-virus type-1 (HIV-1) infection of nonproliferating human monocytes. J.Exp.Med.
174:1477-82.
Weinmaster G. (1998) Notch signaling: direct or what? Cur.Op.Gen.Dev 8:436-42.
Weintraub J.P., Cohen P.L. (1999) Ectopic expression of B7-1 (CD80) on T lymphocytes in
autoimmune Ipr and gld mice. Clin.Immunol. 91(3):302-9.
Weintraub J.P., Godfrey V., Wolthusen P.A., Cheek R.L., Eisenberg R.A., Cohen P.L. (1998)
Immunological and pathological consequences of mutations in both Fas and Fas ligand.
Cell.Immunol. 186:8-17.
Weiss R.A. (1996) HIV receptors and the pathogenesis of AIDS. Science 272:1885-6.
Weissman D., LI Y., Orenstein J.M., Fauci A.S. (1995) Both a precursor and a mature population of
dendritic cells can bind HIV - however, only the mature population that expresses CD80 can pass
infection to unstimulated CD4(+) T-cells. J.Immunol. 155:4111-7.
Weller I.V., Carne C.A., Sattentau Q., Smith A., Tedder R.S., Clapham P., Dalgleish A., Weber
J., Adler M.W. (1987) Human immunodeficiency virus (HIV) infection in the regular sexual partners
of homosexual men with AIDS and persistent generalised lymphadenopathy. J.Med. Virol. 22( 1 ):91 -8.
Wells H., Osborne T. (1911) The biological reactions of vegetable proteins. J. Infect.Dis. 8(77):80.
Welshons W.J. (1971) Genetic basis for two types of recessive lethality at the Notch locus of
Drosophila. Genetics 68(2):259-68.
327
Werner T., Ferroni S., Saermark T., Brackwerner R., Banati R.B., Mager R., Steinaa L.,
Kreutzberg G.W., Erfle V. (1991) HIV-1 nef protein exhibits structural and functional similarity to
scorpion peptides interacting with K+ channels. AIDS 5:1301-8.
Wesselborg S., Janssen O., Kabelitz D. (1993) Induction of activation-driven death (apoptosis) in
activated but not resting peripheral-blood T-cells. J.Immunol. 150:4338-45.
Westendorp M.O., Liweber M., Frank R.W., Krammer P.H. (1994) Human immunodeficiency
virus type-1 Tat up-regulates interleukin-2 secretion in activated T-cells. J. Virol. 68:4177-85.
Wharton K.A., Johansen K.M., Xu T., ArtavanisTsakonas S. (1985) Nucleotide-sequence from
the neurogenic locus Notch implies a gene-product that shares homology with proteins containing
EGF-like repeats. Cell 43:567-81.
Whitacre C.C., Gienapp I.E., Orosz C.G., Bitar D.M. (1991) Oral tolerance in experimental
autoimmune encephalomyelitis .3. Evidence for clonal anergy. J.Immunol. 147:2155-63.
Wilett B.M. (1985) Pocket atlas ofthe World. London: George Philip; ISBN: 0-540-05492-5.
Wilkinson D.A., Operskalski E.A., Busch B.P., Mosley J.W., Roup R.A. (1998) A 32-bp deletion
within the CCR5 locus protects against transmission of parenterally acquired human
immunodeficiency virus but does not affect progression to AIDS-defining illness. J.lnfect.Dis.
178:1163-6.
Willey R.L., Maldarelli F., Martin M.A., Strebel K. (1992) Human-immunodeficiency-virus type-1
vpu protein induces rapid degradation of CD4. J. Virol. 66:7193-200.
Williams C.B., Vidal K., Donermeyer D., Peterson D.A., White J.M., Allen P.M. (1998) In vivo
expression of a TCR antagonist: T cells escape central tolerance but are antagonized in the periphery.
J.Immunol. 161:128-37.
Wilson P.A., HemmatiBrivanlou A. (1997) Vertebrate neural induction: Inducers, inhibitors, and a
new synthesis. Neuron 18:699-710.
Wilson R., Panin V., Papayannopoulos V., Johnston S., Rauskolb C., Vogt T., Irvine K. (1997)
Fringe modulates Notch signalling: Identifying the molecular basis of this interaction. Dev.Biol.
186:B224.
Wingren A.G., Parra E., Varga M., Kalland T., Sjogren H.O., Hedlund G., Dohlsten M. (1995) T
cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit.Rev.Immunol.
15:235-53.
Winkler C., Modi W., Smith M.W., Nelson G.W., Wu X.Y., Carrington M., Dean M., Honjo T.,
Tashiro K., Yabe D., et al. (1998) Genetic restriction ofAIDS pathogenesis by an SDF-1 chemokine
gene variant. Science 279:389-93.
Winzler C., Rovere P., Rescigno M., Granucci F., Penna G., Adorini L., Zimmermann V.S.,
Davoust J., RicciardiCastagnoli P. (1997) Maturation stages ofmouse dendritic cells in growth
factor-dependent long-term cultures. J.Exp.Med. 185:317-28.
Wong B., Arron J., Choi Y.W. (1997) T cell receptor signals enhance susceptibility to Fas-mediated
apoptosis. J.Exp.Med. 186:1939-44.
Wood K.J. (1996) New concepts in tolerance. Clin.Transplant. 10:93-9.
Woodhead V.E., Binks M.H., Chain B.M., Katz D.R. (1998) From sentinel to messenger: an
extended phenotypic analysis of the monocyte to dendritic cell transition. Immunology 94:552-9.
328
Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. (1990) CD14, a receptor for
complexes of lipopolysaccharide (LPS) and LPS binding-protein. Science 249:1431-3.
Wu J.Y., Rao Y. (1999) Fringe: defining borders by regulating the Notch pathway.
Cur.Op.Neurobiol. 9:537-43.
Wu L.J., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A.,
Desjardin E., Newman W., et al. (1996) CD4-induced interaction of primary HIV-1 gpl20
glycoproteins with the chemokine receptor CCR-5. Nature 384:179-83.
Wu L.J., Paxton W.A., Kassam N., Ruffing N., Rottman J.B., Sullivan N., Choe H., Sodroski J.,
Newman W., Koup R.A., et al. (1997) CCR5 levels and expression pattern correlate with
infectability by macrophage-tropic HIV-1, in vitro. J.Exp.Med. 185:1681-91.
Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski
J.G. (1998a) The antigenic structure of the HIV gpl20 envelope glycoprotein. Nature 393:705-11.
Wyatt R., Sodroski J. (1998b) The HIV-1 envelope glycoproteins: Fusogens, antigens, and
immunogens. Science 280:1884-8.
Xu T., Rebay I., Fleming R.J., Scottgale T.N., ArtavanisTsakonas S. (1990) The Notch locus and
the genetic circuitry involved in early Drosophila neurogenesis. Gene.Dev. 4:464-75.
Yagisawa M., Saeki K., Okuma E., Kitamura T., Kitagawa S., Hirai H., Yazaki Y., Takaku F.,
Yuo A. (1999) Signal transduction pathways in normal human monocytes stimulated by cytokines and
mediators: Comparative study with normal human neutrophils or transformed cells and the putative
roles in functionality and cell biology. Exp.Hematol. 27:1063-76.
Yahi N., Fantini J., Mabrouk K., Tamalet C., Demicco P., VanRietschoten J., Rochat H.,
Sabatier J.M. (1994) Multibranched V3 peptides inhibit human-immunodeficiency-virus infection in
human-lymphocytes and macrophages. J.Virol. 68(9):5714-20.
Yahi N., Sabatier J.M., Baghdiguian S., Gonzalezscarano F., Fantini J. (1995) Synthetic
multimeric peptides derived from the principal neutralization domain (V3 loop) of human-
immunodeficiency-virus type-1 (HIV-1) gpl20 bind to galactosylceramide and block HIV-1 infection
in a human CD4-negative mucosal epithelial-cell line. J. Virol. 69(l):320-5.
Yamamoto J.K., Ho E.W., Theilen G.H., Pedersen N.C. (1987) Isolation of a feline T-lymphotropic
lentivirus resembling human-immunodeficiency-virus (HIV). Proc.Am.Assoc.Can.Res. 28:454.
Yanagawa S.I., VanLeeuwen F., Wodarz A., Klingensmith J., Nusse R. (1995) The dishevelled
protein is modified by wingless signaling in Drosophila. Gene.Dev. 9:1087-97.
Yang F., Gustafson K.R., Boyd MLR., Clore M., Gronenborn A., Wlodawer A. (1999) Crystal
structure of a potent FHV-inactivating protein cyanovirin-N shows domain-swapping. Biophys.J.
76: A137.
Yang J.Y., Togni M., Widmer U. (1999) Heterozygous defect in HIV-1 coreceptor CCR5 and
chemokine production. Cytokine 11:1-7.
Yang Y.L., Ashwell J.D. (1999) Thymocyte apoptosis. J.Clin.Immunol. 19:337-49.
Yeh P., Landais D., Lemaitre M., Maury I., Crenne J.Y., Becquart J., Murrybrelier A., Boucher
F., Montay G., Fleer R., et al. (1992) Design of yeast-secreted albumin derivatives for human
therapy - biological and antiviral properties of a serum albumin-CD4 genetic conjugate.
Proc.Nat.Acad.Sci. USA 89:1904-8.
329
Yeung Y.G., Wang Y., Einstein D.B., Lee P.S.W., Stanley E.R. (1998) Colony-stimulating factor-1
stimulates the formation of multimeric cytosolic complexes of signaling proteins and cytoskeletal
components in macrophages. J.Biol.Chem. 273:17128-37.
Yi Y.J., Isaacs S.N., Williams D.A., Frank I., Schols D., DeClercq E., Kolson D.L., Collman R.G.
(1999) Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary
human immunodeficiency virus type 1 (HIV-1) strains: Two distinct mechanisms of HIV-1 dual
tropism. J.Virol. 73:7117-25.
Yochem J., Weston K., Greenwald I. (1988) The Caenorhabditis elegans lin-12 gene encodes a
transmembrane protein with overall similarity to Drosophila Notch. Nature 335:547-50.
Yoshida T., Hachimura S., Kaminogawa S. (1997) The oral administration of low-dose antigen
induces activation followed by tolerization, while high-dose antigen induces tolerance without
activation. Clin.Immunol.Immunopathol. 82:207-15.
Yudin N.S., Vinogradov S.V., Potapova T.A., Naykova T.M., Sitnikova V.V., Kulikov I.V.,
Khasnulin V.I., Konchuk C., VIoschinskii P.E., Ivanov S.V., et at. (1998) Distribution ofCCR5-
delta 32 gene deletion across the Russian part of Eurasia. Hum.Gen. 102:695-8.
Zacharopoulos V.R., Perotti M.E., Phillips D,M. (1997) A role for cell migration in the sexual
transmission ofHIV-1? Cur.Biol. 7:534-7.
Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., Chen I.S.Y. (1990) HIV-1 entry into
quiescent primary lymphocytes - molecular analysis reveals a labile, latent viral structure. Cell
61:213-22.
Zack J.A., Haislip A.M., Krogstad P., Chen I.S.Y. (1992) Incompletely reverse-transcribed human-
immunodeficiency-virus type-1 genomes in quiescent cells can function as intermediates in the
retroviral life-cycle. J.Virol. 66:1717-25.
Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A.,
Santagostino E., Rappaport J., et al. (1998) C-C chemokines, pivotal in protection against HIV
type 1 infection. Proc.Nat.Acad.Sci. USA 95:3857-61.
Zamecnik P.C., Goodchild J., Taguchi Y., Sarin P.S. (1986) Inhibition of replication and
expression of human T-cell lymphotropic virus type-Ill in cultured-cells by exogenous synthetic
oligonucleotides complementary to viral-RNA. Proc.Nat.Acad.Sci.USA 83:4143-6.
Zauli G., Davis B.R., Re M.C., Visani G., Furlini G., Laplaca M. (1992) Tat protein stimulates
production of transforming growth factor-beta-1 by marrow macrophages - a potential mechanism for
human immunodeficiency virus-1-induced hematopoietic suppression. Blood80:3036-43.
Zhang J.L., Choe H., Dezube B.J., Farzan M., Sharma P.L., Zhou X.C., Chen L.B., Ono M.,
Gillies S., Wu Y.M., et al. (1998) The bis-azo compound FP-21399 inhibits HIV-1 replication by
preventing viral entry. Virology 244:530-41.
Zhang L.Q., He T., Huang Y.X., Chen Z.W., Guo Y., Wu S., Kunstman K.J., Brown R.C., Phair
J.P., Neumann A.U., et al. (1998) Chemokine coreceptor usage by diverse primary isolates of human
immunodeficiency virus type 1. J.Virol. 72:9307-12.
Zhang L.Q., Huang Y.X., Yuan H., Chen B.K., Ip J., Ho D.D. (1997) Genotypic and phenotypic
characterization of long terminal repeat sequences from long-term survivors of human
immunodeficiency virus type 1 infection. J.Virol. 71:5608-13.
330
Zhang X.H., Brunner T., Carter L., Dutton R.W., Rogers P., Bradley L., Sato T., Reed J.C.,
Green D., Swain S.L. (1997) Unequal death in T helper cell (Th) 1 and Th2 effectors: Thl, but not
Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J.Exp.Med. 185:1837-49.
Zhang Y.J., Moore J.P. (1999) Will multiple coreceptors need to be targeted by inhibitors of human
immunodeficiency virus type 1 entry? J. Virol. 73:3443-8.
Zhang Z.X., Yang L., Young K.J., DuTemple B., Zhang L. (2000) Identification of a previously
unknown antigen-specific regulatory T cell and its mechanism of supression. Nat.Med. 6(7):782-9.
Zheng L.X., Fisher G., Miller R.E., Peschon J., Lynch D.H., Lenardo M.J. (1995) Induction of
apoptosis in mature T-cells by tumor-necrosis-factor. Nature 377:348-51.
Zhou P., Goldstein S., Devadas K., Tewari D., Notkins A.L. (1997) Human CD4(+) cells
transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition ofmRNA expression.
Nat.Med. 3:659-64.
Zhu T.F., Wang N., Nam D.S., Cao Y.Z., Carr A., Cooper D., Ho D.D. (1995) Preferential
transmission of cell-associated virus and evidence for selection ofHIV-1 in the new host following
sexual contact. J.Cell Biochem. 230.
Zhuang Y., Soriano P., Weintraub H. (1994) The helix-loop-helix gene E2A is required for B-cell
formation. Cell 79:875-84.
Ziegler P. (1969) The Black Death. Glasgow: Collins; ISBN: not assigned.
Zimmerman P.A., BucklerWhite A., Alkhatib G., Spalding T., Kubofcik J., Combadiere C.,
Weissman D., Cohen O., Rubbert A., Lam G., et al. (1997) Inherited resistance to HIV-1 conferred
by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting
clinical phenotypes, defined racial background, and quantified risk. Molec.Med. 3:23-36.
Zimrin A.B., Pepper M.S., Montesano R., Maciag T. (1996) An antisense oligonucleotide to the
notch ligand jagged promotes angiogenesis in bovine microvascular endothelial cells (BMEC) on




All solutions were made up in distilled water. Recipes are listed in the order they are
used in Materials and Methods (Chapter 2). All reagents were obtained from Sigma.




20mM pH 7.3 phosphate buffer (400ml) 112ml 0.02M NaH2P04
288ml 0.02M Na2HP04
0.1M pH2.5 glycine / HC1 buffer (11) 500ml 0.2M glycine
500ml 0.2M HC1
Coomassie blue staining mixture (100ml) 10ml methanol
7ml glacial ethanoic acid
0.25g Coomassie blue
Destain mixture (100ml) 10ml methanol
7ml glacial ethanoic acid
Lowryprotein assay
BSA protein standards (200pl each)
made up in triplicate in 5ml tubes
stock lmg/ml diluted with 0.1M
NaOH
to give 0, 25, 50, 75, 100, 200, 400 pg ml"1
Alkaline carbonate solution (500ml) 5ml 5% (w/v) CuS04.5H20















(All these solutions were filter sterilised)
FITC Labelling Buffer
Final Dialysis Buffer
Make 2 litres, store at 4°C, keep
for up to 2 weeks
0.05M H3BO3
0.2M NaCl
Adjust pH to 7.2 with 5M NaOH
Make 2 litres, store at 4°C
0.1M Tris-HCl buffer pH 7.4
0.2M NaCl
Adjust pH to 7.4 with 5M NaOH
Polymerase chain reaction (PCR) methods
DNA gels





PCR PRIMER / PROBE SEQUENCE DATA



















TGA CGG GGT CAC CCA CAC






CTA GAA GCA TTT GCG GTG




CTC TAG CAG TGG CGC CCG

























































AAG CTG AGA ACC AAG






AGC TCT CCC AGA GCC CCA
GAT CCG ATT TTG G
62.0
Table A2.1. Details of primers used for conventional PCR. References:
Innes and Moore: Primers a gift from Donald Innes and Dr Marilyn Moore,
PPL Therapeutics, Roslin, Midlothian, UK. Tm: theoretical primer melting





Primer / probe sequences (5' —> 3')




S GCT TCG TGT GTG ACG AAC ACT A
AS AAA GGT CGG TCC CAA GT




S TTC CCT CGC CAC TGC TAT CT
AS CTG AGC GGG CAC CAC AAC






S CAT TCT GGA AAT GAC AGT GAA GCA
AS CAG CGC AGC CGT CAT CT




S CGG GTC CAC CAG TTT GAA TG
AS GTT GTA TTG GGT TCG GCA CCA T






S TTC CAG TAA TGG TCC AAT ATT TCT T
AS CAT CCA CTT CAT ACT CAG AGT TGA CA




S GGC TGC AAC ACT GAG GAA TGT
AS TCA GGA GGC AGA AGA ACT GTG A




S CGG CCT CGG ACT CAG TCA
AS GTG TTG AGG TAG GAG TAG




S CTT AAC TGT GGC TTG GAT CTG TTG
AS GTC CTC AGA GGC TGA GTG TGT GT




S CGC TGT ATG AAA GGA GAG AGC AA
AS ACT CCT TAT TTT CCT TCT AAG ACA TTT GT






Primer set purchased from PE Biosystems, sequences not disclosed
Table A2.2. Details of primers and TaqMan® probes used for real time
PCR. The melting temperature (Tm) was 60°C for all sense primers, and
58°C for all anti-sense primers. All TaqMan probes were FAM conjugated
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A functional, discontinuous HIV-1 gpl20 C3/C4
domain-derived, branched, synthetic peptide that
binds to CD4 and inhibits MlP-la chemokine
binding
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ABSTRACT This paper describes a branched syn¬
thetic peptide [3.7] that incorporates sequence dis¬
continuous residues of HIV-1 gpl20 constant re¬
gions. The approach was to bring together residues
of gpl20 known to interact with human cell mem¬
branes such that the peptide could fold to mimic the
native molecule. The peptide incorporates elements
of both the conserved CD4 and CCR5 binding sites.
The 3.7 peptide, which cannot be produced by
conventional genetic engineering methods, is recog¬
nized by antiserum raised to native gpl20. The
peptide also binds to CD4 and competitively inhibits
binding of QS4120 an antibody directed against the
CDR2 region of CD4. When preincubated with the
CD4+ve MM6 macrophage cell line, which ex¬
presses mRNA for the CCR3 and CCR5 chemokine
receptors, both 3.7 and gpl20 inhibit binding of the
chemokine MlP-lod. The peptide also inhibits infec¬
tion of primary macrophages by M-tropic HIV-1.
Thus, 3.7 is a prototype candidate peptide for a
vaccine against HIV-1 and represents a novel ap¬
proach to the rational design of peptides that can
mimic complex sequence discontinuous ligand bind¬
ing sites of clinically relevant proteins.—Howie,
S. E. M., Fernandes, M. L., Heslop, I., Hewson, T. J.,
Cotton, G. J., Moore, M. J., Innes, D., Ramage, R.,
Harrison, D.J. A discontinuous HIV-1 gpl20 C3/C4
domain-derived, branched, synthetic peptide that
binds to CD4 and inhibits MlP-la chemokine bind¬
ing. FASEBJ. 13, 503-511 (1999)
Key Words: antibody • macrophage • PBMC • monoclonal an¬
tibody • CDR2 region
A vaccine against transmitted HIV-1 would ide¬
ally prevent binding of macrophage (M)2 -tropic
gpl20 to CD4 and to toa-chemokine binding core-
ceptor, both of which are required for efficient
infection (1-4). Several taa-chemokine receptors
have been described as coreceptors for primary
M-tropic or dual M and T lymphocyte (T) -tropic
isolates, including CCR3 and CCR5 (3, 4), whereas
adapted T-tropic only strains preferentially use the
alpharChemokine receptor CXCR4 (5, 6). A vaccine
peptide to prevent primary infection would thus
minimally contain conserved regions of the gpl20
CD4- and fota-chemokine receptor binding sites. The
CD4 binding site of gpl20 contains five discontinu¬
ous conserved residues (7, 8). The fofa-chemokine
receptor binding site is not fully characterized, but
conserved residues in the C4 region are involved in
M-tropism (7) and residues in the conserved region
have recently been shown to be involved (9, 10).
Based on the peptide sequence of HIV-1 IIIB
gpl20, we have previously described the synthesis of
a novel 44-mer three-armed, branched peptide [3.7]
(11, 12) containing four residues necessary for CD4
binding (Asp-368 and Glu-370 from C3; Trp-427 and
Asp-457 from C4), an oxidized Cys-Cys turn based on
the disulfide link between Cys-378 and Cys-445, and
two residues, Lys-421 and Gln-422, involved in M-
tropism and the CCR5 binding site (9, 10). Peptide
3.7 has a unique structure that could not be repro¬
duced by conventional genetic engineering. This
rationally designed peptide contains both T and B
lymphocyte epitopes, cross reacts with polyclonal
anti-gpl20 antiserum, binds to the CDR2 region,
domain 1 of CD4, and inhibits macrophage inflam-
1
Correspondence: Department of Pathology, Edinburgh
University Medical School, Teviot Place, Edinburgh EH8
9AG, U.K. E-mail: s.e.m.howie@ed.ac.uk
2 Abbreviations: BSA, bovine serum albumin; FCS, fetal calf
serum; FITC, fluorescein isothiocyanate; Ig, immunoglobu¬
lin; M, macrophage; MlP-la, macrophage inflammatory pro¬
tein-la; PBMC, peripheral blood mononuclear cells; PBS,
phosphate-buffered saline; PCR, polymerase chain reaction;
PE, phycoerythrin; RANTES, regulated on activation, normal
T expressed and secreted; T, T lymphocyte; TRITC, rhoda-
mine.
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matory protein-la (MlP-la) chemokine binding and
infection of primary macrophages by M-tropic
HIV-1. Apart from the relevance to HIV-1, this work
also represents a generic approach to the rational




The synthesis of peptide 3.7 was as described previously (11,
12). Irrelevant peptides FMDV and PSS023 were used as
controls in some experiments. FMDV is a 44-mer peptide
based on a sequence derived from a different virus (bovine
foot and mouth disease virus) and, like 3.7, has a cys-X-cys
bond incorporated in its structure. PSS023 is a random linear
34-mer peptide. There is no sequence homology between 3.7
and either FMDV or PSS023. All peptides were synthesized by
Albachem, Edinburgh, U.K.
Antibodies
Antipeptide polyclonal mouse serum was raised as described
previously (11, 12). The immunoglobulin G (IgG) fraction
was purified using protein G-Sepharose (Pharmacia Biotech
Ltd., St. Alban's, U.K.) in a 0.7 X 10 cm liquid chromatogra¬
phy column (Sigma, Poole, Dorset, U.K.) according to the
manufacturer's protocol. Anti-CD4 monoclonal antibodies
(QS4120 and L120) and sheep anti-gpl20 serum (ARP411)
were supplied by the NIBSC centralized facility for AIDS
Reagents supported by EU programme EVA (contract BMH4
97/2515) and the U.K. Medical Research Council; biotinyl-
ated-anti-CD4 (MT310), and rhodamine (TRITC) -labeled
antimouse immunoglobulin were obtained from Dako Ltd.,
Cambridge, U.K.; phycoerythrin (PE) -labeled goat anti-
mouse immunoglobulin, horseradish peroxidase-conjugated,
and alkaline phosphatase-conjugated-donkey antisheep se¬
rum were purchased from Sigma.
ELISA
Unless otherwise stated, all reagents were purchased from
Sigma. 96-Well ELISA microtiter plates (Corning-Costar Ltd.,
High Wycombe, Bucks, U.K.) were coated overnight at 4°C
with 3.7 peptide, FMDV peptide, bovine serum albumin
(BSA), or baculovirus expressed recombinant gpl20 derived
from the HIV-1 IIIB strain (EVA607 supplied by the NIBSC
centralized facility for AIDS Reagents supported by EU pro¬
gramme EVA (contract BMH4 97/2515) and the U.K. Medi¬
cal Research Council) (100 pl/well) in 0.1 M carbonate/
bicarbonate buffer pH 9.6. The plate was then washed three
times with phosphate-buffered saline (PBS) containing 0.05%
Tween 20. Wells were blocked with 1% BSA in PBS for 1 h at
room temperature. After three additional washes, a 1:500
dilution of sheep anti-gpl20 serum (100 |xl per well, diluted
with 1% BSA in PBS containing 0.05% Tween 20) was added
to the wells and incubated for 2 h at room temperature. The
plate was again washed; optimal dilutions of secondary anti¬
body (horseradish peroxidase-conjugated or alkaline phos-
phatase-conjugated donkey antisheep serum) were added
(100 pi per well) and incubated for 1 h at room temperature.
Unbound conjugate was removed by washing; o-phenylenedi-
amine (0.4 mg/ml in phosphate/citrate buffer pH 5.0 con¬
taining 0.006% H202, 100 p.1 per well) or 3 M /rnitrophenyl
phosphate (in 0.05 M Na2C03, 0.5 mM MgCl2) was added
and the plate was incubated at room temperature. The
coloration reaction was measured at 490 nm for o-phenylene-
diamine or at 405 nm for /rnitrophenylphosphate using a
Dynatech MR5000 microplate reader.
Cell culture
All tissue culture reagents and plastics were purchased from
Life Technologies Ltd., Paisley, U.K., unless otherwise stated.
The human T lymphocyte-derived cell line H9 was obtained
from the European Collection of Animal Cell Cultures,
Porton Down, Salisbury, U.K. The human monocyte/macro-
phage-derived cell line MM6 was the kind gift from Dr. J. A.
Ross, Department of Surgery, University of Edinburgh. Cells
were passaged in RPMI 1640 medium containing 10% (vol/
vol) fetal calf serum (FCS), 2 mM L-glutamine, and antibiotics
(50 IU/ml of penicillin, 50 pg/ml of streptomycin) with the
addition of 2.5 p-g/ml fungizone for H9 cells.
Peripheral blood-derived macrophages were obtained
from single donor Buffy-coat preparations obtained from the
Scottish National Blood Transfusion Service. Peripheral
blood mononuclear cells (PBMC) were isolated by centrifu-
gation over lymphoprep (Nycomed Pharma AS, Oslo, Nor¬
way) and washed in PBS. PBMC were plated into a 24-well
plate at 5 X 106/well in Iscove's medium containing antibi¬
otics as described above and allowed to adhere to the wells for
1 h. Nonadherent cells were then removed, the wells were
washed, and 1 ml Iscove's medium containing antibiotics and
5% heat-inactivated human AB serum (Scottish National
Blood Transfusion Service) were added. The cells were cul¬
tured overnight and any remaining nonadherent cells were
removed. Adherent cells were cultured for another 4 days (at
which point they were >95% CD14+ve, MHC Il+ve and
CD4+ve macrophages by flow cytometry) before infection.
Colocalization of CD4 and 3.7 on the cell surface
MM6 cells were washed three times in PBS, plated in a
microtiter plate at a concentration of 3 X 10 cells/well with
or without 1 |xg/well of 3.7 and incubated on ice for 2 h. The
wells were washed with prechilled binding buffer (1 mg/ml
GMEM, 10% FCS, 1 mg/ml HEPES in distilled H20, pH 7.2)
and incubated with or without 25 |x!/well purified mouse
antipeptide IgG (2.5 |xg) on ice for 1 h. The wells were
washed as above and bound antipeptide antibody was de¬
tected using TRITC-Iabeled antimouse immunoglobulin. Af¬
ter further incubation on ice for 30 min and at room
temperature for 15 min, cells were washed with prechilled
buffer (PBS, 1% BSA, 0.05% NaN3). Biotinylated mouse
antihuman-CD4 mAb was then added and the plate incubated
for an additional 0 min on ice, washed with flow buffer, and
detected with fluorescein isothiocyanate (FITC) -labeled avi-
din (Sigma). Cells were fixed in 0.4% formaldehyde and then
transferred to slides with a single drop of glycerol/PBS before
examination under a Zeiss confocal laser scanning micro¬
scope.
Flow cytometry
Flow cytometric analysis was carried out using a Coulter
EPICS XL Flow Cytometer (Beckmann-Coulter Electronics,
Luton, U.K.) with a 15 mW, single argon ion laser operating
at wavelength 488 nm. FITC and PE fluorescence were
detected depending on the individual experiment. The per¬
centage of positive cells was established relative to back¬
ground fluorescence of cells treated with FITC-labeled avidin
or PE-labeled goat antimouse immunoglobulin only. Relative
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Figure 1. Schematic representation of 3.7. Boxed residues
(D-368, E-370, W-427, and D-457) are critical for CD4 bind¬
ing. Circled residues (K-421 and Q-422) are involved in
M-tropism.
intensities of cell surface staining were determined by com¬
paring the mean fluorescence intensity of cell staining within
individual experiments.
A?iti-CD4 mAb binding
To detect anti-CD4 mAb binding, viable H9 T cells were
isolated by gradient centrifugation on Lymphoprep (Ny-
comed Pharma AS, Oslo, Norway) at 1000 X gfor 25 min and
washed three times in PBS. Cells were then pelleted in a
96-well microtiter plate at a concentration of 105 cells/well
and 10 pi of 20 nM peptide was added. After incubation for
2 h on ice, 10 pi containing 1 pg anti-CD4 mAb was added.
After further incubation on ice for 1 h, wells were washed with
prechilled flow buffer (PBS, 1% BSA, 0.05% NaN,) and
bound mAb was detected with PE-labeled goat antimouse
immunoglobulin (Dako Ltd.). After incubation for 1 h on ice,
the wells were washed in prechilled flow buffer and resus-
pended in 400 pi prechilled flow buffer in scintillation tubes
for analysis.
MlP-la binding
Binding of biotinylated-recombinant MlP-la (R&D Systems
Europe Ltd., Abingdon, U.K.) to MM6 cells was analyzed after
the manufacturer's protocol. Briefly, viable cells were washed
three times in PBS, pelleted in a 96-well microtiter plate at 105
cells/well, and incubated with or without peptide in a total
volume of 10 pi PBS with 1% BSA for 2 h on ice. The cells
were then treated with biotinylated MlP-la, which was de¬
tected using FITC-labeled avidin.
Inhibition of HIV-1 BAL infection of primary macrophage
cultures
Medium was removed from wells containing adherent mac¬
rophages, spun to remove any nonadherent cells and debris,
and reserved. Peptide or gpl20 was added to quadruplicate
wells in 100 pi PBS. The irrelevant random peptide PSS023
and 3.7 were added at 30 pM and recombinant gpl20 from
the M-tropic MN strain (supplied by the NIBSC centralized
facility for AIDS reagents supported by EU programme EVA
(contract BMH4 97/2515) and the U.K. Medical Research
Council) was added at 0.3 pM. Only PBS was added to control
cells. The cells were then incubated for 1 h at 37°C. A
previously titrated amount of HIV-1 BAL supernatant (150
pi) was then added to each well such that virus specific
message would be detected 72 h after exposure of untreated
primary macrophages. Cells were then incubated for 30 min
at 37°C. After this time, 750 pi of the reserved culture
medium was added to each well and the cells were incubated
at 37°C in 5% C02 in a humidified incubator.
RT-PCR
Chemokine expression
Total RNA was isolated (Stratagene, Cambridge, U.K.) and 3
pg of RNA was used for cDNA synthesis using Expand reverse
transcriptase, 5X RT buffer, DTT (Boehringer Mannheim,
TABLE 1. Cross-reaction between polyclonal sheep anti-gpl20 serum [ARP411] [1:500
dilution] and peptide 3. 7 but not the irrelevant peptide FMDV or BSA
Wells coated with OD exp. 2 OD exp. 3
(n = 4) OD exp. 1 [HRP] [alk phos] [alk phos]
BSA 0.1 pM 0.034 ± 0.005 0.158 ± 0.050 0.153 ± 0.041
gpl20 0.1 pM 0.459 ± 0.02* 1.802 ± 0.010* >2.0*
gpl20 0.01 pM ND 1.020 ± 0.010* 1.096 ± 0.024*
FMDV 1.0 pM 0.017 ± 0.001 0.196 ± 0.007 0.216 ± 0.029
FMDV 0.1 pM 0.037 ± 0.010 0.087 ± 0.008 0.114 ± 0.020
3.7 1.0 pM 0.268 ± 0.033* 0.809 ± 0.063* 0.793 ± 0.037*
3.7 0.1 pM 0.211 ± 0.010* 0.042 ± 0.012 0.011 ± 0.010
* Significantly different from binding to FMDV at same concentration, P < 0.02 (Student's t
test).
FUNCTIONAL, DISCONTINUOUS, SYNTHETIC gp120 PEPTIDE 505
Figure 2. a) Sequence comparisons of the re¬
ceptor binding sites of MlP-la, MIP-lpl, and
RANTES (Swiss-Prot database) with 3.7 [424-
432]. b) Hopp and Woods hydropathy value
comparison of the receptor binding sites of
MlP-la (♦), MIP-ip (□), and RANTES (A)
with 3.7 (424-432, x). c) Molecular weight com¬
parison of the receptor binding sites of MlP-la





















































Roche Diagnostics Ltd., Lewes, U.K.), and oligo (dt) (Oswel
Ltd., Southampton, U.K.). Products of this reaction were used
as a template for polymerase chain reaction (PCR) amplifica¬
tion with Taq DNA polymerase (Promega, Southampton,
U.K.) and primers (Oswel Ltd.): CCR5: antisense - CTC GGA
TCC GGT GGA ACA AGA TGG ATT AT, sense - CTC GTC
GAC ATG TGC ACA ACT CTG ACT G; CCR3: antisense -
CCG CTC GAG CAG ACC TAA AAC ACA ATA GAG AGT
TCC, sense - CGC GGA TCC GGG AGA AGT GAA ATG ACA
ACC; CXCR4: antisense - CCG CTC GAG CAT CTG TGT
TAG CTG GAG TGA AAA C, sense - CGC GGA TCC GCG
GTT ACC ATG GAG GGG ATC; p-actin: antisense - CTA GAA
GCA TTT GCG GTG GAC GAT GGA GGG, sense-TGA CGG
GGT CAC CCA CAC TGT GCC CAT CTA.
HIV infection
At 72 and 96 h postinfection total RNA was extracted from
duplicate wells using the Qiagen RNeasy spin column kit as
per the manufacturer's instructions (Qiagen Ltd., Crawley,
U.K.). The extracted RNA samples were each treated with 10
units DNasel (Pharmacia Biotech Ltd.) for 30 min at room
temperature. DNase was inactivated by addition of EDTA and
incubation at 65 °C for 10 min. RNA content of the samples




Figure 3. Binding of purified (protein-G affinity binding)
murine anti-3.7-IgG to 3.7 and an irrelevant peptide FMDV.
was measured on a GeneQuant (Pharmacia, Biotech Ltd.).
RNA (0.1 pg) was used for cDNA synthesis using Expand
reverse transcriptase, 5X RT buffer, DTT (Boehringer Mann¬
heim, Roche Diagnostics Ltd.), and Oligo (dt) (Oswel Ltd.).
Products of this reaction were used as a template for PCR
amplification with Taq DNA polymerase (Helena Bioscience
Ltd., Sunderland, U.K.) and primers (Oswel Ltd.) designed
from the HIV-1/HTLVIII reference genome sequence, Gen-
bank accession number K03455, - antisense (vpu) - CTA
TGA TTA CTA TGG ACC AC; sense [5'LTR] - CTC TAG
CAG TGG CGC CCG AAC AGG G,
RESULTS
Synthesis/structure
Peptide 3.7 was designed from HIV-IIIB gpl20, and
the numbering is based on this sequence. Highly
conserved sequences from the C3 and C4 regions
shared by both T- and M-tropic variants were used.
The sequence numbering is based on the SWISS-
PROT entries P03376 and P04624 (13, 14). Details of
the synthesis and rational design of 3.7 are published
elsewhere (12). Briefly, the peptide Gly459-Cys445
was synthesized automatedly using f-moc chemistry,
Lys was then manually coupled and derivatized and
the automated synthesis restarted with an extra Gly
residue, followed by Gly-431-Lys-421. After removal
of the Dde group on the Lys residue, adding the
Cys-378-Ser-364-Lys sequence completed the pep¬
tide, The extra Lys residue was added to Ser-364 to
give the option of coupling to a carrier. The Cys Cys
bond was oxidized in air to give the completed
peptide. The sequence of the branched peptide
[3.7] is shown in Fig. 1.
From sequence data available in the HIV Molecu¬
lar Immunology Database, this structure contains
human cytotoxic T lymphocyte epitopes and human
and murine antibody epitopes. The residues Lys-421
and Gln-422 are conserved in T-, M-, and dual tropic
isolates but destroy M-tropism when mutated non-
conservatively (7) and have recently been shown to
be involved in the CCR5 binding site (9, 10). The
peptide 3.7 cross reacts with polyclonal sheep anti¬
body raised against baculovirus expressed gpl20
whereas an irrelevant 44 mer peptide with an oxi¬
dized Cys-X-Cys turn (FMDV derived from a differ¬
ent organism) does not, indicating that 3.7 contains
at least some epitopes present in the native molecule
(Table 1).
To determine whether there was any basis for
potential binding of the sequence Lys-421-Gly-431 to
foto-chemokine receptor, the sequence was com¬
pared against that of binding sites on the beta-
chemokines MlPla, MIP1J3, and regulated on acti¬
vation, normal T expressed and secreted (RANTES),
the 9-10 NH2-terminal amino acid residues proximal
to the first Cys-Cys residues (15). There was no
sequence homology, but Hopp and Woods (16)
hydropathy and molecular weight plots showed that
Lys-424-Gly-432 was similar to the chemokines in
terms of charge and size (Fig. 2), such that it might
fit within a receptor for these chemokines.
Detection of peptide with mouse immune IgG
BALB/C mice were immunized with four doses of
3.7, as previously described (12), and the IgG frac¬
tion of serum purified by protein-G-Sepharose col¬
umn affinity purification. The peptide induced a
specific class-switched IgG antibody response without
coupling to a carrier molecule, indicating the pres¬
ence of both helper T and B lymphocyte epitopes
(Fig. 3). The purified IgG did not bind to an
irrelevant peptide, FMDV, of similar size.
3.7 colocalizes with CD4
Dual immunofluorescence studies with CD4-positive
MM6 cells showed that 3.7 bound by antipeptide
antibody and detected with TRITC-labeled goat an-
(i) (ii)
Figure 4. Colocalization of CD4 (7) and 3.7 (ii) on CD4+ve
MM6 cells. Confocal laser scanning photomicrographs at
X1600 original magnification.
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timouse immunoglobulin colocalized with biotinyl-
ated anti-CD4 monoclonal antibody, detected using
FITC labeled avidin (Fig. 4).
3.7 binds to the CDR2 region, domain 1 of CD4
To confirm that 3.7 binds to CD4 and to determine
to which region it binds, the interaction of different
anti-CD4 mAb's with H9 T cells was assessed in the
presence of gpl20 or 3.7 or an irrelevant peptide of
similar size, FMDV. The mAb's used were Q4120 and
LI 20. Q4120 binds to the CDR2 region, domain 1 of
CD4, and inhibits gpl20 binding to CD4; LI20 binds
to domain 4 of CD4 and does not inhibit binding of
gpl20 (12). The mAb's were used at pretitrated
concentrations, which gave 30-50% maximal bind¬
ing to allow inhibition to be detected. Both gpl20
and 3.7 inhibited the binding of Q4120 mAb, but not
TABLE 2. Peptide 3.7 inhibits the binding of QS4120 but not
LI20 to H9 T cells
% inhibition of % inhibition of
H9 preincubated with QS4120 LI 20
3.7 30 pM 22.8 ± 5.3 6.2 ± 3.0
3.7 3 (jlM 16.2 ± 5.8 1.2 ± 1.2
3.7 1 pM 8.3 ± 0.4 1.0 ± 0.3
3.7 0.1 pM 4.8 ± 0.5 1.0 ± 1.0
FMDV 30 pM 5.6 ± 5.1 6.0 ± 3.1
FMDV 3 pM 2.5 ± 1.5 6.4 ± 4.2
FMDV 1 pM 3.0 ± 1.0 0 ± 0
FMDV 0.1 pM 2.0 ± 1.0 0 ± 0
gpl20 0.1 pM 38.0 ± 1.1 0 ± 0
gpl20 0.03 pM 23.8 ± 0.6 3.0 ± 0.1
gpl20 0.01 pM 6.2 ± 0.8 0 ± 0
Figure 5. a) Expression of chemokine receptors by
RT-PCR of MM6 cells, b) Inhibition of MIP-la
binding to MM6 cells by peptide 3.7 detected by
flow cytometry. Both 3.7 and the irrelevant peptide
FMDV were used at 0.1 mM. c) Inhibition of
MIP-la binding by peptide 3.7, gp!20, and the
irrelevant peptide FMDV. FMDV did not inhibit at
0.1 or 0.01 mM. Pooled data from four separate
experiments.
















































Figure 6. Inhibition of HIV-1 BAL infection of primary macrophages by gpl20 and peptide 3.7 after 72 h (a, b) and 96 h (c, d).
a, c) 30 cycle RT-PCR showing markers in lanes 1 and 5, RT-PCR with the HIV primers in lanes 2-4, and with the (3-actin primers
in lanes 6-8. RNA from macrophage cultures preincubated with peptide 3.7 used for lanes 2 and 6, with irrelevant peptide
PSS023 for lanes 3 and 7, and with recombinant HIV-1 MN strain gpl20 for lanes 4 and 8. b, d) Relative densitometry of RT-PCR
with HIV-1 primers to RT-PCR with P-actin primers.
L120 mAb, to H9 cells, although gpl20 was more
efficient on a molar basis (Table 2).
3.7 inhibits the binding of MlP-la to MM6 cells
To investigate the possibility that, like gpl20, 3.7,
may also interact with chemokine receptors, the
ability of 3.7 to inhibit MlP-la binding to MM6
cells was studied. The macrophage-derived MM6
cell line was selected because these cells are CD4
positive, express CCR3 and CCR5 mRNA (Fig. 5a),
and strongly bind recombinant human MlP-la.
Both 3.7 and gpl20 significantly inhibited the
binding of MlP-la to MM6 cells whereas the
irrelevant peptide FMDV did not inhibit binding
(Fig. 5b,c)
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3.7 inhibits HIV-1 infection of primary
macrophages
Since 3.7 bound to both CD4 and chemokine recep¬
tors, its effect on the infectivity of the M-tropic HIV-1
BAL strain in primary peripheral blood-derived mac¬
rophages was investigated (see Fig. 6). Using a
semiquantitative reverse transcription (RT) -PCR
with p-actin as a reference housekeeping gene, re¬
combinant gpl20 blocked infection 72 and 96 h
after infection; the irrelevant peptide PSS023 did not
block at either time point. The 3.7 peptide markedly
inhibited infection on day 3 and to a lesser extent on
day 4.
DISCUSSION
The synthetic branched peptide 3.7 cross reacts with
native gpl20, colocalizes with CD4 on the cell sur¬
face, binds to the CDR2 region of domain 1 of CD4,
and inhibits MIP-1 ot binding to H9 cells. The peptide
was designed to include four of five residues in the
native molecule known to be critical for CD4 binding
(7, 8) and the results suggest that the peptide is
capable of adopting a structure that allows it to bind
to the same region of CD4 as gpl20 does. The
peptide is less efficient on a molar basis than recom¬
binant gpl20, which is not surprising since the
percentage of peptide molecules folded in any one
particular configuration will be relatively small.
The chemokine receptors CCR3 and CCR5 that
bind MlP-la (18, 19) have been shown to be core-
ceptors for macrophage tropic HIV-1 gpl20 binding
(3, 4, 20-22). However, the nature of the chemokine
receptor binding site on gpl20 is not yet fully
understood, although it is known to involve confor¬
mational determinants (9, 10) and the V3 loop (23,
24). M-tropism has been shown to involve residues
Lys-421 and Gln-422 of the C4 region (7), which
were incorporated into the design of 3.7 (12) and
have since been shown to be involved in the CCR5
binding site (9, 10). The Hopp and Woods hydrop¬
athy values and the molecular weights of residues
424-432 of 3.7 suggested that it might be capable of
low affinity binding to receptors for MIP-1 a, MIP-1 (3,
and RANTES in addition to CD4. Like gpl20, 3.7 did
inhibit binding of MlP-la to MM6 cells, suggesting
that the peptide may adopt a structure that allows it
to bind to £<?ta-chemokine receptors as well as CD4 or
that its binding to CD4 causes either a steric alter¬
ation or a down-regulation of MlP-la receptors. We
believe it is unlikely that 3.7 signals through CD4 to
cause chemokine receptor down-regulation or cy-
toskeletal changes that render the receptor less
accessible to MlP-la, because all the experiments
were conducted on ice. The binding inhibition is not
a nonspecific peptide interaction as control irrele¬
vant peptide FMDV had no effect. A number of
mechanisms exist by which 3.7 may be inhibiting
MIP-1 a. First, 3.7 may induce a conformational
change in CD4 that causes CD4 to associate with the
MlP-la receptor and, hence, allosterically occlude
the MlP-la binding site. Second, a single molecule
of 3.7 may bind to both CD4 and the MIP-1 a
receptor simultaneously. Third, separate molecules
of 3.7 may be binding to MIP-1 ct receptor and CD4.
Because of the ability of 3.7 to bind to both CD4
and chemokine receptors, we tested its ability to
inhibit infection with an M-tropic virus. Using pri¬
mary, peripheral blood-derived macrophages, we
found that 3.7 could indeed inhibit infection with
the HIV-1 BAL strain whereas the irrelevant peptide
PSS023 had no effect. It may appear paradoxical that
a sequence derived from a T cell tropic isolate is able
to inhibit ligand binding normally associated with
macrophage tropic isolates, but the sequence used is
conserved in both T and M tropic isolates. Whereas
the V3 loop has been described as necessary for
binding to chemokine receptors (6, 24), other re¬
gions of gpl20 have also been implicated (10, 25-
27). It has been reported that the V3 loop interacts
with residues from the C4 region (28, 29). Hence,
changes in the conformation of the V3 loop may
determine whether the residues involved in corecep-
tor binding from conserved regions of gpl20 are in
a position that allows interaction of the native mol¬
ecule with particular coreceptors.
That the synthetic peptide 3.7 derived from three
discontinuous sequence stretches of conserved re¬
gions can adopt a structure that allows it to interact
with cell surface ligands of native gpl20 and partially
inhibit infection of primary macrophages has impli¬
cations for the development of both therapeutic
intervention and a synthetic vaccine. This approach
also has more general implications for the synthesis
of novel peptides representing complex, sequence
discontinuous ligand binding sites of important bio¬
logical proteins. 0
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Review Article
Interactions of HIV-1 with antigen-presenting cells
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Abstract There is currently much interest in the numerical and functional loss of antigen-presenting cells (APC)
in HIV-1 disease and the contribution that this may make to HIV-1 pathology. The HIV-1 virus can interfere with
the normal function of APC in a number of ways involving inappropriate signalling. These include changes in
cytokine balance, cell-surface molecule expression and intracellular signalling pathways. This review examines
how HIV-1 is able to disregulate APC function and discusses possible outcomes for the function of the immune
system.
Key words: Acquired immunodeficiency syndrome, antigen-presenting cells, dendritic cells, human immuno¬
deficiency virus, immune system, macrophages.
Antigen presenting cell-CD4+T cell interactions
The interaction between MHC class Il-bound antigenic pep¬
tides on the surface of antigen presenting cells (APC) and the
T cell receptor (TCR) and CD4 on the surface of T helper
cells is crucial to the initiation of most antigen-specific
immune responses. In addition to TCR interaction with
antigen-MHC II on the APC cell surface, the T cell must
receive costimulatory signals. If the TCR is triggered in the
absence of costimulation, T cells become anergic or undergo
apoptosis, mediated through Fas/CD95-Fas ligand interac¬
tions.1-9 T helper 1 cells are reported to be more sensitive to
apoptosis via this type of activation than Th2 cells, due to
their up-regulation ofFas-ligand expression.6'10-13 Similarly,
if CD4 alone is cross-linked on the T cell surface, either in
v;7ro14,15 or in vivo,16,17 death of the cell results. There are a
variety of costimulatory signals requiring cell-cell contact,
including ICAM-1/LFA1, CD40/CD40 ligand and CD28/B7,
all ofwhich trigger intracellular activation pathways in the T
cell.18-21 There appears to be distinct costimulatory signal
requirements for memory and naive CD4+ T cells.22-24 In
addition to these direct contact interactions, the APC and
other local tissue cells (e.g. other leucocytes, stromal cells,
epithelial cells, endothelial cells and fibroblasts) release
cytokines and other soluble mediators, which also stimulate
intracellular activation pathways in the T cell.25-35 The
MHC IT B lymphocytes, macrophages, dendritic cells (DC)
and skin Langerhans cells (LC) all process and present anti¬
genic peptides in cell surface MHC II molecules.36-42 The
type of APC with which the T cell interacts can differ in the
cell-surface costimulatory molecules provided and the tissue
microenvironment may determine the soluble mediator milieu.
The overall balance of these signals determines whether a
nai've CD4+T cell differentiates into a Type 1 or a Type 2 helper
cell or whether a memory CD4+T cell becomes functional.
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The functional ability of an APC (in common with many
other cell types) depends on the cell's lineage, history and the
tissue microenvironment. Nai've CD4+ T cells are preferen¬
tially activated by mature dendritic cells compared to
macrophages and B lymphocytes, while memory T cells can
be activated by all three APC types.23,43 Functional compe¬
tence of APC can change over time. For example, LC can
phagocytose antigen, but lack significant costimulatory
activity. When activated by uptake of antigen, they migrate
from the skin and travel in the blood as veiled cells to the
T cell areas of lymph nodes where they once more change
their phenotype, becoming functional DC. Once in the lymph
node, they up-regulate accessory molecules and cytokines
and lose their phagocytic properties. Thus, during the
ontogeny of a DC its functional role changes from that of
acquiring antigen, to transporting antigen, to stimulating
T-cells.44-51
Clinical features of HIV-1 infection
The HIV-1 virus is transmitted by exchange of bodily fluids.
The mode of transmission may involve the transfer of free
virions or HIV-1 infected cells. Initial (acute) infection with
HIV-1 results in clinical symptoms within 1 to 3 weeks in at
least half of those newly infected. These symptoms are similar
to influenza or mononucleosis along with a non-pruritic
macular erythematous rash.52 Shortly after acute infection,
most patients undergo seroconversion. This is followed by a
period of clinical latency, which may last from 3 to more than
15 years, before AIDS develops and the patient eventually dies
of multiple infections and/or malignancies. Progression to
AIDS is accompanied by loss of CD4+ T lymphocytes, with
symptoms being noticed at blood levels less than 500 cells/L.
Although the vast majority of those who are infected with
HIV-1 will develop AIDS, there is mounting evidence that
some people are able to live with the virus for extended
periods of time without developing clinical disease. Such
individuals are termed 'long-term non-progressors', although
only time will tell if this group will also succumb to
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disease.53 Factors that affect the rate of progression to AIDS
(for review see Levy54' include age (most HIV-1 infected
infants progress relatively slowly55,56), general health (the
presence of other infections may speed progression to
AIDS57) and lifestyle (smoking,58 alcohol59 and drug use60
may all speed progression). Differences in the infecting
HIV-1 strain and the host immune response are probably also
important in disease progression rates.
Host factors affecting HIV-1 infection and disease
progression
Several host factors have been shown to effect progression rate
(for review see Roger61). As well as providing clinically useful
prognostic markers, an understanding of the mechanisms
involved in controlling infection and progression rates could be
helpful in the search for novel therapeutic approaches.
Genetic factors so far identified as important include
chemokine receptor polymorphism (discussed later), HLA
polymorphism and less clearly defined host factors that con¬
tribute to differential levels of cytokine and chemokine pro¬
duction and immune cell activity (discussed later).
Polymorphisms in HLA and HIV-1 disease progression
The HLA genotype has been shown to influence the time
taken for HIV-1 disease to progress to AIDS. Certain alleles
or allelic combinations (for example, B27, B51 and (A25 +
TAP2.3)) are protective. Other alleles, such as B37 and (B6
+ TAP2.1 or TAP2.3) indicate for rapid progression.62 Poly¬
morphisms in HLA may exert effects through differences in
HIV-1 antigen presentation, causing different efficiencies of
anti-HIV-1 immune response.63 Alternatively, because the V3
loop of HIV-1 glycoprotein (gp) 120 mimics HLA DR5 and
HLA DR6, the anti-HIV-1 TCR repertoire may be influenced
by the deletion of self reactive CD8+ T-cells during self-
tolerance induction.64
Associations of HLA alleles with disease progression
rates may be due to genetic linkage between HLA loci and
other loci of the MHC, such as those that code for the TNF
and complement components. The TNF can induce HIV-1-
infected cells to produce virus through activation of NF-tcB.
Polymorphisms of the TNF promoter have been associated
with differential rates of disease progression.65,66 The com¬
plement component, C4, has two null alleles that have been
associated with low plasma C4 concentrations, poor antibody
responses and rapid progression.67,68
Other potentially important host factors
A Danish study has shown an association between homozy¬
gosity for loci conferring low serum levels of mannose-
binding protein (MBP) and increased HIV susceptibility and
shortened survival time between AIDS diagnosis and death.69
Many cytokines, especially those that are pro-inflamma¬
tory (TNF, IL-ip and IL-6) up-regulate viral replication in
infected cells, while other cytokines (11-4, IL-10 and IFN-fi)
down-regulate HIV-1 production.70 It is conceivable that
genetic polymorphisms in the inducibility of such cytokines
could influence the HIV-1 disease progression rate.
P-Chemokines inhibit macrophage-tropic HIV-1 infection
and a-chemokines, such as stromal cell-derived factor
(SDF-1), inhibit T cell-tropic HIV-1 infection. A G to A
substitution in the promoter of sdf-1 has been shown to accel¬
erate progression to AIDS.71,72
Virus genetic factors affecting HIV-1 disease
progression
The lack ofHIV-1 disease progression in some long-term sur¬
vivors (LTS) cannot be attributed to any as yet identified host
factor. An alternative explanation for the lack of disease pro¬
gression is that at least some of the LTS are infected with
HIV-1 of a low pathogenicity.73 Rapid clinical progression is
associated with rapid viral replication.74,75 Defects in the viral
genes nef, vif vpr, vpu, tail, revl, gag and env have all been
associated with slowed replication or delayed clinical pro¬
gression.73,76-84 A methionine to isoleucine substitution in the
initial amino-acyl residue of gag and premature stops have
been associated with long-term survival.73 A G to A nucleo¬
tide substitution in the long terminal repeat (LTR) results in
a low viral load and long-term survival.82 A shift from an
M- to a T-tropic virus population, as controlled by the
sequence of env, is associated with disease progression.75
Long-term survivors have also been identified with an
infecting HIV-1 that carries a rare env mutation, which
renders the virus nearly completely unable to infect CD4+ cell
lines, activated PBMC or macrophages.84
Human immunodeficiency virus
The HIV-1 virus is a lentivirus of the family Retroviridae.
Lentiviruses are all associated with a long incubation period
and several are associated with the haematopoietic and
immune systems.54 The HIV-1 has the physical structure
characteristic of a lentivirus; this consists of a truncated cone
shaped core that contains two copies of a single-stranded
RNA genome and the enzyme reverse transcriptase. A protein
matrix enclosed in a lipid envelope that bears 72 knobs of the
envelope glycoprotein gpl60 surrounds the core. gpl60 con¬
sists of an external gp 120 peptide and a gp41 transmembrane
component.
Because HIV-1 uses a reverse transcriptase enzyme with a
low fidelity,85 it has a very high mutation rate and conse¬
quently much diversity. Viral diversity exists on several levels,
but is particularly important in the major immunogenic
protein gpl20 that has several hypervariable (V) regions.
Clades of HIV-1
The comparison of genomic sequences encoding the V3
region of gpl20 has allowed six HIV-1 subtypes (clades) to
be identified (A-F, with the O grouping for outlyers and the
N (New) grouping from Cameroon).86 The clades show
broad, but distinct geographical ranges. Clade A is prominent
in central Africa, clade B in North America and Europe, clade
C in South Africa and India, clade D in central Africa, clade
E in Thailand and clade F in South America. Such a distrib¬
ution pattern could be due to patterns of spread, to differences
in host immunology brought about by the geographical dis¬
tribution of selective pressure from other pathogens and/or
to differences in the predominant transmission mode. The
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HIV-1 epidemic in Thailand is largely due to heterosexual
transmission. There is some suggestion87,88 that the clade E
virus, common in Thailand, is especially well suited to this
transmission route as it is able to replicate better than clade
B viruses in Langerhans cells, which have been implicated in
transmission across the vaginal mucosa. Clade B viruses may
be better adapted to the homosexual and intravenous trans¬
mission routes most common in North America and Europe.
CD4 and HIV-1
The main cell surface receptor for HIV-1 is the CD4 mole¬
cule89 (Fig. 1) and CD4+ T cells are a major cellular target for
infection. The gpl20 envelope protein on the virion surface
binds to CD4 and then to a chemokine receptor (usually
CXCR-4 or CCR-590) on the target cell. After CD4 binding,
a conformational change in gp 120 allows a fusogenic region
of gp41 to become exposed and mediate the fusion of the
viral envelope and the host membrane. CD4 is an important
molecule in the immune system: in addition to acting as an
MHC class II coreceptor on T cells, it also acts as a receptor
for interleukin-16 (IL-16, originally called lymphocyte
chemoattractant factor) on several immune cell types.9' CD4
is also found on activated cells of the monocyte, macrophage
and dendritic lineages; these cells have a role as APC and are
infected by HIV-1 both in vitro and in vivo.
Cellular tropism of HIV-1
The crystal structure of the CD4 binding site has recently been
published and this involves several conserved residues in the
gpl20 molecule.92 However, it had long been suspected that
HIV-1 required an additional, secondary, receptor in order to
infect cells. Research since 1995 (for review see D'Souza and
Harden90) has identified the secondary receptor as being a
member of the chemokine receptor family (Fig. 1). At least 10
different chemokine receptors have been identified. The HIV-
1 can use several of these molecules as a secondary receptor,
but most commonly uses CCR-3, CCR-5 and/or CXCR-4 (for
a review of chemokine and chemokine receptor function and
nomenclature see Baggiolini et a/.93). The type of chemokine
receptor that the virion is able to use depends on the sequence
of its gpl20. The V3 loop of gpl20 is particularly important
in determining receptor usage. The viral DNA encoding this
region is highly variable between viral strains and also
mutates during the course of infection, allowing the virus to
change its coreceptor usage, and therefore its phenotype, with
time. However, it has recently been shown that conserved
regions of gpl20 are also important in binding to chemokine
receptors.94 The conformation of the V3 loop changes on CD4
binding, which may allow previously hidden conserved
residues access to chemokine receptors.
Because of a differential distribution of chemokine recep¬
tors between cell types, the type of receptor that a particular
gpl20 is able to bind to influences the cellular tropism of the
virion. Most primary isolates of virus from patients are
macrophage (M)-tropic, can infect both macrophages and
T cells and use the CCR-5 coreceptor. Lab-adapted strains
grown for many passages on T cell lines only use CXCR-4 as
a coreceptor. Patient isolates ofprimary T cell strains are able
to use both CCR-5 and CXCR-4.95 An alternative classifica¬
tion of HIV-1 tropism refers to the chemokine receptor used
Figure 1 HIV-1 interactions with
APC cell surface receptors. HIV-1
and its shed surface protein gpl20
are able to interact with a number
of receptor molecules on APC.
The gp 120 protein has binding
sites for CD4 and chemokine
receptors such as CCR5. It can
also interact with Fc or comple¬
ment receptors via anti-HIV-1
antibodies. Outcomes of HIV-1
proteins binding to APC receptors
include infection of the cell by
HIV-1 (a process that can be
enhanced by antibodies to HIV-1,
antibody-enhanced infection), and
phagocytosis of receptor com¬
plexes bound to soluble gpl20,
leading to the loss of receptors,
such as CD4, and possible entry of
the receptor/gp 120 complex into
antigen processing pathways. It
should be noted that all of the
HIV-1 receptors are linked to
intracellular signalling pathways
that can be activated on binding
HIV-1 or gpl20 and that this can
lead to disruption of the cell's func¬
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as a coreceptor. Under this scheme HIV-1 may be classified
as R5 (CCR-5) or X4 (CXCR-4) tropic. It is important to
realize that the designation of viral strains to particular tro-
pisms is only an approximation of reality.96 Tropisms overlap
and the infectability of a cell depends on its activation state
as well as its phenotype. Almost all HIV-1 strains enter and
replicate in activated T cells if added to cultures at suffi¬
ciently high concentrations.95 The HIV-1 virus is able to
target a fairly wide range of cell types for infection (see
Levy54 for a comprehensive list), but it may also disrupt the
function of other immune cells without infecting them.
Chemokine receptor polymorphisms and disease
progression rate
The study of coreceptor usage has led to some interesting
clinical observations. Ccr5 and ccr2 are both closely linked
on chromosome 3p21-22.97 CCR-5 has three known alleles:
wild-type (wt) and two mutations, the A32 deletion98 and the
m303 premature truncation.99 Both mutant alleles result in a
failure of functional receptor to appear on the cell surface. In
populations of European descent, a null mutant in the CCR-5
gene is present at surprisingly high frequencies: about 18%
are heterozygous for a ccr5 mutation and about 1% are
homozygous.100 The most frequent ccr5 null mutation is the
A32 deletion.
The mutations do not confer a selective disadvantage, but
they appear, at least when homozygous, to protect the indi¬
vidual against infection by HIV-1 or to confer a long-term
non-progressive disease course.101 The reasons why such
individuals do not become infected by virus using an alter¬
native coreceptor (T-tropic strains using CXCR-4 for
example) are obscure. It could be that M-tropic strains (using
CCR-5) are responsible for the initial mucosal infection of
APC required for sexual transmission of HIV-1.100
During asymptomatic HIV-1 infection, the virus is repli¬
cating rapidly and with low fidelity.102 This produces a great
deal of diversity in most of the viral proteins, which can allow
the virus to evolve resistance to therapeutic drugs. However,
during the asymptomatic phase it is usually only possible to
isolate CCR-5-using virus. It is only during the symptomatic
phase, when the immune system collapses, that broadening of
coreceptor usage is seen. There is also a switch from the non-
syncytium-inducing (NSI) to the more cytopathic syncytium-
inducing (SI) phenotypes. It has been suggested that in the
early stages of infection, the immune system suppresses
viruses with expanded coreceptor specificity,100 although the
mechanism by which this would be achieved remains
obscure.
The extent of protection from infection and disease pro¬
gression gained by the wt/A32 genotype is controversial. Pro¬
tection is probably only partial and may only be from
transmission by heterosexual sex and not from homosexual
and intravenous infection routes.61'103"105 A ccr2b mutation,
641 (a valine to isoleucine substitution), has also been epi-
demiologically linked to reduced disease progression rate in
HIV-1+ individuals.61 The amino-acyl residue substitution
manifested in the 641 allele is conservative and found in a
transmembrane region of the protein. This observation,
together with the fact that HIV-1 rarely uses CCR2b as an
important coreceptor, suggests that the ccr2b64I allele may
not affect disease progression directly, but is merely a linkage
marker for another locus that is able to confer protection. One
candidate locus to show a linkage to ccr2b is the ccr5 pro¬
moter (ccr5p). An A/G polymorphism at the ccr5p locus has
been linked to lower promoter activity and a progression to
AIDS 3 or 4 years more slowly than the wild-type
cct5jp.106'107 Alternatively, the ccr2b64I allele may influence
chemokine secretion or CCR-5 or CXCR-4 expression.108
Human immunodeficiency virus-1 as an antigen
Infected individuals develop CD8+ cytotoxic T cells that
recognize epitopes on a number of HIV-1 proteins, including
gpl20, and these may control initial infection. The surface
glycoprotein gp 120, probably because of its exposed position
on the virion surface, evokes an especially strong antibody
response. However, the anti-gpl20 antibody response is ulti¬
mately ineffective in controlling HIV-1 infection in most
patients, despite the ability ofmany anti-gpl20 antibodies to
block infection in vitro. gpl20 is not only found on the virion
surface, but it can also be shed into the extracellular com¬
partment and found in the plasmalemma of infected cells. In
the extracellular compartment, gpl20 can act as a T cell109
and B cell"0 superantigen and cause the functional loss of
lymphocyte subsets. The anti-gpl20 antibody response of
most patients is very skewed. Antibodies using the VH3 gene
product dominate normal human antibody responses.
However, antibody responses to HIV-1 in infected individu¬
als rapidly lose any contribution from VH3 and there is over-
representation of the VH4 locus. The deletion of VH3 using
B cells is attributed to a gpl20 superantigen incorporating
sites in the C2 and V4C4 domains of gp 120. The exception to
this is seen in long-term non-progressors who do have VH3
antibodies present in their serum, but do not make antibodies
to the superantigen determinant.
Antigen-presenting cell-HIV-1 interactions
The HIV-1 virus interacts with cells of the immune system in
many different ways. Many of the effects of HIV-1 have been
principally investigated using T cells or T cell lines, but it has
become obvious that the interaction of HIV-1 with cells
extends much further than simply infecting CD4+ T cells. It
is possible for HIV-1 to target a fairly wide range of cell types
for productive infection (see Levy54 for a comprehensive list),
which is a multistage process with possibilities for deregu¬
lation of the immune system at every step. In addition, HIV-1
may disrupt the function of, or even kill, other immune cells
without infecting them. Extracellular gp 120 can also alter the
function of APC.
gpl20 induces changes in APC cytokine production
Ankel et al. have reported that gp 120, in the absence of any
other viral component, is able to induce interferon (IFN,
mainly a with some y) production in PBMC.111 The inductive
effect of gpl20 is abrogated by the addition of soluble CD4
(sCD4) and is dependent on the V3 loop. This suggests that
binding and presumably the resultant clustering of CD4 and
a chemokine receptor is required and sufficient for IFN pro¬
duction to result.
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More recent work112 has shown that the ability ofAPC to
produce cytokines in response to gpl20, and the ability of
cells to respond to cytokines, can depend on the differentia¬
tion state of the cell. It has been shown that as monocytes dif¬
ferentiate to macrophages they show an enhanced IFN-j)
production in response to HIV-1 infection, bacterial lipo-
polysaccharide (LPS) or gpl20 treatment. Concomitant to
this, the cell sensitivity to IFN, as measured by the induction
of protection from vesicular stomatitis virus (VSV), granted
by IFN-P increased with differentiation to macrophages
because of up-regulation of IFN receptors.
Interleukin-10 secretion in response to gpl20 has also
been observed, but the level of this did not depend on the
cells' differentiation state. Interleukin-10 secretion could
cause the switch from Thl to Th2 helper subtypes observed
in HIV-1 disease.113 The cells only produce IL-12 in response
to gpl20 if they had been previously primed by IFN-p. Only
macrophages could be primed by IFN-P, presumably due to
their greater sensitivity to this cytokine.
The effects that the cytokines have on the rest of the
immune system and on HIV-1 replication are complex
(Fig. 2). Interferon is able to down-regulate HIV-1 expression
in macrophages."4 In contrast, TNF has been shown to up-
regulate HIV-1 expression. The exact role ofmany cytokines,
including the novel chemokines, awaits further investigation.
Does HIV-1 induce a Thl to Th2 switch?
The Th 1 to Th2 switch hypothesis, as proposed by Clerici and
Shearer, states that progression to AIDS is dependent on a
switch from Thl to Th2 as the dominant Th subset."3 The
evidence to support this assertion includes the observation
that in short-term PBMC culture, cells taken from patients of
increasing clinical progression show a concomitant increase
in IL-4 and IL-10 production and a loss of IL-2 and IFN-y
production. There are also data that show that T cell clones
from HIV infected skin biopsies are more likely to be classi¬
fied as Th2 clones than clones derived from healthy control
skin."5'116 Clerici and Shearer have shown that many HIV-1
exposed, but uninfected, individuals are able to generate
strong Thl type responses and suggest that these individuals
are protected from disease by the failure to undergo the
normal Thl to Th2 switch.113
The mechanism by which the switch operates may involve
T cell- or APC-produced cytokines to bias the Th response to
Th2. For example, Ito et al. have shown that in PBMC and
lung macrophages the HIV-1 protein Tat inhibits production
of the Thl cytokine IL-12.117
There is, however, some evidence that argues against the
Thl toTh2 switch hypothesis.118"120 Romagnani et al.115 have
been unable to reproduce the observations by Clerici and
Shearer113 on IFN-y, IL-1 and IL-4 production in their short-
term PBMC culture system. They have argued against using
PBMC for such experiments because as well as containing Th
cells, PBMC contain monocytes, B cells, NK cells and CD8+
T cells, all of which are capable of producing cytokines. The
proportions and absolute numbers of these different cell types
will change as disease progresses. Changes in the cytokine
profile attributed to a Th subtype switch could be due to
selective deletion of Th-cell subtypes. The T cells present in
skin biopsies may not reflect the types found elsewhere in the
body.
The Thl to Th2 switch hypothesis has recently become
more complicated with evidence that Th2 and ThO cells are
able to replicate HIV-1 more efficiently than Thl cells.120,121
Whether this translates into a longer or shorter life span for
the infected cells is unclear. InterIeukin-4 has been shown to
up-regulate and IL-12 to down-regulate CXCR-4 expression
and therefore infectability by the T cell-tropic HIV-1 strains
associated with disease progression.122,123 This observation
Figure 2 Regulation of virus
production by APC. The rate of
HIV-1 production by APC is
highly influenced by the activation
state of the cell. Signalling through
cell surface receptors such as CD4
(see Fig. 1) can affect the cellular
state. Cytokines produced by other
cells in response to HIV-1 or other
pathogens also have an influence
on HIV-1 production. Interferon
and interleukin-10 have been
shown to down-regulate HIV-1
production and other cytokines
such as TNF may stimulate an
increase in HIV-1 production.
Finally, the cell's maturation/dif¬
ferentiation state, as influenced by
the tissue micro-environment and
cytokines, such as granulocyte-
macrophage colony-stimulating
factor, can alter the cell's suscepti¬
bility to infection or the production
rate of HIV-1 by an infected cell.
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may argue for a Th2 (IL-4) shift increasing selective pressure
on the virus to use CXCR-4. However, another Th2 cytokine,
IL-10, increases CCR5 (associated with macrophage
tropism) expression, so the picture is far from clear.
gpl20 induces a cell-signalling defect
Hubert et al. showed that in T cells, gpl20 is able to cause a
dissociation of cell-surface CD4 from cytoplasmic p56LCK.124
This results in a down-regulation of CD4 expression (a pos¬
sible mechanism of avoiding HIV-1 superinfection) and an
abrogation of signalling through the TCR/CD3 complex. In
the context ofmacrophages, CD4 plays a different role to that
in T cells.91 The p56LCK kinase has never been found in
monocytes or macrophages, although other src kinases, such
as Lyn, are present. It is possible that gpl20 can inhibit
signalling through CD4 in macrophages, causing CD4/src
kinase dissociation and reduced CD4 expression.
Work at the Department of Pathology, University of Edin¬
burgh has shown that recombinant purified gpl20 is able to
induce a substantial loss of CD4 from the surface of cultured
primary macrophages.125 This loss is only observed with
gp 120 derived from an mRNA sequence from a macrophage
tropic primary patient isolate. It was not observed using
gp 120 from the T cell line-adapted IIIB strain of HIV-1. This
strain specificity, together with the failure to observe CD4
loss in ccr5A32 mutant macrophages (effectively ccr5 null)
suggests the involvement of the CCR5 chemokine receptor in
gpl20-induced CD4 down-regulation on APC (Fig. 1).
gpl20 may also interfere more directly with CD4 function
by directly competing with its other ligands (MHC class II
proteins and IL-16). It has also been suggested,54 although
not proven, that anti-idiotypic antibody mirroring gpl20 may
have a role in HIV-1 pathogenesis.
Other HIV-1 proteins induce cell-signalling effects
Nef and Vpu are two other HIV-1 proteins that have been
shown to induce cell-signalling defects in infected cells.
Many activities have been attributed to Nef and the function
for which it has evolved is still not fully understood. It is
needed to maintain high viral loads126 and may achieve this
by inhibiting the superinfection of cells (this could result in
the death of a cell before it had been used to produce many
virions127) or by optimizing protein sorting to the viral mem¬
brane during virus particle assembly.128
When the monocyte/macrophage-like cell line, U937, was
transfected with nef, De et al. observed a down-regulation of
FcyRI and FcyRII and a changed cytokine response to LPS
and PMA.'27 In these myeloid cells, ne/transfection caused
an up-regulation of MHC class I surface expression. In con¬
trast, in T cells Nef induced a down-regulation of MHC class
I129 by causing rapid endocytosis of Nef and MHC class I
complexes.130 Nef has also been demonstrated to induce a
CD4 down-regulation, at least inT cells.131 The HIV-1 protein
Vpu is unique among primate Antiviruses in being only
found in HIV-1 and the closely related SIVcpz.132 Vpu com¬
plexes with nascent CD4 in the endoplasmic reticulum and
leads to its retention and degradation.133
The role of gpl20 in inducing leucocyte apoptosis
It has been reported that gpl20 interacting with its receptors,
in the absence of signalling through the TCR, can lead to
T cell anergy and priming of the T cell for activation-induced
cell death (AICD), a form of apoptosis, upon receiving a sub¬
sequent signal via the TCR.134 Whether gpl20 can prime
APC for apoptosis and what trigger would result in cell death
is not known.
It has also been reported that HIV-1-infected APC can
prime T cells to undergo AICD (Fig. 3).135 The priming of
cells requires two signals from the APC to the T cell to be
delivered simultaneously. The first signal is antigen specific
and is delivered through the TCR. The second signal is deliv¬
ered (presumably via CD4 and/or chemokine receptors) by
gpl20 expressed on the surface of the APC. Experiments
involving the transfection of monocytes to express single
HIV-1 proteins have shown that gp 160 alone is sufficient to
constitute the second signal and that no other viral compo¬
nent is required.
Activation-induced cell death can result in hidden damage
to the immune system in the absence of a significant decline
inT cell numbers. T cell clones, which are required to provide
protection against HIV-1 and other pathogens present in the
host, are selectively destroyed because it is these T cells that
will receive antigen-specific signals from APC.
It may be that HIV-1 infected APC are unable to deliver
appropriate cosignals to CD4+ T cells136 and this may result
in T cell anergy or apoptosis. Monocytes/macrophages in
HIV-1 disease may produce subnormal levels of IL-12, result¬
ing inT cell death.137-139 T cell deletion in HIV-1 disease may
be the result of an HIV-encoded super-antigen; although this
has yet to be identified, some authors have suggested Nef as
a candidate.140'141 There is some evidence that the HIV-1 gene
Tat can be secreted by infected cells142'143 and taken up by
surrounding non-infected cells.144-146 Once in cells, Tat can
induce oxidative stress by activating NF-kB and TNF-a
expression;147 such oxidative stress can prime cells for apop¬
tosis. Additionally, Tat may be able to directly down-regulate
the expression of bcl-2, an anti-apoptotic gene.148
Other HIV-1 proteins can be cytotoxic in isolation. gp41
is toxic to cells, probably through alterations of membrane
permeability.149 Domains ofNef, Tat and gp41 all show sim¬
ilarities to neurotoxins.150-151 Nef can change the membrane
potential of cells150 and Tat has been demonstrated to cause
neurone death.152 The effects on other cell types are less well
known.
Cell/HIV-1 binding and membrane fusion: Potential for
disregulation
As discussed earlier, HIV-1 binds to the surface of target cells
by using gpl20, which interacts with host CD4 and a chemo¬
kine receptor. Although both cellular receptors are usually
required for infection, there have been reports of infection of
CD4 "T cells.153 The mechanisms of this are poorly understood
and may involve infection of double-positive thymocytes.
The efficiency of infection of APC and other cell types
bearing Fc or complement receptors can be enhanced
by HIV-1 opsonized for the receptor via a non-neutralizing
antibody, a phenomenon known as antibody-dependent
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Figure 3 HIV-1 control of anti¬
gen presentation and APC-T cell
interaction. Anti-HIV-1 T cell
responses are observed in HIV
disease, so APC must be able, on
occasion, to present HIV-1 protein
epitopes together with costimula-
tory signals to T cells. However,
HIV-1 infection is able to induce
B7 (CD80) loss from the surface
of APC; this can result in antigen
(from HIV-1 and other pathogens)
being presented to T cells in a
context that, rather than activating
the T cell, can induce T cell
anergy or activation-induced cell
death. As well as giving inappro¬
priate signals to mature T cells,
HIV-l-infected APC can disrupt
thymocyte development by inap¬
propriate intrathymic signalling.
Antigen-presenting cells infected
with HIV-1 can also affect the
nature of a T cell response by pro¬
ducing cytokines, such as inter¬
feron and interleukin-10, which
cause immune deviation from a
Thl to a Th2 response. The Th2
response is less effective at com¬
bating HIV-1 disease. A1CD, acti¬
vation-induced cell death.
enhancement (ADE; Fig. I).'54 In some studies, ADE abro¬
gated the requirement for CD4 binding and allowed the infec¬
tion of CD4~ cells.155 In other studies, CD4~gpl20 binding
was reported as essential for infection.156 Ligation of Fc and
complement receptors must also have implications with
respect to intracellular signalling, regardless ofwhether infec¬
tion is the end result.
In some cases, HIV-1 may bind to the surface of a cell in
the absence of envelope/plasmalemma fusion and without
infection of the cell. However, bound virion may 'piggy-back'
on a migrating cell and lead to the dissemination of the virus.
Dendritic cells have been implicated in transporting bound
virus from the mucosal site of entry to the lymph nodes.31
After virion binding, in order for infection to become
established, the target plasmalemma must fuse with the viral
envelope. Fusion appears to be mediated by a fusogenic
portion of gp41.157 It is important to remember that both the
inner and outer lipid monolayers must fuse and that each
fusion may be an independent event. It is possible that partial
fusion could result with the core unable to enter the cyto¬
plasm. Neutralizing antibodies mostly act by preventing
virion binding; some, especially those against gp41, may
interfere with the envelope protein's fusogenic function.
The replicative cycle of HIV-1
After cell fusion, the viral core enters the host cytoplasm and
the genome and reverse transcriptase molecules are unpacked;
the single-stranded RNA genome is reverse transcribed and
eventually forms double-stranded DNA. This DNA is then
transported to the cell nucleus where it is circularized and
integrated into a random site on the host DNA. Non-
integrated viral DNA may be able to produce infectious HIV-
l,158 but integration is a requirement for efficient, long-term
virion production.
Sun et al. have shown that HIV-1 can enter resting CD4+ T
cells and that the initiation of reverse transcription can take
place in these cells.I5<) Formation of the full length viral DNA
requires the cell to be activated by TCR ligation (signal one),
a signal that normally regulates the GO to G1 transition. Trans¬
port of the viral DNA to the nucleus to allow for integration
requires an additional signal (signal two, costimulation via
CD28 ligation). The second signal has been shown to be IL-2
receptor dependent and sensitive to cyclosporin A. The
signals required to stimulate HIV-1 production in APC may be
different from those required by T cells, but the differentiation/
activation state of the cell will still be important. For a discus¬
sion of the dynamics ofHIV-1 replication see elsewhere. I6°-'62
Although macrophages express less CD4 than their mono¬
cyte precursors, macrophages are more susceptible than
monocytes to HIV-1 infection. In contrast to T cells, non-
dividing, resting macrophages can become productively
infected.163 However, macrophages produce HIV-1 at a slower
rate than do T cells; this may be a result of reduced intra¬
cellular pools of nucleotides and other precursors in macro¬
phages, which show slower division rates than T cells.
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) has been implicated in some of the signals controlling
Thymocyte interactions
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HIV-1 production by APC of the monocyte/macrophage
lineage. Crowe and Lopez showed that GM-CSF, a cytokine
produced by many cell types including activated T cells, can
affect the replication of HIV-1 in cells ofmacrophage lineage
at several levels.164
Monocyte survival is promoted by GM-CSF through the
inhibition of apoptosis and the stimulation of proliferation,
which increases the number ofHIV-1 targets. The differentia¬
tion of monocytes is also promoted by GM-CSF. On its own,
GM-CSF stimulates differentiation to macrophages; with
IL-4 also present, monocytes are driven to become dendritic-
like cells. Differentiation of monocytes down either of these
pathways appears to result in the down-regulation of surface
CD 14,165 although one study claims that in the monocyte/
macrophage cell line Ul, GM-CSF up-regulates CD 14 expres¬
sion.166 Differentiation driven by GM-CSF may be important
in HIV-1 disease because it turns monocytes, cells that are
relatively resistant to infection, into more likely target cells.
The long-terminal repeat: The HIV-1 promoter
After HIV-1 DNA has been integrated into a host chromo¬
some, the production of new virions requires the transcription,
by host transcriptases, of the provirus, to produce both viral
mRNA and genomic viral RNA for packaging. Transcription
of viral genes is under the control of the long terminal repeat
(LTR), a viral promoter found directly 3' and 5' to the viral
genes. The effects of cellular activation and cytokines on
HIV-1 expression can be explained in terms of the transcrip¬
tional effects on the LTR.
The initiation of HIV-1 transcription is under the control
of cellular factors that bind to the LTR. Nuclear factor-KB,
nuclear factor of activated T cells (NFAT), activation protein
1 (AP-1, consisting of a Jun/Fos heterodimer) and Sp-1 have
all been shown to activate HIV-1 transcription (for review see
Gaynor167). Once transcription has begun, the viral protein
Tat (transactivator) can interact with the transactivation
responsive (TAR) regulatory element and the requirement for
cellular transcription factors may be reduced.
The transcription factor NF-kB in resting T cells is
sequestered in an inactive form bound to an inhibitory
subunit, I-kB. Activation signals received by the cell through
the TCR have the downstream effect of phosphorylating I-kB
and this allows NF-kB to be released, bind to and activate
both host and viral genes. Alcami et al. have shown that tran¬
scriptional activation by NF-kB is an absolute requirement
for HIV-1 transcription and that Tat/TAR mediated amplifi¬
cation can only occur as a result of earlier NF-kB effects.168
CD14 levels can also be important in the control of HIV-1
expression. CD 14 acts as a receptor for LPS/LPS binding
protein complexes and thus mediates responses to LPS.169





Figure 4 Other HIV-1/APC
induced cellular damage. Macro¬
phages infected with HIV-1 have
been shown to produce nitric
oxide, which is a neurotoxin. The
damage done to neurons in this
way may contribute to AIDS-
related dementia. Immune system
damage may result from the HIV-1
proteins gp41 and gpl20 leaking
onto the plasmalemma of infected
cells. In the case of gp41, this can
be directly cytotoxic due to the for¬
mation of pores in the cell mem¬
brane. Leaking of viral proteins to
the cell surface can also induce
cell-cell fusion in a fashion similar
to cell-virion fusion. The resulting
syncytium not only results in the
loss of the daughter cells, but the
cell-cell fusion can be advanta¬
geous to the virus, because it
brings together nuclear factors
important for HIV-1 transcription,
such as nuclear factor (NF)-kB
and Spl, in the same cell and this
allows for accelerated virus pro¬
duction. Syncytia may also be sites
at which interstrain recombination
can take place increasing virus
genome variability.
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regulation ofHIV-1 expression in HIV-1 infected monocytes.
This up-regulation is abrogated by anti-CD14 antibodies.166,170
It has also been shown that GM-CSF has a more direct
effect on HIV-1 expression by enhancing in vitro virus pro¬
duction in primary monocytes and macrophages, but not in
T cells or Langerhans cells.164
Thornton et al, in work on the U937 monocytic cell line,
presented evidence to suggest that HIV-1 can subvert the
normally antiviral interferon response to control viral repli¬
cation.153 The HIV-1 has a sequence in its regulatory region
mimicking the IFN-stimulated response element (ISRE). The
ISRE normally activates transcription of antiviral defence
genes in response the binding a member of the IFN regula¬
tory factor (IRF) family. Use of IRF-dependent transcription
could be an advantage to HIV-1, because IRF proteins are
activated on viral infection.
Syncytia induced by HIV-1: Implications for HIV-1
transcription
An important in vivo and in vitro feature of HIV-1 is its ability
to induce syncytia (multinucleate cells) by the fusion of an
infected cell with other infected or uninfected cells (Fig. 4).
Cell-to-cell fusion and syncytia formation involves CD4,
chemokine receptors, gpl20 and gp41 and appears to be
similar to cell-virion fusion. Fusion to syncytia may result
from gpl60 leaking onto the plasmalemma of infected cells
and interacting with CD4 and chemokine receptors on other
cells. Usually primary macrophage tropic strains, using CCR-
5, do not form syncytia in T cell lines, whereas viruses able
to utilize CXCR-4 often do. The categorization of strains into
syncytium-inducing (SI) and non-SI (NSI) phenotypes is,
undoubtedly, an oversimplification, although coreceptor
usage must be important.95
Burke suggests that cell-to-cell fusion is an important
HIV-1 evolutionary strategy, analogous to sex, which facili¬
tates recombination between viral strains by allowing them to
come together in a syncytium, a structure likened to a mating
ground.171 From a molecular-biological point of view, syn¬
cytium formation may be important in bringing together tran¬
scription factors from different cells to allow efficient HIV-1
expression. It has been suggested that syncytium formation
could allow HIV-1 replication to take place in non-activated
memory T cells.172 Experiments have shown that NF-kB and
Sp-1 are both vital transcription factors for HIV-1. They have
suggested that non-activated T cells fail to express HIV-1
because they contain Sp-1 but not NF-kB. Purified dendritic
cells fail to support HIV-1 replication because they lack
Sp-1, despite containing high levels ofNF-kB. Dendritic cell/
T cell syncytia bring together the two factors and allow up-
regulation of viral transcription in the absence of immune
stimulation.172
Immune status and HIV-1 replication rate
A recent paper by Wahl and Orenstein reviews work that sug¬
gests that the activation state of the host immune system has
an important control over HIV-1 replication rates.57 Evidence
is presented to show that vaccination and infection can both
activate the immune cells and lead to an increase in viremia.
Increased HIV-1 replication under the influence of other
microbes can be a result of changes in immune cell activation
or of a more direct interaction. For example, early gene-
products of human herpes virus can exert an effect on the
HIV-1 LTR and enhance HIV-1 expression.167
Loss of APC numbers in HIV-1 disease
Human immunodeficiency virus-1 disease leads to a reduc¬
tion in the number of APC in the periphery (losses in skin,
blood and gut have all been described).173 There are several
possible reasons for this loss in cell number.
The loss of cells may be due to the lysis of infected cells
by the CTL response. In vitro, DC can be targeted by anti-
HIV-1 CTL.173 It may be that the killing of an APC by the
CTL that it has just activated is part of a normal negative-
feedback mechanism of controlling excessive T cell activa¬
tion. Such a mechanism would only become a problem in
HIV-1 disease, because of the persistence of infection
(leading to sustained, long-term loss ofAPC) and the reduced
capacity for APC replacement (see later).
Loss of Langerhans cells from the skin may simply reflect
migration of cells from the periphery to the lymph nodes in
response to activation. Alternatively, APC may be lost by
being fused with T cells during syncytia formation or they
may die in situ by apoptosis as a direct result of infection.
Levy suggests that host cells could be destroyed in an
autoimmune fashion by other immunocytes, which recognize
host proteins on these cells as foreign because they are linked
to an HIV-1 protein (gpl20, for example) acting as a hapten.54
Antibodies to cellular proteins and a wide range of auto¬
immune disorders have been detected in HIV-1 infection.174
Whether APC are targeted in this way is not known.
A reduction in Langerhans cell numbers in skin could be
due to a failure of haematopoiesis or a failure of tissue coloni¬
zation by cells from bone marrow progenitors. Knight and
Patterson report that CD34+ bone marrow-derived stem cells
show little capacity to develop (morphologically or function¬
ally) into DC in patients with advanced AIDS.173
Damage done to the immune system by APC in the
presence of HIV-1
As has been previously noted, HIV-1-infected APC or APC
that have interacted with HIV-1 proteins show a reduced
capacity to stimulate T cell effector function and may even
prime T cells for AICD. The decline in stimulatory capacity
is probably the result of the loss of immunologically impor¬
tant surface molecules by APC in HIV-1 infection.
Gabrilovich et al. have shown that infected DC down-regulate
MHC class II, CD44 and CD54.175
Antigen-presenting cells are not only important in initiat¬
ing an immune response, but in determining the direction that
the response takes. Kuchroo et al. suggest that the divergence
of theT cell response to theThl (cytotoxic) orTh2 (humoral)
subtype is controlled by differential expression of B7.1 and
B7.2 by APC.176 A switch from a Thl (IL-2 and IFN-y medi¬
ated) to a Th2 (IL-4 and IL-10 mediated) response has been
suggested as a critical step in HIV-1-disease establishment
and progression. This switch is absent in many seronegative
HIV-1-exposed ('resistant') individuals, who continue to
generate Thl-type responses to HIV-1.113
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The type of APC and the concentration and type of
antigen may be important in fixing the response type.173 It
would be interesting to know if the primary macrophage
culture system used in our laboratory in the Department of
Pathology to show gpl20-induced down-regulation of CD4
could be used to demonstrate a gpl20-induced shift in
response type (manifested by changing B7.1 /B7.2 expression
on the macrophage or by changes in cytokine production).
Not only do APC exert an effect on T cells during the
induction of an immune response, they are also important
regulators ofT cell development. Infected DC in the thymus
may result in inappropriate signalling to developing thymo¬
cytes. This would result in the development of an abnormal
T cell repertoire.173
In her controversial danger hypothesis, Matzinger sug¬
gests a mechanism whereby Langerhans cells in the skin can
induce tolerance (i.e. anergy or death) in CD4+T cells.177 Her
idea is that Langerhans cells in the skin express self-
antigen/MHC class II complexes, but not costimulatory mol¬
ecules. T cells interacting with these Langerhans cells would
receive signal one but not signal two and would be tolerized.
Matzinger suggests that tissue Langerhans cells may phago-
cytose and present environmental antigen, but viral antigen
may also be presented by Langerhans cells (at the site of
initial infection) to virus specific CD4+T cells and this would
result in the deletion or anergy of these T cells.
Of course, it is not only cells of the immune system that
are damaged by HIV-1. Bukrinsky et al. showed that HIV-1
infection induced macrophages to produce nitric oxide, a
molecule implicated in the neurological disease seen in some
AIDS patients.178
Role of APC in HIV-1 dissemination
Acquired immune deficiency syndrome is a systemic disease
with HIV-1 infecting cells throughout the body. After sexual
transmission, HIV-1 is initially localized to the point of entry.
Antigen-presenting cells have been implicated in allowing
the virus to spread throughout the body.
Simian immunodeficiency virus (SIV) infection in rhesus
macaques has been used as a model for the early events in
heterosexual HIV-1 infection.179,180 When macaques are inoc¬
ulated intravaginally with SIV, the virus first appears in, or
bound to, DC of the lamina propria of the vaginal mucosa.
Within 2 days, infected cells are detectable in the draining
lymph nodes and by day 5 the infection becomes systemic
with SIV detectable in the blood.180
Weissman et al. have reported that DC can bind HIV-1 and
that once these cells have matured and are expressing co-
stimulatory molecules (B7.1, this would be in the lymph node
in vivo) they can stimulate T cells.181 The stimulation of the
T cells activates them and allows them to support productive
infection by the virus passed from the infected DC.
Conclusions
It has been 17 years since AIDS was first identified. Approx¬
imately 40 million people are now infected with HIV-1 (1%
of the world's sexually active population). There have been
some recent advances in treatment (for review see Clumeck
and Hermans182), which have allowed the life-span of HIV-1 +
patients to be increased. Most of the progress in drug treat¬
ment has come from an increased understanding of HIV-1
virology and biochemistry. However, in order to find
improved treatments and eventually a cure and to start to
think about reconstructing a battered immune system after
successful treatment to reduce viral load, a greater under¬
standing of immunology will be required.
The APC appears to play a central role in the immune
system, regulating the actions of other cell types. The goal of
HIV vaccine development may also be served by a greater
understanding ofAPC interactions with the viral components
of a putative vaccine. A successful outcome of vaccination
depends on appropriate APC/HIV interactions as the first
stage of a protective immune response, rather than APC/HIV
interactions acting to cause immune system dysfunction and
disruption.
An understanding of APC-HIV-1 interactions may hold
the key to many of the remaining mysteries of AIDS.
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